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1 ABSTRACT (EN) 
This thesis is focused mainly on understanding mechanisms of regulatory roles of 
C-terminal Src kinase (CSK) and phosphoprotein associated with glycosphingolipid-
enriched microdomains (PAG) in the high-affinity IgE receptor (FcɛRI)-mediated 
signaling of murine mast cells. FcɛRI activation is initiated by aggregation of the 
receptor by complexes of multivalent antigen with IgE, followed by activation and 
enhanced activities of protein tyrosine kinases, phosphatases, adaptor proteins and 
number of other signal transduction molecules. The signaling events result in mast cell 
degranulation and release of variety of proinflammatory mediators, responsible for 
initiation of allergy and other inflammatory diseases. Understanding the function of key 
regulatory molecules controlling FcεRI-mediated mast cell activation, degranulation, 
and cytokines production could have therapeutic impact. 
CSK is a major negative regulator of Src family tyrosine kinases (SFKs) that play 
a critical role in various immunoreceptor signaling events. However, its function in mast 
cell activation has not been completely understood. Because of its cytoplasmic 
localization, CSK was assumed to be brought to the vicinity of the plasma membrane-
bound SFKs via binding to membrane-bound adaptors and PAG was a major candidate. 
To determine the roles of CSK and PAG in FcɛRI signaling, we used as a model bone 
marrow-derived mast cells (BMMCs) from wild-type or PAG knockout (PAG-KO) 
mice with reduced amount of CSK (CSK-KD) or with reduced amount of both proteins 
(CSK-KD/PAG-KO).  We found that antigen-activated cells with CSK-KD exhibited 
significantly higher degranulation, calcium response and chemotaxis. Unexpectedly, 
PAG played an opposite role in these processes and cells with CSK-KD, similarly as 
PAG-KO, displayed impaired phosphorylation of the transcription factor STAT5. This 
was probably caused by enhanced enzymatic activity of Src homology region 2 domain-
containing phosphatase-1 (SHP-1), which resulted in inhibition of proinflammatory 
cytokines and chemokines production. Our data also showed distinct involvement of 
adaptor proteins LAT and NTAL in CSK- or PAG-dependent signaling in BMMCs. 
Several lines of evidence suggested, that CSK binds not only to PAG, but also to some 
other anchors, which could serve better than PAG for positioning of CSK in the vicinity 
of SFKs and thus more efficiently contribute to their inactivation. Based on these data 
we postulated a new model of CSK-PAG interplay in mast cell activation. 
Since these studies required sensitive detection of various cytokines released or 
utilized by mast cells, part of the thesis was dedicated to development of such assay. In 
collaborative studies we used this method, called nano-iPCR, for detection of clinically 
relevant markers in cerebrospinal fluid of patients and compared it with routinely used 
enzyme-link immunosorbent assays (ELISAs). 
 We also used this method for elucidating the role of ORMDL3 protein in mast 
cell signaling. The key finding was determination of ORMDL3 as a negative regulator 
of proinflammatory cytokines production, mediated via AKT and NF-κB-directed 
signaling pathways. Our results also showed that mast cell chemotaxis is regulated by 
ORMDL3 and CD9. Furthermore, we examined mode of action of widely used 
dissolving agent, ethanol, and cellular cholesterol remover, methyl-β-cyclodextrin, on 
FcɛRI activation. Our data indicated that ethanol has an inhibitory effect on function of 
FcɛRI signalosomes in which cholesterol plays an indispensable role. These data were 




2 ABSTRAKT (CZ) 
Tato disertační práce je zaměřena především na pochopení regulační úlohy C-
terminální Src kinázy (CSK) a proteinu asociovaného s mikrodoménami bohatými na 
glykosfingolipidy (PAG) v FcɛRI zprostředkované signalizaci myších žírných buněk. 
FcɛRI aktivace je zahájena agregací receptoru komplexem multivalentního antigenu 
s IgE a následnou aktivací protein tyrozin kináz, protein tyrozin fosfatáz a dalších 
molekul signální transdukce. Signalizační děje vedou k degranulaci žírných buněk a 
uvolnění prozánětlivých mediátorů zodpovědných za vznik alergických onemocnění. 
Poznání funkce klíčových regulačních molekul, které kontrolují  FcɛRI 
zprostředkovanou aktivaci, degranulaci a cytokinovou produkci žírných buněk, může 
mít terapeutický dopad. 
CSK je hlavním negativním regulátorem protein tyrozin kináz z rodiny Src (SFK), 
které hrají kritickou úlohu v různých imunoreceptorových dějích. Funkce CSK v 
žírných buňkách však není zcela objasněna. Předpokládá se, že CSK lokalizovaná v 
cytoplazmě je translokována do blízkosti membránově vázaných SFK s využitím 
membránových adaptorových proteinů a PAG byl hlavním kandidátem. Pro určení 
úlohy proteinů CSK a PAG v FcɛRI signalizaci jsme jako model použili žírné buňky 
odvozené z kostní dřeně (BMMC) myší divokého typu  nebo myší deficientních 
v proteinu PAG (PAG-KO) nebo myší se sníženou expresí CSK (CSK-KD) nebo se 
sníženou expresí obou těchto proteinů (CSK-KD/PAG-KO). Konkrétně jsme ukázali, 
že antigenem aktivované buňky s CSK-KD vykazují významně vyšší degranulaci, 
vápníkovou odpověď a chemotaxi. Překvapivě, PAG měl v těchto dějích opačnou úlohu 
a buňky s CSK-KD, stejně jako PAG-KO, vykazovaly narušenou fosforylaci 
transkripčního faktoru STAT5. To bylo pravděpodobně způsobeno zvýšenou 
enzymatickou aktivitou fosfatázy SHP-1, čímž docházelo k inhibici produkce 
prozánětlivých cytokinů a chemokinů. Naše výsledky také ukázaly odlišné zapojení 
adaptorových proteinů LAT a NTAL v CSK- nebo PAG-závislé signalizaci BMMC. 
Získané výsledky podporují hypotézu, že se CSK váže nejenom na PAG, ale také na 
jiné adaptorové proteiny, které mohou fungovat lépe než PAG pro lokalizaci CSK v 
blízkosti SFK, a tím efektivněji přispět k jejich inaktivaci. Na základě těchto výsledků 
jsme navrhli nový model souhry proteinů CSK a PAG v signalizaci žírných buněk. 
Protože tyto studie vyžadovaly citlivou detekci různých cytokinů uvolněných 
z žírných buněk nebo jimi spotřebovávaných, byla část práce věnována vývoji takové 
metody. Ve spolupráci s dalšími laboratořemi, jsme tuto metodu, nazvanou nano-iPCR, 
použili pro detekci klinicky významných reportérů v mozkomíšním moku pacientů a 
srovnali ji s běžnými imunotesty využívající enzymově značené komplexy antigen-
protilátka ukotvené na pevných nosičích (ELISAs). 
Tuto metodu jsme také použili pro určení úlohy ORMDL3 proteinu v signalizaci 
žírných buněk. Klíčovým zjištěním bylo, že ORMDL3 je negativní regulátor produkce 
prozánětlivých cytokinů, přes AKT- NF-κB řízenou signální dráhu. Naše výsledky také 
ukázaly, že chemotaxe žírných buněk je regulována proteiny ORMDL3 a CD9. Dále 
jsme zkoumali vliv běžně používaného rozpouštědla etanolu a látky odstraňující 
membránový cholesterol, methyl-β-cyclodextrinu, na FcɛRI signalizaci. Naše výsledky 
ukázaly, že etanol inhibuje funkci FcɛRI signalozomu, a že cholesterol zde hraje 
nezastupitelnou úlohu. Tyto výsledky jsme potvrdili na myších in vivo s využitím testu 





AA  amino acid 
AF  Alexa Fluor 
ATP adenosine triphosphate 
BCR B cell receptor 
BLK B-lymphoid tyrosine kinase  
BMCP basophil/mast cell progenitor 
BMMC bone marrow-derived mast cell 
BSA bovine serum albumin 
C/EBP CCAAT-enhancer-binding proteins 
     CAP cytoplasmic adaptor protein 
CD  cluster of differentiation 
CHO Chinese hamster ovary cell 
CMML chronic myelomonocytic leukemia 
CMP common myeloid progenitor 
CSK C-terminal Src kinase 
Ct  cycle threshold 
DOK downstream of tyrosine kinase 
ELISA enzyme-linked immuno sorbent assay  
ERK extracellular regulated kinase 
ERM ezrin, radixin, moesin protein family 
FcɛRI high-affinity IgE receptor  
FcγRII Fc receptor for IgG 
FGR Gardner-Rasheed feline 
FITC fluorescein isothiocyanate 
GADS Grb2-related adaptor downstream of Shc 
GATA GATA-binding transcription factor 
GMP granulocyte-macrophage progenitor 
GPCR G-protein-coupled receptor 
GRB2 growth factor receptor-bound protein 2 
HCK hematopoietic cell kinase 
HEK human embryonic kidney 293 cells 
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HRP horseradish peroxidase 
HSC hematopoietic stem cell 
Ig  immunoglobulin 
IL  interleukin 
IL3R receptor for IL-3 
iPCR immuno-PCR 
ITAM immunoreceptor tyrosine-based activation motif 
ITIM immunoreceptor tyrosine- based inhibitory motif 
IκB  inhibitor of κB 
JAK Janus kinase 
KD  knockdown 
kDa  kilodalton 
KO  knockout 
KTIM kinase tyrosine-based inhibitory motif 
LAMP1  lysosomal-associated membrane protein 1 
LAT linker for activation of T cells 
LAX linker for activation of X cells 
LCK leukocyte C-terminal Src kinase 
LPS lipopolysaccharide 
LPS lipopolysaccharide 
LTC leukotriene C 
LYP lymphoid-tyrosine phosphatase 
mAb monoclonal antibody 
MAPK mitogen-activated protein kinase 
MCP mast cell progenitor 
MEM minimal essential medium 
MIRR multichain immune recognition receptor 
MITF microphthalmia-associated transcription factor 
MPP multi-potent progenitor 
MβCD methyl-β-cyclodextrine 
Nano-iPCR     gold nanoparticle-based-iPCR 
NCBI  National Center for Biotechnology Information 
NFAT nuclear factor of activated T-cells 
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NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
NRTK non-receptor tyrosine kinase 
NTAL non-T-cell activation linker 
OE  overexpressor 
OPD o-phenylenediamine  
ORMDL     ORM-like 
PAG phosphoprotein associated with glycosphingolipid-enriched microdomains 
PAGE polyacrylamide gel 
PBS phosphate buffer solution 
PCA passive cutaneous anaphylaxis 
PDZ post-synaptic density protein 95  
PGD prostaglandin D 
PI3  inositol-1,4,5-triphosphate 
PI3K phosphatidylinositol-3 kinase 
PIP3 phosphatidylinositol-3,4,5-trisphosphate 
PKC protein kinase C 
PLC phospholipase C 
PSA passive systemic anaphylaxis 
PTK protein tyrosine kinase 
PTP protein tyrosine phosphatase 
PY20 phospho-tyrosine specific monoclonal antibody 
RBL rat basophilic leukemia 
RNA ribonucleic acid 
RNAi RNA interference 
RTK receptor tyrosine kinase 
SCF stem cell factor 
SDS sodium dodecyl sulphate 
SFK Src family kinase 
SH  Src-homology    
SHIP SH2 domain-containing inositol 5-phosphatase 
SHP SH2 domain containing phosphatase   
shRNA short hairpin RNA 
    siRNA small interference RNA 
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SLP-76 SH2 domain-containing leukocyte protein of 76 kDa 
STAT signal transducer and activator of transcription 
SYK spleen tyrosine kinase 
TBS tris buffer solution 
TBST tris buffer tween solution 
TCR T-cell receptor 
Th  T helper 
TNF tumor necrosis factor 
TPBS phosphate buffer tween solution 
TRAP transmembrane adaptor protein    
VAV guanine nucleotide exchange factor 





4.1 MAST CELL 
4.1.1 Origin and development 
Mast cells origin and details regarding their differentiation and maturation are 
still incompletely understood [1]. Mast cells are hematopoietic cells of the myeloid 
linage originated in bone marrow. In human beings, mast cells develop from 
CD34+/CD117+/CD13+ multipotent hematopoietic progenitors, while mouse mast cells 
originate from CD34+/CD117+ pluripotent hematopoietic progenitors. Majority of other 
hematopoietic cells are released into the bloodstream primarily in a mature state, 
however mast cells progenitors enter to the blood circulation in an immature state and 
migrate through blood vessels to peripheral tissues where maturate under the influence 
of local environment [2]. Despite of the growing understanding of hematopoiesis, the 
origin of mast cells is a subject of controversy [3-5]. 
 
 
Figure 1. Current models describing the origin of murine mast cells and their differentiation. In 
adult mice, mast cells originate and develop from hematopoietic stem cells in bone marrow. Mast cell 
progenitors (MCPs) are currently thought to develop from multi-potent progenitors (MPPs) or common 
myeloid progenitors (CMPs) in the bone marrow. On the other hand, they also might differentiate from 
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granulocyte/monocyte progenitors (GMPs) via a common basophil/mast cell progenitor (BMCP), only 
found in the spleen, or a pre-basophil/mast cell progenitor (pre-BMP). Adapted from [6]. 
To what lineage the mast cells belong and whether they have their own 
progenitors or share them with basophils is still debated [6]. Advances in multicolor 
flow cytometry techniques enabled extensive studies of mast cells origin and thus to 
understand their relationship to other cells. In Figure 1, the current models of mast cell 
origin and development are summarized [6]. In mice, bone marrow derived 
hematopoietic stem cell (HSC) give arise to multi-potent progenitor (MPP), which is 
capable directly differentiate into mast cell progenitor (MCP) [7] or common myeloid 
progenitor (CMP) with potential to give arise MCP via Sca-1 low fraction of CMP (SL-
CMP) population. This progenitor is more closely related to megakaryocyte/erythrocyte 
specification [8]. On the other hand, granulocyte/monocyte progenitor (GMP) can 
develop to the common basophil/mast cell progenitor (BMCP), present only in mouse 
spleen, which can progress to MCP or basophil progenitor (BA) [4], suggesting a close 
developmental relationship between basophil and the mast cell lineage. In contrast, more 
recent study described that BMCP exhibit very low potential to give arise to BA [9]. 
Subsequent studies identified phenotypically different progenitor called pre-
basophil/mast cell progenitor (pre-BMP), which can develop to both MCP and BA 
progenitor [5].   
Mast cells progenitor population has been extensively characterized in terms of 
its surface markers. After commitment, both mast cells and basophils express high 
affinity receptor for IgE (FcɛRI).  In contrast, basophils typically mature in bone marrow 
and enter blood as a fully mature cells. Identification of mast cell progenitors is crucial 
for understanding the mechanisms of allergy diseases and various type of mastocytosis, 
characterized by uncontrolled mast cell proliferation and accumulation within various 
organs [10]. Recently, Dahlin et al. identified a novel circulating human mast cell 
progenitor population present in bloodstream in immature state of healthy individuals 
that can only develop into MCP. Importantly, it has been shown that this progenitor 
significantly increase in asthma patients with reduced lung function [11].  
Differentiation of mast cells from CMP, GMPs or BMCP progenitors is tightly 
regulated by CCAAT/enhancer binding protein α (C/EBPα), microphthalmia-associated 
transcription factor (MITF), signal transducer and activator of transcription (STAT5), 




Figure 2. Transcription factors involved in putative pathways of mast cell development. Adapted 
from [6]. 
As shown Figure 2, absence of transcription factor C/EBPα result in 
development of mast cells, but not basophils [12, 13]. Thus, for mast cell progenitors 
commitment, MITF is upregulated and C/EBPα is further downregulated, whereas for 
BA commitment, MITF is downregulated and C/EBPα is upregulated [13]. 
4.1.2 Diversity in phenotype and tissue localization 
Although all mast cells can be identified by their receptor expression profile, 
mature mast cells exhibit great histochemical, biochemical and functional heterogeneity 
[14]. The plasticity of mast cells phenotype leads to development of phenotypically 
distinct populations based on animal species, anatomical localizations and processes 
which physiologically change tissue microenvironment such as hormones, cytokines 
and chemokines or pathological alteration such as reactive oxygen and nitrogen species, 
and divers mediators released during inflammation and numerous diseases. 
Heterogeneity among mast cells populations allow greater flexibility of immunological 
responsiveness in host defense, allergic reactions and communication with adjacent 
immune cells [15]. Apart of this, mast cell phenotype is dynamically changed in 
accordance with current conditions. Mast cells can be find in all blood vessels and 
peripheral connective tissues, such as skin, joints, lung, nasal mucosa and intestine. In 
rodents, mast cells are also present in peritoneal cavity and can be easily isolated in 
contrast to mast cells located in solid tissue. Tissue-resident mast cells are very long-
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lived and even after degranulation they are still alive. In rodents, two mast cell 
populations have been described, mucosal-type and connective tissue-type mast cells, 
which differ in content of the secretory granules [16].  
Majority of proteins found in rodent and human mast cell granules are proteases. 
In mice, mucosal-type mast cells preferentially express mast cell protease-1 and -2, 
whereas connective tissue-type mast cells express mast cell protease -4, -5 and -6 and 
carboxypeptidase. Another difference between these two mast cell types is in the 
presence or absence of proteoglycan heparin, which is only found in connective tissue-
type mast cells. In contrast, all human mast cells contain heparin, but exhibit 
heterogeneity in content of serine proteases. According to the content of proteases, 
human mast cells are classified as tryptase-only, chymase-only or both type tryptase and 
chymase-positive mast cells [2]. 
4.1.3 Growth factors 
Although mast cells are widely distributed among tissues, they represent a minor 
cell population [17, 18]. Sources of homogenous mast cells and appropriate isolation 
techniques have therefore been searched for experimental studies [19-21]. The  major  
limitation of these techniques is their poor yield, making biochemical analyses difficult 
[18]. For this reason, mast cell lines of mouse, rat and human origin, such as rat 
basophilic leukemia (RBL), have been extensively used; however it has been shown that 
stable cell lines are not very useful for some biochemical studies [22, 23]. On the other 
hand, cultured mast cells from pluripotent hematopoietic precursors from bone marrow 
permitted such studies. Considerable numbers of pure primary mouse mast cells can 
indeed be generated and kept in culture for several months. Development of murine 
mast cells is dependent on the presence of two growth factors, interleukin (IL)-3 and 
stem cell factor (SCF). Therefore, these components need to be added into culture media 
used for production of bone marrow-derived mast cell (BMMCs).  
SCF (also known as c-KIT-ligand or steel factor) is produced by fibroblasts and 
endothelial cells throughout the body, promoting proliferation, migration, survival, and 
differentiation of hematopoietic progenitors, melanocytes, and germ cells. Soluble SCF, 
which has molecular size of 18.5 kDa, binds to its plasma membrane receptor, c-KIT, 
and thereby enhances mast cell development, potentiates antigen-mediated activation, 
degranulation and cytokines/chemokines production in mast cells [24, 25]. Importance 
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of c-KIT and its ligand for mast cells development is demonstrated by phenotype of 
mice, with loss-of-function mutations in this receptor or its ligand SCF, which are 
virtually mast cell deficient [26]. 
Interleukin (IL)-3 was found to be one of the factors in conditioned media of 
activated lymphocytes, which was responsible for mast cell survival, development, and 
maturation. Although IL-3 contributes in increasing of murine BBMCs in vitro, its effect 
in vivo is not essential [27]. Screening of various cell lines revealed that WEHI-3, a 
myelomonocytic leukemia B cell line, constitutively produced large amount of IL-3 and 
Chinese hamster ovarian (CHO) cell line are source of SCF suitable for in vitro BMMCs 
cultivation [28-30]. 
Bone marrow progenitors cultured in SCF- and IL-3-supplemented media 
undergo optimal proliferation and maturation in vitro and therefore quality of the media 
is a presumption for preservation of the homogeneous population. Differences in the 
concentration of SCF and other cytokines such as IL-3 can determine number and 
phenotype of mast cells. For instance, IL-3 in rodents induce histamine secretion [2] and 
activates STAT5 pathway, which regulates apoptosis and cytokines production [31]. 
Mast cell heterogeneity causes by suboptimal concentration of growing factors makes 
experiments difficult due to inaccurate response to stimulatory signals [32].  
4.2 MAST CELL FUNCTIONS 
Mast cells can function as a both effector and immunomodulatory cells during 
innate and adaptive immune responses [15]. Effector functions include several 
physiological and pathological processes, such as IgE-mediated allergic diseases, 
asthma, autoimmune disorders, inflammation, homeostatic responses, angiogenesis, 
wound healing and tissue remodeling. On the other hand,  mast cells have also anti-
inflammatory and immunosuppressive functions, because they promote clearance of 
pathogens by phagocytosis and/or by secretion of anti-microbial peptides and degrade 
toxic endogenous peptides or components of venoms [33].  
 
Mast cells are characteristic by a large amount of cytoplasmic granules 
containing biologically active compounds which are released upon cell activation [15]. 
Activation of mast cells by antigen-specific IgE binding and crosslinking FcεRI, the 
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high-affinity IgE receptor, results in downstream event that lead to the rapid secretion 
of large amount of preformed and newly synthetized mediators, by process called 
degranulation. As shown in Figure 3, during early stage of degranulation mast cells 
release biogenic amines (histamine, serotonin), lysosomal enzymes (β-glucuronidase, 
β-hexosaminidase), several serine and other proteases (chymases, tryptases), 
proteoglycans (heparin, chondroitin sulphate), and cytokines, such as tumor necrosis 
factor-α (TNF-α) [32]. 
 
 
Figure 3.  Mast cells can be activated to release preformed and/or de novo-generated products. The 
secretion of mast cell products can have numerous effects on other cell types and on pathogens and 
endogenous and exogenous peptides, which can lead to improved innate and/or acquired immune 
responses. Adapted from [32]. 
Thus, mast cells have a potential to be the first responders following recognition 
of an invading pathogens, including parasites, bacteria and probably viruses. Releasing 
of these mediators by mast cells is signal for recruitment of neutrophils, eosinophils and 
basophiles accompanied by immediate effect on epithelial, endothelial and nerves, result 
in increased epithelial permeability, production of mucus, smooth muscle contraction 
and vasodilation. Late phase of degranulation is characteristic not only by continued 
mediator release, but also de novo synthetized compounds which mediate sustained 
inflammatory response long after the effect of histamine has fade away. These mediators 
occur though activation of arachidonic acid metabolic pathways, involving leukotriene 
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C4 (LTC4), prostaglandin D2 (PGD2), and other products, such as chemokines and 
cytokines which drive activation of leukocytes and another tissue resident cells. These 
early and late phase of degranulation results in allergic and/or inflammatory responses 
accompanied by characteristic symptoms [2, 32-34]. Generally, histamine and nitric 
oxide stimulates vasodilatation, heart rate, and together with LTC4 increase vascular 
permeability, PGD2 is responsible for bronchoconstriction and TNF-α activates 
neutrophils and promote synthesis of chemokines [33, 35].  
 
In certain cases, mast cells and basophiles mediate anaphylaxis, a severe allergy 
reaction, which can result in airway obstruction, cardiovascular collapse and sometimes 
death. Generally believed mechanism of anaphylaxis is based on crosslinking of IgE 
and aggregation of FcɛRI, following by activation the signaling pathways result in 
massive and rapid degranulation within seconds or minutes. Molecular mechanism of 
degranulation is described later in Chapter 4.4.2, at page 35. Anaphylaxis is also induced 
by activation of phospholipase A2, cyclooxygenases and lipoxygenases, arachidonic 
acid metabolites and proinflammatory cytokines [35].  
  
A number of cytokines (e.g. IL-1, 2, 5, 6, 8, 9, 13, TNF) are synthesized de novo 
and released several hours upon mast cell activation. Of particular interest in humans is 
the production of tumor necrosis factor (TNF-α, β), and interleukin (IL)-4, IL-5, IL-6, 
IL-1β and IL-13 [36]. For instance, mast cell derived TNF-α and IL-4 modulate 
adhesion molecules on endothelial cells and thereby allow other circulating 
inflammatory cells to adhere to the endothelium and to migrate into the surrounding 
tissue during inflammation. Moreover, TNF-α also promote activation and antigen 
presentation of dendritic cells and mast cell derived IL-6 stimulates the proliferation and 
differentiation of activated B-cells, and can enhance neutrophil activity against some 
bacteria. Different mechanisms could contribute to the increase in the number of mast 
cells at the sites of inflammation: resident mast cell precursors could proliferate, 
released compounds and/or their progenitors could migrate to the site of inflammation 
[37, 38]. A potent mast cell chemoattractant acting in autocrine/paracrine fashion is SCF 
which recognize c-KIT receptor, antigen, which binds to IgE recognized by FcɛRI, 
leukotrienes and eicosanoids (LTC4, PGD2), and chemokines, which bind to various G-
protein-coupled receptors (GPCRs) [39].  
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4.3 SIGNAL TRANSDUCTION 
4.3.1 Receptors 
Mast cells expressed on its surface array of receptors that recognized wide 
variety of stimuli, such as receptor for stem cell factor (c-KIT), receptor for IL-3, 
lipopolysaccharide (LPS), certain products of complement activation and some 
neuropeptides. However, the best-studied mechanism for the mast cell activation is via 
FcɛRI. Immunologically specific function of this receptor is interaction with complex 
of IgE-antigen [15]. 
FcɛRI on mast cells and basophils is a member of a family related antigen/Fc 
receptors, called Multichain Immune Recognition Receptors (MIRRs), which have 
conserved structural features and similar roles in initiating intracellular signaling 
cascades. The FcɛRI has a heterotetrameric structure consist of one α-subunits, one 
membrane-tetraspanning β-subunits, and two identical γ-subunits linked with disulphide 
bound (Figure 4) [23, 40, 41]. The α-subunit has a short intracellular tail that does not 
contribute to transduction events, however consist of binding site for IgE [23, 40]. The 
α-subunit of FcɛRI is responsible for binding to the Fc part of monomeric IgE at a very 
high affinity (Kd=10
-9-10-10) [23].  
 
 
Figure 4. FcεRI structure. The FcεRI is transmembrane (TM) tetrameric receptor composed of 3 chains: 
one α chain with 2 domains, the second domain is capable of binding to the two IgE Cε3 domain heavy 
chains. One β chain which amplifies the downstream signal, and two γ chains bound together by a 
disulphide bridge, they are the site where the downstream signal initiates. Adapted from [40]. 
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The cytoplasmic part of β and γ chains is important for initiation and downstream 
of signal transduction cascade, since they each contain an immunoreceptor tyrosine-
based activation motifs (ITAMs), that serves as a docking sites for Src family kinases 
possessing phosphotyrosine-binding Src homology (SH)2-domains [22]. The rapid 
phosphorylation leads to the receptor aggregation and induction multiple signaling 
pathways that regulates diverse effector responses. These include the secretion of 
allergic mediators and induction of cytokine gene transcription, resulting in secretion of 
proinflammatory mediators [42]. Therefore, FcɛRI is central to the induction and 
maintenance of an allergic response and also may confer physiological protection in 
parasitic infections [23]. FcɛRI receptor is the most important receptor on mast cells and 
its expression on the surface of mast cells, together with c-KIT, a receptor for SCF, is a 
characteristic hallmark for mature mast cells population.  
c-KIT (CD117) is a type III tyrosine kinase and belongs to superfamily of the 
transmembrane receptors with intrinsic tyrosine kinase activity and is highly, but not 
exclusively, expressed in hematopoietic lineage [43, 44]. The extracellular part of the 
receptor contains 5 Ig-like motifs, which regulate binding of the SCF to the receptor. 
Ligand binding is followed by receptor dimerization and activation of the inherent 
catalytic activity associated with tyrosine kinase domain present at the cytosolic region 
of the receptor [45].  
SCF-mediated activation of the c-KIT, both directly and indirectly, leads to the 
downstream of the signaling molecules such as LYN and FYN kinases that activates 
phosphatidylinositol-3 kinase and serine-threonine kinase AKT (PI3K-AKT) pathway, 
Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway and 
mitogen-activated protein kinase (MAPK) pathway [43, 44]. Downstream signaling 
events of c-KIT leads to regulation of transcription activity to prevent mast cells from 
undergoing apoptosis. On the other hand, mast cells without present of SCF exhibit 
manifestations of apoptosis and die approximately within 2 days [46]. As was mentioned 
above, mice defective in functional KIT or SCF are deficient in mast cells [47, 48]. This 
showing that SCF-induced KIT activation is crucial for maturation of mast cells from 
their progenitors, homing in the site of residence in vivo, as well as chemotactic 
properties of SCF for both human and mouse mast cells [39]. 
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4.3.2 Adaptor proteins 
Adaptor proteins play an essential role in downstream of the receptor-mediated 
signals into an appropriate cellular response. They are lacking any enzymatic and 
transcriptional activity, but instead of this they possess multiple motifs capable mediated 
protein-protein and/or protein-lipid interaction with other signaling molecules and 
serves as a docking site for cytoplasmic signaling molecules. There are two major group 
of adaptor proteins: transmembrane adaptor proteins (TRAPs) and cytoplasmic adaptor 
proteins (CAPs) [49, 50]. In mast cells five TRAPs have been identified: PAG 
(phosphoprotein associated with glycosphingolipid-enriched microdomains), LAT 
(linker for activation of T cells), NTAL (non-T cell activation linker), LAX (linker for 
activation of X cells) and growth factor receptor-bounded protein 2 (GRB2)-binding 
adaptor protein [51-53]. In the following chapters, some of the adaptor proteins most 
relevant for this work is described. 
4.3.2.1 LAT and NTAL 
Transmembrane adaptor protein, LAT, is present in several cell types, whereas 
NTAL is mainly expressed in B cells, natural killer cells, monocytes and mast cells, but 
not in T cells in comparison with LAT. Several studies showed, that LAT could be 
phosphorylated by spleen tyrosine kinase (SYK) and thus phosphorylated LAT 
associates directly or indirectly with numerous signaling molecules, such as GRB2, 
PLCγ, guanine nucleotide exchange factor (VAV), CBL, SH2 domain-containing 
leukocyte protein of 76 kDa (SLP-76), and Grb2-related adaptor downstream of Shc 
(GADS) [50].  
As other TRAPs, LAT possess a very short extracellular part (four amino acid), a 
single transmembrane domain with dual palmitoylation, and a long cytoplasmic region, 
without any enzymatic activity, but composed of various binding motives (Figure 5). 
The more distal tyrosine on cytoplasmic tail of LAT serve as a binding site for SH2 
domain-containing inositol 5-phosphatase 1 (SHIP1), which negatively regulates FcεRI 
signaling by inhibiting PI3K-dependent pathway. Although LAT and NTAL have 
structural similarities, the amino-acid sequences differ to each other. NTAL possesses 
10 tyrosines within the cytosolic tail: five of them within the putative Grb2-binding sites 
and one within the putative SH2 domain containing phosphatase (SHP-1)/Src kinase-
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binding site (YIDP). In contrast to LAT, NTAL is lacking the PLCγ1 binding motif. In 
FcεRI stimulated mast cells, NTAL was rapidly phosphorylated by SYK and LYN 
kinase. Interestingly, these kinases are produced entirely different pattern of 
phosphorylation of the individual tyrosines [54].  
4.3.2.2 PAG 
PAG (also known as CSK-binding protein; CBP) was simultaneously described 
in 2000 by two groups, one in Prague [55] and another in Japan [56] . PAG is 
ubiquitously expressed transmembrane adaptor protein with relatively highest 
expression in the immune cells, lungs, heart and placenta. PAG is a major 
phosphoprotein in resting T cells and its expression correlates with the proliferative 
capacity of this cells. PAG is also well expressed in B cells and mast cells. Interestingly, 
different expression of PAG was found in several of cancer cells [57]. PAG is consist 
of a short extracellular domain, a transmembrane domain for localizing PAG to the lipid 
raft, and a long cytoplasmic tail with multiple tyrosine-based motifs (Figure 5).  
 
 
Figure 5. Schematic illustration of TRAPs studied in human and mouse mast cells. TRAPs are 
characterized by a short extracellular domain, a transmembrane domain, and a cytoplasmic domain with 
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various motifs. LAT, NTAL, and PAG possess juxtamembrane CxxC palmitoylation site for their 
interactions with lipids and localization in detergent-resistant membranes. All TRAPs have a various 
tyrosine-based motif which after phosphorylation serve as binding sites for the indicated SH2-containing 
proteins. PAG also contains proline-rich domains serving as anchor for SH3-containingnproteins. 
Number of amino acids (AA) in each TRAP as well as accession numbers in the GenBank sequence 
database provided by National Center for Biotechnology Information (NCBI) are also shown. Adapted 
from [50]. 
Nine of these motifs preferred phosphorylation by Src family kinases (SFKs). In 
resting T-cells, PAG is phosphorylates mainly by FYN kinase and thus binding site for 
SH2 domain of C-terminal Src kinase (CSK) is creates. Phosphorylated Tyr 314 in 
mouse PAG has been shown to be essential for CSK binding [56]. Following T-cell 
receptor (TCR) activation, SFKs are activated and they phosphorylate their target 
proteins including PAG. Phosphorylated PAG then recruits CSK to plasma membrane 
to the vicinity of active SFKs, as described in Chapter 4.3.4.1, page 30. After 
inactivation of SFKs by CSK, phosphorylation of PAG returns to the basal level and 
CSK simultaneously dissociate from the membrane. A negative regulatory role of PAG 
in T cell signaling was shown in experiments with PAG knockdowns (KDs) [58], and 
very recently this model was validated in PAG-knockout (KO) mice [59], confirming 
negative regulatory role of PAG in vitro and in vivo. Interestingly, in T cells from PAG-
KO mice, CSK becomes more associated with alternative partners such as PTPN22 and 
adaptor protein DOK; downstream of tyrosine kinases [59]. PAG also possesses two 
proline-rich sequences that serve as binding sites for proteins with SH3 domains and a 
VTRL motif at the C-terminus for interaction with the post-synaptic density protein 95 
(PDZ) domain of the cytoskeletal linker ezrin/radixin/moesin-binding protein, EBP50. 
In mast cells, PAG regulates FcεRI signaling by a mechanism more similar to B cell, 
than T cells. Following FcεRI triggering PAG is phosphorylated by LYN kinase instead 
of FYN kinase as in case of T cell, which results in recruitment of CSK to lipid raft and 
negative regulation of SFKs activity by phosphorylation of its C-terminal regulatory 
tyrosines [57].  
4.3.3 Src family protein tyrosine kinases 
Phosphorylation plays a pivotal role in many cellular and extracellular processes 
[60]. Protein tyrosine kinases (PTKs) carry out the phosphorylation reactions by 
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transferring the γ-phosphates of adenosine triphosphate (ATP) onto hydroxyl groups of 
tyrosine residues in various substrates including lipids, sugars or amino acids.  PTKs, 
which are exclusively present only in animals, are involved in controlling animal-
specific cellular functions such as rapid cell-cell communication via plasma membrane.  
PTKs are classified into two major groups: receptor tyrosine kinases (RTKs) and 
non-receptor tyrosine kinases (NRTKs). RTKs are various cell surface receptors and are 
autophosphorylated upon binding of the ligand to the extracellular part of the molecule. 
In mast cells, accumulated evidence suggests that RTKs play a role in both a positive 
and negative manner to control cell activation [45, 61]. In mast cell, one the most 
important and extensively studied RTK is c-KIT, the receptor for stem cell factor (SCF). 
The second group of PTKs, the cytoplasmic NRTKs, are also activated in response to 
extracellular stimuli via physical and functional interactions with particular 
transmembrane receptors, thereby activate specific signaling pathways in cells.  
 
The SFKs are the major family of NRTKs expressed in multiple types of 
mammalian cells. The discovery of SFKs was based on breakthrough finding that a virus 
could cause cancer. This responsible oncogene was called viral (v)-SRC (Rous sarcoma 
virus) and related gene found in chickens, as a normal cellular counterpart, was termed 
cellular (c)-SRC or simply SRC. SRC was identified as a first proto-oncogene and first 
protein with intrinsic tyrosine kinase activity, respectively. Since the discovery of their 
biochemical activity and involvement in signaling pathways, SFKs have been the 
subject of intensive investigation over the several decades [62]. To the family of SFKs 
belongs eight members, SRC, LYN, YES, FYN, FGR, HCK, LCK and  B-lymphoid 
tyrosine kinase (BLK), that regulate wide range of fundamental cellular processes, 
including cell growth, differentiation, survival, migration, adhesion, division and 
specialized cell function such as immune response. [62-66]. Some of these SFKs such 
as LYN, FGR, HCK, LCK, BLK, are mainly expressed in hematopoietic cells, whereas 
SRC, FYN, YES are widely distributed in various cells of the body [67].  
Structure of SFKs is consists of four Src homology (SH) domains: SH1, SH2, 
SH3 and SH4 (Figure 6A) [68]. SFKs are highly conserved among the family members, 
with the exception of the N-terminal SH4 unique region (~50 residues) possessing the 
lipid modification [69, 70]. Lipid modification such as myristoylation occurs as a co-
translational modification, in which N-terminal methionine is removed and the resulting 
N-terminal glycine is myristoylated by myristoyl-coenzyme A. All members of the Src 
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family are co-translationally myristoylated, and with the exception of SRC and BLK, 
are also post-translationally palmitoylated (Figure 6B) [66]. Different state of 
palmitoylation regulates cellular localization and mechanism of cellular trafficking of 
the each SFKs. For instance, LYN and FYN, the crucial SFKs, promoting signaling 
from FcεRI, possess distinct state of palmitoylation. In contrast to mono-palmitoylated 
LYN which is transported to the plasma membrane via secretory pathway of Golgi, the 
dually-palmitoylated FYN is directly target to the plasma membrane [71], while SRC 
kinase is rapidly exchanged between late endosomes  or  lysosomes  and  the  plasma  
membrane due to myristoylation alone [72].  
 
 
Figure 6.  The Src family kinases (SFKs). (A) Domain organization of SFKs. (B) Amino acid 
alignments of  N-terminal unique domain, activation loop and C-terminal regulatory tail in SFKs. Adapted 
from [66]. 
Palmitoylation has been implicated in localization of SFKs in the cholesterol-
enriched membrane microdomains and recruitment of activated SFKs via 
transmembrane adaptor PAG/CBP to this microdomain leading to efficient suppression 
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of SFK-induce transforming potential of fibroblasts [73]. This poorly conserved domain 
is believed to provide unique functions and is specific to each SFK member [74].  
SFKs possess domains that mediate protein-protein, protein-lipid, and protein-
DNA interactions. The main function of SH3 domain (~60 residues) is regulation of its 
own kinase activity through an intermolecular interaction and direct binding to the 
specific adaptor proteins, many of which are also their substrates [68]. SH3 domain is 
able to bind proline-rich sequences of various signaling proteins, such as PI3K or CAS. 
The SH2 domain is compact domain of ~100 residues that binds phosphotyrosine 
residues in a sequence-specific manner. The SH1 domain corresponds to the kinase 
domain and contains the autophosphorylation site responsible for activation of SFKs. 
One of the hallmarks of the SFKs is their possession of two important regulatory 
tyrosine phosphorylation sites, which regulate kinase activity in opposite way. 
Phosphorylation of Tyr-527 (in human SRC), located in the carboxy-terminal tail, 
negatively regulate SFK activity, while phosphorylation of a second regulatory site Tyr-
416 (in human SRC), an autophosphorylation site present in the activation loop of SH1 
domain, leads to increase in enzymatic activity of SFKs.  
 
Figure 7. Mechanism of SFK activation. (A) Schematic models of inactive and active forms of c-Src 
(B) A predicted mechanism of SFK activation. Adapted from [66]. 
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The importance of phosphorylation sites is underscored by oncogenic v-SRC, 
which lacks the negative regulatory site Tyr-527, results in constitutive activation and 
uncontrolled growth of infected cells [75-77]. 
Structural similarities of SFKs allows for common mechanism of their regulation 
based on the phosphorylation of regulatory tyrosines (Tyr-527 and Tyr-416) and the 
intramolecular interactions among the SH2 and SH3 domains. Detailed mechanism of 
SFKs regulation was resolved by analysis of their crystal structure. As indicated in 
Figure 7, in resting cells, the SFKs are mostly in inactive conformation and Tyr-527 is 
phosphorylated. This closed conformation is stabilized by binding of phosphorylated 
Tyr-527 to its own SH2 domain and by the simultaneous binding of SH2 linker to the 
SH3 domain. Both intramolecular interaction affect the configuration of catalytic pocket 
leading to disruption of Mg-ATP binding site [66]. Dephosphorylation of Tyr-527 leads 
to conformational changes in the SH2 and kinase domain resulting in trans-
autophosphorylation of Tyr-416 in the activation loop. This autophosphorylation events 
keep catalytic domain in active conformation and facilitates access of the substrates to 
the active site [66]. 
Molecular mechanism of SFKs activation may vary depending on cell types, but 
in general, is achieved by following events: Firstly, activated receptor or adaptor or 
effector molecule interact with SH2/SH3 domains of inactive SFKs leading to open up 
conformation and keeping SFKs in appropriate cellular localization. Next, 
phosphorylated tyrosine 527 (pTyr-527) is dephosphorylated by protein tyrosine 
phosphatase, whereby stabilize active conformation of SFKs. Then, activated SFKs 
undergo intermolecular auto-phosphorylation on Tyr-416 and thus achieved fully active 
conformation, which in turn phosphorylate substrate proteins and at the same time create 
binding site for another SFKs. This events represent a positive-feedback loop of SFKs 
activation [66]. 
4.3.4 Regulation of SFKs 
4.3.4.1 C-terminal Src kinase 
CSK is a negative regulator of the SFKs that play pivotal role in various cell 
signaling [78]. Key function of CSK is specific phosphorylation of tyrosine residues 
located in the C-terminal tails of SFKs (Tyr-527), thereby inducing an intramolecular 
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interaction between the C-terminal phosphotyrosine and the SH2 domain and allows 
them to fold in an inactive conformation (Figure 7). This interaction renders the catalytic 
domain of SFKs inaccessible to substrates [79-81].  
The negative regulatory role and indispensableness of CSK was demonstrated in 
vivo by mice deficient in CSK. These mutant embryos died in early embryonic stages 
and embryonic tissue exhibited constitutively phosphorylated SFKs [82]. Loss of CSK 
induced defects in T cell development [83], hyperplasia of epidermis [84], acute 
inflammation of the skin and lungs, adhesiveness and chemotaxis [85]. Granulocytes 
isolated from these mice exhibit increase in both spontaneous and ligand-induced 
degranulation and production of TNF-α [85]. In rat basophil leukemia cells (RBL) with 
overexpressed CSK were observed decreased in LYN kinase activity at the resting cells 
suggested that CSK negatively regulates FcɛRI-mediated signaling [86].  
CSK is highly conserve across the animal kingdom and possess similar primary 
structure of SH2 and SH3 functional domains with SFKs. But differ from the structure 
of SFKs in several striking features: the absence of autophosphorylation site in the 
activation loop as well as absence of inhibitory tyrosine residue close to C-terminal tail, 
N-terminal fatty acid modification and the different orientation of SH2 and SH3 domain, 
enabling interaction with others molecules. Because of the lack of transmembrane 
domain, CSK is localized predominantly in cytoplasm, whereas its substrate SFKs are 
anchored to the membrane via N-terminal myristoylation and/or palmitoylation 
moieties. Thus, recruitment of cytosolic CSK to the membrane-associated SFKs is 
crucial for its regulatory function.  
An important regulator of CSK function is a transmembrane adaptor protein 
PAG, which specifically binds the CSK SH2 domain when phosphorylated. PAG 
anchored to lipid rafts recruits CSK to lipid raft-associated SFKs, mediates a link to 
actin cytoskeleton and interacts with several other important cytoplasmic and plasma 
membrane-associated proteins (Figure 8) [57]. Further, CSK also associates through its 
SH3 domain with the protein tyrosine phosphatase PTP-PEST and lymphoid-tyrosine 
phosphatase LYP (mouse orthologue PEP). As these phosphatases dephosphorylate the 
positive regulatory tyrosine residue in Src family kinases, it is thought that they 





Figure 8. Model of negative regulation loop in SFK signaling mediated by PAG-CSK. PAG present 
in lipid rafts can associate with and become phosphorylated by SFKs (1). Phosphorylation of PAG creates 
docking sites for SH2 domains of SFKs and their negative regulator CSK. CSK bound to PAG then 
phosphorylates the inhibitory tyrosine residue at the C termini of SFKs (2) and inactivates them. Adapted 
from [57]. 
Accumulating evidence suggest that CSK may play role in tumor suppression by 
inhibiting the oncogenic activity of SFKs. Indeed, overexpression of CSK can inhibit 
tumor growth of human colon cancer cells [87]. However, there is no convincing 
evidence that supports the direct involvement of CSK in human cancer. Although CSK 
is downregulated in some cancers, it is likely that CSK is expressed at normal levels in 
many types of cancer cells, and there have been no reports of somatic mutation in the 
csk gene, as well as mutation in SFKs genes has not been detected. Therefore, molecular 
mechanism underlying the causes of SFKs dysregulation in various diseases remain 
unclear [66]. 
4.3.4.2 Phosphatases 
Although the CSK has been consider as a major negative regulator of SFKs, the 
little is known about precise protein tyrosine phosphatases (PTPs) responsibility to 
dephosphorylate activation loop or C-terminal inhibitory site of the SFKs, although 
numerous have been involved in this processes [68]. In FcεRI-mediated activation of 
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mast cells and basophils, the protein tyrosine phosphorylation is critical early signaling 
events reflects the balance between the action of PTKs and PTPs.  
One of the extensively studied PTPs involved in mast cell signaling are Src 
homology 2 (SH2) domain-containing nonreceptor phosphatases SHP-1. SHP-1 is a 
cytoplasmic PTPs expressed in hematopoietic and epithelial cells [88-90]. The major 
function of SHP-1 is to limit extend of activation and cellular response by 
dephosphorylation its target molecules. SHP-1 is generally considered as a negative 
regulator of various immuno-receptor mediated signaling, including TCR-, B cell 
receptor, (BCR-) , FcɛRI-, c-KIT- and IL3R- mediated signaling [91-93].  
Mice with the recessive motheaten or allelic viable motheaten mutations suffer 
from severe autoimmune diseases. Mice homozygous for these mutations do not 
expressed any SHP-1 or expressed catalytic inactive form of SHP-1, which results in 
autoantibody production with early mortality due to pneumonitis and inflammatory 
lesion found in various organs. In contrast, heterozygous mice live longer and exhibits 
an increased incident of lymphoma development with minimal symptoms of 
autoimmune disease. Using bone marrow-mast cells isolated from motheatean mice was 
shown, that SHP-1 plays a negative regulatory role in FcεRI-induced activation of 
mitogen-activated protein kinases (MAPKs), cytokine gene transcription and 
production of cytokines, whereas the phosphorylation of phospholipase C, calcium 
mobilization and degranulation are positively regulated by SHP-1 [94]. Moreover, SHP-
1-defficient mice exhibit enhanced ovalbumin-induced airway inflammation and 
anaphylactic response including hypothermia. This data suggest a direct role of SHP-1 
in regulating Th2 immune response in the lung and inhibitory role in regulation of 
allergic inflammation and allergen-induced anaphylaxis in mice [95, 96]. However, 
there is inconsistent report investigated rat basophil leukemia cells, where function of 
SHP-1 seems to be rather a positive regulator of TNF-α production via JNK activation, 
although in vivo studies shows the opposite effect. SHP-1 expressed in mast cells 
interacts with ITAMs of FcɛRI β and γ subunits, SYK kinase, SLP-76-related adaptors, 
VAV and PI3´kinase [97-101].  
In humans, reduced expression of SHP-1 is associated with some leukemia and 
lymphoma cell lines, due to inability of SHP-1 antagonized activity of transcription 
factor STAT5 which becomes hyperphosphorylated. This raises the question about the 
molecular mechanism and exact role of SHP-1 and STAT5 in the pathogenesis of 
leukemia. Studies on phospholipase Cβ3 knockout (PLCβ3-KO) mice, which suffer 
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with chronic myelomonocytic leukemia (CMML)-like disease shows, that PLCβ3 
functions as a scaffolding protein for STAT5 and SHP-1 molecules and thus allows 
SHP-1 dephosphorylates and inactivates STAT5 [1, 102]. In mast cells, function of 
PLCβ3-SHP-1-STAT5 signalosome was studied in respect with FcɛRI-dependent 
immune response. It was shown, that PLCβ3-KO mice exhibits mast cell dependent late-
phase, but not acute, anaphylactic reaction accompanied by elevated cytokine 
production, but normal degranulation. Molecular mechanism of this events based on 
abrogated phosphorylation of SHP-1 at Y536 and Y564, resulting in constitutive 
activation of STAT5. Furthermore, LYN kinase, the only one member of SFKs 
possessing KTIM motive, which is recognized by SHP-1 [103], was identified as an 
indispensable kinase for maximal SHP-1 phosphatase activity [104]. 
 Activation signals in mast cells are strictly counterbalanced by another negative 
signaling molecules such as SHIP1. SHIP1 (SH2-containing inositol polyphosphate 5´- 
phosphatase specific for hematopoietic cells) is a lipid phosphatase playing crucial role 
in mast cells, B cells and macrophages signaling [105]. In mast cells, SHIP1 is well 
known as a master negative regulator of degranulation and cytokines production through 
FcɛRI-mediated activation. This is attributed to its ability to hydrolyze the 5´phosphate 
of PIP3, a second messenger generated in activated cells by PI3K. SHIP1 binds via its 
SH2 domain to the tyrosine phosphorylated ITIM of FcγRII. B cells deficient in SHIP-
1 were enhanced antigen receptor activation, elicited calcium fluxes and activation ERK 
and AKT pathway [106].  
Phosphatases play an important role not only in setting activation threshold of 
mast cells by removal of aggregated FcɛRI but also in the regulation of several signal 
transduction molecules. Numerous PTPs have recently been found in mast cell signaling 
and may explain some of the pending questions in mast cell signaling [104].  
 
4.4 FcɛRI-MEDIATED SIGNALING PATHWAYS 
4.4.1 Initiation of FcɛRI signaling  
In mast cell, LYN the major SFK, is involved in the initial stages of FcεRI-
mediated signaling. Several model have been proposed to explain mechanistically how 
the FcεRI becomes phosphorylated by LYN (Figure 9). The first, transphosphorylation 
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model assumes, that in resting cells non-phosphorylated FcεRI β subunits is non-
covalently associate with LYN which is unable phosphorylate its carrier receptor. 
Aggregation of the IgE-FcεRI complexes with multivalent antigen initiates LYN-
dependent phosphorylation of the neighboring receptor within the aggregate. This 
process is called transphosphorylation. This model was supported by several 
experimental finding [107-110], however, in conflict with this theory was shown, that 
aggregated FcεRI is becomes phosphorylated, even in the absence of β subunits [111] 
and next, that chimeric receptor possess only γ subunit of the FcεRI becomes 
phosphorylated upon activation [112]. Therefore, the next model takes into consider the 
observation that biological membranes are composed of microdomains having a lipidic 
cholesterol- and sphingomyelin-rich structure with the presence of limited set of 
proteins. 
 
Figure 9. Models of FcεRI phosphorylation. Transphosphorylation model presumes that active Lyn is 
constitutively associated with non-phosphorylated FcεRI; upon FcεRI aggregation, Lyn phosphorylates 
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adjacent receptors in the aggregate. Lipid raft model postulates that FcεRI and Lyn are localized in 
different plasma membrane microdomains; after aggregation FcεRI is translocated to lipid rafts where it 
is phosphorylated by lipid raft-associated Lyn kinase. PTK–PTP interplay model assumes that PTPs set 
the threshold of FcεRI tyrosine phosphorylation; after FcεRI triggering there is a shift in the PTK–PTP 
steady state in favor of PTKs Adapted from [113]. 
In this lipid raft model was postulated that FcεRI in resting cells is physically separated 
from active LYN kinase present in lipid raft domains. After aggregation, the FcεRI 
translocated to the lipid raft microdomain and then LYN associates with its β subunits, 
which in turn leads to the receptor phosphorylation. In attempt to explain some 
conflicting experimental data of lipid raft model, the third PTK-PTPs-interplay model 
was postulated. This model raised from experimental data on B cells, where extent of 
immunoreceptor phosphorylation is not depend only on PTKs but, at least,  partly also 
on the activity of PTPs [113].  
4.4.2 Signaling pathways leading to degranulation  
Cross-linking of the IgE-FcεRI complexes by multivalent antigen result in 
phosphorylation of the immunoreceptor tyrosine-based motifs (ITAMs) in the 
cytoplasmic tails of the FcεRI β and γ subunits by LYN kinase. When phosphorylated, 
ITAM of β and γ subunits provide high-affinity docking site for binding another 
molecules of LYN and SYK through their Src homology SH2 domains. SYK upon 
binding to receptor changed its conformation to active and became phosphorylated by 
LYN. As shown in Figure 10, SYK and LYN then phosphorylated several targets 
molecules, including adaptor proteins LAT and NTAL, which is crucial for coordination 
of the downstream signal pathways that are required for calcium release, degranulation 
and activation of transcription factors. Phosphorylated LAT serve as a direct binding 
partners for various signaling molecules possessing SH2-binding domain, including 
PLCγ, GRB2, GADS, and SHIP1. Activated PLCγ then catalyze hydrolysis of the 
membrane phosphatidylinositol-4,5-bisphosphate to generate two second messengers, 
soluble inositol-1,4,5-trisphosphate and the membrane bound diacylglycerol, which 
induced intracellular calcium mobilization and protein kinase C (PKC) activation, 
respectively. Formation of GRB2-SOS-VAV signalosomes is accompanied by 
activation of the small GTPases, Ras, Rac, Rho and ERK that control activation of 
transcription factors.  Studies carried out in mast cells isolated from LAT-KO mice 
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showed decreased calcium mobilization, degranulation and production of transcription 
factors due impaired LAT-regulated PLCγ activation [50]. However, LAT deficiency in 
T cells results in absolutely impaired immunoreceptor signaling, in mast cells was still 
observable residual calcium mobilization, degranulation and cytokine production. This 
residual signal is based on NTAL-dependent signalization which partially compensate 
loss of LAT. On the other hand, NTAL possess tyrosines which are directly 
phosphorylated by LYN and as well as by SYK. In contrast to LAT, NTAL did not 
possess direct binding site for PLCγ, however could modulate calcium signaling 
indirectly via PI3 signaling pathway. When NTAL is missing, LAT becomes more 
phosphorylated, which results in enhanced binding of PLCγ and activation of various 




Figure 10. FcεRI-mediated signaling events in WT mast cells. Downstream signaling pathway in 
antigen-mediated signaling include activation of SFKs, such as LYN and SYK, which phosphorylates 
adaptor proteins LAT and NTAL. Phosphorylated LAT directly binds PLCγ and GADS, which formed 
complex with SLP-76 and VAV. On the other hand, NTAL binds GRB2 and several another signaling 
molecules with exception of PLCγ. These events regulate complex signaling networks leading to calcium 
mobilization, degranulation and activation of transcription factors [50].  
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NTAL-KO cells exhibited enhanced phosphorylation of LAT, PLCγ1, PLCγ2, 
extracellular signal-regulated kinase (ERK), calcium mobilization, degranulation, and 
cytokines production. Interestingly, mast cells lacking both LAT and NTAL exhibited 
a stronger block in FcεRI signaling than LAT-KO mast cells, demonstrating that NTAL 
could play both positive and negative roles in FcεRI signaling [114, 115]. 
4.4.3 Signaling pathways leading to cytokine production  
Cross-linking of the IgE-FcεRI complexes by multivalent antigen leads to 
activation of numerous PTKs, PTPs, adaptor proteins and other signaling molecules 
results in the formation of a macromolecular signaling complexes, which allows the 
diversification of downstream signaling that is required for the production of the 
numerous pro-inflammatory mediators. As in degranulation, production of cytokines is 
reduced in mast cells with LAT-KO, however the exact mechanism that leads from LAT 
to cytokine production has been less defined as in degranulation.  It was reported, that 
gene expression and production of cytokines and eicosanoids, including LTC4 and 
PGD2, initiate by activation of VAV and SOS follows the activation of RAS, which 
positively regulates RAF signaling pathway and subsequently activate ERK1, ERK2, 
JNK, and P38 [52]. These molecules, in turn, activates various transcription factors, 
including activator protein 1 (AP1), FOS and JUN, nuclear factor of activated T cells 
(NFAT) and nuclear factor-κB (NF-κB). This pathway is directed by PLCγ-dependent 
calcium signalization.  In this connection, parallel signaling pathway initialize by 
activation of PI3K and AKT is involved in regulation of cytokine production. AKT 
positively regulates the function of transcription factor NF-κB by phosphorylating 
inhibitor of NF-κB (IκB) [116]. However, exact mechanism of activation specific 
signaling factors for cytokine gene expression require further study. Another recent mast 
cells study showed, that PLCβ3 can form multimolecular complex together with SHP-1 
and STAT5 and in LYN-dependent manner regulate cytokines production, but 
interestingly, not degranulation [102, 104]. In mast cell, STAT5 pathway could be 
positively regulated by FYN kinase after FcɛRI engagement which leads to selectively 
dependent production of cytokines via STAT5B, but not through STAT5A isoform 
[117].    
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4.4.4 Signaling pathways leading to chemotaxis 
The crucial signal for mast cells progenitors homing and mature mast cell 
recruitment into peripheral tissue where the inflammation takes place is directed by 
several chemical compounds named chemoattractant [118]. A potent mast cell 
chemoattractant acting in autocrine/paracrine fashion is antigen, which binds to IgE 




Figure 11. FcεRI-mediated chemotaxis. Adapted from [39]. 
Antigen-induced chemotaxis is initialized by aggregation of the FcεRI by 
multivalent antigen. This leads to rapid Lyn kinase-mediated phosphorylation of 
tyrosine residues in ITAM motifs of the FcεRI β and γ subunits and is followed by 
anchoring of SYK to FcεRI γ through interaction of SYK SH2 domains with 
phosphorylated ITAMs. SYK then phosphorylates transmembrane adaptor proteins 
NTAL and LAT and creates binding sites for various SH2-containing proteins like 
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GRB2. In this way it brings PI3K and GAB2 to the plasma membrane. Activated PI3K 
generates PIP3, a binding site for PH-domain containing protein BTK [119].  
This leads to further propagation of the signal through activation of PLCγ, 
resulting in Ca2+ release and actin rearrangement. Levels of free intracellular Ca2+ are 
positively regulated by aggregated STIM1. Another PI3K-dependent pathway 
contributes to activation of p38 and consequently to enhanced chemotactic response. 
GRB2 orchestrates activation of Ras by recruiting small GTPases Ras and Rho family, 
SOS, VAV, and other signaling molecules, resulting in actin rearrangement and 
chemotaxis. NTAL could play a negative regulatory role in chemotaxis through 
activation of Rho/ROCK pathway that is responsible for controlling cell migration. 
ROCK could also activate the PTEN phosphatase which inhibits activity of PI3K and in 




5 AIMS  
The aim of this thesis was to contribute to deeper understanding, in molecular 
terms, of the FcεRI-mediated signaling pathways leading to mast cell activation, 
degranulation and cytokines production. Particularly, we aimed to comprehend the role 
of PAG and CSK at the earliest stages of mast cell activation and their impact on 
inflammation and/or anaphylaxis. The second challenge of this thesis was to investigate 
the role of selected proteins (ORMDL3, CD9) or chemical compounds on mast cell 
activation in vitro as well as in vivo. Integral part of these studies, at initial period, was 
to develop a new method for simplified and sensitive detection of biologically important 
molecules, and use this method subsequently through these studies.  
  
The specific objectives of this thesis were:  
 
1. To determine the role of PAG in production of cytokines in activated mast 
cells in vitro and in vivo 
a. To determine the role of PAG in production of TNF-α, IL-13 and IL-6 
b. To quantify the level of IgE in serum of PAG-KO mice 
 
 2. To determine the regulatory roles of CSK in antigen-induced mast cell 
signaling 
a. To produce BMMCs with CSK-KD or CSK-OE  
b. To determine the role of CSK in FcεRI-mediated degranulation 
c. To elucidate the role of CSK in FcεRI -mediated Ca2+ response 
d. To determine the role of CSK in FcεRI -mediated production of 
proinflammatory cytokines and chemokines 
e. To examine the role of CSK in internalization of Ag-IgE-FcεRI complexes 
f. To elucidate the role of CSK in chemotaxis and adhesion on fibronectin  
g. To determine the role of CSK in FcεRI -induced tyrosine phosphorylation 
of early signaling proteins 




3. To contribute to understanding of the role of ORMDL3 in FcεRI-mediated 
activation 
a. To prepare BMMCs with ORMDL3-KD using short hairpin (sh)RNA 
lentiviral strategy 
b. To produce ORMDL3-myc constructs for generation of ORMDL-OE 
c. To determine the role of ORMDL3 in production of proinflammatory 
cytokines 
 
4. To contribute to understanding the role of FcεRI-cholesterol signalosome 
under in vivo conditions 
To determine effect of ethanol on FcεRI-mediated degranulation under 
in vivo conditions using PCA 
 
5. To contribute to understanding the role of CD9 in FcεRI-mediated 
activation 
a. To purify a CD9-specific monoclonal antibody (mAb)  
b. To prepare BMMCs with CD9-KD using shRNA lentiviral strategy 
 
6. To develop a new method for detection of cytokines and other proteins in 
complex biological samples  
a. To find conditions for production of gold nanoparticles functionalized with 
antibodies and oligonucleotides and to set the protocols for sensitive 
detection of various proteins  
b. To compare the sensitivity of newly developed gold nanoparticle-based-
iPCR (nano-iPCR) with standard enzyme-linked immuno-sorbent assays 
(ELISAs) and immuno-PCR (iPCR). 
c. To verify the nano-iPCR for detection of biologically important proteins, 









6 SUMMARY OF METHODS 
All methods used to solve the particular aims of this study are described in more 
details in the Materials and Methods section of the relevant publications (Chapter 7).  
 
BMMCs generation and cultivation 
Bone marrow cells were isolated from the femurs and tibias of 6- to 8-week-old PAG-
KO mice or their WT littermates. Cells were cultured in RPMI 1640 medium 
supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, 71 μM 2-
mercaptoethanol, minimum essential medium (MEM) nonessential amino acids, 0.7 
mM sodium pyruvate, 2.5 mM l-glutamine, 12 mM d-glucose, recombinant mouse SCF 
(15 ng/ml), mouse recombinant IL-3  (15 ng/ml), and 10% fetal bovine serum. In some 
experiments 5% WEHI supernatant and 5% CHO supernatant were used insted of 
recombinant proteins. 
 
BMMCs sensitization and activation 
BMMCs were cultured for 48 h in medium without SCF (only for PAG study), followed 
by incubation for 4-12 h in SCF- and IL-3-free medium supplemented with IgE (1 
μg/ml). Sensitized cells were washed in buffered salt solution (BSS; 20 mM HEPES, 
pH 7.4, 135 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 5.6 mM glucose, 1 mM MgCl2, 0.1% 
BSA). 
 
Degranulation (β-glucuronidase) assay 
To quantify degranulation, the cells (0.2 × 106) in 30-μl aliquots were transferred into 
the wells of a 96-well plate and challenged with 30 μl of antigen, thapsigargin, or SCF 
at the various concentrations. Degree of degranulation was quantified as amount of β-
glucuronidase released into the supernatant. Briefly, 40-μl aliquots of the cell 
supernatants were mixed in white wells of a 96-well plate (Nunc) with 40 μl of β-
glucuronidase substrate (40 μM 4-methylumbelliferyl-β-d-glucuronide hydrate). After 
incubation, the reaction was stopped by adding 0.2 M glycine buffer, pH 10.0, and 
fluorescence was determined in an Infinite M200 microtiter plate reader (Tecan) with 
355-nm excitation and 460-nm emission filters. The total content of the enzyme in the 
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cells was evaluated by measuring the levels of enzyme in the supernatant from cells 
lysed in 1% Triton X-100. 
 
Calcium release assay 
Calcium response was analyzed in IgE-sensitized BMMCs using Fura-2-AM 
cytoplasmic reporter. Levels of intracellular Ca2+ were determined by 
spectrofluorometry using the Infinite 200 M plate reader with excitation wavelengths at 
340 and 380 nm and with a constant emission at 510 nm. 
 
Cell adhesion 
Adhesion to fibronectin was quantified in 96-well plates coated overnight with 
fibronectin (10 µg/ml in PBS), blocked with 4% BSA in PBS and washed twice with 
PBS. IgE-sensitized BMMCs were loaded with Calcein-AM  for 30 min at 37°C, washed 
and transferred into the fibronectin-coated wells. After activation with antigen or SCF, 
unbound cells were washed out using microplate washer (HydroSpeed, TECAN) and 
bound cells were determined using an Infinite 200M Fluorimeter with excitation and 
emission filters at 485 nm and 538 nm, respectively. 
 
Flow cytometry 
To quantify the surface expression of FcɛRI and c-KIT, BMMCs were double-stained 
with anti-mouse FcɛRI-FITC and anti-mouse c-KIT-allophycocyanin antibodies for 30 
min on ice. After labeling, the cells were washed with ice-cold PBS and analyzed with 
an LSRII flow cytometer and further processed using FlowJo software. For analysis of 
surface LAMP1, BMMCs were activated or not with various concentrations of antigen. 
Activation was stopped by centrifugation at 4°C. The cells were then resuspended in 
PBS-1% BSA containing 200-fold-diluted V450-conjugated rat anti-mouse CD107a 
and stained on ice for 30 min. To analyze IgE internalization, IgE-sensitized cells were 
activated with antigen and fixed by 4% paraformaldehyde. IgE was stained using 




Whole-cell extracts from nonactivated or Ag-activated BMMCs were prepared by 
solubilizing of cell pelletes in sodium dodecyl sulphate (SDS) sample buffer, followed 
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by sonication and boiling. Proteins were size fractionated on 10% SDS-polyacrylamide 
(PAGE) gel electrophoresis, electrophoretically transferred onto nitrocellulose 
membrane, and analyzed by immunoblotting with protein- or phosphoprotein-specific 
antibodies and detected with HRP-conjugated secondary antibodies. The HRP signal 
was detected with chemiluminescence reagent and quantified by a Luminescent Image 
Analyzer LAS 3000. Aida software was used for signal quantification. Protein levels 
were normalized to the corresponding controls and/or GRB2 loading control protein 
after stripping of the membrane in stripping buffer. 
  
Immunoprecipitation 
For FcεRI immunoprecipitation, cells were solubilized in ice-cold immunoprecipitation 
buffer supplemented with 0.2% Triton X-100. After incubation on ice for 30 min, the 
lysates were centrifuged and postnuclear supernatants were immunoprecipitated with 
rabbit anti-IgE antibody prebound to UltraLink-immobilized protein A. The 
immunoprecipitated proteins were size-fractionated by SDS-PAGE as described above, 
transferred to nitrocellulose membrane and immunoblotted with phosphotyrosine-
specific mAb PY20 conjugate or with FcεRI-β chain-specific antibody followed by 
HRP-conjugated anti-mouse IgG. 
 
Cloning 
Several mammalian expression vectors were prepared in the course of these studies 
using standard cloning techniques. cDNA of proteins of interest were purchase from 
various vendors or were kindly provided by other researchers from Institute of 
Molecular Genetics in Prague. cDNA containing mCherry or myc-tag was then inserted 
into pCDH-based lentiviral vectors. All constructs were verified by sequencing. 
 
Lentiviral vectors and gene transduction 
Lentiviral transductions were done using HEK 293 T/17 packaging cells for virus 
preparation. A set of four murine CSK-specific shRNAs constructs based on pLKO.1 
vector were purchased from Open Biosystems. Cells were transduced with individual 
shRNAs or with a pool of shRNAs prepared by mixing shRNAs in equimolar ratios. 
Individual constructs or pool of the constructs (14 µg) was mixed with OptiMEM, 21 
µl of lentiviral packaging mix (Invitrogen), and 105 µl polyethyleneimine. Then, 
supernatant containing virus was collected in 48h and 72h of HEK 293 T/17 cultivation, 
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filtered in 0.2 membranes, and added to BMMCs. Positive selection of BMMCs were 
achieved by incubation with 4µg/ml puromicin.  
 
Detection of cytokines by Nano-iPCR 
Briefly, anti-TNF-α, anti-IL-6, or anti-IL-13 in 100 mM borate buffer (pH 9.5) was 
dispensed in 50-μl aliquots into the wells of a real-time PCR 96-well plate. After 
overnight incubation at 4°C, each well was washed and the remaining binding sites were 
blocked by 2 h of incubation at 37°C with TBST supplemented with 2% BSA. After 
washing, serial dilutions of recombinant TNF-α, IL-6, or IL-13 (used for construction 
of calibration curves) or the tested samples diluted in PBS–1% BSA was added. The 
samples were incubated for 1 h at 37°C, and after washing with TBST, 50 μl of Au-NPs 
armed with thiolated DNA oligonucleotide template and with the corresponding 
cytokine-specific antibody was applied into each well. Fifty-microliter aliquots of qPCR 
master mix solution supplemented with the corresponding oligonucleotide primers were 
then dispensed into each well. The plates were sealed, and the amount of template DNA 
bound to antigen-anchored functionalized gold nanoparticles was evaluated by real-time 
PCR. For calculation of cytokines concentrations, the corresponding Ct values of the 
cytokines were substituted into the regression equations obtained from the calibration 
curves constructed from the concentration series of appropriate recombinant proteins. 
 
Detection of cytokines and α-tubulin by iPCR 
Twenty-five microliter aliquots of capture anti-tubulin antibody DM1A (5 μg/ml) in 100 
mM borate buffer (pH 9.5) were dispensed into each well of TopYield strips. The wells 
were incubated for 2 h at 37 °C and washed with TBST. Free binding sites were blocked 
with BSA/TBS. After 2 h at 37 °C, the strips were washed, followed by adding of 
standards or tested samples diluted in 1% BSA in PBS. The strips were further incubated 
for 1 h at 37 °C and then overnight at 4 °C, followed by four washings. Subsequently, 
25 μl aliquots of biotinylated anti-tubulin antibody TU-07 (1 μg/ml in TBS–1% BSA) 
were added and the samples were incubated for 1 h at 37 °C. After washing, the wells 
were filled with extravidin (0.1 μg/ml) in TBS–1% BSA, incubated for 1 h at 37 °C and 
then washed as before. The next step consists in the addition of 25 μl of biotinylated 
DNA template (0.27 pg/ml). The strips were then incubated for 1 h at 37 °C followed 
by washing with TBST and with MilliQ water. Template DNA immobilized on antigen 




Detection of SCF and IL-3 by ELISA 
Wells of the TopYield or NUNC strips were coated with Ag-specific polyclonal 
antibody, blocked with TPBS-2% BSA and then mixed with antigen as described above 
for iPCR. The wells were then washed with TPBS, followed by addition of biotinylated 
antibody (1 μg/ml, in TPBS-1% BSA), incubation for 1 h at 37 °C and washing with 
TPBS. One hundred microliters of streptavidin-horseradish peroxidase (HRP) conjugate 
was then added. After incubation for 1 h at 37 °C the wells were washed with TPBS. 
Finally, 100 μl PBS containing o-phenylenediamine (OPD) and H2O2 (0.015%) was 
dispensed into each well. After 10 min at 37 °C, the reaction was stopped by adding 100 
μl of H2SO4 (4 M). The absorbance was determined at 492 nm using Infinite M200 plate 
reader. 
 
Detection of IgE in mouse serum by ELISA 
96-wells plate were coated with rat antibody specific for mouse IgE (1 μg/ml in PBS). 
Wells were washed and blocked by TBST–2% BSA. After 2 h, the plates were washed 
and incubated with various concentrations of mouse IgE standard or mouse serum 
samples. Then, the wells were washed and the captured IgE was detected with 
biotinylated rat anti-mouse IgE antibody (2 μg/ml in PBS–1% BSA), then washed, and 
incubated for 30 min with streptavidin-HRP conjugate. Peroxidase substrate solution 
was used for colorimetric reaction. The reaction was stopped by adding 4 M H2SO4, and 
the absorbance at 492 nm was determined using an Infinite M200 plate reader (Tecan). 
 
PCA 
Mice were anesthetized by intraperitoneal injection of a cocktail containing ketamine 
xylazine and atropine and then sensitized by intradermal injection of anti-TNP-specific 
IgE in PBS into the left ear; the right ear was injected with PBS alone. Twenty-four 
hours later, dilution series of ethanol in PBS was injected intraperitoneally (0.5 ml per 
mouse weighing 20 g). One hour after ethanol in PBS or PBS alone injection, each 
mouse was challenged with an intravenous injection of antigen containing 1% Evans 
blue. The mice were sacrificed 30 min later and their ears were removed for 
measurement of the amount of the Evans blue extravasated. The dye was extracted from 
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Transmembrane Adaptor Protein PAG/CBP Is Involved in both
Positive and Negative Regulation of Mast Cell Signaling
Lubica Draberova,a Viktor Bugajev,a Lucie Potuckova,a Ivana Halova,a Monika Bambouskova,a Iva Polakovicova,a Ramnik J. Xavier,b,c
Brian Seed,b Petr Drabera
Department of Signal Transduction, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republica; Center for Computational and
Integrative Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USAb; Broad Institute of Harvard University and Massachusetts
Institute of Technology, Cambridge, Massachusetts, USAc
The transmembrane adaptor protein PAG/CBP (here, PAG) is expressed in multiple cell types. Tyrosine-phosphorylated PAG
serves as an anchor for C-terminal SRC kinase, an inhibitor of SRC-family kinases. The role of PAG as a negative regulator of
immunoreceptor signaling has been examined in several model systems, but no functions in vivo have been determined. Here,
we examined the activation of bone marrow-derived mast cells (BMMCs) with PAG knockout and PAG knockdown and the cor-
responding controls. Our data show that PAG-deficient BMMCs exhibit impaired antigen-induced degranulation, extracellular
calcium uptake, tyrosine phosphorylation of several key signaling proteins (including the high-affinity IgE receptor subunits,
spleen tyrosine kinase, and phospholipase C), production of several cytokines and chemokines, and chemotaxis. The enzymatic
activities of the LYN and FYN kinases were increased in nonactivated cells, suggesting the involvement of a LYN- and/or a FYN-
dependent negative regulatory loop. When BMMCs from PAG-knockout mice were activated via the KIT receptor, enhanced
degranulation and tyrosine phosphorylation of the receptor were observed. In vivo experiments showed that PAG is a positive
regulator of passive systemic anaphylaxis. The combined data indicate that PAG can function as both a positive and a negative
regulator of mast cell signaling, depending upon the signaling pathway involved.
Mast cells are widely distributed in the body, where they playimportant roles in innate as well as adaptive immune re-
sponses (1). To fulfill their role in adaptive immune responses, the
cells express the high-affinity IgE receptor FcεRI on their plasma
membranes. Aggregation of this tetrameric immunoreceptor,
2, induces cell signaling events leading to the release of pre-
formed inflammatory mediators and the de novo synthesis and
release of leukotrienes, cytokines, and chemokines. The first well-
defined biochemical step after FcεRI triggering is tyrosine phos-
phorylation of the immunoreceptor tyrosine-based activation
motifs in the cytoplasmic tail of the FcεRI  and  subunits by the
SRC family protein tyrosine kinase (PTK) LYN (2, 3). The phos-
phorylated  and  subunits then serve as binding and activation
sites for LYN kinase and spleen tyrosine kinase (SYK), respec-
tively. These two enzymes, together with FYN and other kinases,
then phosphorylate various adaptor proteins and enzymes with a
variety of functions in signal transduction pathways. The exact
molecular events preceding LYN-mediated tyrosine phosphoryla-
tion of the FcεRI  subunit are not clear, and several models have
been proposed, including the transphosphorylation model (4),
the lipid raft model (5), and the PTK-protein tyrosine phospha-
tase (PTP) interplay model (6).
Our previous study with murine bone marrow-derived mast
cells (BMMCs) showed that FcεRI triggering induced transient
hyperphosphorylation of LYN kinase on its C-terminal regulatory
tyrosine (Tyr 487), leading to the formation of a closed inactive
conformation where the SRC homology 2 (SH2) domain interacts
with phospho-Tyr 487 and transiently decreases LYN enzymatic
activity (7). This finding was surprising because in T cells the
corresponding SRC family kinase (SFK), LCK, showed decreased
tyrosine phosphorylation of the C-terminal regulatory tyrosine
and enhanced enzymatic activity after activation through T cell
immunoreceptors (8, 9). Phosphorylation of the C-terminal in-
hibitory tyrosine in SFKs is catalyzed by the C-terminal SRC ki-
nase (CSK) (10), a cytoplasmic PTK that can be anchored through
its SH2 domain to PAG (11), also termed CBP (12). PAG/CBP
(here, PAG) is a ubiquitously expressed transmembrane adaptor
protein containing a short extracellular domain, a transmem-
brane domain, and a long cytoplasmic tail with multiple tyrosine-
based motifs. Phosphorylated Tyr 314 in mouse PAG has been
shown to be essential for CSK binding. PAG also possesses two
proline-rich sequences that serve as binding sites for proteins with
SH3 domains and a C-terminal VTRL motif for interaction with
the PDZ domain of the cytoskeletal linker ezrin/radixin/moesin-
binding protein of 50 kDa (13). Similar to some other transmem-
brane adaptor proteins, such as the non-T cell activation linker
and linker for activation of T cells (LAT), PAG has two conserved
cysteine residues, located in the vicinity of the transmembrane
domain, which are the subject of posttranslational palmitoylation
and which contribute to the poor solubility of the proteins in
nonionic detergents and their presumed localization in mem-
brane microdomains called lipid rafts (14, 15).
PAG in resting T cells associates with FYN kinase, which con-
stitutively phosphorylates PAG on Tyr 314 to create a docking site
for the CSK SH2 domain. This binding brings CSK to the vicinity
of its substrate, SFK LCK, and enhances CSK catalytic activity,
leading to phosphorylation of the LCK-inhibitory C-terminal ty-
rosine. Upon T cell receptor activation, PAG is rapidly dephospho-
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rylated, CSK is released from PAG, and LCK is dephosphoryla-
ted on its C-terminal tyrosine. This modification increases the
activity of LCK, leading to increased tyrosine phosphorylation of
T cell receptor subunits and other substrates. A negative regula-
tory role of PAG in T cell signaling was confirmed in experiments
with PAG knockdowns (KDs) (16) but not with PAG knockouts
(KOs) (17, 18), suggesting that developmental compensatory
mechanisms are involved.
In mast cells, PAG is phosphorylated by LYN kinase instead
of FYN kinase, and following FcεRI triggering, the decrease in
PAG phosphorylation is replaced by an increase (19, 20). Over-
expression of PAG has been reported to inhibit FcεRI-medi-
ated degranulation in rat basophilic leukemia (RBL) cells (21).
Further experiments showed that FcεRI activation of BMMCs
from LYN-deficient mice resulted in enhanced degranulation,
whereas FYN-deficient cells showed the opposite effect (22–
24). This finding supports the concept that SFKs are tightly
regulated in the course of mast cell activation and important
differences exist between early regulatory events induced by
engagement of the T cell receptors and FcεRI. The exact role of
PAG in mast cell activation remains to be determined.
Herein we present data on FcεRI-mediated activation events in
BMMCs derived from mice deficient in PAG (PAG-KO mice) and
from the corresponding wild-type (WT) mice (PAG-WT mice).
We also attempted to determine whether any differences in acti-
vation are detectable between BMMCs in which PAG is down-
regulated by RNA interference and the corresponding control
cells. Furthermore, we examined the role of PAG in cells activated
through another important mast cell surface receptor, KIT. The
combined data indicate that PAG functions as a positive or nega-
tive regulator of mast cell signaling and that the specific effect
depends on the particular signaling pathway. We also show that
PAG-deficient mice have a distinct phenotype in vivo, as assessed
by induction of a passive systemic anaphylaxis response.
MATERIALS AND METHODS
Mice and cells. Mice deficient in PAG were generated by use of a modified
bacterial artificial chromosome technology as previously described (25,
26). Briefly, the bacterial artificial chromosome clones were electropo-
rated into strain 129Sv/J embryonic stem cells. Targeting in clone 7 was
confirmed by fluorescence in situ hybridization. PAG-KO mice derived
from clone 7 were born in the expected Mendelian frequency and were
healthy. Transgenic founders were backcrossed to C57BL/6 mice for more
than eight generations. For experiments, PAG-KO mice were mated with
C57BL/6 mice, and their F1 descendants were genotyped by PCR using the
following primers: PAG 1 F (5=-GAC AGC ACA GGA AAG GCC AAG-
3=), PAG 2 R (5=-GTG TCC ACC GGT CCC TTC TG-3=), and PAG ZEO
R (5=-CCA GGG TGT TGT CCG GCA C-3=), giving PCR products of 498
and 390 bp for the WT and PAG-KO alleles, respectively. Bone marrow
cells were isolated from the femurs and tibias of 6- to 8-week-old PAG-KO
mice or their WT littermates (PAG-WT mice). All animal studies were
performed in compliance with the Guide for the Care and Use of Labora-
tory Animals (27) and were approved by the Animal Care and Usage Com-
mittee of the Institute of Molecular Genetics. Cells were cultured in RPMI
1640 medium supplemented with 100 U/ml penicillin, 100 g/ml strep-
tomycin, 71 M 2-mercaptoethanol, minimum essential medium
(MEM) nonessential amino acids, 0.7 mM sodium pyruvate, 2.5 mM
L-glutamine, 12 mM D-glucose, recombinant mouse stem cell factor (SCF;
20 ng/ml; PeproTech EC), mouse recombinant interleukin-3 (IL-3; 20
ng/ml; PeproTech EC), and 10% fetal calf serum (FCS).
Antibodies and reagents. The following monoclonal antibodies
(MAbs) were used: anti-LAT (28), anti-LYN (29), anti-FcεRI  chain
(30), trinitrophenol (TNP)-specific immunoglobulin E (IgE) (IGEL b4.1)
(31), and anti-hypoxanthine guanine phosphoribosyltransferase (anti-
HPRT; Santa Cruz Biotechnology Inc.). Antipaxillin was obtained from
BD Transduction Laboratories. Polyclonal antibodies specific for LYN
and LAT were prepared in the Department of Signal Transduction,
Prague, Czech Republic, by immunization of rabbits with the correspond-
ing recombinant proteins or their fragments (32). Rabbit anti-IgE was
prepared by immunization with whole IGEL b4.1. Polyclonal antibodies
specific for FYN, actin, phospholipase C 1 (PLC1), PLC2, GRB2, CSK,
KIT, STAT5, SHIP1, phospho-KIT (Y568/570), and phospho-focal adhe-
sion kinase (phospho-FAK; Y925), as well as horseradish peroxidase
(HRP)-conjugated donkey anti-goat IgG, goat anti-mouse IgG, and goat
anti-rabbit IgG, were obtained from Santa Cruz Biotechnology Inc. Anti-
bodies specific for phospho-SYK (Y525/Y526), phospho-STAT5 (Y694),
phospho-SH2-containing inositol 5=-phosphatase 1 (SHIP1; Y1020), and
the Myc tag were obtained from Cell Signaling. PAG-specific rabbit poly-
clonal antibody was from Exbio. HRP-conjugated antiphosphotyrosine
MAb (PY-20) was obtained from BD Biosciences. Antibodies specific for
tumor necrosis factor alpha (TNF-), IL-6, and IL-13 were purchased
from PeproTech EC. Anti-mouse FcεRI labeled with fluorescein isothio-
cyanate (FITC) and anti-mouse KIT–allophycocyanin (APC) conjugates
were obtained from eBiosciences. 45Ca (specific activity, 773 MBq/mg
Ca2) and [-32P]ATP (specific activity, 222 TBq/mmol) were purchased
from the Institute of Isotopes Co., Ltd. (Budapest, Hungary). A donkey
anti-rabbit IgG–Alexa Fluor 488 conjugate and thapsigargin were ob-
tained from Invitrogen. Mowiol 4-88 mounting solution was from Merck.
Colloidal gold nanoparticles (Au-NPs; diameter, 30 nm), consisting of
approximately 2  1011 Au-NPs/ml, were obtained from BBInterna-
tional. All other reagents were from Sigma-Aldrich.
Lentivirus shRNA constructs and cell transduction. A set of four
murine Pag1 (Swiss-Prot accession number Q3U1F9) short hairpin
(shRNA) constructs based on the pLKO.1 vector (TRCN0000124814
[shRNA14], TRCN0000124815 [shRNA15], TRCN0000124816 [shRNA16],
and TRCN0000124817 [shRNA17]) were obtained from Open Biosys-
tems. Each of the Pag1 shRNA constructs (14 g) was mixed with Opti-
MEM (1 ml; Invitrogen), 21 l of ViraPower lentiviral packaging mix
(Invitrogen), and 82 l of Lipofectamine 2000 (Invitrogen). The mixture
was homogenized by vortexing for 10 s and then incubated at room tem-
perature for 20 min before it was added to semiconfluent (70%) HEK-
293FT packaging cells growing in 20 ml of freshly added Dulbecco’s me-
dium supplemented with antibiotic and 10% FCS in 150-cm2 tissue
culture flasks. Three days later, the viruses in the culture supernatant were
concentrated by centrifugation at 25,000 rpm for 2 h using a JA-25.50
rotor (Beckman Coulter). The pellets were resuspended in 1 ml of culture
medium and added to 29 ml of culture medium containing 5  107
BMMCs. After 2 days, the medium was changed to virus-free medium and
the cells were cultured for an additional 2 days (recovery period). Stable
selection was achieved by culturing the transduced cells for 1 week in the
presence of puromycin (5 g/ml). Cells were pooled and analyzed for
PAG expression by immunoblotting. Cells with the highest reduction in
the amount of PAG, obtained with shRNA14 and shRNA15, were used for
further experiments. Cells transfected with empty pLKO.1 vector were
used as negative controls. For rescue experiments, mouse Pag1 cDNA
(RefSeq accession number BC145761; catalog number 40131064; Open
Biosystems) was amplified using forward primer 5=-AAAGAATTCGCCG
CCACCATGGGCCCTGCAGGAAGCGT-3= (the EcoRI restriction site is
underlined, the coding sequence is in bold) and reverse primer 5=-TTTG
TCGACGAGCCTGGTGACATCTCTGC-3= (the SalI restriction site is
underlined, the coding sequence is in bold). The amplified DNA was
cloned via the EcoRI and SalI restriction sites (upstream of Myc) into the
pFLAG-CMV-5a expression vector (Sigma-Aldrich) modified to express
the Myc tag (kindly provided by V. Korinek). The cassette encoding the
Myc-tagged Pag1 sequence was then amplified with the same forward
primer described above and reverse primer 5=-TTTGCGGCCGCTTACA
GGTCCTCCTCTGAGA-3= (the NotI restriction site is underlined, the
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coding sequence is in bold) and recloned via EcoRI and NotI restriction
sites into the pCDH-CMV-MCS-EF1-Puro expression lentivector
(pCDH; catalog number CD510B-1; System Biosciences). The construct
was verified by DNA sequencing. Viruses with pCDH-Pag-myc or empty
pCDH were produced as described above. Medium with virus (30 ml) was
filtered through a 0.22-m-pore-size filter and divided into two aliquots.
The first aliquot was used to transduce the WT or PAG-KO BMMCs at day
0. The second aliquot was preserved at 4°C and used for the second trans-
duction of the same cells at day 3. Stable selection was achieved by cultur-
ing the cells for 7 days in the presence of puromycin (2 g/ml), added 5
days after the first transduction.
Flow cytometry. To determine the surface expression of FcεRI, cells
were exposed to FITC-conjugated anti-FcεRI (1 g/ml). The samples
were evaluated by flow cytofluorometry using a FACSCalibur instrument
(BD Biosciences). For rescue experiments, cells were sensitized with TNP-
specific IgE for 20 h of incubation in culture medium without IL-3 and
SCF. Then they were washed and activated by antigen (TNP-bovine se-
rum albumin [BSA] conjugate; 15 to 25 mol of TNP/mol of BSA; 100
ng/ml) for 90 min and fixed in 4% paraformaldehyde for 10 min at 37°C.
The cells were washed once in phosphate-buffered saline (PBS), and free
binding sites were blocked with 5% normal donkey serum (Jackson Im-
munoResearch Laboratories) in PBS. After washing, the cells were incu-
bated for 45 min with anti-TNF antibody diluted 1:100 in PBS with 0.5%
BSA. After repeated washing, the cells were incubated for 30 min with a
secondary donkey anti-rabbit IgG–Alexa Fluor 488 antibody conjugate,
washed, and analyzed by flow cytometry using an LSR II flow cytometer
(Becton Dickinson). For analysis of peritoneal mast cells, mice were sac-
rificed and injected intraperitoneally with 5 ml of PBS supplemented with
1% FCS. The peritoneal cavity was gently massaged for 30 s, and the
injected PBS with free peritoneal fluid cells was withdrawn. One milliliter
of PBS with peritoneal cells was spun down (400  g, 5 min), and the cells
were washed in cold PBS and stained for FcεRI (as described above) or
KIT using the anti-mouse KIT–APC conjugate.
Cell activation. Before the experiments, BMMCs were cultured for 48
h in medium without SCF, followed by incubation for 12 to 16 h in SCF-
and IL-3-free medium supplemented with IgE (1 g/ml). Sensitized cells
were washed in buffered salt solution (BSS; 20 mM HEPES, pH 7.4, 135
mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 5.6 mM glucose, 1 mM MgCl2, 0.1%
BSA). To quantify degranulation, the cells (0.15  106) in 30-l aliquots
were transferred into the wells of a 96-well plate and challenged with 30 l
of antigen (TNP-BSA conjugate), thapsigargin, or SCF at the concentra-
tions indicated in Results. The degree of degranulation was determined as
the amount of -glucuronidase released into the supernatant, as de-
scribed previously (33). Briefly, 40-l aliquots of the cell supernatants
were mixed in white wells of a 96-well plate (Nunc) with 40 l of -gluc-
uronidase substrate (40 M 4-methylumbelliferyl--D-glucuronide hy-
drate). After incubation for 60 min at 37°C, the reaction was stopped by
adding 200 l of ice-cold 0.2 M glycine buffer, pH 10.0, and fluorescence
was determined in an Infinite M200 microtiter plate reader (Tecan) with
355-nm excitation and 460-nm emission filters. The total content of the
enzyme in the cells was evaluated by measuring the levels of enzyme in the
supernatant from cells lysed in 1% Triton X-100.
Extracellular calcium uptake. Calcium uptake was determined by a
modification of a previously described procedure (34). Briefly, IgE-sensi-
tized BMMCs (2  106) were resuspended in 100 l BSS-BSA with 1 mM
Ca2, mixed with 100 l of BSS-BSA supplemented with 45Ca2 and
various concentrations of antigen or thapsigargin, and incubated for se-
lected time intervals at 37°C. The reactions were terminated by placing the
tubes on ice and then suspending 100-l aliquots on the walls of micro-
test tubes to make them separated by air space from the 12% BSA in PBS
(300 l) at the bottoms. Cells with bound 45Ca2 were separated from free
45Ca2 by centrifugation through 12% BSA at 3,220  g for 15 min at 4°C.
The cell pellets were recovered by freezing the tubes and slicing off the
tube bottoms, and the cell pellets were solubilized with 1 ml of 1% Triton
X-100. The radioactivity was counted in 10 ml scintillation liquid (Eco-
Lite; ICN Biomedicals) in a scintillation counter with QuantaSmart soft-
ware (PerkinElmer).
Immunoprecipitation and immunoblotting. Cells were pelleted and
solubilized in ice-cold lysis buffer for immunoprecipitation (25 mM Tris-
HCl, pH 8.0, 140 mM NaCl, 1 mM Na3VO4, 2 mM EDTA, 1 g/ml
aprotinin, 1 g/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride) sup-
plemented with 1% n-dodecyl--D-maltoside and 1% Nonidet P-40 (for
most experiments), 0.2% Triton X-100 (for FcεRI immunoprecipitation),
or 1% Brij 96 (for kinase assays). After incubation (30 min on ice), the
lysates were spun down (16,000  g for 5 min at 4°C) and postnuclear
supernatants were immunoprecipitated with the corresponding antibod-
ies prebound to UltraLink-immobilized protein A or G (Pierce, Thermo
Scientific). The immunoprecipitates were size fractionated by sodium do-
decyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immu-
noblotted with phosphotyrosine-specific PY-20 –HRP conjugate or with
protein-specific antibodies, followed by HRP-conjugated anti-mouse or
anti-rabbit IgG antibody. Some phosphorylated proteins were deter-
mined by direct immunoblotting with phosphoprotein-specific antibod-
ies, followed by immunoblotting with the corresponding secondary HRP-
conjugated anti-mouse or anti-rabbit IgG. The HRP signal was detected
by chemiluminescence. Immunoblots were quantified by use of a lumi-
nescent image analyzer (LAS-3000; Fuji Photo Film Co., Tokyo, Japan)
and further analyzed by Aida image analyzer software (Raytest). The
amount of phosphorylated proteins was normalized to the amount of
immunoprecipitated proteins after stripping off the membranes, followed
by development with the corresponding antibodies. In some experiments,
parallel immunoblots instead of stripped membranes were used.
Sucrose density gradient fractionation. Sucrose density gradient sep-
arations were performed as previously described (35), with some modifi-
cations. Briefly, BMMCs (30  106) were lysed with 0.8 ml ice-cold lysis
buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 10 mM EDTA, 1 mM
Na3VO4, 10 mM glycerophosphate, 1 mM phenylmethylsulfonyl fluoride,
100 diluted protease inhibitor cocktail, 5 mM iodoacetamide) supple-
mented with 1% Brij 96. The lysates were homogenized by passing them
10 times through a 27-gauge needle and adjusted to 40% (wt/vol) using
80% stock sucrose in 25 mM Tris-HCl, pH 7.5, 125 mM NaCl, and 2 mM
EDTA. The gradient was prepared by adding 0.5 ml 80% sucrose at the
bottom of a polyallomer tube (11 by 60 mm; Beckman Instruments),
followed by 1.5 ml of 40% sucrose containing the cell lysate, 2 ml of 30%
sucrose, and 1 ml of 10% sucrose. The gradient was ultracentrifuged at
210,000  g for 4 h at 4°C using an SW55 Ti rotor (Beckman Instru-
ments), and 0.5-ml fractions were collected from the top.
Immunocomplex kinase assay. The in vitro kinase assays were per-
formed as previously described (36), with some modifications. FcεRI,
LYN, and FYN were immunoprecipitated from nonactivated or antigen-
activated cells lysed in lysis buffer for immunoprecipitation. Proteins im-
mobilized to antibody-armed protein A beads were washed with kinase
buffer (25 mM HEPES–NaOH, pH 7.2, 3 mM MnCl2, 0.1% Nonidet P-40,
100 mM Na3VO4, 20 mM MgCl2) and then resuspended in 25 l kinase
buffer supplemented with 2.5 Ci (92.5 kBq) of [-32P]ATP, 100 M
ATP, and 0.5 g/l of acid-denatured enolase as the exogenous substrate.
After incubation for 30 min at 37°C, the immunoprecipitates were eluted
from the beads with reducing 2-concentrated SDS-PAGE sample buffer
and boiled for 7 min. The 32P-labeled proteins were size fractionated by
SDS-PAGE, transferred to a nitrocellulose membrane, and visualized by
autoradiography. Films were quantified with Aida image analyzer soft-
ware.
Cytokine and chemokine detection. IgE-sensitized BMMCs were ac-
tivated with different concentrations of antigen. One hour later, mRNA
was extracted using a TurboCapture 96 mRNA kit (Qiagen). Single-
stranded cDNA was synthesized with Moloney murine leukemia virus
reverse transcriptase (Invitrogen) according to the manufacturer’s in-
structions. Real-time PCR amplifications of cDNAs were performed in
10-l reaction volumes of a quantitative PCR (qPCR) mix containing 1 M
1,2-propanediol, 0.2 M trehalose, and SYBR green 1 (37) in 384-well
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plates sealed with LightCycler 480 sealing foil (Roche Diagnostics) and
analyzed in a LightCycler 480 apparatus (Roche Diagnostics). The follow-
ing primer sets (sense/antisense) were used for amplification of the differ-
ent cDNA fragments (the sizes of the amplified fragments are indicated in
parentheses): actin, 5=-GATCTGGCACCACACCTTCT-3=/5=-GGGGTG
TTGAAGGTCTCAAA-3= (138 bp); glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH), 5=-AACTTTGGCATTGTGGAAGG-3=/5=-ATCCA
CAGTCTTCTGGGTGG-3= (69 bp); ubiquitin, 5=-ATGTGAAGGCCAA
GATCCAG-3=/5=-TAATAGCCACCCCTCAGACG-3= (160 bp); TNF-,
5=-CCCTCACACTCAGATCATCTTCT-3=/5=-GCTACGACGTGGGCT
ACAG-3= (61 bp); IL-6, 5=-GAGGATACCACTCCCAACAGACC-3=/5=-
AAGTGCATCATCGTTGTTCATACA-3= (141 bp); IL-13, 5=-AGACCA
GACTCCCCTGTGCA-3=/5=-TGGGTCCTGTAGATGGCATTG-3= (123
bp); CCL3, 5=-CATCGTTGACTATTTTGAAACCAG-3=/5=-GCCGGTT
TCTCTTAGTCAGGAA-3= (72 bp); and CCL4, 5=-CTTGGAGTTGAAC
TGAGCAGC-3=/5-AGAGGGGCAGGAAATCTGAA-3= (126 bp). The
following cycling conditions were used: 3 min at 95°C, followed by 50
cycles of 10 s at 95°C, 20 s at 60°C, and 20 s at 72°C. Threshold cycle (CT)
values were determined by automated threshold analysis of the cycler. The
specificity of the PCR was evaluated by examining melting curves. The
genes for actin, GAPDH, and ubiquitin were used as reference genes, and
the expression levels of all mRNAs were normalized to the geometric
mean level of expression of these genes. The relative increase in the ex-
pression level of a cytokine was normalized to the level of expression by
nonactivated WT cells in each experiment.
For detection of cytokines, an immuno-PCR method was used as de-
scribed previously (38). Briefly, anti-TNF- (1 g/ml), anti-IL-6 (2 g/
ml), or anti-IL-13 (1 g/ml) in 100 mM borate buffer (pH 9.5) was dis-
pensed in 50-l aliquots into the wells of a real-time 96-well plate
(Eppendorf). After overnight incubation at 4°C, each well was washed
four times with 200 l of Tris-buffered saline (10 mM Tris-HCl, pH 7.4,
150 mM NaCl) containing 0.05% Tween 20 (TBST), and the remaining
binding sites were blocked by 2 h of incubation at 37°C with TBST sup-
plemented with 2% BSA. After washing, 50 l of serial dilutions (0.1 to
100 ng/ml) of recombinant TNF-, IL-6, or IL-13 (all from PeproTech
EC) or the tested samples diluted in PBS–1% BSA was added. The samples
were incubated for 1 h at 37°C, and after washing with TBST, 50 l of
Au-NPs armed with thiolated DNA oligonucleotide template (5=-thiol
modifier C6 S-S/18-atom hexa-ethyleneglycol spacer-CCTTGAACCT
GTGCCATTTGAATATATTAAGACTATACGCGGGAACA-3=] and with
the corresponding cytokine-specific antibody was applied into each well. The
wells were incubated for 1 h at 37°C and washed with TBST and deionized
water. Fifty-microliter aliquots of qPCR master mix solution (see above) sup-
plemented with 60 nM oligonucleotide primers 5=-CCTTGAACCTGTGCC
ATTTG-3= and 5=-GTCCCTCCATCTTCCTACTGTTCCACATGTTC
CCGCGTATAGTCTT-3= were then dispensed into each well. The plates
were sealed, and the amount of template DNA bound to antigen-anchored
functionalized Au-NPs was evaluated by real-time PCR using a Realplex4
Mastercycler apparatus (Eppendorf) with the following cycling conditions: 2
min at 94°C, followed by 40 cycles of 20 s at 94°C, 20 s at 53°C, and 20 s at 72°C.
For the calculation of TNF-, IL-6, and IL-13 concentrations, the corre-
sponding CT values were substituted into the regression equations obtained
from the calibration curves constructed from the concentration series of ap-
propriate recombinant proteins.
Chemotaxis assay. Chemotaxis responses were assayed in 24-well
Transwell chambers (Corning) with 8-m-pore-size polycarbonate filters
in the upper wells. Chemoattractants (antigen or SCF) in 0.6 ml che-
motaxis medium (RPMI 1640 supplemented with 1% BSA and 20 mM
HEPES, pH 7.4) were added to the lower wells. IgE-sensitized BMMCs
(0.3  106 in 120 l chemotactic medium) were added to the upper wells.
Cells migrating into the lower wells during the 8 h of incubation (37°C,
5% CO2) were counted using an Accuri C6 flow cytometer (BD Biosci-
ences).
Confocal microscopy. BMMCs (3  105) were attached to fibronec-
tin-coated multitest slides (MP Biomedicals). Cells were fixed with 4%
paraformaldehyde for 15 min at room temperature and permeabilized in
0.3% Triton X-100 for 20 min. Free binding sites were blocked with 5%
normal donkey serum, and the cells were stained with rabbit anti-Myc tag
antibody, followed by labeling with secondary antibody (donkey anti-
rabbit IgG–Alexa Fluor 488 conjugate). After 60 min, the cells were
washed and mounted in Mowiol 4-88 mounting solution supplemented
with Hoechst 33258 nucleic acid stain (1 g/ml; Molecular Probes) to
label the nuclei. Samples were examined with a confocal laser scanning
microscope (Leica TCS SP5) equipped with a 63 (numerical aperture,
1.4) oil immersion objective.
Passive systemic anaphylaxis. The systemic anaphylactic reaction is
accompanied by the release of histamine from activated mast cells, leading
to a decreased body temperature (39). The body temperature was mea-
sured with an accuracy of 0.1°C using a VitalView data acquisition sys-
tem with ER-4000 energizer receivers, G2 E-mitter transponders, and
VitalView software (Mini Mitter). G2 probes were implanted intra-ab-
dominally into mice while they were under systemic anesthesia with iso-
flurane (Abbott Laboratories). Monitoring of body temperature was ini-
tiated 9 days after the surgery. Mice aged 11 to 18 weeks were sensitized by
tail vein injection of TNP-specific IgE (3 g in 100 l PBS per mouse), and
24 h later, anaphylaxis was induced by intravenous administration of
antigen (500 g in 100 l PBS per mouse). The body temperature was
recorded at 1-min intervals for at least 3 h after antigen challenge.
Serum IgE quantification. Ninety-six-well enzyme-linked immu-
nosorbent assay plates (Nunc) were coated for 16 h at 4°C with rat anti-
body specific for mouse IgE (1 g/ml in PBS; 50 l/well; BD Biosciences).
Wells were washed (four times with TBST) and blocked by incubation at
22°C with TBST–2% BSA. After 2 h, the plates were washed and incubated
for 1 h at 22°C with various concentrations of mouse IgE standard (1.95 to
125 ng/ml in PBS–1% BSA; BD Biosciences) or mouse serum samples
(diluted 1:5 in PBS–1% BSA). Then, the wells were washed and the cap-
tured IgE was detected with biotinylated rat anti-mouse IgE antibody (2
g/ml in PBS–1% BSA; BD Bioscience), washed, and incubated for 30
min with streptavidin-HRP conjugate (diluted 1:1,000 in PBS–1% BSA;
BD Biosciences). Peroxidase substrate solution (0.5 mg/ml o-phenylene-
diamine and 0.015% H2O2 in 0.1 M NaH2PO4, pH 6.0) was used for
colorimetric reaction. The reaction was stopped by adding 50 l of 4 M
H2SO4, and the absorbance at 492 nm was determined using an Infinite
M200 plate reader (Tecan).
Statistical analysis. The significance of intergroup differences was
evaluated by Student’s t test.
RESULTS
Positive regulatory role of PAG on antigen-induced degranula-
tion. To examine the role of PAG in mast cell signaling, we isolated
bone marrow cells from homozygous F1-descendant PAG-KO
and PAG-WT mice and cultured them in the presence of IL-3 and
SCF to obtain BMMCs. Cells with or without PAG exhibited com-
parable growth parameters under in vitro conditions (not shown),
suggesting that PAG had no effect on the growth response of mast
cells to IL-3 and SCF. The same PAG-WT BMMCs were used for
the production of PAG-KD cells after transduction with lentiviral
vectors containing PAG shRNA constructs based on a pLKO vec-
tor (shRNA14 to shRNA17), followed by selection in puromycin.
PAG-WT BMMCs infected with empty lentiviral vector were used
as a negative control (pLKO). PAG-KO and PAG-WT cells ex-
pressed comparable amounts of surface FcεRI, as detected by flow
cytometry (Fig. 1A). Similarly, no difference in surface FcεRI was
observed among various PAG-KD cells and controls (not shown).
As expected, we found no detectable PAG in PAG-KO cells us-
ing immunoblotting with PAG-specific antibody (Fig. 1B). The
amount of PAG in PAG-KD cells was substantially reduced com-
pared to that in control (pLKO) cells. The strongest inhibition was
observed in the cells infected with the shRNA14 and shRNA15
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constructs, which reduced PAG expression by 73% and 75%,
respectively (Fig. 1C). Infection with constructs containing
shRNA16 and shRNA17 reduced PAG expression by 25% and 51%,
respectively. Guided by these data, we used viruses containing
shRNA14 and shRNA15 for further experiments with BMMCs. Be-
cause of the similar knockdown characteristics of these constructs,
data from BMMCs infected with these shRNAs were combined and
are presented under the common heading of PAG-KDs.
Using BMMCs with PAG-KO and PAG-KD and the corre-
sponding controls, we first investigated whether PAG deficiency
has any effect on mast cell degranulation after FcεRI triggering.
Degranulation was estimated from the amount of -glucuroni-
dase released from activated cells. BMMCs were sensitized with
TNP-specific IgE and then exposed to various concentrations of
antigen. After 30 min, PAG-KO cells exhibited significantly lower
levels of degranulation than WT cells at all concentrations of the
antigen tested (0.05 to 1.0 g/ml; Fig. 1D); the total amount of
-glucuronidase released from both cell types by Triton X-100
was similar (data not shown). These data indicate that the absence
of PAG reduces antigen-induced degranulation but does not in-
terfere with the production of -glucuronidase in secretory vesi-
cles. Significant inhibition of degranulation was also observed in
PAG-KO cells activated with various concentrations of thapsi-
gargin (0.1 to 2.0 M; Fig. 1E). Thapsigargin induces the release of
Ca2 from intracellular stores by inhibiting the endoplasmic re-
ticulum (ER) ATPase (40). The combined data suggest that PAG
not only is involved in the CSK-mediated FcεRI-proximal regula-
tion of SFKs but also could still have other functions distal to
FcεRI regulation.
To test whether compensatory developmental alterations
could be responsible for the unexpected properties of PAG-KO
BMMCs, we examined antigen- and thapsigargin-induced de-
granulation in cells with PAG-KD and the corresponding con-
trols. The data shown in Fig. 1F and G demonstrate that stimula-
tion of PAG-KD cells with antigen or thapsigargin decreased the
level of degranulation compared to that in the pLKO controls,
supporting previous findings that PAG is a positive regulator of
mast cell degranulation.
Positive regulatory role of PAG on Ca2 response. Early
events in mast cell signaling involve the release of Ca2 from in-
tracellular stores followed by the influx of extracellular Ca2
through store-operated Ca2 (SOC) channels in the plasma mem-
brane (41). To determine whether PAG has a role in this process,
we quantified Ca2 uptake in PAG-deficient and control BMMCs.
The data presented in Fig. 2A show that stimulation with antigen
causes significantly lower levels of uptake of extracellular 45Ca2
in PAG-KO cells than in PAG-WT cells, reaching a peak at ap-
proximately 5 min after triggering in both cell types. Inhibition of
Ca2 uptake in PAG-KO cells was observed 5 min after triggering
at all concentrations of the antigen tested (Fig. 2B). Significant
inhibition of Ca2 uptake in PAG-KO cells was also seen after
stimulation for various time intervals (Fig. 2C) or with various
FIG 1 Positive regulatory role of PAG in antigen- or thapsigargin-induced
degranulation. (A) BMMCs derived from WT mice (PAG-WT) or PAG-defi-
cient mice (PAG-KO) were stained for surface FcεRI by use of an anti-FcεRI-
FITC conjugate. Unstained WT cells were used as negative controls. Samples
were analyzed by flow cytometry. (B, C) The presence of PAG in lysates from
PAG-WT and PAG-KO BMMCs (B) or WT BMMCs infected with empty
pLKO lentiviral vector (pLKO) or lentiviral vectors shRNA14 to shRNA17 (C)
was determined by immunoblotting (IB). As loading controls, the membranes
were also developed for LYN (B) or actin (C). The amount of PAG normalized
to its amount in cells infected with the empty pLKO vector and actin loading
control (fold) is also shown (C). For each panel, the results of one representa-
tive experiment out of a minimum of three performed are shown. (D, E)
PAG-WT or PAG-KO BMMCs were sensitized (D) or not (E) with TNP-
specific IgE (1 g/ml) and then stimulated for 30 min with various concentra-
tions of antigen (Ag) (D) or thapsigargin (Th) (E). (F, G) PAG-WT BMMCs
were infected with empty pLKO lentiviral vector (pLKO) or with PAG
shRNA14 and shRNA15 vectors (PAG-KD), and stable transfectants were ac-
tivated with antigen (F) or thapsigargin (G), as described above. The amount
of -glucuronidase (-glucur.) released from the cells was determined 30 min
after triggering. Data represent means  SEs calculated from 11 independent
experiments performed in duplicate or triplicate in panels D and E and from 6
to 8 independent experiments performed in duplicate or triplicate in panels F
and G. The statistical significance of differences between PAG-WT and
PAG-KO cells or pLKO and PAG-KD cells is shown: ***, P 	 0.001.
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concentrations of thapsigargin (Fig. 2D). A positive regulatory
role of PAG in calcium uptake after antigen (Fig. 2E) or thapsi-
gargin (Fig. 2F) activation was also evident when PAG-KD cells
were compared to the corresponding PAG-expressing (pLKO)
controls. These data imply that the observed inhibition of degran-
ulation in PAG-deficient cells could be at least in part attributable
to decreased calcium mobilization.
Localization of CSK in lipid rafts depends on PAG. Previous
studies localized PAG almost exclusively to lipid rafts, where it
could interact with CSK and through this interaction negatively
regulate lipid raft-associated SFKs (15). This conclusion was based
on data evaluating the distribution of PAG in fractions after su-
crose density gradient ultracentrifugation of lysates from cells dis-
integrated in nonionic detergents (11, 12) or 0.5 M NaHCO3 (21).
However, there are inconsistencies regarding the role of PAG in
the localization of CSK in lipid rafts. One study found that the
level of lipid raft-associated CSK in thymocytes was greatly re-
duced in the absence of PAG (18), whereas another concluded that
PAG is dispensable for the localization of CSK in lipid rafts (17).
To determine whether PAG contributes to the localization of CSK
in lipid rafts in BMMCs, nonactivated or antigen-activated
PAG-WT and PAG-KO BMMCs were solubilized in a buffer sup-
plemented with 1% Brij 96 and fractionated by sucrose density
gradient ultracentrifugation, and their presence in individual frac-
tions was analyzed by immunoblotting. The distribution of LYN
kinase, a well-known lipid raft marker in BMMCs, was also exam-
ined. In accordance with previous data (42), most of the LYN
(88%) in nonactivated cells was associated with detergent-resis-
tant membranes (DRM; fractions 1 to 3). Five minutes after acti-
vation with antigen, this amount was reduced by approximately
half (Fig. 3A). In the same gradient fractions, less PAG was found
in DRMs (55%), and no significant changes were observed after
stimulation with antigen. Only a small fraction of CSK was
found in DRM fractions (4%), and no significant changes were
observed after activation with antigen. When lysates from
PAG-KO BMMCs were analyzed, no CSK was found in DRM
fractions from activated and nonactivated cells even after a longer
exposure (Fig. 3B), suggesting that PAG is involved in the local-
ization of CSK in DRMs.
PAG and tyrosine phosphorylation of signal transduction
proteins. The first biochemically defined step after FcεRI trigger-
ing is tyrosine phosphorylation of the FcεRI subunits by SFK LYN,
followed by engagement of other kinases and phosphorylation of a
number of signal transduction proteins. To specify the role of
PAG in these processes, we examined tyrosine phosphorylation of
FcεRI and several selected proteins involved in early stages of an-
tigen-induced mast cell signaling (SYK, LAT, extracellular signal-
regulated kinase [ERK]) (43), as well as proteins involved in cell
movement (FAK and paxillin) (44). In initial experiments, we
looked for proteins phosphorylated on tyrosine in total cellular
FIG 2 Positive regulatory role of PAG on antigen- or thapsigargin-induced
calcium uptake. (A, B) PAG-WT and PAG-KO BMMCs were sensitized with
IgE and then stimulated for various time intervals with antigen (0.5 g/ml) (A)
or with various concentrations of antigen for 5 min (B) in the presence of 1
mM extracellular 45Ca2. The reactions were terminated by centrifugation of
the cells through a BSA gradient, and cell-bound radioactivity (in the sedi-
ment) was determined. (C, D) PAG-WT and PAG-KO BMMCs were activated
for various time intervals with 1 M thapsigargin (C) or with various concen-
trations of thapsigargin for 5 min (D), and the uptake of 45Ca2 was deter-
mined as described above. (E, F) PAG-WT BMMCs were infected with empty
pLKO lentiviral vector (pLKO) or with PAG shRNA vectors (PAG-KD), and
stable transfectants were activated with antigen (E) or thapsigargin (F) and
analyzed as described above. Data represent means  SEs from three to six
independent experiments performed in duplicate or triplicate. *, P 	 0.05; **,
P 	 0.01; ***, P 	 0.001.
FIG 3 Localization of CSK in lipid rafts depends on PAG. IgE-sensitized
PAG-WT BMMCs (A) or PAG-KO BMMCs (B) were nonactivated (Control)
or activated for 5 min with antigen (250 ng/ml). After solubilization in lysis
buffer containing 1% Brij 96, the whole-cell lysates were fractionated by su-
crose density gradient ultracentrifugation as described in Materials and Meth-
ods. Individual fractions were collected and analyzed by immunoblotting for
the presence of PAG, CSK, and LYN. Fractions containing DRMs are indi-
cated. Representative data from three independent experiments are shown.
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lysates. We found that PAG-WT cells differed from PAG-KO cells
in several tyrosine-phosphorylated proteins not only after antigen
stimulation but also in the nonactivated state (Fig. 4A). Further
analysis showed that FcεRI triggering caused an increase in ty-
rosine phosphorylation of FcεRI  and  chains in WT cells and
that this process was significantly reduced in PAG-KO cells (Fig.
4B). Tyrosine phosphorylation of SYK (Fig. 4C) and its substrates,
LAT (Fig. 4D) and ERK (Fig. 4E), was also impaired in PAG-
deficient cells. In contrast, FAK (Fig. 4F) and the focal adhesion-
associated adaptor protein paxillin (Fig. 4G) showed elevated
basal levels of tyrosine phosphorylation in PAG-KO cells; this dif-
ference was maintained after FcεRI triggering (Fig. 4F and G).
The observed decrease in tyrosine phosphorylation of FcεRI 
and  subunits in antigen-activated PAG-KO cells suggested an
imbalance between PTKs and PTPs in the vicinity of the receptor.
To examine FcεRI-associated PTK activity toward its endogenous
substrate, FcεRI was immunoprecipitated from nonactivated and
antigen-activated PAG-WT and PAG-KO cells, and the immuno-
complexes were analyzed by in vitro kinase assays with [-32P]ATP.
Using PAG-WT cells, we observed a significant increase in radio-
activity bound to FcεRI  and  receptor subunits after activation
with antigen (Fig. 5A and B). Surprisingly, when the receptor was
precipitated from PAG-KO cells, strong phosphorylation of the
receptor  and  subunits was observed in nonactivated cells and
was decreased after FcεRI triggering. These data, together with the
results of immunoblotting experiments showing weak and com-
parable tyrosine phosphorylation of the  and  subunits of FcεRI
isolated from nonactivated PAG-WT and PAG-KO cells, suggest
that the activity of PTKs bound to FcεRI isolated from PAG-KO
cells is enhanced.
To determine the enzymatic activities of total LYN and FYN, the
kinases were immunoprecipitated and their activities were assessed
by an in vitro kinase assay. To overcome the problem with possible
variation in the extent of nonphosphorylated residues in the target
proteins, we used acid-denatured enolase as the exogenous substrate
in immunocomplex kinase assays. The data in Fig. 5C to F show low
but significantly higher levels of autophosphorylation of the LYN and
FYN kinases immunoprecipitated from PAG-KO cells than of those
immunoprecipitated from PAG-WT cells. Importantly, enolase
phosphorylation was also enhanced in LYN and FYN immunopre-
cipitates obtained from PAG-KO cells. In contrast to the findings of
previous studies (3, 19), we did not observe any increase in the activity
of the kinases after FcεRI triggering, which is probably due to the
different culture condition used (45).
LYN is a positive regulator of PTPs (46, 47), which could be
responsible for the decreased tyrosine phosphorylation of several
substrates, as shown in Fig. 4A to E. One of the phosphatases
involved in the regulation of mast cell degranulation and calcium
responses is SHIP1. LYN kinase phosphorylates SHIP1 and thus
enhances its enzymatic activity and downregulates degranulation
(47, 48). In further experiments, we therefore examined tyrosine
phosphorylation of SHIP1 in BMMCs from PAG-WT and
PAG-KO mice. In nonactivated WT cells, SHIP1 showed baseline
phosphorylation which was enhanced after FcεRI triggering (Fig.
5G and H). Compared to PAG-WT cells, nonactivated PAG-KO
cells exhibited significantly higher levels of SHIP1 tyrosine phos-
phorylation. After activation with antigen, the difference between
PAG-WT and PAG-KO cells became insignificant.
Different regulatory roles of PAG in SCF signaling. An im-
portant surface receptor of mast cells is KIT, which binds SCF and
thereby triggers mast cell activation and enhances activation in-
duced by FcεRI (49). However, no data on the involvement of
PAG in SCF-induced activation are available. To determine a pos-
sible role of PAG in KIT-mediated activation, PAG-WT and
PAG-KO BMMCs were activated with different concentrations of
SCF and degranulation was examined. PAG-WT cells released in-
creasing amounts of -glucuronidase when activated with 25 to
200 ng/ml SCF. The extent of SCF-induced degranulation was
higher than that described in previous studies (50, 51) and was
apparently related to the growth of bone marrow cells in the pres-
ence of both IL-3 and SCF. When BMMCs were derived from
cultures containing IL-3 alone, their SCF-induced degranulation
was low (45). PAG-KO cells released significantly more -gluc-
uronidase than PAG-WT cells at all concentrations of SCF tested
(Fig. 6A). This effect was associated with higher levels of KIT ty-
rosine phosphorylation in PAG-KO cells (Fig. 6B and C). How-
ever, an opposite effect of PAG on FcεRI- and KIT-mediated sig-
naling events was absent when tyrosine phosphorylation of
PLC1 was examined. Stimulation of PAG-WT cells with antigen
as well as with SCF resulted in tyrosine phosphorylation of PLC1,
even though it was slower in SCF-activated cells. Similar findings
have been previously described (50) and indicate that FcεRI-acti-
vated PTKs are more potent for the phosphorylation of PLC1
than that of KIT. In PAG-KO cells, the extent of PLC1 tyrosine
phosphorylation was significantly inhibited in both antigen- and
SCF-triggered cells (Fig. 6D and E). A similar effect was observed
when PLC2 was examined (data not shown). No significant ef-
fect of PAG was observed when the tyrosine phosphorylation of
several other signaling molecules (SYK, LAT, FAK, paxillin) was
examined in PAG-WT and PAG-KO cells. Furthermore, no effect
of PAG on the calcium response was observed in SCF-activated
BMMCs (not shown).
An important aspect of mast cell physiology is chemotaxis di-
rected by various ligands (52). Here we compared chemotaxis
toward antigen or SCF in cells differing in PAG expression. In
transwell migration assays, PAG-WT BMMCs exhibited faster mi-
gration toward the antigen than PAG-KO cells. The difference was
almost 2-fold and was significant (Fig. 6F). When SCF was used as
a chemoattractant, both cell types migrated faster and no signifi-
cant difference between them was evident. To exclude possible
compensatory developmental alterations in PAG-KO cells, we
also compared the chemotaxis of BMMCs with PAG-KD and their
corresponding controls (pLKO cells). We found significantly
lower levels of migration of PAG-KD cells than of pLKO cells after
exposure to antigen. Again, no significant difference between the
two cell types was observed when SCF was used as a chemoattrac-
tant (Fig. 6G).
Positive regulatory role of PAG in cytokine and chemokine
production. Previous studies showed that activation of mast cells
resulted in the rapid tyrosine phosphorylation of several tran-
scription factors. We selected STAT5, which has been extensively
studied in FcεRI- or KIT-activated cells (53, 54), as the transcrip-
tion factor. To elucidate the role of PAG in this process, we exam-
ined tyrosine phosphorylation of STAT5 in nonactivated and an-
tigen- or SCF-activated PAG-WT and PAG-KO cells (Fig. 7A and
B). Antigen-induced tyrosine phosphorylation of STAT5 was pos-
itively regulated by PAG. A significantly lower level of phosphor-
ylation of STAT5 in PAG-KO cells was observable even without
activation, but activation intensified the difference. Phosphoryla-
tion of STAT5 was also observed in cells stimulated with SCF
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(Fig. 7A and B). However, no significant difference between
PAG-WT and PAG-KO cells was observed.
The decreased phosphorylation of STAT5 in antigen-stimulated
PAG-KO cells suggested the reduced production of cytokines and
chemokines in such cells (55). Detailed analysis at the protein and
mRNA levels showed that, indeed, the levels of three selected cyto-
kines, TNF-, IL-6, and IL-13, were significantly reduced in antigen-
stimulated PAG-KO cells compared with their levels in PAG-WT
cells at both the protein and mRNA levels (Fig. 7C). Antigen-acti-
vated PAG-KO BMMCs also exhibited significant inhibition of tran-
scription of two chemokines, CCL3 and CCL4 (Fig. 7D).
Phenotype rescue of PAG-KO cells. Next, we attempted to
confirm the role of PAG as a positive regulator of cytokine pro-
duction. We prepared a PAG-myc construct in the pCDH vector
and transfected it into PAG-KO BMMCs. Control cells were
transfected with the empty pCDH vector, and puromycin-resis-
tant cells were further analyzed. Staining for myc after cell per-
meabilization and confocal microscopy showed the association of
the PAG-myc with the plasma membrane (Fig. 8A). No signal was
observed in cells transduced with empty pCDH (Fig. 8B). Further-
more, immunoblotting analysis with Myc tag-specific antibody
confirmed the expression of PAG-myc in cells transduced with the
pCDH-PAG-myc vector but not the pCDH empty vector (Fig.
8C). These data suggest that PAG-myc was expressed as expected.
Next, we examined the production of TNF- in antigen-activated
PAG-WT and PAG-KO cells transfected with empty pCDH and
PAG-KO cells transfected with pCDH-PAG-myc. For this analysis
we selected flow cytometry, which allowed us to evaluate TNF--
positive cells, after gating out the cellular debris detected in for-
ward and side scatter plots. This eliminated the problem associ-
ated with the presence of different proportions of living cells and
debris in various transduction experiments. Data presented in Fig.
8D indicate that the level of production of TNF- in cells trans-
fected with the empty pCDH vector was significantly lower in
PAG-KO cells than in PAG-WT cells. PAG-KO cells transfected
with pCDH-PAG-myc produced significantly more TNF- than
pCDH transfectants. These data confirm the phenotype rescue in
PAG-KO cells.
Impaired passive systemic anaphylaxis in PAG-KO mice. Fi-
nally, we examined degranulation in antigen-activated mast cells
under in vivo conditions. We induced passive systemic anaphy-
laxis in PAG-KO and PAG-WT mice by sensitizing them with
TNP-specific IgE MAb and subsequent challenge with antigen. In
control mice, the decrease in body temperature was observable
within the first 60 min and was followed by slow recovery for more
than 180 min after antigen injection (Fig. 9A). In PAG-KO mice,
the decrease in body temperature was less pronounced and recov-
ery was faster, being complete 150 min after antigen administra-
tion. The difference in body temperature between PAG-WT and
PAG-KO mice was significant in the interval ranging from 45 to
170 min after antigen administration. The observed decrease in
systemic anaphylaxis was not likely attributable to decreased
numbers of mast cells in PAG-KO mice, as inferred from compa-
rable mast cell (KIT and FcεRI positive) counts in the peritoneal
lavage fluid of PAG-WT and PAG-KO cells (Fig. 9B). Further-
more, we found no significant difference in serum IgE levels be-
tween PAG-WT and PAG-KO mice (Fig. 9C). This finding indi-
cates that the production of IgE is not affected by the absence of
PAG and that the decreased anaphylactic response in PAG-KO
mice is not caused by enhanced production of IgE, which might
preclude sensitization with antigen-specific IgE.
DISCUSSION
In this study, we used BMMCs derived from PAG-KO and
PAG-WT mice to understand the role of PAG in FcεRI and SCF
signaling. To minimize the possible effect of compensatory devel-
opmental alterations in PAG-KO cells, we also used BMMCs with
PAG-KD and corresponding controls. Several lines of evidence
indicate that PAG has positive as well as negative regulatory roles
in FcεRI- or KIT-mediated signaling, depending on the receptor
triggered and the signaling pathway involved.
First, when stimulated with antigen, mast cells derived from
PAG-KO mice exhibited decreased degranulation. In view of pre-
vious results obtained with other immunoreceptors (17, 18, 26),
this was an unexpected finding because phosphorylated PAG was
regarded as a plasma membrane anchor of CSK, a negative regu-
lator of SFKs. Furthermore, overexpression of PAG reportedly
resulted in decreased degranulation in RBL-2H3 cells (21). The
positive regulatory role of PAG in FcεRI-mediated signaling de-
scribed here was not the consequence of developmental changes
caused by the absence of PAG, since a similar phenotype was also
observed in PAG-KD BMMCs where PAG expression was down-
regulated by RNA interference, nor was the decreased degranula-
tion caused by the reduced production of -glucuronidase or the
reduced expression of FcεRI in PAG-KO and PAG-KD cells. In-
terestingly, a defect in degranulation was also observed in PAG-
deficient cells activated by thapsigargin, a noncompetitive inhib-
itor of ER Ca2 ATPase.
Second, antigen-activated PAG-KO cells exhibited decreased
tyrosine phosphorylation of FcεRI  and  subunits. This change
implies that the reduced degranulation in PAG-deficient cells is
caused at least in part by inhibition of the earliest stages of mast
cell signaling, starting from reduced phosphorylation of the FcεRI
 and  subunits, followed by impaired membrane anchoring,
phosphorylation, and activation of SYK. The exact molecular
mechanism of the impaired phosphorylation of FcεRI in PAG-
FIG 4 Antigen-induced tyrosine phosphorylation of signal transduction proteins is dependent on PAG. (A to G) IgE-sensitized PAG-WT and PAG-KO cells
were activated (Activ.) for the indicated time intervals with antigen (250 ng/ml). The cells were lysed, and total cellular lysates were analyzed by immunoblotting
with the tyrosine-specific MAb PY-20 –HRP conjugate (PY). Alternatively, FcεRI (B), LAT (D), and paxillin (G) were immunoprecipitated (IP) from the lysates
and examined by immunoblotting with tyrosine-specific MAb as in the experiment whose results are shown in panel A. For SYK (C), ERK (E), and FAK (F),
size-fractionated proteins in cell lysates were directly analyzed by immunoblotting with the corresponding phosphoprotein-specific antibodies. For loading
controls, the membranes were analyzed by immunoblotting for LYN kinase (A), the FcεRI  chain (B), SYK (C), LAT (D), ERK (E), FAK (F), and paxillin (G).
Panel A and the tops of panels B to G show representative immunoblots from at least three experiments. The bottoms of panels B to G show the results of
densitometry analysis of the corresponding immunoblots in which signals from tyrosine-phosphorylated proteins in activated cells were normalized to the
signals in nonactivated cells and loading control proteins. Means  SEs were calculated from a minimum of four independent experiments. The statistical
significance of the differences between PAG-WT and PAG-KO cells is also shown: *, P 	 0.05; **, P 	 0.01; ***, P 	 0.001. p-SYK, p-ERK, and p-FAK,
phosphorylated SYK, ERK, and FAK, respectively.
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deficient cells is unknown and is likely connected to local changes
in the activity and/or the topography of SFKs and PTPs within
the FcεRI signalosome. Our finding that FcεRI immunocom-
plexes isolated from nonionic detergent-solubilized nonactivated
PAG-KO cells show kinase activity higher than those isolated from
PAG-WT cells would be compatible with this hypothesis, pro-
vided that PTKs are more stably associated with isolated FcεRI
immunocomplexes than PTPs. Furthermore, we found that ty-
FIG 5 PAG-dependent regulation of LYN and FYN kinase (kin.) activities and SHIP1 tyrosine phosphorylation. (A) IgE-sensitized PAG-WT and PAG-KO
BMMCs were activated or not for 2 min with antigen (250 ng/ml) and then solubilized with lysis buffer containing 1% Brij 96. FcεRI-IgE complexes were
immunoprecipitated and incubated in a kinase buffer containing [-32P]ATP. After the kinase assay, 32P-labeled proteins were size fractionated, transferred to
nitrocellulose membranes, and examined by autoradiography. The relative amounts of the FcεRI  chain were determined by immunoblotting. The positions of
FcεRI  and  chains are indicated. (B) Autoradiograms obtained as described in the legend to panel A were quantified, and the signals corresponding to the FcεRI
 and  chains were normalized to the signals in nonactivated PAG-WT cells and the amount of FcεRI  chain immunoprecipitated. (C to F) The cells were
activated and solubilized as described in the legend to panel A. LYN (C and D) and FYN (E and F) were immunoprecipitated and incubated in kinase buffer
supplemented with [-32P]ATP and acid-denatured enolase, used as an exogenous substrate. Kinase assays and further analyses were performed as described in
the legend to panel A. Autoradiograms were quantified, and the signals corresponding to LYN, FYN, and enolase were normalized to the signals in nonactivated
PAG-WT cells and the amount of immunoprecipitated LYN (D) or FYN (F). (G and H) IgE-sensitized PAG-WT and PAG-KO BMMCs were activated for the
indicated time intervals with antigen as described in the legend to panel A. The cells were lysed and analyzed by immunoblotting with phosphorylated-SHIP1
(p-SHIP1)-specific antibody. The amount of SHIP1 was used as a loading control. (H) Densitometry analysis of the immunoblots in which the signal for
phospho-SHIP1 was normalized to the signal in nonactivated PAG-WT cells and the amount of SHIP1. The results of representative experiments are shown in
panels A, C, E, and G. The means  SEs in panels B, D, F, and H were calculated from three to five independent experiments. The statistical significance of
intergroup differences is indicated: *, P 	 0.05; **, P 	 0.01; ***, P 	 0.001.
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rosine phosphorylation of SHIP1, a negative regulator of mast cell
activation (48, 56), is increased in nonactivated PAG-KO cells.
This could be caused by the enhanced enzymatic activity of LYN,
which phosphorylates and activates SHIP1 (47), and in this man-
ner could contribute to decreased calcium and degranulation re-
sponses (48, 56).
In contrast to FcεRI and several other signaling proteins in-
volved in the calcium response (SYK, LAT, and PLC), FAK and at
FIG 6 Different regulatory roles of PAG in KIT and FcεRI signaling. (A) PAG-WT and PAG-KO BMMCs were stimulated for 30 min with various concentrations
of SCF, and the amount of -glucuronidase released into the supernatant was determined. (B) PAG-WT and PAG-KO cells were exposed to SCF (50 ng/ml) for
different time intervals and lysed, and tyrosine phosphorylation of KIT was analyzed by immunoblotting with phosphorylated-KIT (p-KIT)-specific antibody.
Immunoblotting with KIT-specific antibody served as a loading control. The results of one representative experiment out of three performed are shown. (C) The
immunoblots obtained as described in the legend to panel B were analyzed by densitometry, and the amounts of tyrosine-phosphorylated KIT were normalized
to the amounts of tyrosine-phosphorylated KIT in nonactivated PAG-WT cells and loading controls. (D and E) PAG-WT and PAG-KO BMMCs were activated
for different time intervals with antigen (250 ng/ml) or SCF (50 ng/ml) and lysed, and PLC1 was immunoprecipitated. The immunoprecipitates were analyzed
by immunoblotting with tyrosine-specific MAb PY-20 –HRP conjugate (PY) (D). As loading controls, the membranes were also analyzed by immunoblotting for
PLC1. Representative immunoblots out of three performed are shown. The immunoblots obtained were analyzed by densitometry, and the relative amounts of
tyrosine-phosphorylated proteins were normalized to the amounts of the proteins immunoprecipitated and to the amounts of tyrosine-phosphorylated proteins
in nonactivated PAG-WT cells (E). (F) IgE-sensitized PAG-WT or PAG-KO BMMCs were analyzed in a chemotactic assay with chemotaxis medium alone
(Control) or with chemotaxis medium supplemented with antigen (250 ng/ml) or SCF (100 ng/ml) in the lower wells. The numbers of cells migrating into the
lower wells were determined after 8 h. (G) The experiments were performed as described in the legend to panel F, except that cells with PAG-KD and the
corresponding controls (pLKO) were used. Means  SEs were calculated from a minimum of nine independent experiments performed in triplicate (A), three
independent experiments (C, E, and G), or six independent experiments (F). The statistical significance of differences between PAG-WT/PAG-KO cells (A, C, E,
and F) and pLKO/PAG-KD cells (G) is shown: *, P 	 0.05; **, P 	 0.01; ***, P 	 0.001.
Regulation of Mast Cell Signaling by PAG/CBP Adaptor
December 2014 Volume 34 Number 23 mcb.asm.org 429560
FIG 7 Decreased tyrosine phosphorylation of STAT5 and production of cytokines and chemokines in antigen-activated PAG-KO BMMCs. (A) Cells were
activated for different time intervals with antigen (250 ng/ml) or SCF (50 ng/ml), lysed, and analyzed for STAT5 tyrosine 694 phosphorylation by
immunoblotting. As loading controls, the membranes were also immunoblotted with STAT5-specific antibody. Representative immunoblots are shown.
(B) The immunoblots were analyzed by densitometry, and the relative amount of tyrosine-phosphorylated STAT5 (p-STAT5) was normalized to its
amount in nonactivated cells and the corresponding loading control. (C, D) The levels of production of cytokines (TNF-, IL-6, and IL-13) at the protein
level (C, top) and mRNA level (C, bottom) and chemokines (CCL3 and CCL4) (D) were evaluated at the mRNA level in PAG-WT and PAG-KO BMMCs
activated with various concentrations of antigen for 1 h (mRNA) or 6 h (protein). Specific proteins and mRNAs were quantified by immuno-PCR and
qPCR, respectively. Means  SEs were calculated from 4 to 12 independent experiments. The statistical significance of differences between PAG-WT and
PAG-KO cells is shown: *, P 	 0.05; **, P 	 0.01; ***, P 	 0.001.
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least one of its substrates, the multidomain scaffolding adaptor
protein paxillin, showed enhanced tyrosine phosphorylation in
PAG-KO cells. The molecular mechanism of enhanced phosphor-
ylation of FAK and paxillin in PAG-KO cells remains to be deter-
mined but apparently reflects changes in the activity of SFKs and
PTPs which use FAK and paxillin as a substrate (57, 58).
Third, PAG-deficient BMMCs showed reduced calcium up-
take after activation with antigen. This could be attributed to the
reduced tyrosine phosphorylation and activity of PLC, which
cleaves the plasma membrane-bound phosphatidylinositol 4,5-
bisphosphate into diacylglycerol and inositol 1,4,5-trisphosphate;
the latter binds to its receptors and regulates the release of calcium
from intracellular organelles. Increases in cytoplasmic calcium
lead to the influx of extracellular calcium into the cytoplasm
through SOC channels. Reduced calcium uptake in PAG-KO cells
was observed not only after exposure to antigen but also after
activation with thapsigargin. This could be related to previous
findings documenting that PLC is involved in thapsigargin-in-
duced Ca2 entry (59–61) and reduced phosphorylation of PLC
in PAG-deficient cells. Furthermore, it has been shown that
STIM1, which is indispensable for opening SOC channels in mast
cells (62, 63), needs for its function expression and phosphoryla-
tion of SYK and LYN kinases (64). Enhanced tyrosine phosphor-
ylation of SHIP1 and, presumably, its increased enzymatic activity
(45, 46) could also contribute to decreased calcium mobilization
in activated PAG-KO cells.
Fourth, PAG-KO cells exhibited higher degranulation when
activated by SCF. SCF binds to KIT, a type III plasma membrane
receptor tyrosine kinase. After SCF binding, the receptor forms a
dimer that stimulates its intrinsic tyrosine kinase activity, creating
phosphotyrosine binding sites for FYN (65) and LYN (66) kinases
and many other signaling molecules, including SHIP1 and PLC
(67). These molecules are apparently integrated into signaling cir-
cuits regulated by PAG.
Fifth, it has previously been shown that activation through
FcεRI as well as KIT rapidly stimulates STAT5 tyrosine phosphor-
ylation and that STAT5 deficiency greatly reduces early and late
mast cell responses (68). PAG-KO cells exhibited lower tyrosine
phosphorylation of STAT5 when activated via FcεRI but not when
activated via KIT. This difference could be explained by the differ-
ent kinases involved in STAT5 phosphorylation. In SCF-activated
cells, KIT activates STAT5 partly through the tyrosine kinase JAK2
(69). In contrast, JAK2 is dispensable in IgE-activated cells, which
use FYN for STAT5 phosphorylation (53). Phosphorylated
STAT5 serves as a transcription factor for a number of inflamma-
tory genes (55). The reduced transcription of genes for cytokines
(TNF-, IL-6, and IL-13) and chemokines (CCL3 and CCL4) and
the reduced production of TNF-, IL-6, and IL-13 in antigen-
activated PAG-KO cells could be a direct consequence of impaired
STAT5 tyrosine phosphorylation.
Sixth, IgE-sensitized PAG-KO cells exhibited decreased che-
motaxis toward antigen. Mast cell chemotaxis is a complex
process dependent on numerous signaling molecules and cell sig-
naling pathways (52). The observed inhibition of tyrosine phos-
phorylation of the FcεRI  and  subunits, SYK, and LAT in an-
FIG 8 Phenotype rescue of PAG-KO BMMCs. (A, B) PAG-KO BMMCs were
transfected with the pCDH-PAG-myc vector (A) or the control empty vector
(pCDH) (B). Puromycin-resistant transfectants were isolated and attached to
fibronectin-coated slides. Then, the cells were fixed, permeabilized, and la-
beled for PAG-myc with an anti-Myc tag/anti-IgG–Alexa Fluor 488 conjugate
(green) and Hoechst 33258 (blue). Bars, 10 m. (C) Puromycin-resistant
pCDH-PAG-myc- or empty pCDH vector-transfected cells were solubilized,
and the presence of PAG-myc was determined by immunoblotting with anti-
Myc tag antibody. As loading controls, the membranes were developed for
HPRT. (D) PAG-WT or PAG-KO BMMCs stably transfected with the pCDH
vector (PAG-WTpCDH and PAG-KOpCDH, respectively) or PAG-KO
BMMCs transfected with pCDH-PAG-myc (PAG-KOpCDH-PAG-myc)
were sensitized overnight with IgE and then activated with antigen (100 ng/
ml). After 90 min the cells were fixed and stained with TNF- specific rabbit
antibody, followed by anti-rabbit IgG–Alexa Fluor 488 conjugate. The cells
were analyzed by flow cytometry, and the ratios of the mean fluorescence
intensity between activated and nonactivated cells were normalized to those
for the pCDH-transfected PAG-WT controls. Data show means  SEs calcu-
lated from three independent experiments. The statistical significance of the
differences is indicated: *, P 	 0.05; ***, P 	 0.001.
FIG 9 Decreased passive systemic anaphylaxis in PAG-KO mice. (A)
PAG-WT (n 
 17) and PAG-KO mice (n 
 16) were passively sensitized with
TNP-specific IgE (3 g/mouse) and 24 h later were challenged with antigen
(500 g per mouse) to induce systemic anaphylaxis. Body temperature re-
sponses at various time intervals after antigen administration were recorded.
Means  SEs are shown. Statistically significant differences (P 	 0.05) between
PAG-WT and PAG-KO mice are indicated by the black line below the curves.
i.v., intravenous. (B) Percentage of mast cells (KIT and FcεRI positive) in
peritoneal lavage fluid of PAG-WT and PAG-KO mice. (C) Serum IgE levels in
PAG-WT and PAG-KO mice. Data are means  SEs calculated for three (B) or
four (C) animals in each group.
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tigen-activated PAG-deficient cells could partly explain the
reduced antigen-induced chemotaxis (70). In contrast, PAG-KO
BMMCs showed no inhibition of KIT and LAT tyrosine phos-
phorylation after SCF triggering, and this could be related to a
normal chemotaxis response toward SCF in these cells. These
findings indicate that either PAG is not involved in the regulation
of KIT-mediated chemotaxis or the positive regulatory roles of
PAG are compensated for by activation of other molecules, such as
PTPs, which also bind to KIT (71, 72).
Seventh, experiments in vivo showed that PAG is a positive
regulator of passive systemic anaphylaxis, manifested by a de-
creased body temperature after administration of antigen into
IgE-sensitized mice. It is widely accepted that the anaphylactic
reaction is initiated by inflammatory mediators released from
mast cells (73, 74). Experiments with mice deficient in histidine
decarboxylase and therefore lacking histamine suggested that the
histamine released from mast cells controls body temperature
(39). Our finding of impaired degranulation in PAG-KO cells
could thus be directly related to the impaired anaphylactic re-
sponse. A positive regulatory role of PAG in passive systemic ana-
phylaxis is the first well-defined in vivo trait that is regulated
by PAG.
Although previous data from studies using other cell types
have implicated the phosphorylation of PAG and PAG-CSK inter-
actions as an important regulatory step in immunoreceptor sig-
naling (11, 12), no dramatic changes in tyrosine phosphorylation
of PAG were observed in the course of FcεRI-mediated activation
of BMMCs (19; our unpublished data). Furthermore, only a small
fraction of CSK colocalized with PAG in lipid raft fractions in
PAG-WT BMMCs. In PAG-KO cells, CSK was not detected in
lipid raft fractions, suggesting that in mast cells PAG could be a
major anchor of CSK in lipid rafts. These data corroborate the
results of a previous study documenting that PAG in lipid rafts
from mouse thymocytes is a major anchor of CSK (18). On the
other hand, they stand in contrast to the findings of another study
(17) showing that the amount of lipid raft-associated CSK in thy-
mus cells is not affected by the absence of PAG. However, we
would like to point out that different detergents and cell/detergent
ratios were used in these various studies and that the association of
proteins with lipid rafts is sensitive to these parameters (75, 76).
In summary, the data reported in this study provide compel-
ling evidence that PAG functions as both a positive and a negative
regulator of mast cell signaling, depending on the signaling path-
way involved. It seems that through interaction with CSK, PAG
serves as a negative regulator of SFKs, which are involved in both
positive and negative regulatory loops in mast cell activation. Fur-
thermore, we show for the first time that PAG-deficient mice ex-
hibit a distinct phenotype in terms of a passive systemic anaphy-
laxis response.
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37. Horáková H, Polakovičová I, Shaik GM, Eitler J, Bugajev V, Dráberová
L, Dráber P. 2011. 1,2-Propanediol-trehalose mixture as a potent quan-
titative real-time PCR enhancer. BMC Biotechnol. 11:41. http://dx.doi
.org/10.1186/1472-6750-11-41.
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7.3 C-TERMINAL SRC KINASE REGULATES FcɛRI ACTIVATION 
LEADING TO DEGRANULATION AND CYTOKINES/CHEMOKINES 
PRODUCTION IN OPPOSITE WAYS, INDEPENDENTLY OF THE 
TRANSMEMBRANE ADAPTOR PROTEIN PAG. 
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C-terminal Src kinase (CSK) is an important negative regulator of Src family 
tyrosine kinases (SFKs) that play critical roles in immunoreceptor signaling. CSK is 
brought in contiguity to the plasma membrane-bound SFKs via binding to a 
transmembrane adaptor PAG (Cbp). Recent finding that PAG can function as a positive 
or a negative regulator of bone marrow mast cells (BMMCs) signaling suggested that 
PAG and CSK have some non-overlapping regulatory functions in mast cell activation. 
To determine regulatory roles of CSK in FcεRI activation we derived from wild-type or 
PAG knockout (KO) mice BMMCs with reduced or enhanced expression of CSK and 
analyzed their FcεRI-mediated activation events. We found that antigen-activated 
BMMCs with CSK knockdown (KD) exhibited, in contrast to PAG-KO cells, 
significantly higher degranulation, calcium response, and tyrosine phosphorylation of 
FcεRI, SYK, and phospholipase C. On the other hand, cells with CSK-KD showed 
impaired phosphorylation of the transcription factor STAT5 and production of 
proinflammatory cytokines/chemokines. BMMCs with CSK-KD/PAG-KO resembled 
those with CSK-KD. The combined  data indicate that CSK and PAG are, respectively, 
negative and positive regulators of events leading to degranulation, whereas they are 













Aggregation of the high-affinity IgE receptor (FcɛRI)-IgE complexes by 
multivalent antigen in mast cells leads to the release of variety of mediators which play 
important roles in innate and adaptive immunity (1). Activated mast cells release 
mediators pre-stored in cytoplasmic granules, such as histamine, proteases, 
proteoglycans, and cytokines, as well as de novo synthetized lipids, cytokines, and 
chemokines. The first biochemically well defined step in FcɛRI-activated cells is 
tyrosine phosphorylation of the immunoreceptor tyrosine-based activation motives 
(ITAMs) in the cytoplasmatic domains of the FcɛRI β and γ subunits by a Src family 
kinase (SFK) LYN, followed by recruitment of protein tyrosine kinase (PTK) SYK to 
the FcεRI γ and its activation. LYN and SYK, together with FYN and some other PTKs 
phosphorylate tyrosine motives of transmembrane adaptor proteins (TRAPs) such as 
linker for activation of T cells (LAT; official name LAT1; (2), non-T cell activation 
linker (NTAL; official name LAT2; (3) and phosphoprotein associated with 
glycosphingolipid-enriched microdomains (PAG; official name PHAG1, also known as 
CSK-binding protein (Cbp); (4-6), which serve as anchors for other signal-transduction 
molecules that govern the biochemical signals responsible for initiating cell 
degranulation and cytokines and chemokines production. How exactly phosphorylation 
of the FcεRI subunits by LYN kinase is initiated is not completely understood and 
several models have been proposed, including the transphosphorylation model (7), lipid 
raft model (8) and PTK-protein tyrosine phosphatase (PTP) interplay model (9, 10). 
The catalytic activity of LYN kinase is tightly regulated by 
phosphorylation/dephosphorylation of two conserved tyrosines at position 397 (Y397) 
and 508 (Y508) (11-13). Phosphorylation of Y397 stabilizes the activation loop of the 
catalytic domain and increases LYN activity. In contrast phosphorylation of Y508, at the 
C terminus of LYN, promotes a conformation in which intramolecular binding of the 
Src homology 2 (SH2) domain with phosphorylated Y508 stabilizes the inactive 
conformation of the catalytic domain. Y397 of LYN is autophosphorylated in trans, 
whereas Y508 phosphorylation is catalyzed by C-terminal Src kinase (CSK). A critical 
role of CSK in cell physiology has been demonstrated by phenotype of mice lacing CSK. 
These mice die in early embryonic stages and their tissues possess SFKs with increased 
enzymatic activity (14-16). When CSK was inactivated in immature thymocytes, T cell 
development was significantly impaired (17). Furthermore, mice possessing 
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granulocytes with CSK inactivated by conditional mutagenesis, developed acute 
inflammatory responses (18).  
In contrast to SFKs, which are anchored to the plasma membrane via their N-
terminal myristoyl and/or palmitate moieties, CSK lacks a transmembrane domain and 
fatty acyl modifications and is predominantly localized in the cytosol (16). Thus, 
recruitment of cytosolic CSK to the vicinity of the plasma membrane-bound SFKs is 
involved in CSK-SFK cross-talk. An important anchor of CSK in the plasma membrane 
and regulator of CSK function is PAG. PAG is ubiquitously expressed and like other 
TRAPs, has a short extracellular domain, a transmembrane domain followed by 
palmitoylation site and a cytoplasmic domain with 10 potential tyrosine phosphorylation 
sites. In mouse PAG, phosphorylated Y314 binds CSK through its SH2 domain. Based 
on initial studies it has been postulated that PAG in resting T cells is constitutively 
phosphorylated and associated with CSK, which phosphorylates C-terminal tyrosines of 
SFKs in the vicinity of PAG, and inactivates them in this way. Activation through the T 
cell receptor (TCR) leads to rapid PAG dephosphorylation, which results in the release 
of CSK from PAG and relief of Csk-mediated inhibition of SFKs. This leads to an 
increased activity of LCK SFK, tyrosine phosphorylation of CD3 ITAMs and further 
propagation of the signal to downstream substrates (4, 19-21) 
In contrast to T cell, in mast cells FcεRI activation results in rapid tyrosine 
phosphorylation of PAG, peaking at 2 – 3 min after triggering and then returns to basal 
levels. This suggested that together with LYN and CSK, PAG initiates a negative 
regulatory loop contributing to signal termination (22, 23). It should be noted, however, 
that recent experiments showed that even in resting T cells, PAG shows a low basal 
level of tyrosine phosphorylation that increases upon T cell activation and that the 
inhibitory function of PAG on TCR is seen in effector, but not naive T cells (24, 25). 
Our recent study showed that bone marrow derived mast cells (BMMCs) with 
PAG knockout (KO) or PAG knockdown (KD) exhibited impaired antigen-induced 
degranulation, calcium response, tyrosine phosphorylation of FcεRI, SYK and some 
other signal transduction molecules, production of several cytokines and chemokines 
and chemotaxis. At the same time, enzymatic activites of LYN and FYN kinases were 
increased in nonactivated cells, suggesting the involvement of LYN and/or FYN-
dependent negative regulatory loop (26). These data, together with our finding of 
enhanced degranulation and c-KIT receptor phosphorylation in stem cell factor (SCF)-
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activated BMMCs with PAG KO, suggested that PAG can function as a positive or 
negative regulator of mast cell signaling, depending on the signaling pathway involved.     
To better understand contribution of CSK and PAG in FcεRI-mediated signaling 
we examined in this study antigen-induced activation events in BMMCs  from WT and 
PAG-KO mice with reduced or enhanced expression of CSK and corresponding 
controls. We also analyzed involvement of CSK and PAG in adhesion to fibronectin and 
chemotaxis towards antigen and SCF. Our data indicate that CSK and PAG in mast cells 
are, respectively, negative and positive regulators of events leading to degranulation and 
chemotaxis towards antigen and SCF, whereas they are both positive regulators of 
FcɛRI-induced production of cytokines and chemokines. 
 
 
MATERIALS AND METHODS  
 
Antibodies and reagents. The following monoclonal antibodies (mAbs) were used: 
mouse IgE mAb specific for 2,4,6-trinitrophenol (TNP) clone IGEL b4.1 (27), anti-
FcεRI β chain JRK (28), and SYK-specific mAb (29). Polyclonal antibodies specific for 
NTAL, LAT and LYN were prepared in this laboratory, by immunization of rabbits with 
the corresponding recombinant proteins or their fragments (30). Rabbit anti-IgE was 
prepared by immunization with whole IGEL b4.1. Polyclonal antibodies specific for 
CSK [catalogue number (Cat. No.) sc-286], STAT5 (Cat. No. sc-835), SHP-1 (Cat. No. 
sc-287), FYN (Cat. No. sc-16), phospholipase C (PLC) γ1  (Cat. No. sc-12943) and 
GRB2 (Cat. No. sc-255), as well as horseradish peroxidase (HRP)-conjugated goat anti-
mouse IgG (Cat. No. sc-2005), and goat anti-rabbit IgG (Cat. No. sc-2004) and donkey 
anti-goat IgG (Cat. No. sc-2056), were obtained from Santa Cruz Biotechnology Inc. 
Antibodies specific for phospho-LynY507 (in mouse LynY508) (Cat. No. 2731), phospho-
SFKsY416 (in mouse LYNY397; Cat. No. 2101), phospho-SYKY525/Y526 (Cat. No. 2711), 
phospho-STAT5Y694 (Cat. No. 9351), and phospho-SHP-1Y564 (Cat. No. 8849) were 
obtained from Cell Signaling. Phospho-LATY191 (Cat. No. 07-278) was obtained from 
Millipore. Anti-mouse β1 integrin specific antibody HM β1-1 (Cat. No. 553837) was 
purchase from BD Biosciences. Secondary antibody AF488-conjugated goat Ab 
specific for hamster IgG (Cat. No. A-21110) was obtained from Life Technologies). 
HRP-conjugated anti-phosphotyrosine mAb (PY20) and V450-conjugated rat anti-
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mouse CD107a (Cat. No. 560648) were obtained from BD Biosciences. Anti-mouse 
FcεRI-fluorescein isothiocyanate (FITC; Cat. No. 11-5898) and anti-mouse c-KIT 
(CD117)-allophycocyanin (APC; Cat. No. 17-1171) conjugates were obtained from 
eBiosciences. Polyclonal antibodies specific for mouse tumor necrosis factor (TNF)-α 
(Cat. No. 500-P64), interleukin (IL)-13 (Cat. No. 500-P178), recombinant (r) mouse 
TNF-α (Cat. No. 315-01A), rIL-13 (Cat. No. 210-13), and rIL-6 (Cat. No. 216-16) were 
obtained from PeproTech. Murine anti-IL-6 (Cat. No. 553414) was purchased from 
Becton Dickinson. Colloidal gold nanoparticles (Au-NPs; diameter, 30 nm; Cat. No. 
EM.GC30), consisting of approximately 2 × 1011 Au-NPs/ml, were obtained from BB 
International. TNP-bovine serum albumin (BSA) conjugate (15 to 25 mol TNP/mol 
BSA) was produced as described previously (31). 45Ca (specific activity, 773 MBq/mg 
Ca2+) and [γ-32P] ATP (specific activity, 222 TBq/mmol) were purchased from the 
Institute of Isotopes Co., Ltd. (Budapest, Hungary). All other reagents were from Sigma-
Aldrich. 
 
Mice and cells. Mice deficient in PAG and their WT littermates of C57BL/6 genotype 
were used in this study. The mice were maintained according to the protocols approved 
by the Animal Care and Usage Committee of the Institute of Molecular Genetics (Permit 
number 12135/2010-17210) and national guidelines (2048/2004-1020). PAG-KO mice 
were generated by modified bacterial artificial chromosome (BAC) technology as 
previously described (32), (33). For experiments, PAG-KO mice were mated with 
C57BL/6 mice and their F1 descendants were genotyped by PCR and the expression of 
PAG was verified at protein level as previously described (26). Bone marrow cells were 
isolated from the femurs and tibias of 8 - 12 week-old mice. The cells were cultured for 
6 - 10 weeks in RPMI-1640 medium supplemented with 100 U/ml penicillin, 100 µg/ml 
streptomycin, 71 µM 2-mercaptoethanol, minimum essential medium (MEM) non-
essential amino acids, 0.7 mM sodium pyruvate, 2.5 mM L-glutamine, 12 mM D-
glucose, recombinant mouse stem cell factor (SCF, 15 ng/ml, PeproTech EC), mouse 
recombinant interleukin (IL)-3 (15 ng/ml, PeproTech EC), and 10% fetal calf serum 
(FCS).  
 
Lentiviral vectors and gene transduction. Lentiviral transductions were done as 
described previously using HEK 293 T/17 packaging cells for virus preparation (26). A 
set of murine csk-specific short hairpin (sh) RNAs constructs based on pLKO.1 vector 
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(TRCN0000023735 [shRNA 35], TRCN0000023736 [shRNA 36], TRCN0000361164 
[shRNA 64], TRCN0000321790 [shRNA 90]) were purchased from Open Biosystems. 
Cells were transduced with individual shRNAs or with a pool of shRNAs prepared by 
mixing shRNAs 35, 36, 64, and 90, in equimolar ratios. Individual constructs or pool of 
the constructs (14 µg) was mixed with OptiMEM (1 ml; Invitrogen), 21 µl of  lentiviral 
packaging mix (Invitrogen), and 105 µl polyethyleneimine (PEI; Sigma) and virus was 
produced and transduced as described (26). The pilot degranulation experiments were 
performed with individual shRNAs vectors, but because the individual vectors gave 
similar results as the pooled shRNA vectors, further experiments were done with shRNA 
pool denoted in further text as CSK-KD. For experiments with stable CSK 
overexpression, a pMX plasmid encoding human Csk (hCsk), kindly provided by T. 
Brdička (Laboratory of Leukocyte Signaling, Institute of Molecular Genetics, Prague) 
was used for recloning casette of hCSK-mCherry into the vector pCDH-CMV-MCS-
EF1-Puro (Systembio; pCDH). For PCR, the forward primer 5´- 
AAATCTAGAGCCACCATGTCAGCAATACAGGCC-3´ (the XbaI restriction site is 
underlined) and reverse primer 3´-
TTTGCGGCCGCCTACTTGTACAGCTCGTCCAT-5´ (the NotI restriction site is 
underlined) was used. For recloning casette of hCSK-myc we used the same forward 
primer but different reverse primer 3´-
TTTGCGGCCGCTCACAGATCCTCTTCAGAGAT-5´ (the NotI restriction site is 
underlined). The constructs were verified by sequencing and denoted hCSK-mCherry 
and hCSK-myc. In all experiments, empty pLKO.1 or empty pCDH vectors were used 
as controls. In some experiments related to CD107a and β-glucuronidase detection, we 
also used pLKO.1 vector containing nontarget (NTG) shRNA (Sigma-Aldrich) as a 
control. 
 
Flow cytometry analysis. To quantify the surface expression of FcɛRI and c-KIT, 
BMMCs were double-stained with anti-mouse FcɛRI-FITC and anti-mouse c-KIT-
allophycocyanin antibodies for 30 min on ice. After labeling, the cells were washed 3 
times with ice-cold PBS and analyzed with an LSRII flow cytometer (BD Biosciences) 
and further processed using FlowJo software (Ashland, OR). For analysis of surface 
LAMP1, BMMCs were activated or not with various concentrations of antigen (10-100 
ng/ml) for 10 min at 37°C. Activation was stopped by centrifugation at 4°C. The cells 
were then resuspended in 50 μl of PBS-1% BSA containing 200-fold-diluted V450-
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conjugated rat anti-mouse CD107a and stained on ice for 30 min. After washing with 
PBS, the cells were examined as described above. For analysis of IgE internalization, 
IgE-sensitized cells were activated with antigen (500 ng/ml TNP-BSA) or not for  
various time intervals (5, 15, or 30 min) at 37°C. Activation were stoped by 
centrifugation at 4°C (300×g; 3min), cells were fixed by 4% paraformaldehyde for 15 
minutes and washed with PBS. IgE was stained using AF488-conjugated anti-mouse 
IgG (cross-reacting with IgE) and analyzed as described previously (34). To quantify 
surface expression of  β1 integrin, the cells were exposed for 30 min on ice to β1 integrin 
specific antibodies HM β1-1 followed by 30 min incubation with AF488-conjugated 
goat Ab specific for hamster IgG. After 30 min incubation, the cells were washed in ice-
cold PBS and evaluated as previously described (35).  
 
β-glucuronidase release and Ca2+ response. BMMCs were cultured for 4 h in SCF- 
and IL-3-free medium supplemented with TNP-specific IgE (1 μg/ml). The IgE-
sensitized cells were washed and degranulation assay, based on evaluation of β-
glucuronidase release, was performed and evaluated, as previously described (26). 
Fluorescence was determined by an Infinite 200M (Tecan) plate reader at 355-nm 
excitation and 460-nm emission wavelengths. Calcium response was analyzed using 
Fura-2, AM (Life Technologies) cytoplasmatic reporter, as described previously (26). 
Levels of intracellular Ca2+ were determined by spectrofluorometry using the Infinite 
200 M plate reader with excitation wavelengths at 340 and 380 nm and with a constant 
emission at 510 nm. 
 
Cytokines and chemokines detection. mRNA was extracted from IgE-sensitized and 
antigen-activated BMMCs using a TurboCapture 96 mRNA kit or RNeasy miniKit 
(Qiagen). Single-stranded cDNA was synthesized with M-MLV reverse transcriptase 
(Invitrogen) according to the manufacturer’s instructions. Real-time quantitative 
polymerase chain reaction (RT-qPCR) amplifications of cDNAs and oligonucleotide 
primers used were described previously (26), (36). Actin, GAPDH and ubiquitin were 
used as reference genes and the expression levels of TNF-α, IL-13, IL-6, CCL3, and 
CCL4 mRNAs were normalized to the geometric mean of the reference genes in 
nonactivated control cells. For quantification of cytokines, an immuno PCR method 
with nangold particles armed with immobilized DNA template and cytokine specific 
antibodies were used as described previously  (26), (37). Briefly, anti-TNF-α, anti-IL-
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6, or anti-IL-13 in 100 mM borate buffer (pH 9.5) was dispensed in 50-μl aliquots into 
the wells of a real-time 96-well plate (Eppendorf). After overnight incubation at 4°C, 
each well was washed four times with 200 μl of Tris-buffered saline (10 mM Tris-HCl, 
pH 7.4, 150 mM NaCl) containing 0.05% Tween 20 (TBST), and the remaining binding 
sites were blocked by 2 h of incubation at 37°C with TBST supplemented with 2% BSA. 
After washing, 50 μl of serial dilutions (0.1 to 100 ng/ml) of recombinant TNF-α, IL-6, 
or IL-13 (used for construction of calibration curves) or the tested samples diluted in 
PBS–1% BSA was added. The samples were incubated for 1 h at 37°C, and after 
washing with TBST, 50 μl of Au-NPs armed with thiolated DNA oligonucleotide 
template and with the corresponding cytokine-specific antibody was applied into each 
well. The wells were incubated for 1 h at 37°C and washed with TBST and deionized 
water. Fifty-microliter aliquots of qPCR master mix solution (see above) supplemented 
with 60 nM of the corresponding oligonucleotide primers were then dispensed into each 
well. The plates were sealed, and the amount of template DNA bound to antigen-
anchored functionalized Au-NPs was evaluated by real-time PCR using a Realplex4 
Mastercycler apparatus (Eppendorf). For calculation of cytokines concentrations, the 
corresponding CT values of the cytokines were substituted into the regression equations 
obtained from the calibration curves constructed from the concentration series of 
appropriate recombinant proteins. 
 
Cell chemotaxis and adhesion assay. Chemotaxis responses were assayed in 24-well 
Transwell chambers (Corning) with 8-μm-pore-size polycarbonate filters in the upper 
wells as previously described (26). Chemoattractants, antigen (250 ng/ml) or SCF (100 
ng/ml), in 0.6 ml chemotaxis medium (RPMI 1640 supplemented with 1% BSA and 20 
mM HEPES, pH 7.4) were added to the lower compartments and IgE-sensitized 
BMMCs (0.3 × 106 in 120 μl chemotactic medium) were added into each upper 
compartment. Cells migrating into the lower compartments during the 8 h of incubation 
(37°C, 5% CO2) were counted using an Accuri C6 flow cytometer (BD Biosciences). 
Adhesion to fibronection was quantified in 96-well plates coated overnight with 
fibronectin (10 µg/ml in PBS), blocked with 4% BSA in PBS (1 h at 37°C) and washed 
twice with PBS. IgE-sensitized BMMCs were loaded with Calcein-AM (4 mM) for 30 
min at 37°C, washed and transferred into the fibronectin-coated wells (105 cells/well). 
After activation with antigen  (100 ng/ml, 30 min) or SCF (100 ng/ml, 30 min), unbound 
cells were washed out using microplate washer (HydroSpeed, TECAN) and bound cells 
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were determined using an Infinite 200M Fluorometer with excitation and emission 
filters at 485 nm and 538 nm, respectively. 
 
Immunoprecipitation and immunoblotting. Whole-cell extracts from nonactivated or 
Ag-activated (250 ng/ml) cells were prepared by solubilizing cell pelletes in sodium 
dodecyl sulfate (SDS) sample buffer (38), followed by sonication and boiling of samples 
at 97°C for 5 min. Proteins were size fractionated on 10% SDS-polyacrylamide gel 
electrophoresis (39), electrophoretically transferred onto nitrocellulose membrane, and 
analyzed by immunoblotting with protein- or phosphoprotein-specific antibodies. 
Bound primary antibodies were detected with HRP-conjugated secondary antibodies. 
The HRP signal was detected with chemiluminescence reagent (40) and quantified by a 
Luminescent Image Analyzer LAS 3000 (Fuji Photo Film Co.). Aida software (Raytest 
GmbH) was used for signal quantification. Protein levels were normalized to the 
corresponding controls and/or GRB2 loading control protein after stripping of the 
membrane in stripping buffer (62.5 mM Tris-HCl, pH 6.7, 100 mM 2-mercaptoethanol, 
2% SDS) at 50oC for 30 min. For FcεRI immunoprecipitation, cells were solubilized in 
ice-cold immunoprecipitation buffer (25 mM Tris-HCl, pH 8.0, 140 mM NaCl, 1 mM 
Na3VO4, 2 mM EDTA, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 mM 
phenylmethylsulfonyl fluoride) supplemented with 0.2% Triton X-100. After incubation 
on ice for 30 min, the lysates were centrifuged (16,000 x g for 5 min at 4°C) and 
postnuclear supernatants were immunoprecipitated with rabbit anti-IgE antibody 
prebound to UltraLink-immobilized protein A (Pierce, Thermo Scientific). The 
immunoprecipitated proteins were size-fractionated by SDS-PAGE as described above, 
transferred to nitrocellulose membrane and immunoblotted with PY20 conjugate or with 
FcεRI-β chain-specific antibody followed by HRP-conjugated anti-mouse IgG.  
 
Immunocomplex kinase assay. The in vitro kinase assays were performed as 
previously described (41), with some modifications. FcεRI, LYN, and FYN were 
solubilized in immunoprecipitation buffer-0.2% Triton X-100. Proteins immobilized to 
antibody-armed protein A beads were washed with kinase buffer (25 mM HEPES–
NaOH, pH 7.2, 3 mM MnCl2, 0.1% Nonidet P-40, 100 mM Na3VO4, 20 mM MgCl2) 
and then resuspended in 25 μl kinase buffer supplemented with 2.5 μCi (92.5 kBq) of 
[γ-32P]ATP, 100 μM ATP, and 0.5 μg/μl of acid-denatured enolase as the exogenous 
substrate. The 32P-labeled proteins were size fractionated by SDS-PAGE, transferred to 
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a nitrocellulose membrane, and visualized by autoradiography. Films were quantified 
with Aida image analyzer software (Raytest). 
 
Statistical analyses. The significance of intergroup differences was evaluated by 
Student’s t test, except experiments evaluating calcium responses where intergroup 
differences were determined by one-way ANOVA with Tukey’s post-test; *, p<0.05; 
**, p<0.01; ***, p<0.001. Microsoft Excel 2010 or GrafPad Prism 5 (GraphPad 





Production of BMMCs with reduced or enhanced expression of CSK. To determine 
the role of CSK in mast cell signaling we prepared BMMCs from C57BL/6 mice with 
reduced or enhanced expression of CSK. For CSK silencing we used four CSK-specific 
shRNAs (35, 36, 64, and 90) in lentiviral pLKO.1 vector.  As controls, BMMCs 
transduced with empty pLKO.1 vector or pLKO.1 vector containing non-target 
sequence were used; because there were no significant differences between the results 
obtained with these different control vectors the data were pooled and are presented 
together as control pLKO.1 vector. Lentiviral-mediated delivery of individual CSK-
specific shRNAs resulted in a decrease of CSK protein to 26% (shRNA 35), 18% 
(shRNA 36), 26% (shRNA 64), and 36% (shRNA 90) when compared to cells 
transduced with control pLKO.1 (Fig. 1 A, B). BMMCs were also transduced with a 
pool of individual CSK-specific shRNAs, which reduced the level of CSK in these cells 
in average to 19% of controls (Fig. 1C, D). To get enhanced expression of CSK, 
BMMCs were transduced with pCDH lentiviral vector containing Csk cDNA tagged 
with mCherry (hCSK-mCherry) or with myc (hCSK-myc). Empty pCDH vector was 
used as a control. Ten days after transduction and growing in media with puromycin, 
more than 90% of cells transduced with hCSK-mCherry construct expressed detectable 
mCherry (not shown). Immunoblotting analyses showed that cells transduced with 
hCSK-mCherry or hCSK-myc vectors, denoted as CSK overexpressors (OE) exhibited, 
respectively, about 2- to 3-fold higher CSK levels than cells transduced with  empty 
pCDH vector (Fig. 1E and F). To find out whether altering CSK expression by 
transduction procedure and selection in puromycin has any effect on surface expression 
of FcɛRI and c-KIT receptor we examined various cell types by flow cytometry. We 
found that cells transduced with individual CSK-specific shRNAs (not shown), pooled 
CSK-specific shRNA (CSK-KD), or hCSK-mCherry and hCSK-myc (CSK-OE; Fig. 
1G) displayed surface expression of FcɛRI and c-KIT receptor comparable to 
corresponding control cells transduced with empty vectors (pLKO.1 and pCDH; Fig. 
1G and H).  
 
Enhanced degranulation and calcium response and reduced FcεRI-IgE complexes 
internalization in BMMCs with CSK-KD. To find out whether reduced expression of 
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CSK in BMMCs affects their FcεRI-mediated degranulation, the cells transduced with 
individual shRNAs (35, 36, 64 and 90) or pooled shRNAs were sensitized with IgE and 
activated with various concentrations of antigen. Degranulation was quantified based 
on β-glucuronidase released from the cells upon antigen exposure or spontaneously. In 
non-activated cells there were no significant changes in spontaneous β-glucuronidase 
released from the cells transduced with various individual shRNAs vectors or empty 
vector (Fig. 2A). After FcɛRI triggering with antigen at a concentration 100 ng/ml or 
250 ng/ml, significantly increased degranulation was observed in all cell types 
transduced with various shRNAs when compared to pLKO.1 control cells (Fig. 2A). 
Significantly increased degranulation was also observed when cells transduced with 
pooled shRNAs were used for transduction (Fig. 2 B). It should be noted that total 
amount of β-glucuronidase present in all cell types was similar (not shown), indicating 
a negative regulatory role of CSK on FcεRI-mediated degranulation, rather than on 
enhanced production of β-glucuronidase. Because the results obtained with cells 
transduced with individual shRNAs or pooled shRNAs were similar, we decided to 
combine the data and present them as data from cells with CSK-KD. 
Previous studies showed that mast cell degranulation is accompanied by enhanced 
surface expression of CD107a (LAMP1) (42). To determine whether CSK has any effect 
on this process, we examined levels of CD107a expression by flow cytometry in BMMC 
with CSK-KD and control cells before and after activation with antigen. The results 
showed that BMMCs with CSK-KD activated for 10 min with various concentrations 
of antigen exhibited significantly higher surface expression of CD107a than pLKO.1 
control cells (Fig 2C). We also examined CD107a expression in BMMCs transduced 
with empty pCDH vector or the vectors possessing hCSK-mCherry or hCSK-myc 
constructs and found no significant differences in CD107a surface expression among 
the cell types activated with various concentrations of antigen (Fig. 2D).  
 FcɛRI-mediated activation induces rapid Ca2+ mobilization, which is required for 
mast cell degranulation (43). To determine the role of CSK in Ca2+ signaling, IgE-
sensitized cells with CSK-KD or CSK-OE (hCSK-mCherry and hCSK-myc) were 
loaded with intracellular Ca2+ indicator Fura-2 and mobilization of Ca2+ was measured 
upon antigen stimulation.  We found that Ca2+ levels were significantly increased in 
BMMCs with CSK-KD when compared to cells transduced with empty pLKO.1 vector 
(Fig. 2E). On the other hand, no significant difference in antigen-mediated Ca2+ 
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mobilization was observed among BMMCs transduced with pCDH vector alone or 
possessing hCSK-mCherry or hCSK-myc (Fig. 2F).  
To determine whether enhanced degranulation and calcium response in BMMCs 
with CSK KD are related to changes in the FcεRI internalization, we used flow 
cytometry and measured fraction of total IgE remaining on the cell surface at various 
time intervals after antigen-mediated aggregation of the FcεRI-IgE complexes. We 
found that upon antigen triggering BMMCs with CSK-KD showed significantly reduced 
internalization of the antigen-IgE-FcεRI complexes when compared to pLKO.1 control 
cells (Fig. 2G).   
 
Negative and positive regulatory roles of CSK in tyrosine phosphorylation of early 
signal-transduction molecules. To contribute to understanding the molecular 
mechanism by which CSK regulates degranulation and Ca2+ response after FcɛRI 
triggering, we first examined tyrosine phosphorylation profiles. We found no dramatic 
differences in global tyrosine phosphorylation between nonactivated BMMCs with 
CSK-KD and control cells (pLKO.1). One minute after antigen-mediated activation, 
control cells exhibited enhanced tyrosine phosphorylation of several substrates, which 
was down-regulated 5 min after triggering. Similar set of proteins showed enhanced 
phosphorylated in cells with CSK-KD, but the extent of phosphorylation was for most 
of the proteins higher than in control cells at 1 and 5 min after triggering (Fig. 3A). 
Next we analyzed the role of CSK in tyrosine phosphorylation of individual 
proteins involved in early signal transduction events after FcɛRI triggering. BMMCs 
with CSK KD or the corresponding control cells were sensitized with IgE, activated or 
not with antigen for various time intervals, solubilized, and tyrosine phosphorylation of 
the immunoprecipitated FcɛRI chains was examined by immunoblotting (Fig. 3B) and 
analyzed by densitometry (Fig. 3C). Data show that after antigen-mediated activation, 
FcεRI β and γ chains are rapidly tyrosine phosphorylated in both cell types. However, 
cells with CSK KD, when compared to corresponding control cells, exhibited 
significantly higher phosphorylation of the FcεRI β and γ chains in nonactivated state 
as well as 1 min after triggering. 
 In further experiments we examined tyrosine phosphorylation of SYK and PLCγ 
in antigen-activated BMMCs using phosphotyrosine specific antibodies and found that 
both proteins showed higher tyrosine phosphorylation in cells with CSK-KD than 
control cells (Fig. 3D - F).   
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Previous study showed that inhibition of CSK enzymatic activity in T cells 
resulted in enhanced tyrosine phosphorylation of adaptor protein LAT (44). However, 
there are no data on the regulatory role of CSK for another adaptor protein similar to 
LAT, but absent in nonactivated T cells, NTAL, which is expressed together with LAT 
in mast cells (45). Next we therefore examined tyrosine phosphorylation of both adaptor 
proteins in antigen-activated BMMCs with CSK-KD and controls. In nonactivated cells, 
tyrosine phosphorylation of LAT and NTAL was low and comparable in both cell types. 
When compared to corresponding controls, antigen-activated BMMCs with CSK-KD 
exhibited comparable tyrosine phosphorylation of the LAT adaptor protein but 
significantly decreased tyrosine phosphorylation of the NTAL adaptor (Fig. 3G - I).  
Tyrosine phosphorylations of the FcεRI subunits and also LAT and NTAL are 
mediated at least in part by LYN kinase activity (46). Enzymatic activity of LYN is 
regulated in positive way by auto-phosphorylation of its Y397 and negative way by CSK-
mediated phosphorylation of its C-terminal Y508 (16).  To determine the role of CSK in 
phosphorylation of these tyrosines, the cells were sensitized with IgE, activated or not 
with various concentration of antigen, and analyzed by immunoblotting with 
phosphotyrosine specific antibodies. In control BMMCs, transduced with empty 
pLKO.1 vector, LYNY508 was phosphorylated in nonactivated cells and after activation 
its phosphorylation did not show significant changes (Fig. 3J and K). As expected, 
BMMCs with CSK-KD, when compared to controls, showed significantly reduced 
phosphorylation of LYNY508 in nonactivated as well as activated cells. When auto-
phosphorylation of LYNY397 was analyzed in nonactivated cells, no significant changes 
were observed between BMMCs with CSK-KD and control cells. After antigen-
mediated activation, both cell types exhibited significant decrease in phosphorylation of 
SFKsY397 and again no significant difference was observed between them (Fig. 3J and 
L).  
Protein tyrosine kinases are negatively regulated by protein tyrosine phosphatases 
(PTPs) (47) . PTP, Src homology region 2 domain-containing phosphatase-1 (SHP-1), 
is involved in regulation of FcεRI signaling and directly interacts with LYN (48). To 
determine whether CSK is involved in SHP-1 regulation in the course of FcεRI-
mediated activation, we analyzed phosphorylation of SHP-1by immunoblotting. In 
nonactivated cells, there was only weak tyrosine phosphorylation of this phosphatase 
and CSK had no significant effect on it. Upon antigen stimulation, phosphorylation of 
SHP-1 was significantly higher in cells with CSK-KD than pLKO.1 control cells (Fig. 
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3M and N). The data suggest that CSK is a negative regulator of SHP-1 tyrosine 
phosphorylation.    
 
Different regulation of LYN, FYN, and FcεRI-bound kinase activity by CSK. The 
observed changes between BMMCs with CSK KD and corresponding controls in 
phosphorylation of signal transduction molecules led us to compare regulatory role of 
CSK on LYN kinase activity in nonactivated and antigen-activated cells. For these 
experiments LYN was immunoprecipitated and its auto-phosphorylation and 
phosphorylation of the exogenous substrate, an acid-denaturated enolase, was examined 
by an in vitro kinase assay. LYN kinases from nonactivated BMMCs with CSK-KD and 
control cells exhibited comparable enzymatic activities as reflected by similar 
autophosphorylation and enolase phosphorylation (Fig. 4A - C). However, upon antigen 
stimulation, immunoprecipitated LYN from cells with CSK-KD showed lower auto-
phosphorylation but no significant difference in phosphorylation of enolase when 
compared to LYN from control cells (Fig. 4A - C).  
We also analyzed in the kinase assay an enzymatic activity of FYN kinase, which 
is an important regulator of FcεRI-induced degranulation and found no difference in 
auto-phosphorylation and enolase phosphorylation between FYN immunoprecipitated 
from non-activated or antigen-activated BMMC with CSK-KD or control cells (Fig. 4D 
- F).  
Finally, we examined phosphorylation of FcɛRI subunits by the FcεRI-associated 
kinases. The FcεRI-IgE complexes were isolated by immunoprecipitation from 
nonactivated or antigen-activated BMMCs with CSK-KD or control cells and examined 
by an in vitro kinase assays. In non-activated cells FcεRI β and γ subunits showed 
significantly higher phosphorylation when derived from BMMCs with CSK-KD than 
from control cells. After activation there was significant increase in phosphorylation of 
the receptor subunits from control cells, but no significant change when the receptor 
was obtained from cells with CSK-KD (Fig. 4G – I). These data are in accord with 
tyrosine phosphorylation of the FcɛRI subunits as detected by immunoblotting (Fig. 3B, 
C). 
 
CSK is a positive regulator of cytokines and chemokines production, and STAT5 
phosphorylation. Production and release of cytokines and chemokines is cardinal 
feature of the FcεRI-induced mast cell activation (1). In further experiments we 
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therefore compared these responses between BMMCs with CSK-KD and pLKO.1 
control cells. IgE-sensitized cells were activated with antigen and mRNA levels of 
various cytokines (TNF-α, IL-13, IL-6) and chemokines (CCL3 and CCL4) were 
analyzed by RT-qPCR. Interestingly, the mRNA levels of all studied cytokines (Fig. 
5A) and chemokines (Fig. 5B) were significantly reduced in BMMCs with CSK-KD 
when compared to control cells. Next, we measured secretion of the cytokines into the 
media. In nonactivated cells there were no significant differences in basal levels of 
secreted cytokines between BMMCs with CSK-KD and control cells. Upon 6-hr 
stimulation with various concentration of antigen, concentrations of secreted TNF-α 
(Fig. 5C), IL-13 (Fig. 5D) and IL-6 (Fig. 5E) were significantly lower in BMMCs with 
CSK-KD than in control cells. It is known that TNF-α is an early secreted mediator in 
antigen-activated cells (49, 50). Therefore, we also examined secretion of TNF-α at 
earlier time points. Cells with CSK-KD exhibited significantly lower TNF-α secretion 
into the media even 1 h and 2 h after antigen triggering (Fig. 5F). 
To understand the mechanism how CSK positively regulates FcεRI-induced 
cytokines production, we examined tyrosine phosphorylation of transcription factor 
STAT5, which is one of the key regulators of cytokines production in mast cells (51). 
In control BMMCs antigen induced gradual increase of STAT5 tyrosine 
phosphorylation, but in BMMCs with CSK-KD no such increase was observed and 
significant difference between cells with CSK KD and controls in STAT5 
phosphorylation was observed 5 min after FcεRI triggering (Fig. 5G and H).  
 
CSK regulates adhesion to fibronectin and chemotactic responses in opposite 
direction. We also examined a role of CSK in adhesion of antigen- or SCF-activated 
BMMCs on fibronectin-coated wells. Upon activation with various concentrations of 
antigen, BMMCs with CSK-KD exhibited significantly lower adhesion on fibronectin 
than control cells at all antigen concentrations tested (Fig 5I). When the cells were 
activated by SCF, cells with CSK KD exhibited less dramatic reduction of adhesion to 
fibronectin than control cells; the difference was significant when SCF was used at a 
concentration giving maximum adhesion (50 ng/ml; Fig. 5J). It should be noted that 
reduced adhesion in cells with CSK KD was not caused by changes in expression of β1-
integrine (not shown). 
An important feature of mast cells is their ability to migrate towards 
chemoattractant, which can be simulated by an in vitro transwell-migration assay (52). 
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When compared to control cells, BMMCs with CSK-KD exhibited enhanced migration 
towards antigen as well as towards SCF, which is more potent chemoattractant than 
antigen (Fig. 5K). 
 
Production of PAG-KO BMMCs with reduced or enhanced CSK expression. 
Previous studies showed that CSK is anchored to the plasma membrane by 
transmembrane adaptor protein PAG (4, 5, 26). Removal of PAG by gene KO caused 
positive or negative regulation of mast cell activation depending on the activation event 
analyzed. Properties of BMMC with PAG KO were in part similar to those with CSK 
KD described in this study. However, because PAG interacts with many other signal 
transduction molecules (24), we also examined properties of PAG-deficient mast cells 
with reduced or enhanced expression of CSK. To this end, we used BMMCs from PAG 
KO mice and performed CSK-KD by lentiviral-mediated delivery of CSK-specific 
shRNA (pool of four shRNAs), followed by selection of puromycin-resistant clones, as 
described above. Immunoblotting and densitometry analyses of such cells showed a 
decreased expression of CSK by approximately 80% when compared to control cells 
transduced with an empty pLKO.1 vector (Fig. 6A and B). For production of PAG-KO 
BMMCs with enhanced expression of CSK, we used lentiviral system for transduction 
of pCDH vectors containing CSK cDNA tagged with mCherry (hCSK-mCherry) or myc 
(hCSK-myc). As a control, empty pCDH vector was used. Immunoblotting analyses 
combined with densitometry showed approximately 2- or 3-fold increase of CSK 
expression in the cells transduced with hCSK-mCherry or hCSK-myc, respectively (Fig. 
6C and D). More than 90% of PAG-KO BMMCs transduced with hCSK-mCherry or 
hCSK-myc expressed detectable mCherry (not shown).  
To find out whether altering CSK expression in BMMCs with PAG KO has any 
effect of FcεRI and c-KIT expression, we examined surface expression of all transduced 
cell types and found that CSK-KD or CSK-OE in PAG-KO BMMCs had no significant 
effect on the surface expression of the FcɛRI and c-KIT (Fig. 6E and F).  
 
PAG-KO BMMCs with CSK-KD exhibit enhanced degranulation, calcium 
response and tyrosine phosphorylation of early signal transduction proteins. Our 
previous study showed that BMMCs isolated from mice with PAG-KO exhibited 
significantly reduced tyrosine phosphorylation of several molecules involved in early 
FcεRI-mediated signaling, including FcɛRI chains, SYK, LAT, and pPLCγ, which 
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resulted in reduced degranulation and Ca2+ mobilization after antigen-mediated 
activation (26). On the other hand this study showed that degranulation and Ca2+ 
responses were enhanced in cells with CSK KD. In order to better understand regulatory 
roles and cross-talks between CSK and PAG during FcεRI-mediated mast cell signaling, 
we first compared degranulation and Ca2+ response in PAG-KO BMMCs with CSK-KD 
(labeled as CSK-KD/PAG-KO) and PAG-KO cells with normal level of CSK 
(pLKO.1/PAG-KO).  
To determine β-glucuronidase response in BMMCs with CSK-KD/PAG-KO, the 
cells were sensitized with IgE and then activated with various concentrations of antigen 
(Fig. 7A). Results showed that even nonactivated CSK-KD/PAG-KO cells exhibited 
enhanced β-glucuronidase release in comparison with pLKO.1/PAG-KO control cells. 
Upon stimulation with various concentration of antigen, CSK-KD/PAG-KO cells 
exhibited significantly elevated levels of β-glucuronidase in all antigen concentration 
tested when compared to the control cells (Fig 7A). Next, we determined surface 
localization of CD107a in antigen-activated or nonactivated CSK-KD/PAG-KO cells. 
Consistent with the β-glucuronidase release, we observed significantly increased surface 
localization of CD107a after antigen activation, when compared to pLKO.1 control cells 
(Fig. 7B). Next, we analyzed CD107a surface localization in PAG-KO cells with 
enhanced expression of CSK. PAG-KO BMMCs were transduced with hCSK-mCherry 
or hCSK-myc constructs (CSK-OE) and CD107a was analyzed by flow cytometry. We 
found a moderate decreased surface expression of CD107a in CSK-OE/PAG-KO 
BMMCs when compared to control cells (Fig. 7C). We also analyzed Ca2+ response in 
BMMCs with CSK-KD/PAG-KO. The cells were sensitized with IgE, loaded with Fura-
2 and activated with antigen. In such cells Ca2+ response was significantly higher when 
compared to Ca2+ response in control cells (Fig. 7D). These data indicate that CSK in 
BMMCs is a negative regulator of degranulation and Ca2+ response, regardless of the 
presence of PAG adaptor. 
To further explore whether PAG has a role in downstream of FcεRI signaling in 
BMMCs with CSK-KD, we analyzed tyrosine phosphorylation of the antigen-
aggregated FcɛRI in CSK-KD/PAG-KO and control cells. Cells were sensitized with 
IgE, activated or not with antigen for various time intervals and tyrosine 
phosphorylation of FcɛRI in immunoprecipitates were examined (Fig. 7E). 
Quantification of the data showed that tyrosine phosphorylation of FcɛRI β and γ chains 
were significantly increased in BMMCs with CSK-KD/PAG-KO in comparison with 
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control cells (Fig. 7F). Further, we examined tyrosine phosphorylation of SYK (pSYK), 
LAT (pLAT) and NTAL (pNTAL) in IgE-sensitized and antigen-activated or 
nonactivated CSK-KD/PAG-KO BMMCs cells (Fig. 7G). Statistical evaluation of 
intergroup differences showed an increased tyrosine phosphorylation of SYK in CSK-
KD/PAG-KO cells after antigen stimulation in comparison with control cells (Fig. 7G 
and H). Phosphorylation of LAT and phosphorylation of NTAL was also significantly 
higher in antigen-activation CSK-KD/PAG-KO cells than control BMMCs (Fig. 7G, I 
and J).  
Collectively, these data suggested that CSK deficiency is dominant over PAG 
deficiency in BMMCs with respect to antigen-induced degranulation and Ca2+ 
mobilization. On the other hand, PAG-deficient BMMCs with CSK-KD exhibit 
different phosphorylation pattern of adaptor protein LAT and NTAL in comparison with 
CSK-KD cells.  
 
PAG-KO BMMCs with CSK-KD exhibit reduced cytokines production, STAT5 
phosphorylation and adhesion to fibronectin, but enhanced chemotaxis towards 
antigen and SCF. Our previous study showed that in antigen-activated BMMCs, PAG 
adaptor exhibited positive regulatory role in cytokines secretion and migration towards 
antigen (26). In this study we observed a positive regulatory role of CSK on cytokines 
and chemokines production but a negative regulatory role on antigen-mediated 
chemotaxis. To determine whether there is an additive effect of PAG-KO and CSK-KD 
in regulation of these signaling pathways, we further examined secretion of cytokines 
into the media in antigen-stimulated BMMCs with CSK-KD/PAG-KO and control cells, 
with PAG-KO alone. In nonactivated cells there were no significant differences in basal 
level secretions of the cytokines between BMMCs with CSK-KD/PAG-KO and 
pLKO.1/PAG-KO control cells. Upon stimulation with various concentration of 
antigen, secretion of TNF-α (Fig. 8A) and IL-13 (Fig. 8B) was significantly decreased 
in cells with CSK-KD/PAG-KO when compared with control cells at the highest 
concentration of antigen used. No significant inhibition was observed between the cells 
when IL-6 production was analyzed. (Fig. 8C).  In agreement with this results we 
observed significantly decreased phosphorylation of STAT5 in CSK-KD/PAG-KO 
cells, which was reduced not only upon antigen activation but also in nonactivated cells 
(Fig. 8D and E).  
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Next, we examined adhesion on fibronectin-coated wells of IgE-sensitized 
BMMCs with CSK-KD/PAG-KO and control cells activated with antigen or SCF. Upon 
activation, BMMCs with CSK-KD/PAG-KO exhibited significantly reduced adhesion 
to fibronectin than control cells at all concentrations of antigen (Fig. 8F) and SCF (Fig 
8G) tested.   
To determine cross-talk between PAG and CSK in chemotaxis response, we 
examined in transwell-migration assay, migration of BMMCs with normal level of PAG 
and CSK (WT), PAG-KO and CSK-KD/PAG-KO towards antigen or SCF (Fig. 8H). 
There were no differences among the cell types in the absence of chemoattractant. In 
cells exposed to antigen, PAG-KO reduced chemotaxis, as expected (26), while cells 
CSK-KD/PAG-KO exhibited enhanced migration towards antigen in comparison with 
cells with cells with PAG-KO alone. When we analyzed chemotaxis towards SCF, the 
migration of cells with CSK-KD/PAG-KO was significantly higher than migration of 
WT cells and PAG-KO cells (Fig. 8F). It should be noted that WT cells showed similar 
migration as cells transduced with empty pLKO.1 vector.  The data suggested, that both 




Our previous report on the biochemical activity and responses of PAG-deficient 
mast cells (26) has provided a glimpse of positive and negative regulatory roles of PAG 
in various signaling pathways. PAG serves as an anchor for CSK and in this way could 
negatively regulate activity of SFKs. However, PAG interacts with numerous other 
signal transduction proteins (24), whose contribution to FcεRI- or c-Kit-mediated mast 
cell activation is poorly understood. Here we explored the role of CSK-PAG cross-talk 
in mast cell activation by examining activation of BMMCs with CSK-KD or CSK-OE 
alone or in combination with PAG-KO. Summary of the data comparing properties of 
FcεRI-activated control BMMC and BMMCs with CSK-KD, CSK-KD/PAG-KO (this 
study) and PAG-KO (26) is shown in Table 1 and Figure 9. Several lines of evidence in 
this study indicate that CSK regulates FcεRI-mediated activation events leading to 
degranulation and chemotaxis versus cytokines/chemokines production in opposite 
ways. At least some of them seem to be regulated by CSK independently of the PAG. 
First, in IgE-sensitized BMMCs with PAG-KO exposure to antigen resulted in 
significantly decreased degranulation when compared to antigen-activated wild-type 
cells (26), indicating that PAG is a positive regulator in this process. When BMMCs 
with CSK-KD were activated by antigen, degranulation was significantly increased as 
determined by measurement of β-glucuronidase release or levels of CD107a expressed 
on the cell surface. Furthermore, BMMCs with PAG-KO combined with CSK-KD 
exhibited antigen-induced degranulation higher than PAG-KO control cells, resembling 
to cells with CSK-KD. These data suggested that negative regulation of FcεRI-induced 
degranulation by CSK does not require PAG. Reduced degranulation in BMMCs with 
PAG-KO cells and enhanced degranulation in cells with CSK-KD and PAG-KO/CSK-
KD could be explained by existence of CSK binding proteins, other than PAG, which 
are more relevant for the inhibitory action of CSK than PAG and by competition for the 
substrate between PAG and hypothetical other adaptors. Thus, in the absence of PAG, 
CSK could bind more to the other adaptors and inhibit more efficiently relevant SFKs. 
Our finding that only relative small fraction of CSK (~4%) is found in 1% Brij 96-
resistant membranes, that this fraction is not changed after FcεRI triggering and that the 
fraction disappears in cell extracts from PAG-KO BMMCs (26), suggests that the 
hypothetical CSK anchor resides in detergent soluble fraction of the cell extracts. 
Experiments with BMMCs with LYN-KO showed that LYN is a negative regulator of 
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mast cell degranulation (23, 53, 54). However, increased degranulation in cells with 
CSK-KD and presumably increased activity of LYN kinase in vivo, as revealed by 
enhanced FcεRI phosphorylation, suggested that other SFKs with positive regulatory 
role in FcεRI-mediated degranulation, such as FYN (53), are also affected. It should be 
noted, however, that in in vitro kinase assay enzymatic activity of FYN kinase, was not 
affected by CSK-KD.  
Enhanced release of β-glucuronidase was observed not only after antigen-induced 
stimulation, but also in resting cells with CSK-KD. This finding together with enhanced 
phosphorylation of FcεRI β and γ subunits in nonactivated cells indicated that CSK 
contributes to setting activation threshold in mast cells. This conclusion is consistent 
with previous finding that CSK-deficient granulocytes exhibit elevated spontaneous and 
ligand-induced degranulation (18). When BMMCs with PAG and two- to three-fold 
increased levels of CSK were examined and compared to control cells, no significant 
decrease in spontaneous or FcεRI-induced degranulation was observed. However, cells 
with CSK-OE combined with PAG-KO exhibited significant inhibition of antigen-
induced degranulation, suggesting that PAG could compete for CSK binding with other 
more relevant CSK-binders. Negative regulatory role of CSK was previously observed 
in rat basophilic leukemia cells (RBL-2H3) in which enhanced expression of CSK 
delayed histamine release observable only a few minutes upon antigen stimulation (55). 
In molecular terms, CSK in the vicinity of SFKs phosphorylates their C-terminal 
tyrosines and in this way inactivates their kinase activity. As expected, in cells with 
CSK-KD, phosphorylation of LYN-Y508 was significantly reduced in nonactivated cells 
and after activation phosphorylation of this tyrosine remained significantly lower than 
in controls. In control cells, FcεRI-triggering did not induce any decrease in tyrosine 
phosphorylation of LYN C-terminal tyrosine, which is in line with our previous study 
(56) indicating importance of this tyrosine for control of both proximal and distal 
signaling pathways in FcεRI-activated cells. On the other hand, phosphorylation of LYN 
positive regulatory tyrosine Y397 was not affected by CSK-KD and was down-regulated 
after antigen stimulation in both control cells and cells with CSK-KD. Although there 
was dramatic defect in phosphorylation of Y508 in Lyn from BMMCs with CSK-KD, 
kinase activity measured by an in vitro kinase assay with exogenous substrate enolase 
was not different when LYN was immunoprecipitated from cells with CSK-KD or 
control cells, and auto-phosphorylation was even significantly decreased in LYN from 
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cells with CSK-KD. This could be caused in part by coprecipitation of the inhibitory 
molecules such as phosphatases. In fact, using antibody specific for SHP-1Y564 we found 
significantly increased phosphorylation of this phosphatases, which is known to be 
present in complexes containing FcεRI and LYN (57), is likely to recognize LYN as a 
substrate via kinase tyrosine-based inhibitory motif (KTIM) located within the kinase 
domain of the kinase (58), and dephosphorylates LYN at Y396 (57).  
Second, antigen-activated BMMCs with PAG-KO, exhibited significantly 
decreased calcium response when compared to control cells (26). In contrast, BMMCs 
with CSK-KD showed significantly higher calcium response. In BMMCs with CSK-
KD combined with PAG-KO, calcium response was significantly higher than in cells 
with PAG-KO alone. Calcium response in antigen-activated cells is dependent on LYN-
SYK-LAT-PLCγ-dependent signaling pathway (53). CSK-KD had stimulatory effect on 
this pathway as reflected by significantly increased tyrosine phosphorylation of SYK, 
LAT (only in cells with CSK-KD/PAG-KO), and PLC-γ. Interestingly, in BMMCs with 
CSK-OE no significant changes in antigen-induced calcium response were observed, 
which is in accord with previous studies using WEHI-231 cells in which CSK-OE was 
unable to alter BCR-induced signaling  (59) and RBL-2H3 cells in which CSK-OE only 
delayed calcium response (55). Data obtained with BMMCs contrast with those showing 
that overexpression of CSK in T cell line resulted in significant inhibition of TCR-
induced activation events (60). Our data with BMMCs are, however, in line with recent 
experiments showing that in TCR-activated T cells with CSK catalytic activity inhibited 
by a small inhibitor, phosphorylation of ZAP-70, LAT and PLCγ were significantly 
increased when compared to control cells (44).   
Third, despite the fact that LAT and NTAL TRAPs share structural similarities (3, 
61), they are differently phosphorylated depending on signaling pathway used (2, 62). 
When pLKO.1 control BMMCs were compared with CSK-KD cells, there was no 
difference in basal tyrosine phosphorylation of LAT and NTAL. However, after 
activation,   LAT was phosphorylated to the same extent in both cell types, whereas 
NTAL showed significantly lower phosphorylation in cell with CSK-KD. In our 
previous study we found that LAT was less phosphorylated in cells with PAG-KO than 
control cells and therefore, we expected that combined CSK-KD/PAG-KO will deepen 
the defect in LAT phosphorylation. However, cells with PAG-KO/CSK-KD showed 
higher LAT phosphorylation than cells with PAG-KO alone. Even more dramatic 
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differences were observed when NTAL phosphorylation was compared in cells with 
CSK-KD alone, PAG-KD alone, PAG-KO/CSK-KD and corresponding controls. CSK-
KD alone reduced NTAL phosphorylation significantly, PAG-KO alone had only week 
effect (not shown), but PAG-KO combined with CSK-KD significantly enhanced 
NTAL phosphorylation. Apparently, complex interactions involving SFKs modulated 
by CSK, TRAPs and phosphatases are involved in the processes. The observed 
difference in phosphorylation of LAT and NTAL in antigen-activated cells with or 
without CSK could be in part explained by the finding that phosphotyrosines in LAT 
could bind not only positive regulators but also negative regulators and that there is a 
competition between LAT and NTAL for binding of the phosphatases (63). Taking into 
account that NTAL and LAT occupy different membrane microdomains (45), removal 
of CSK, PAG or both these signal transduction regulators could have different effect on 
phosphorylation of LAT and NTAL adaptors, binding of kinases and phosphatases to 
the adaptors and to other target structures, and modulation of FcεRI-mediated activation 
as described in this study.  
Fourth, FcεRI activation rapidly stimulates tyrosine phosphorylation of the 
transcription factor STAT5, which serves as a positive regulator of expression of genes 
for cytokines and chemokines (64, 65). In FcεRI-activated BMMCs with PAG-KO 
tyrosine phosphorylation of STAT5, transcription of cytokine genes, and production of 
cytokines were substantially reduced (26). Similar inhibition of STAT5 
phosphorylation, transcription of cytokine genes TNF-α, IL-13 and IL-6, and production 
of the corresponding cytokines was observed in BMMCs with CSK-KD. Interestingly, 
cells with PAG-KO/CSK-KD, when compared to cells with PAG-KO alone, exhibited 
higher inhibition of TNF-α and IL-13, but there was no significant difference when IL-
6 was examined. The observed additive effects of PAG-KO and CSK-KD suggests that 
CSK and PAG could regulate cytokine production by independent pathways which 
converge at the level of STAT5 tyrosine phosphorylation. CSK could regulate this 
pathway through phosphorylation of negative regulatory tyrosine in FYN, which 
phosphorylates STAT5 (51), whereas PAG through interaction with signal transduction 
molecules of the PAG interactome (24). Reduced cytokines production could by also 
direct consequence of enhanced phosphorylation of SHP-1, resulting in increased 
phosphatase activity and thereby negative regulation of STAT5 phosphorylation at 
Y694 (48, 57). In connection with these experiments it should be mentioned that positive 
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regulatory role of CSK in production of TNF-α and IL-6 has been also described in 
macrophage cell line RAW 264.7 (66). 
Fifth, migration towards antigen is positively regulated by PAG (26) but 
negatively by CSK (this study). In cells with CSK-KD/PAG-KO, the positive regulatory 
role of PAG in chemotaxis towards antigen was neutralized by CSK-KD.  When 
chemotaxis towards SCF was measured, cells with PAG-KO/CSK-KD exhibited 
significantly higher response when compared to PAG-KO cells. Our finding that PAG 
is a positive regulator of chemotaxis towards antigen without any effect on chemotaxis 
towards SCF, whereas CSK is a negative regulator of antigen- as well as SCF-mediated 
chemotaxis, suggest that the CSK and PAG have different regulatory role in these 
processes. Mast cell chemotaxis is a complex process involving numerous molecules 
(52) and it is not clear at which step CSK is involved. One possibility is that CSK affects 
integrins, which are involved in chemotaxis. However, our findings that antigen- or 
SCF-activated cells with CSK-KD, PAG-KO or CSK-KD/PAG-KO exhibit similarly 
reduced adhesion to fibronectin, which is dependent on activity of integrins, suggest that 
integrins are not the negative regulators of antigen- or SCF-mediated chemotaxis. In our 
previous study we found an important role of NTAL in chemotaxis towards antigen 
(67). In antigen-activated cells, NTAL was rapidly phosphorylated and served as 
negative regulator of degranulation and calcium response (45, 68), a positive regulator 
of adhesion to fibronectin, and a negative regulator of chemotaxis towards antigen  (67), 
properties which are shared with CSK. NTAL seems to signals to mast cell cytoskeleton 
via the small GTPase RhoA and it is possible that this pathway is affected by CSK. In 
fact it has been already reported that there is a cross-talk between CSK and Rho-family 
GTPases, which could contribute to cell migration (69). Cytoskeleton is known to be 
involved in FcεRI internalization (39, 70, 71). Our finding that CSK-KD leads to 
reduced antigen-induced internalization of FcεRI is in line with reduced adhesion to 
fibronectin and reduced phosphorylation of NTAL, which is a positive regulator of cell 
adhesion (67). Reduced internalization is known to contribute to prolonged generation 
of FcεRI-induced signal and enhanced degranulation (72, 73). Thus, CSK through its 
negative regulation of FcεRI internalization could contribute to enhanced degranulation. 
Taken together, our results support the conclusion that CSK is a negative regulator 
of FcεRI-mediated activation leading to degranulation, calcium response and 
chemotaxis, but a positive regulator of cytokines and chemokines production and 
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adhesion to fibronectin. At least some of these regulatory functions of CSK are not 
dependent on its binding to PAG, which seems to have some other not yet fully 
understood functions. Opposite effect of CSK-KD and PAG-KO on antigen-induced 
degranulation as well as enhanced degranulation in cells with PAG-KO combined with 
CSK-KD suggest that CSK binds not only to PAG, but also to some other anchors, 
which could serve better than PAG for positioning CSK in the vicinity of SFKs and thus 
more efficient inactivation of SFKs involved in FcεRI signaling. These alternative CSK 
anchor proteins remains to be identified. 
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FIG 1 Production of BMMCs with reduced or enhanced expression of CSK. (A) 
Determination of CSK protein by immunoblotting (IB) in whole-cell lysates from 
BMMCs transduced with individual CSK-specific shRNAs (35, 36, 64, and 90) or 
control empty vector (pLKO.1). (B) Quantification of the relative amounts of CSK 
normalized to the relative amounts of GRB2 used as loading controls and amount of 
CSK in pLKO.1 control cells. (C) Determination of CSK in whole-cell lysates from 
BMMCs transduced with a pool of CSK-specific shRNAs (labeled as CSK-KD) or 
pLKO.1 control vector. (D) Quantification of the relative amounts of CSK analyzed as 
in Fig. 1B. The results in B and D are shown as means ± SD from 8 - 13 independent 
experiments. (E) Determination of CSK by immunoblotting in whole-cell lysates from 
BMMCs transduced with empty vector (pCDH), pCDH vector containing hCSK-
mCherry construct or hCSK-myc construct. Positions of endogenous (En.) and 
exogenous (Ex.) CSKs are indicated by arrows. The results are representative of 3 
experiments. (F) Quantification of the relative amounts of CSK and CSK constructs 
normalized to the relative amounts of GRB2 used as loading controls and amount of 
CSK in cells transduced with pCDH control vector. (G) Flow cytometry analysis of the 
surface expression of FcɛRI and c-KIT receptor in BMMCs with CSK-KD, CSK-OE 
(hCSK-mCherry or hCSK-myc) and appropriate control cells (pLKO.1 and pCDH). (H) 
Quantification of surface FcɛRI and c-KIT receptors, obtained in experiments as in Fig. 
1G. The data represent means ± SD from 7-13 independent experiments.   
   
FIG 2 Enhanced degranulation and calcium response, but reduced FcεRI-IgE 
complexes internalization in BMMCs with CSK-KD. (A) β-glucuronidase release was 
analyzed in BMMCs transduced with individual CSK-specific shRNAs (35, 36, 64, and 
90) in pLKO.1 vector or empty pLKO.1 vector (pLKO.1). The cells were sensitized 
with IgE and activated with various concentration of antigen (Ag; TNP-BSA). The data 
represents means ± SEM from 4-8 independent experiments performed in duplicates or 
triplicates. (B) β-glucuronidase release from BMMCs transduced with a pool of shRNAs 
or empty pLKO.1 vector was analyzed as in Fig. 2A. The data represent means ± SEM 
from 8 independent experiments performed in duplicates or triplicates. (C, D) Surface 
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expression of CD107a in BMMCs with CSK-KD (C) or CSK/OE (hCSK-mCherry or 
hCSK-myc; D). The cells were sensitized with IgE, activated with various concentration 
of antigen and surface expression of CD107a was analyzed by flow cytometry. The 
results shown are means ± SEM from 3 (C) or 4  (D) independent experiments 
performed in duplicates. (E, F) Calcium response examined in BMMCs with CSK-KD 
and corresponding controls (E) or CSK-OE and controls (F). The cells were sensitized 
with IgE, loaded with Fura-2 and activated with antigen added as indicated by arrows. 
Data represent means ± SEM calculated from 3-6 independent experiments each 
performed in duplicates. (G) IgE internalization in BMMCs with CSK-KD or control 
pLKO.1 cells. The IgE-sensitized cells were activated with antigen for various time 
intervals and fixed with 4% parafolmaldehyde. IgE was quantified using AF488-labeled 
anti-IgE antibody and flow cytometry. Means ± SEM calculated from 3 independent 
experiments are shown.  Statistical significance of intergroup differences, determined 
as described in Materials and methods, is also shown. 
 
FIG 3  Negative and positive regulatory roles of CSK in tyrosine phosphorylation of  
early signal-transduction molecules. (A) Total tyrosine phosphorylation of IgE-
sensitized BMMCs with CSK-KD or control pLKO.1 cells activated or not with antigen 
for various time intervals. The cells were lysed and analyzed by immunoblotting with 
the tyrosine specific mAb PY20-HRP conjugate (PY20). GRB2 was used as a loading 
control. A representative immunoblot from 3 experiments is shown. Numbers on the 
right indicate positions of molecular weight standards. (B) FcɛRIs  were 
immunoprecipitated (IP) from the lysates of nonactivated or Ag-activated BMMCs with 
CSK-KD or control cells (pLKO.1). The immunoprecipitates were examined by 
immunoblotting with PY20-HRP mAb. For loading controls, FcɛRI β-chain specific 
antibody was used. Position of  FcɛRI β and γ chains is marked by arrows. A 
representative immunoblot from 3 performed is shown. (C) Densitometry analysis of 
immunoblots as from panel B in which signals from tyrosine phosphorylated FcεRI β 
and γ subunits in activated cells were normalized to the signals from nonactivated cells 
and loading control protein. Means ± SEM were calculated from 3 experiments. (D - N) 
IgE-sensitized BMMCs with CSK-KD or control pLKO.1 cells were activated with 
antigen for various time intervals and whole-cell lysates were analyzed by 
immunoblotting for tyrosine phosphorylated SYK (pSYK; D and E), PLCγ (pPLCγ; D 
100
and F), phosphorylated LAT (pLAT; G and H), phosphorylated NTAL (pNTAL; G and 
I), pLYNY508 (J and K), pLYNY397 (J and L), and phosphorylated SHP-1 (pSHP-1; M 
and N).  Corresponding proteins were used as loading controls. Representative 
immunoblots from 4 to 7  experiments for each phosphorylated protein is shown on the 
left (D, G, J, and M). Densitometry analysis of the immunoblots as in left panels in 
which signals from tyrosine phosphorylated proteins in activated cells were normalized 
to the signals in nonactivated cells and loading control proteins. Means ± SEM 
calculated from 4 to 7 experiments are shown. Statistical significance of intergroup 
differences is also shown. 
 
FIG 4  Different regulation of LYN, FYN and FcεRI-bound kinase aktivity by CSK. (A) 
LYN kinase was immunoprecipitated from nonactivated or Ag-activated BMMC with 
CSK-KD or control cells (pLKO.1) and then incubated with kinase buffer containing 
[γ-32P]ATP and acid-denatured enolase, used as an endogenous substrate. 32P-labeled 
proteins were size fractionated, transfered to nitrocellulose membranes, and examined 
by autoradiography. (B, C) Signals from autoradiograms were quantified and those 
corresponding to LYN (B) and enolase (C) were normalized to the amount of 
precipitated LYN and to the signals in nonactivated pLKO.1 BMMCs. (D) Kinase 
activity of immunoprecipitated FYN was determined as above, except that anti-FYN 
antibody was used for immunoprecipitation. (E, F) Signals from autoradiograms of FYN 
(E) and enolase (F) were quantified and normalized to the amount of precipitated FYN 
and to the signals in nonactivated control cells. (G) Kinase activity bound to 
immunoprecipitated FcεRI was determined as above except that anti-IgE was used for 
IgE-FcεRI complexes precipitation and fosforylation of FcεRI β and γ chain was 
examined. (H, I) Signals from autoradiograms of FcεRI β chain (H) and FcεRI γ chain 
(I) were quantified and normalized to the amount of precipitated FcεRI β chain and to 
the signals in nonactivated control cells. The means ± SEM were calculated from 5 
independent experiments in each panel. The statistical significance of differences 
between cells with CSK-KD and control pLKO.1 cells is also shown.  
 
FIG 5  CSK is a positive regulator of cytokines and chemokines production, STAT5 
phosphorylation, and adhesion to fibronectin, but a negative regulator of chemotaxis 
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towards antigen and SCF. (A, B) IgE-sensitized BMMCs with CSK-KD or control cells 
were activated for 1 h with antigen and mRNAs encoding cytokines (TNF-α, IL-6 and 
IL-13; A) or chemokines (CCL3 and CCL4; B) were quantified by RT-qPCR. Means ± 
SEM were calculated from 4 independent experiments. (C-E) IgE-sensitized BMMCs 
with CSK-KD or pLKO.1 control cells were activated or not for 6 h with various 
concentrations of antigen and concentration of cytokines TNF-α (C), IL-13 (D) and IL-
6 (E) secreted into the supernatants were determined. Means ± SEM were calculated 
from 4-8 independent experiments performed in duplicates or triplicates. (F) The cells 
were analyzed as in C except that they were activated with only one concentration of 
antigen (50 ng/ml) for 30 min or 120 min. Means ± SEM were calculated from 4 
independent experiments performed in duplicates.  (G) Representative immunoblot of 
whole-cell lysates from BMMCs with CSK-KD or pLKO.1 control cells activated or 
not with antigen and analyzed by immunoblotting with antibodies to tyrosine 
phosphorylated STAT5. For loading controls the membranes were analyzed by 
immunobloting for GRB2.  (H) Densitometry analysis of the immunoblots as from panel 
G in which signals from pSTAT5 in activated cells were normalized to the signals from 
nonactivated control cells and loading control protein. Means ± SEM were calculated 
from 3 experiments. (I, J) Cell adhesion to fibronectin-coated surfaces. BMMCs with 
CSK-KD or pLKO.1 control cells were sensitized with IgE, loaded with calcein and 
activated with various concentration of antigen (I) or SCF (J). Fluorescence was 
determined before and after washing out the non-adherent cells, and percentages of 
adherent cells were calculated. The results indicate means ± SEM from 5 independent 
experiments. (K) BMMCs with CSK-KD or pLKO.1 control cells were sensitized with 
IgE and their migration toward antigen or SCF was determined. Means ± SEM (n = 5) 
are shown. Statistical significance of differences between BMMCs with CSK-KD and 
control cells is also shown. 
   
FIG 6  Production of PAG-KO BMMCs with reduced or enhanced CSK expression. 
(A) CSK protein expression determined by immunoblotting with whole-cell lysates 
from PAG-KO BMMCs transduced with CSK-specific shRNAs (pooled shRNAs; CSK-
KD) or empty pLKO.1 vector. GRB2 was used as a loading control. (B) Quantification 
of the relative amounts of CSK normalized to amounts of GRB2 used as a loading 
control and CSK level in pLKO.1 control cells. (C) CSK expression determined by 
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immunoblotting in whole-cell lysates from PAG-KO BMMCs after transduction with 
empty vector pCDH or pCDH vector containing hCSK-mCherry or hCSK-myc (CSK-
OE). Positions of endogenous (En.) and exogenous (Ex.) CSKs are indicate by arrows. 
(D) Quantification of the relative amounts of CSK normalized to the amounts GRB2 
used as a loading control and CSK level in pCDH control cells. The results in B and D 
are shown as the means ± SD from 3-5 independent experiments. (E) Flow cytometry 
analysis of the surface expression of FcɛRI and c-KIT receptor in PAG-KO BMMCs 
with CSK-KD, CSK-OE (hCSK-mCherry, hCSK-myc) and corresponding controls. (F) 
Quantification of surface expression of FcɛRI and c-KIT from experiments as in E. The 
data represent means ± SD from 5-8 independent experiments.   
 
FIG 7 PAG-KO BMMCs with CSK-KD exhibit enhanced degranulation, calcium 
response and tyrosine phosphorylation of early signal transduction proteins. (A) β-
glucuronidase release was determined in IgE-sensitized PAG-KO BMMCs with CSK-
KD or pLKO.1/PAG-KO control cells activated or not with various concentrations of 
antigen. The data represent means ± SEM from 5 independent experiments performed 
in duplicates or triplicates. (B, C) Surface expression of CD107a was analyzed by flow 
cytometry in IgE-sensitized and Ag-activated PAG-KO BMMCs with CSK-KD or 
PAG-KO BMMCs with hCSK-mCherry, hCSK-myc (CSK-OE) and appropriate 
controls. The results shown are means ± SEM from 5-7 (B) or 3 (C) independent 
experiments performed in duplicates. (D) Calcium response examined in PAG-KO 
BMMCs with CSK-KD or control pLKO.1 cells. IgE-sensitized cells were loaded with 
Fura-2, exposed to antigen (arrow) and Fura-2 fluorescence was analyzed for 300 s. The 
data represent means ± SEM calculated from 4 independent experiments each performed 
in duplicates. (E) FcɛRI  were immunoprecipitated from the lysates of PAG-KO 
BMMCs with CSK-KD or control pLKO.1 cells activated with antigen or not and 
examined by immunoblotting with tyrosine specific mAb (PY20). For loading controls, 
FcɛRI β-chain specific antibody was used. (F) Densitometry analysis of the 
immunoblots as from panel E in which combined signals from tyrosine phosphorylated 
FcεRI β and γ chains in activated cells were normalized to the signals from nonactivated 
cells and a loading control protein, FcεRI β subunit. A representative immunoblot from 
three obtained is shown. (G) IgE-sensitized PAG-KO BMMCs with CSK-KD or 
pLKO.1 controls were activated or not with antigen and whole-cell lysates were 
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analyzed by immunoblotting for tyrosine phosphorylated SYK (pSYK), LAT (pLAT) 
and NTAL (pNTAL). For loading controls, SYK-, LAT- and GRB2-specific antibodies 
were used. Representative immunoblots from 4-6 experiments are shown. (H - J) 
Densitometry analyses of the pSYK (H), pLAT (I) and pNTAL (J) from immunoblots 
as in panel H in which signals from tyrosine phosphorylated proteins in activated cells 
were normalized to the signals from nonactivated cells and corresponding loading 
control proteins. Means ± SEM were calculated from 4-6 independent experiments. 
Statistical significance of intergroup differences is also shown. 
 
FIG 8  PAG-KO BMMCs with CSK-KD exhibit reduced cytokines production, STAT5 
phosphorylation and adhesion towards fibronectin, but enhanced chemotaxis towards 
antigen and SCF. (A – C) IgE-sensitized PAG-KO BMMCs with CSK-KD or pLKO1 
control cells were activated for 6 h with various concentration of antigen. Concentration 
of cytokines TNF-α (A), IL-13 (B) and IL-6 (C) secreted into the supernatants of 
nonactivated or activated cells were determined by immuno-iPCR. The means ± SEM 
were calculated from 4-8 independent experiments performed in duplicates or 
triplicates. (D) STAT5 phosphorylation in whole-cell lysates from PAG-KO BMMCs 
with CSK-KD or pLKO.1 control cells activated for various time intervals with antigen. 
Phosphorylation was determined by immunoblotting with antibodies to tyrosine 
phosphorylated STAT5 (pSTAT5). Because of poor performance of anti-STAT5 specific 
antibody on stripped membrane, GRB2 was used as a loading control. (E) Densitometry 
analysis of the immunoblots from gels as in G in which signals from tyrosine pSTAT5 
in activated cells were normalized to the signals from pSTAT in nonactivated cells and 
loading control protein. The results are shown as the means ± SEM from 3-5 
independent experiments. (F, G) Adhesion of PAG-KO BMMCs with CSK-KD or 
pLKO.1 controls to fibronectin-coated surfaces. The cells were sensitized with IgE, 
loaded with calcein and activated with various concentration of antigen (F) or SCF (G). 
Fluorescence was determined before and after washing out the non-adherent cells, and 
percentages of adherent cells were calculated. The results are means ± SEM calculated 
from 5 experiments. (H) Chemotaxis of BMMCs with PAG-KO, PAG-KO together with 
CSK-KD or wild type cells was determined in Boyden chambers. The cells were 
sensitized with IgE and their migration toward antigen and SCF was determined. Means 
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± SEM (n = 5) are shown. The statistical significance of intergroup differences is also 
shown. 
 
FIG 9 Proposed models of FcεRI signaling in BMMCs with CSK-KO,  PAG-KO or 
CSK-KD/PAG-KO. For simplicity, only one FcɛRI with bound antigen (Ag)-IgE 
complex is shown. Activated WT cells (A) with normal signal transduction machinery 
and Ag-mediated responses (Ca2+ response, degranulation, cytokines and chemokines 
production, chemotaxis and adhesion to extracellular matrix proteins (EMP)) are 
compared to activated cells with CSK-KD (B) or cells with PAG-KO (C). Cells with 
CSK-KD/PAG-KO (D) are compared with cells with PAG-KO alone (C). Formation of 
multivalent Ag-IgE-FcɛRI complexes leads to FcɛRI aggregation and tyrosine 
phosphorylation of FcɛRI β and γ subunits by the LYN kinase, followed by binding and 
activation of SYK and FYN kinases. (A) In activated WT cells, CSK binds to 
phosphorylated PAG and/or other so far not identified TRAP(s) and phosphorylates the 
C-terminal inhibitory tyrosine residues of LYN and other SFKs. Together with PTPs, 
such as SHP-1, and in cooperation with adaptor proteins, LAT and NTAL, CSK sets a 
treshold for mast cell activation, which involves GRB2, PLCγ, STAT5 and numerous 
other molecules, which are activated and/or inhibited by 
phosphorylation/dephosphorylation of various tyrosines. (B) In cells with CSK-KD, 
phosphorylation of FcɛRI subunits, SYK and PLCγ is significantly increased, resulting 
in enhanced calcium response and degranulation. LYN kinase, which is not 
phosphorylated at C-terminal inhibitory tyrosine (Y508) phosphorylates more its 
substrate, SHP-1 at Y564, thereby increasing its phosphatase activity, which in turn 
leads to reduced phosphorylation of STAT5 at Y694. This leads to reduced production of 
cytokines and chemokines. SHP-1 could also bind to NTAL, but not LAT, and in this 
way alters balance between signaling proteins anchored to these adaptors. Changes in 
NTAL tyrosine phosphorylation lead to enhanced chemotaxis and reduced adhesion to 
EMPs. (C) Cells with PAG-KO exhibit different changes in signaling events when 
compared to WT cells and cells with CSK-KD. PAG KO cells exhibit reduced tyrosine 
phosphorylation of FcɛRI β and γ subunits, SYK, LAT, PLCγ and STAT5, resulting in 
reduced Ca2+ response, degranulation, migration, and cytokines, and chemokines 
production. (D) In cells with CSK-KD/PAG-KO, phosphorylation of SYK, NTAL, LAT 
and PLCγ is increased, resulting in enhanced calcium response, degranulation and 
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chemotaxis. However, phosphorylation of STAT5 is reduced and this leads in reduced 
production of cytokines in the cells. Cells with CSK-KD/PAG-KO resemble in 
properties more to cells with CSK-KD than to cells with PAG-KO.  
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Table 1. Summary of responses of BMMCs with CSK-KD, PAG-KO and CSK-





Degranulation    
       β-glucuronidase ↑ ↓ ↑ 
       CD107a ↑ ↓ ↑ 
Ca2+ response ↑ ↓ ↑ 
Production of cytokines  
       TNF-α ↓ ↓ ↓ 
        IL-13 ↓ ↓ ↓ 
        IL-6 
Production of chemokines  
↓ ↓ - 
        CCL3 ↓ ↓ n.a. 
        CCL4 ↓ ↓ n.a. 
Adhesion    
        Ag ↓ - ↓ 
        SCF ↓ - ↓ 
Chemotaxis    
        Ag ↑ ↓ ↑ 
        SCF ↑ - ↑ 
Kinase activity    
        FcɛRI ↑ ↑ n.a. 
        LYN ↓ ↑ n.a. 
        FYN - ↑ n.a. 
phospho-FcɛRI ↑ ↓ ↑ 
phospho-LYNY508  ↓ n.a. n.a. 
phospho-LYNY397 - n.a. n.a. 
phospho-SYK ↑ ↓ ↑ 
phospho-PLCγ ↑ ↓ ↑ 
phospho-LAT - ↓ ↑ 
phospho-NTAL ↓ - ↑ 
phospho-STAT5 ↓ ↓ ↓ 
    
↑ increase; ↓ decrease; – no changed; n.a. not analyzed 
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Fig. 5 Potuckova et al. 
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Fig. 8 Potuckova et al. 











































































































































































7.4 NEGATIVE REGULATORY ROLES OF ORMDL3 IN THE FcɛRI-
TRIGGERED EXPRESSION OF PROINFLAMMATORY MEDIATORS 
AND CHEMOTACTIC RESPONSE IN MURINE MAST CELLS. 
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Abstract Single-nucleotide polymorphism studies have
linked the chromosome 17q12-q21 region, where the human
orosomucoid-like (ORMDL)3 gene is localized, to the risk of
asthma and several other inflammatory diseases. Although
mast cells are involved in the development of these diseases,
the contribution of ORMDL3 to the mast cell physiology is
unknown. In this study, we examined the role of ORMDL3
in antigen-induced activation of murine mast cells with
reduced or enhanced ORMDL3 expression. Our data show
that in antigen-activated mast cells, reduced expression of
the ORMDL3 protein had no effect on degranulation and
calcium response, but significantly enhanced phosphoryla-
tion of AKT kinase at Ser 473 followed by enhanced
phosphorylation and degradation of IjBa and translocation
of the NF-jB p65 subunit into the nucleus. These events
were associated with an increased expression of proinflam-
matory cytokines (TNF-a, IL-6, and IL-13), chemokines
(CCL3 and CCL4), and cyclooxygenase-2 dependent syn-
thesis of prostaglandin D2. Antigen-mediated chemotaxis
was also enhanced in ORMDL3-deficient cells, whereas
spreading on fibronectin was decreased. On the other hand,
increased expression of ORMDL3 had no significant effect
on the studied signaling events, except for reduced antigen-
mediated chemotaxis. These data were corroborated by
increased IgE-antigen-dependent passive cutaneous
anaphylaxis in mice with locally silenced ORMDL3 using
short interfering RNAs. Our data also show that antigen
triggers suppression of ORMDL3 expression in the mast
cells. In summary, we provide evidence that downregulation
of ORMDL3 expression in mast cells enhances AKT and
NF-jB-directed signaling pathways and chemotaxis and
contributes to the development of mast cell-mediated local
inflammation in vivo.
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ORMDL3 knockdown  Prostaglandin D2  Degranulation 
Chemotaxis  Proinflammatory cytokines
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Orosomucoid-like (ORMDL)3 protein has attracted
increased attention since the discovery of single-nucleotide
polymorphisms (SNPs) in the chromosome 17q12-q21
region that were associated with onset of asthma in
childhood [1]. Further studies confirmed these data in
ethnically diverse populations [2, 3]. Interestingly, SNPs
associated with 17q12-q21 were also linked to chronic
obstructive pulmonary disease [4], ulcerative colitis [5],
primary biliary cirrhosis [6], type 1 diabetes [6], Crohn
disease [6, 7] and rheumatoid arthritis [8]. It has been
suggested that the risk alleles for asthma mapped in the
17q12-q21 region are linked to increased levels of the
ORMDL3 gene transcript [1, 6], but the risk alleles
implicated in the predisposition to primary biliary cirrho-
sis, type 1 diabetes and Crohn disease are associated with
decreased ORMDL3 mRNA levels [6]. Since ORMDL3 is
only one of several genes in the chromosome 17q12-q21
region, the observed data underline the complexity of
inflammatory diseases [6, 9].
Human and mouse ORMDL3 genes encode 153 aa
proteins belonging to the conserved ORMDL family con-
sisting of three members. All three members of this family
(ORMDL1–3) are embedded in the endoplasmic reticulum
membrane [10]. Pivotal studies of ORMDL3 yeast homo-
logs, orosomucoid (ORM)1 and ORM2, showed that ORM
proteins are negative regulators of sphingolipid synthesis
[11, 12] and that knockdown of all three ORMDL isoforms
resulted in increased ceramide production in distinct
mammalian cell lines [11, 13, 14]. Further experiments
showed that disruption of sphingolipid homeostasis in the
mouse model increased bronchial reactivity in the absence
of inflammatory stimulus [15]. ORMDL3 has also been
found to play a role as a regulator of Ca2? homeostasis in
the endoplasmic reticulum [16, 17] and as a trigger of
unfolded protein response [16, 18, 19].
Several studies attempted to explain the physiological
role of ORMDL3 in cells and tissues relevant to asthma.
Mice challenged with allergen exhibited enhanced expres-
sion of ORMDL3 in macrophages, eosinophils and lung
epithelial cells [18]. Furthermore, a lung epithelial cell line
transfected with ORMDL3 cDNA showed increased tran-
scription of genes encoding metalloproteases, chemokines
and oligoadenylate synthetases [18]. In addition, bone
marrow-derived eosinophils transduced with ORMDL3
cDNA showed enhanced rolling and nuclear localization of
the phosphorylated NF-jB p65 subunit [20]. Transgenic
mice overexpressing human ORMDL3 exhibited increased
levels of serum IgE and showed spontaneous development
of enhanced airway responsiveness. This correlated with
increased numbers of CD4? cells, macrophages, eosino-
phils and neutrophils, and enhanced Th2 cytokine levels in
the lungs of transgenic mice [19]. Although mast cells are
crucial effector cells in IgE-dependent allergic disorders
[21, 22] and are critical for promoting the severity of col-
lagen-induced arthritis, which is an autoimmune
inflammatory disease [23], the involvement of ORMDL3 in
FceRI-dependent activation and mast cell-mediated
inflammation has not yet been determined.
In this study, we decided to test the hypothesis that
changes in the expression levels of ORMDL3 could mod-
ulate mast cell proinflammatory responses. Bone marrow-
derived mast cells (BMMCs) with enhanced or reduced
expression of ORMDL3 were produced and examined. We
focused on the NF-jB signaling axis, which is an important
player in the transcription of proinflammatory cytokines
and immunoregulatory proteins [24] and is involved in the
promotion of inflammation [25–27]. We found that
ORMDL3-deficient cells exhibited significantly increased
translocation of the NF-jB p65 subunit into the nucleus.
These events were accompanied by enhanced expression of
genes encoding proinflammatory cytokines, chemokines,
and cyclooxygenase (COX)-2, an inducible enzyme
involved in prostaglandin (PG)D2 synthesis [28]. In an
attempt to identify the signaling pathway that precedes
activation of NF-jB, we found that AKT kinase exhibited
increased phosphorylation. We also studied the roles of
ORMDL3 in the migration of mast cells toward antigen
(Ag) and changes in ORMDL3 expression after high-
affinity IgE receptor (FceRI) triggering. Altogether, our
data provide evidence that in mast cells, ORMDL3 func-
tions predominantly as a negative regulator of FceRI-
mediated signaling events leading to the expression of
proinflammatory mediators and chemotaxis. These data
were corroborated by the finding of enhanced passive
cutaneous anaphylaxis (PCA) in mice with locally silenced
ORMDL3.
Materials and methods
Cells and lentiviral infection
BMMCs were derived from femurs and tibias of 8- to
10-week-old BALB/c mice bred, maintained, and used in
accordance with the Institute of Molecular Genetics
guidelines (Permit number 12135/2010-17210) and
national guidelines (2048/2004-1020). The cells were cul-
tured in RPMI-1640 medium supplemented with 100 U/ml
penicillin, 100 lg/ml streptomycin, 71 lM 2-mercap-
toethanol, MEM non-essential amino acids, 0.7 mM
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sodium pyruvate, 2.5 mM L-glutamine, 12 mM D-glucose,
recombinant mouse stem cell factor (15 ng/ml, PeproTech
EC), mouse recombinant IL-3 (20 ng/ml, PeproTech EC)
and 10 % FCS. Lentiviral transductions were done as
described previously using HEK 293 T/17 packaging cells
for virus preparation [29]. A set of murine ORMDL3 short
hairpin (sh)RNAs cloned into the pLKO.1 vector
(TRCN0000126200, TRCN0000126201, TRCN0000126
202, TRCN0000126203; denoted in further text as indi-
cated by numbers in bold) were purchased from Open
Biosystems. To generate the myc-ORMDL3 vector, mouse
ORMDL3 cDNA (Open Biosystems) was first amplified
using forward primer 50-AAAGAATTCGGAATGTGGGC
ACAGCACAC-30 and reverse complementary primer 50-
TTTGCGGCCGCTCAGTACTTATTGATTCCAAA-30,
introducing EcoRI and NotI restriction endonuclease sites
(underlined), respectively. Amplified ORMDL3 was then
inserted into a pCMV-myc eukaryotic expression vector
(Clontech). Myc-ORMDL3 was recloned by PCR into the
vector pCDH-CMV-MCS-EF1-Puro (Systembio; pCDH)
using forward primer 50-AAATCTAGAGCCGCCACCAT
GGAGCAGAAGCTGATCTCA-30 and reverse comple-
mentary primer 50-TTTGCGGCCGCTCAGTACTTATTG
ATTCCAAA-30, introducing XbaI and NotI restriction
endonuclease sites (underlined), respectively. The con-
struct was verified by sequencing and denoted myc-O3.
The pCDH vector Myc-ORMDL3 was also used to clone
murine ORMDL1 and ORMDL2 cDNAs (OpenBiosys-
tems). Specific primers for ORMDL1 (forward primer 50-
AAAGAATTCGGAATGTTGGAGTTGCCCAC-30 and
reverse complementary primer 50-TTTGCGGCCGCTCA
ATACTTATTAATTCCAAA-30) and ORMDL2 (forward
primer 50-AAAGAATTCGGAATGTGGGGGTGGCACA
C-30 and reverse complementary primer 50-TTTGCGGC
CGTTAGTATTTGTTGATTCCAAA-30) were designed to
be cloned into pCDH using EcoRI and NotI restriction
endonuclease sites (underlined). To prepare an expression
vector for ORMDL3 with C-terminal myc-tag, ORMDL3
cDNA was amplified using forward primer 50-AAAGAAT
TCGCCGCCACCATGAATGTGGGCACAGCACAC-30
and reverse complementary primer 50-TTTGGATCCGTA
CTTATTGATTCCAAA-30, introducing EcoRI and BamHI
restriction endonuclease sites (underlined), respectively.
Amplified ORMDL3 was then cloned into pCDH-myc. The
construct, denoted O3-myc, was verified by sequencing.
Both constructs were used to produce lentiviruses as
described [29]. BMMCs were transduced with the len-
tiviruses and stable transfectants were obtained by
culturing the transduced cells for 2 weeks in the presence
of puromycin (5 lg/ml). Cells were analyzed for FceRI and
c-Kit expression using flow cytometry, while ORMDL3
expression was examined by qPCR and immunoblotting as
described below. In all experiments, more than 80 % of
cells were alive and the selected populations were main-
tained for less than 3 weeks in culture. In all experiments,
empty pLKO.1 or empty pCDH vectors were used as
controls. In most of the functional studies, comparison
between nontransduced cells and cells transduced with
pLKO.1 was performed. In some experiments related to
AKT/IjB signaling, we also used as a control pLKO.1
vector containing nontarget (NT) shRNA (Sigma-Aldrich)
as a control.
Antibodies and reagents
Mouse IgE mAb specific for 2,4,6-trinitrophenol (TNP),
clone IGEL b4 1 [30], SYK-specific mAb [31], and Lyn-
specific mAb [32] were produced in our laboratory. Anti-
mouse KIT (CD117)-allophycocyanin conjugate [catalog
number (#) 17-1171] and anti-mouse FceRI a-FITC con-
jugate (#11-5898) were obtained from eBioscience. Rabbit
anti-COX-2 (#12282), rabbit anti-pSYK (Tyr525/526;
#2710), rabbit anti-p65 subunit of NF-jB (#8242), rabbit
phospho-AKT (Thr 308; #2965) and mouse anti-pIjBa
(Ser32/36; #9246) were obtained from Cell Signaling.
Anti-HPRT mAb (#sc-376938), rabbit anti-actin polyclonal
Ab (#sc-8432), rabbit anti-p65 subunit of NF-jB (#sc-372),
rabbit phospho-AKT1/2/3 (#sc-7985), rabbit ERK1 (#sc-
93), rabbit phospho-ERK (Tyr204; #sc-7976), goat anti-
AKT1 (#sc-1618), rabbit anti-IjBa (#sc-371), mouse anti-
Myc (#sc-40), rabbit anti-GRB2 (#sc-255), HRP-conju-
gated goat anti-mouse IgG (#sc-2005), HRP-goat anti-
rabbit IgG (#sc-2004), and HRP-donkey anti-goat IgG
(#sc-2056) were obtained from Santa Cruz Biotechnology,
Inc. Donkey anti-rabbit-IgG Alexa Fluor 488 conjugate
(#A21206) and goat anti-rabbit-IgG Alexa Fluor 568
(#A11036) were from Molecular Probes. Antibodies
specific for mouse TNF-a (#500-P64), IL-13 (#500-P178),
the corresponding recombinant proteins, and recombinant
IL-6 were obtained from PeproTech. Murine anti-IL-6
(#553414) was purchased from Becton–Dickinson. Anti-
bodies used for immunoblotting of ORMDL proteins were
obtained after immunization of rabbits with a peptide
corresponding to the middle part of ORMDL3
(TPFETPDQGKARLLTHWEQMDC) conjugated to key-
hole limpet hemocyanin via an extra cysteine residue
(underlined). This antibody is designated TPF. For
immunofluorescence studies, rabbit polyclonal serum
raised against the N-terminal ORMDL3 peptide
(CNVGTAHSEVNPNTR) was used. This antibody was
prepared as described above and is designated NVG. The
peptides used for immunization share high similarities with
ORMDL1 and ORMDL2 proteins and both polyclonal sera
recognize all three members of the ORMDL family.
Therefore, we refer to the 17 kDa band on immunoblots as
ORMDL. The sera were affinity purified using a
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SulfoLinkTM Immobilization Kit for Peptides (Pierce)
according to the manufacturer’s instructions. Fura-2, AM
was obtained from Life Technologies. All other reagents
were obtained from Sigma-Aldrich.
b-Glucuronidase release and Ca21 response
BMMCs were sensitized with TNP-specific IgE (IGEL b4
1 mAb, 1 lg/ml) in stem cell factor- and IL-3-free culture
medium for 16 h, unless stated otherwise. Then the cells
were washed in buffered saline solution (BSS; 135 mM
NaCl, 5 mM KCl, 1.8 mM CaCl2, 5.6 mM glucose,
20 mM HEPES, pH 7.4) supplemented with 0.1 % BSA
and activated with Ag (TNP–BSA conjugate, 15–25 mol
TNP/mol BSA). The extent of degranulation was evalu-
ated by determining b-glucuronidase concentrations as
described previously [33] except that an Infinite 200 M
(TECAN) plate reader was used at 355 nm excitation and
460 nm emission wavelengths. Calcium mobilization was
determined using Fura-2 acetoxymethyl ester (Fura-2 AM;
Life Technologies) as a reporter. Cells were incubated
with Fura-2 AM (1 ng/ml) and probenecid (2.5 mM) in
BSS supplemented with 0.1 % BSA and incubated in the
shaker for 30 min at 37 C. Fura-2 AM-loaded cells were
washed twice with 2.5 mM probenecid in BSS-0.1 % BSA
and then transferred to BSS-0.1 % BSA supplemented
with 2.5 mM probenecid and incubated in Thermomixer
(Eppendorf; 15 min, 37 C, 500 rpm). Cells were pelleted
by centrifugation at 5009g for 3 min, resuspended in
BSS-0.1 % BSA and transferred to white polysorp 96 well
plate (NUNC, Thermo Scientific). After 1 min, BSS-0.1 %
BSA supplemented with Ag (final concentration 100 ng/
ml) was added using the TECAN injector system. Mea-
surement continued up to 200 s. Levels of Ca2? were
determined by spectrofluorometry using the Infinite 200 M
plate reader with excitation wavelengths at 340 and
380 nm and with a constant emission at 510 nm. To
determine basal concentrations of free intracellular Ca2?
([Ca2?]i) in various cell types, Triton X-100 (0.1 % final
concentration) was added to the Fura-2-loaded cells and
Fura-2 fluorescence was determined. Then, EGTA
(16 mM final concentration) was added and Fura-2 fluo-
rescence was again determined. Calcium concentrations
were then calculated using the formula: [Ca2?]i =
Kd 9 Sf2/Sb2 9 (R - Rmin)/(Rmax - R), where Kd repre-
sents the dissociation constant for Fura-2 (224 nM), Sf2
the average fluorescence obtained at 380 nm after EGTA
addition, Sb2 the average fluorescence obtained at 380 nm
after addition of Triton X-100, Rmin the mean ratio cal-
culated from the data acquired after EGTA addition,
Rmax the mean of ratio calculated from data acquired after
addition of Triton X-100, and R the ratio of fluorescence
obtained at 340/380.
Detection of ORMDL, cytokines, and chemokines
at the mRNA level
IgE-sensitized BMMCs were activated with different con-
centrations of Ag. One hour later, mRNA was extracted
using a TurboCapture 96 mRNA kit or RNeasy miniKit
(Qiagen). Single-stranded cDNA was synthesized with
M-MLV reverse transcriptase (Invitrogen) according to the
manufacturer’s instructions. Real-time PCR amplifications
of cDNAs were performed in 10 ll reaction volumes of
qPCR mix containing 1 M 1,2-propanediol, 0.2 M tre-
halose and SYBR green 1 [34] in 384-well plates sealed
with LightCycler 480 sealing foil and analyzed by
LightCycler 480 (Roche Diagnostics). The following
cycling conditions were used: 3 min at 95 C, followed by
50 cycles of 10 s at 95 C, 20 s at 60 C and 20 s at 72 C.
Threshold cycle (Ct) values were determined by automated
threshold analysis of the cycler. Specificity of the PCR was
evaluated by examining the melting curves. For data pre-
sented in Fig. 2a, actin, GAPDH, ubiquitin, TBP, SDHA,
and HPRT were used as reference genes and the expression
levels of ORMDL3 mRNA were normalized to the geo-
metric mean of the reference genes in nonactivated control
cells. In all other experiments, actin, GAPDH, and ubiq-
uitin were used as the reference genes. The relative
changes in the mRNA expression levels were normalized
to the ones of the corresponding controls. The following
primer sets were used for amplification of different cDNA
fragments (sense/antisense; numbers in square brackets are
sizes of the fragments in bps): actin, 50-GATCTGGCAC
CACACCTTCT-30/50-GGGGTGTTGAAGGTCTCAAA-30
[138]; GAPDH, 50-AACTTTGGCATTGTGGAAGG-30/
50-ATCCACAGTCTTCTGGGTGG-30 [69]; ubiquitin, 50-
ATGTGAAGGCCAAGATCCAG-30/50-TAATAGCCACC
CCTCAGACG-30 [160]; HPRT, 50-CTGGTGAAAAG
GACCTCTCGAA-30/50-CTGAAGTACTCATTATAGTC
AAGGGCAT-30 [109]; TBP, 50-GAAGAACAATCCAG
ACTAGCAGCA-30/50-CCTTATAGGGAACTTCACATC
ACAG-30 [128]; SDHA, 50-AAGGCAAATGCTGGAG
AAGA-30/50-TGGTTCTGCATCGACTTCTG-30 [112];
ORMDL3, 50- CCAACCTTATCCACAACCTGG-30/50-
GACCCCGTAGTCCATCTGC-30 [124]; ORMDL2, 50-C
ACAGCGAAGTAAACCCCAAC-30/50-AGGGTCCAGA
CAACAGGAATG-30 [134]; ORMDL1, 50-ACAGTGA
GGTAAACCCCAATACT-30/50-GCAAAAACACATACA





AGATGGATTG-30 [123]; CCL3, 50-CATCGTTGACT
ATTTTGAAACCAG-30/50-GCCGGTTTCTCTTAGTCA
GGAA-30 [72]; CCL4, 50-CTTGGAGTTGAACTGAGCA





CAATTCGTTGGAGCCCCAT-30 [120]; COX-2, 50-TG
AGCAACTATTCCAAACCAGC-30/50-GCACGTAGTCT
TCGATCACTATC-30 [74].
For detection of cytokine secretion, the nano-iPCR
method was used as described [35]. Briefly, anti-TNF-a,
anti-IL-13 (each at 1 lg/ml), or anti-IL-6 (2 lg/ml) in
100 mM borate buffer (pH 9.5) was dispensed in 50 ll
aliquots into wells of a real-time 96-well plate (Eppendorf).
After overnight incubation at 4 C, each well was washed
four times with 200 ll of TBST (10 mM Tris–HCl, pH 7.4,
150 mM NaCl, and 0.05 % Tween 20) and the remaining
binding sites were blocked by 2 h incubation at 37 C with
TBST supplemented with 2 % BSA. After washing, 50 ll
of serial dilutions (0.1–100 ng/ml) of recombinant TNF-a,
IL-13 or IL-6, or the tested samples diluted in PBS-1 %
BSA were added. The samples were incubated 1 h at 37 C
and after washing with TBST, 50 ll of gold nanoparticles
armed with thiolated DNA oligonucleotide template were
added and further processed as described [35]. For calcu-
lation of the cytokine concentrations, the obtained Ct
values were compared with those from the corresponding
calibration curves.
PGD2 measurements
IgE-sensitized mast cells were seeded at 2 9 105 cells per
well in 100 ll of BSS–BSA buffer in a 96-well culture
plate. Cells were stimulated by adding 100 ll of Ag to a
final concentration of 100 ng/ml for 5 h. Cell-free super-
natants were collected and assessed for PGD2 using
competitive enzyme immunoassay based on measurement
of PGD2-methoxylamine hydrochloride derivate according
to the manufacturer’s conditions (Cayman Chemicals). For
detection, the Infinite 200 M plate reader was used.
Supernatants of nonactivated and activated cells were
diluted 1/10 and 1/40, respectively, to be read within the
range of the respective standard curve.
Gel electrophoresis and immunoblotting
Whole-cell extracts were prepared by washing the cells in
cold PBS, solubilizing them in hot SDS-sample buffer [36],
sonicating, and boiling for 5 min. Proteins were size frac-
tionated on 10 or 12.5 % SDS-PAGE gels,
electrophoretically transferred onto nitrocellulose mem-
brane, and analyzed by immunoblotting with protein- or
phosphoprotein-specific Abs. Bound primary Abs were
detected with HRP-conjugated secondary Abs. The HRP
signal was detected with chemiluminescence reagent [37]
and quantified by a Luminescent Image Analyzer LAS
3000 (Fuji Photo Film Co.). Aida software (Raytest GmbH)
was used for signal quantification. Protein levels were
normalized to the corresponding controls.
Flow cytometry analysis
To quantify the surface expression of FceRI and KIT,
BMMCs (3 9 105/ml) were exposed simultaneously to
anti-mouse FceRI-FITC and anti-mouse KIT-allophyco-
cyanin for 30 min on ice. Then, the cells were washed with
ice-cold PBS and evaluated using an Accuri C6 flow
cytometer (BD Biosciences).
Cell adhesion and spreading
IgE-sensitized BMMCs were loaded with calcein-AM and
transferred into a 96-well plate (Thermo Scientific) coated
with fibronectin (10 ng/ml) diluted in PBS [38]. Cells acti-
vated for 30 min with 100 ng/ml of Ag were examined for
adhesion assay using the Infinite 200 M plate reader with
excitation and emission filters at 485 nm and 538 nm,
respectively. For cell spreading, wells in 96-well glass-
bottom plates (InVitroSci) were coated with fibronectin
(50 ll; 50 lg/ml) diluted in PBS. Wells were then washed
with PBS, and 30 9 103 cells in BSS-0.1 % BSA were
added per well. Cells were allowed to attach for 30 min at
37 C, washed, and activated or not with Ag. After 30 min,
cells were fixed with 3 % paraformaldehyde in PBS for
30 min at room temperature. For filamentous (F)-actin
staining, cells were exposed to Alexa Fluor 488-phalloidin
conjugate (Invitrogen, #A12379), diluted 1:100 in PBS
supplemented with L-a-lysophosphatidylcholine (80 lg/
ml). After 1 h, cells were washed and kept in PBS supple-
mented with Hoechst 33258 stain (1 lg/ml) until
measurement. Cells were then examined with the ScanR
system (Olympus).
Chemotactic response
Ag-Mediated chemotactic responses were evaluated using
24-well Transwell chambers (Corning) with 8 lm poly-
carbonate filters as described previously [38]. Cells
migrating into lower compartments within the 8-h incu-
bation period were counted using an Accuri C6 Flow
Cytometer (Becton–Dickinson).
F-actin assay
The total amount of F-actin in nonactivated and Ag-activated
cells was determined byflowcytometry. BMMCs in a 96-well
plate (5 9 104 cells per well) were exposed to various stimuli
at 37 C, fixed with 3 % paraformaldehyde in phosphate-
buffered saline, and then permeabilized and stained in a single
step by a mixture of lysophosphatidylcholine (200 mg/ml)
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and 10009 diluted Alexa Fluor 488-phalloidin (Molecular
Probes) in phosphate-buffered saline. The fluorescence
intensity was measured using LSRII flow cytometer (Becton–
Dickinson). The acquired data were analyzed using FlowJo
software (Tree Star Inc).
Confocal microscopy
IgE-sensitized BMMCs (3 9 105) were attached (60 min
at 37 C) to a fibronectin-coated multitest slide (MP
Biomedicals) and then activated by Ag. After 30 min, the
cells were fixed with 4 % paraformaldehyde for 15 min at
room temperature and permeabilized with 0.3 % Triton
X-100 for 20 min. Free binding sites were blocked with
5 % donkey serum (Jackson ImmunoResearch Laborato-
ries) in PBS and the cells were stained with a mixture of
rabbit Abs against p65 subunit of NF-jB diluted 1:400
(#8242) and 1:200 (#sc-372), followed by labeling with
secondary antibody, donkey anti-rabbit-Alexa Fluor 488
conjugate, and diluted 1:200 in PBS containing 1 % BSA.
ORMDL was labeled with rabbit polyclonal serum (de-
scribed in Antibodies and reagents) followed by labeling
with donkey anti-rabbit-Alexa Fluor 568 (1:100). After
60 min incubation, the cells were washed and mounted in
Mowiol 4-88, supplemented with 1 lg/ml Hoechst 33258
to label nuclei. Samples were examined with a confocal
laser scanning microscope Leica TCS SP5 equipped with
an X63/1.4.N.A. oil-immersion objective. STIM1-YFP
(kind gift of Dr. T. Meyer, Stanford University Medical
School) was used as an endoplasmic reticulum marker.
Golgi marker (YFP-GT) was from Clontech Laboratories.
ORMDL3-YFP was cloned into the N1-YFP plasmid
(Clontech) using forward primer 50-AAACTC-
GAGGCCGCCACCATGAATGTG GGCACAGCAC-30
and reverse complementary primer 50-AAA-
GAATTCGGTACTTATTGATTCCAAAG-30, introducing
XhoI and EcoRI restriction endonuclease sites (underlined),
respectively. Amaxa Nucleofector II (Lonza Cologne AG,
Cologne, Germany) was used to nucleofect mast cells using
a Mouse Macrophage Kit and program Y-001.
Image analysis
Image processing and analysis were performed using
CellProfiler software (Broad Institute, Boston, MA) [39].
For cell spreading, areas corresponding to individual cells
were identified by F-actin staining with Alexa Fluor
488-phalloidin and the mean values were calculated from
200 to 400 cells in each sample. The fraction of NF-jB p65
subunit in the nucleus was determined as the difference
between NF-jB mean fluorescence in the nucleus (stained
with Hoechst 332578) and NF-jB mean fluorescence in the
cytoplasm as described [40]. Fifty to hundred cells were
evaluated per sample and the values obtained for each cell
were plotted in GraphPad Prism (San Diego, CA, USA).
Other charts were done in SigmaPlot 8.0 (San Jose, CA,
USA).
Short interfering RNA (siRNA)-mediated inhibition
of ORMDL3 expression and measurements of PCA
To silence ORMDL3 in the mouse ear, we followed the
experimental procedure described by Kanada et al. [41]
with some modifications. The specificity of ORMDL3
siRNAs was first confirmed by immunoblotting analysis of
lysates from BMMCs nucleofected by Amaxa Nucleofector
II 48 h earlier with 1 lg of ORMDL3 siRNA pool (Accell
Mouse Ormdl3 siRNA; E-049023-00-0005; Dharmacon) or
1 lg control siRNAs ORMDL3 (O3_siRNA; Accell Non-
targeting Pool; D-001910-10-05; Dharmacon) using a
Mouse Macrophage Kit and program Y-001 as recom-
mended by the manufacturer (Lonza). For PCA, 20 lL of
PBS containing 4 lg/ml of anti-TNP-specific IgE and
2.5 lg of ORMDL3 siRNAs pool was injected into the
right ear. As a control, 20 lL of anti-TNP-specific IgE
(4 lg/ml) and 2.5 lg of control siRNA was injected
intradermally into the left ear. After 48 h, the mice were
challenged with an intravenously injected PBS (200 ll)
containing Ag (100 lg TNP–BSA) and 1 mg of Evans
blue. Two hours later, the mice were killed and the ears
removed for measurement of the amount of extravasated
dye. Formamide (0.75 ml) was then added to each ear,
which was then homogenized with the T-25 ULTRA-
TURRAX Digital High-Speed Homogenizer Systems
(IKA) and incubated at 80OC for 2 h. The samples were
centrifuged at 14,0009g for 15 min and supernatants were
used for measurement of absorbance at 620 nm.
Statistical analyses
Unless stated otherwise, the significance of intergroup dif-
ferences was evaluated by Student’s t test; *, P\ 0.05; **,
P\ 0.01; ***, P\ 0.001. Microsoft Excel 2010 or
GraphPad Prism was used for statistical analysis evaluation.
Results
Properties of BMMCs with reduced or enhanced
expression of ORMDL3
Although ORMDL3 expression was described in various
cells of the immune system [1, 18], its presence in mast
cells has not yet been determined. Here, we used RT-PCR
to show the expression of ORMDL3 in BMMCs. We found
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that ORMDL3 as well as ORMDL1 and ORMDL2 are
expressed in BMMCs (Fig. 1a). We did not observe any
variations in the expression of ORMDL3 during BMMC
cultivation in medium supplemented with IL-3 and SCF
(data not shown). Using BMMCs transduced with markers
of endoplasmic reticulum or Golgi apparatus, we confirmed
previous findings [16, 18] that endogenous ORMDL pro-
teins detected by the NVG antibody recognizing all three
ORMDLs (Fig. S1a, c, d) are associated with the endo-
plasmic reticulum and perinuclear membrane, but not with
the Golgi apparatus (Fig. 1b). Next, we examined whether
the changes in ORMDL3 expression influence mast cell
effector functions. To induce ORMDL3 knockdown
(O3_KD), BMMCs were transduced using the pLKO.1
lentiviral vector with ORMDL3 shRNAs (200, 201, 202,
and 203, Fig. 1c). As controls, BMMCs were transduced
with the empty pLKO.1 vector. Quantification of
ORMDL3 mRNA expression by RT-qPCR showed its
30–80 % decrease after transduction of ORMDL3 shRNAs
(Fig. 1c). To find out whether silencing of ORMDL3 is
accompanied by changes in expression of other ORMDL
family members, we assessed the expression of all mem-
bers of the ORMDL family in BMMCs with O3_KD. Data
in Fig. 1d indicate that silencing with the O3_KD vector
(shRNA 200) led to a significant reduction of ORMDL3
mRNA without any effect on the expression of ORMDL1
and ORMDL2 mRNA. For production of cells with
enhanced expression of ORMDL3, we used pCDH vectors
containing ORMDL3 cDNA tagged with myc at the N
terminus (myc-O3) or C terminus (O3-myc). Cells trans-
duced with ORMDL3 cDNAs exhibited an 8- to 12-fold
increase in ORMDL3 mRNA when compared with cells
transduced with the empty pCDH vector, but expression of
ORMDL1 and ORMDL2 mRNAs was not significantly
changed (Fig. 1e). It should be noted that orientation of the
tag attached to ORMDL3 influenced the mobility of the
proteins in the gel ([11]; Fig. 1f). However, because in
functional assays we did not see any significant differences
between cells transduced with the two constructs, the data
obtained with both of them were pooled and are presented
as cells with ORMDL3 overexpressors (O3_OE). The
observed downregulation or upregulation of ORMDL3
mRNA in cells with O3_KD or O3_OE, respectively,
resulted in the expected changes in the intensity of the band
corresponding to the ORMDL family proteins as detected
by immunoblotting with polyclonal serum. The amount of
the band corresponding to the ORMDL proteins was
reduced by 60–80 % depending on the shRNA used
(Fig. 1f). The characteristics of the rabbit serum used for
immunoblotting (TPF) are shown in Fig. S1b, c. Both sera
(NVG and TPF) recognize other members of the ORMDL
family, as determined by their reactivity with cells
expressing cDNAs encoding ORMDL1 and ORMDL2
(Fig. S1c). Therefore, we refer to the corresponding band
of 17 kDa as ORMDL. In BMMCs transfected with myc-
O3 or O3-myc vectors, ORMDL3 protein was enhanced
approximately three to fourfold (Fig. 1f), although the
increase of ORMDL3 expression at the mRNA level was
more prominent (Fig. 1e). BMMCs with both O3_KD (all
four shRNAs) and O3_OE (myc-O3 or O3-myc vectors)
had preserved expression of FceRI and KIT receptors on
the plasma membrane (Fig. S2), but statistical evaluation
revealed that shRNAs 201 and 202 exhibited significant
changes in the expression of c-Kit (P\ 0.05) and shRNA
201 as well as in FceRI expression (Fig. 1g; P\ 0.05).
Based on these results, we excluded shRNAs 201 and 202
from further work. All experiments with O3_KD are based
on shRNA 200. Cells transduced with shRNA 203 exhib-
ited similar properties to those with shRNA 200. Based on
these findings, experimental data were pooled and all data
are presented as O3_KD. Alcian blue staining of cytospin
slides showed that the morphology of O3_KD and O3_OE
mast cells was not different from that of cells transduced
with appropriate controls (see examples in Fig. 1h).
Ag activation of BMMCs induces downregulation
of ORMDL3
A previous study showed that challenge with allergen
induced expression of ORMDL3 in mouse bronchial
epithelial cells, lung macrophages, or BM-derived eosino-
phils, but not in peripheral blood neutrophils [18].
Moreover, increased ORMDL3 expression in bronchial
airway epithelial cells was stimulated with IL-4 and IL-13
[18] and in eosinophils triggered with IL-3 and eotaxin-1
[20]. In further experiments, we therefore examined whe-
ther FceRI activation of BMMCs would also lead to
changes in ORMDL3 expression. Interestingly, in IgE-
sensitized cells, activation with Ag resulted in a significant
decrease of ORMDL3 mRNA expression 1, 4, and 6 h
after FceRI triggering, but ORMDL1 and ORMDL2
mRNA expression was not significantly affected (Fig. 2a).
At the protein level, for detection we used polyclonal
antibodies recognizing all members of the ORMDL family
(Fig. S1a–c). Data presented in Fig. 2b and c indicate that
there is a slight, but significant decrease in ORMDL family
member expression in cells activated for 8–24 h with Ag.
Attenuation of ORMDL3 transcription in activated cells
was also observed in cells with O3_KD, in which the
residual amount of ORMDL3 mRNA was further lowered
(Fig. 2d). Thus, FceRI-activated mast cells exhibit down-
regulation of ORMDL3 and in this regard differ from
activated eosinophils, lung macrophages, and bronchial
airway epithelial cells.
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BMMCs with reduced or enhanced expression
of ORMDL3 do not exhibit changes in SYK tyrosine
phosphorylation, degranulation, and Ca21 response
after FceRI triggering
FceRI-mediated signaling events are initiated by tyrosine
phosphorylation of the FceRI b and c subunits by Src
family kinase LYN, followed by propagation of the signal
through activity of the Src family kinases and SYK kinase
[22]. To examine a possible role of ORMDL3 in FceRI
signaling, we first examined phosphorylation of SYK in
Ag-activated BMMCs with reduced or enhanced ORMDL3
expression. Our data indicate that cells with O3_KD
(Fig. 3a) or O3_OE (Fig. 3b) show similar SYK phos-
phorylation as the corresponding controls.
Next, we examined Ag-induced degranulation estimated
by the release of b-glucuronidase from preformed secretory
lysosomes. We found that BMMCs with O3_KD (Fig. 3c)
or O3_OE (Fig. 3d) exhibited similar degranulation as the
control cells. We also compared cells transduced with
pLKO.1 and nontransduced wild-type (WT) cells to show
that mast cell degranulation is not changed by lentivirus
transduction (Fig. S3a).
Previous studies have shown that ORMDL3 affects
Ca2? mobilization in lymphocytes and eosinophils [16, 17,
20] and regulates the expression of sarco/endoplasmic
reticulum Ca2? ATPase (SERCA)2b [19]. Interestingly,
BMMCs with O3_KD (Fig. 3e) or O3_OE (Fig. 3f)
exhibited similar Ca2? mobilization to cells transduced
with empty pLKO.1 or pCDH vectors. We also compared
cells transduced with pLKO.1 and WT cells to show that
calcium mobilization in mast cells is not changed by len-
tivirus transduction (Fig. S3b). We also found that
expression of mRNA for SERCA2b was not significantly
changed in activated and nonactivated mast cells with
O3_KD (Fig. 3g) or O3_OE (Fig. 3h) when compared with
the corresponding controls. The mRNA levels of SER-
CA2b in cells transduced with pLKO.1 were comparable to
those in WT cells (Fig. S3c). In line with the SERCA2b
expression, the basal levels of [Ca2?]i were not changed in
O3_KD (Fig. S4a) or O3_OE (Fig. S4b) when compared
with the corresponding controls. We conclude that early
FceRI-induced activation events, including SYK tyrosine
phosphorylation, degranulation, and calcium responses in
mast cells, are not affected by enhanced or reduced
expression of ORMDL3. Furthermore, we show that
changes in ORMDL3 protein levels have no significant
effect on SERCA2b expression.
Negative regulatory role of ORMDL3
in the expression of cytokines and chemokines
Mast cells are potent producers of various cytokines and
chemokines involved in both asthma and autoimmune
diseases [22, 23, 42, 43]. In further experiments, we
therefore quantified the levels of mRNA encoding cytoki-
nes (TNF-a, IL-6, and IL-13; Fig. 4a) and chemokines
(CCL3 and CCL4; Fig. 4b) in BMMCs with O3_KD.
Using RT-qPCR, we found that all the studied transcripts
for cytokines and chemokines were significantly increased
in cells with O3_KD when compared with control cells
transduced with empty pLKO.1 vector in both nonactivated
and Ag-activated cells (Fig. 4a, b). The observed increase
in cytokine mRNA levels corresponded to enhanced
secretion of the cytokines TNF-a, IL-6 and IL-13 from Ag-
activated BMMCs with O3_KD (Fig. 4c). In contrast, no
significant changes in the transcription of TNF-a, IL-6, and
IL-13 at the RNA (not shown) or protein (Fig. 4d) level
were observed when BMMCs with O3_OE were compared
with the corresponding controls. These data indicate that
ORMDL3 in mast cells is a negative regulator of the pro-
duction of proinflammatory cytokines such as TNF-a, IL-6,
and IL-13 and chemokines CCL3 and CCL4.
ORMDL3 functions as a negative regulator
of Ag-mediated chemotaxis
The observed changes in the expression of genes for
cytokines and chemokines depending on the expression of
bFig. 1 Properties of BMMCs with reduced or enhanced ORMDL3
expression. a Expression of ORMDL1-3 mRNAs in BMMCs as
determined by RT-PCR followed by agarose gel electrophoresis and
staining with ethidium bromide. DNA marker in bps is shown in line
M. b Colocalization of endogenous ORMDL proteins (shown in red
pseudocolor) with STIM1-YFP, a marker of endoplasmic reticulum
(ER upper panel; green pseudocolor), but not with GT-YFP, a marker
of Golgi (lower panel green pseudocolor) is shown. Nuclei were
stained with Hoechst 33258 (shown in blue pseudocolor); bars 5 lm.
c BMMCs with O3_KD were obtained after transduction with
lentiviruses containing four shRNAs denoted 200, 201, 202, and 203.
Control cells were transduced with empty pLKO.1 vector. ORMDL3
mRNAs were quantified by RT-qPCR. d RT-qPCR quantification of
individual ORMDL family members in cells with O3_KD or in
control cells transduced with empty pLKO.1 vector. e BMMCs with
O3_OE were obtained after transduction with lentiviruses containing
ORMDL3 cDNAs terminally tagged with myc at the N-(myc-O3) or
C-(O3-myc) end. Control cells were transduced with empty pCDH
vector. The levels of ORMDL1 and ORMDL2 mRNAs are shown.
RT-qPCR data in c–e were normalized as described in ‘‘Materials and
methods’’ and represent the means and SEMs calculated from three to
seven independent experiments. f Quantification of ORMDL proteins
(serum not specific for ORMDL3) by immunoblotting in whole-cell
lysates after transduction of the cells as in c and e. Numbers under the
immunoblots indicate the amounts of ORMDL proteins normalized to
control cells transfected with pLKO.1 vector (for O3_KD) or pCDH
vector (for O3_OE) and to the amount of b-actin used as a loading
control (fold change). The positions of endogenous (En.) and
exogenous (Ex.) ORMDL3 and b-actin are indicated by arrows.
g Statistical evaluation of FceRI and c-Kit expression in the
transduced BMMCs. h Alcian blue staining of cytospin preparations
of BMMCs transduced as above; bars 10 lm
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ORMDL3 led us to examine the capability of IgE-sensitized
cells to migrate toward Ag and to adhere and spread on
fibronectin-coated substrates. BMMCs with O3_KD exhib-
ited a significantly stronger chemotactic response to all
tested concentrations of Ag when compared with control
cells transfected with empty pLKO.1 vector (Fig. 5a). In
contrast, BMMCs with O3_OE showed a less efficient
chemotactic response than the corresponding control cells
(Fig. 5b). We also compared cells transduced with pLKO.1
andWT cells to show that mast cell migration is not changed
by lentivirus transduction (Fig. S3d). When adhesion to
fibronectin was measured, cells with O3_KD (Fig. S5a) or
O3_OE (Fig. S5b) exhibited adhesion similar to the corre-
sponding control cells. In contrast, spreading on fibronectin-
coated surfaces after exposure to Ag was reduced in cells
with O3_KD (Fig. 5c, d). When compared to control cells,
cells with O3_OE exhibited no significant difference in Ag-
induced spreading (Fig. 5e, f). We also compared cells
transduced with pLKO.1 and WT cells and showed that Ag-
induced mast cells adhesion to and spreading on fibronectin
was not changed by lentivirus transduction (Fig. S3e, f).
Finally, we examined the depolymerization of F-actin in Ag-
activated cells with O3_KD (Fig. S5c) or O3_OE (Fig. S5d)
and corresponding controls and found that F-actin content
was independent of ORMDL3 expression levels.
Upregulation of NF-jB signaling axis in mast cells
with O3_KD
Previous studies with eosinophils showed that increased
expression of ORMDL3 enhanced translocation of NF-jB
into the nucleus and its activation [20]. Based on our
findings that reduced expression of ORMDL3 upregulated
the expression of cytokine and chemokine genes (Fig. 4a–
d) and that these mediators were directed by transcription
factor NF-jB [44–48], we decided to analyze the NF-jB
signaling axis in BMMCs with enhanced or decreased
ORMDL3 protein levels. First, we examined the phos-
phorylation of IjBa, a negative regulator of NF-jB
signaling. We found that 5 min after Ag activation,
BMMCs with O3_KD exhibited higher phosphorylation of
IjBa than control pLKO.1 cells. Interestingly, we found
that IjBa in activated BMMCs with O3_KD is more
degraded than in control cells (Fig. 6a). This is in accord
with the previously described observation that phosphory-
lation of IjBa triggers its degradation [49]. Densitometry
evaluation of the data and normalization of pIjBa to LYN
cFig. 2 Changes in ORMDL3 expression in Ag-activated BMMCs.
a BMMCs were sensitized for 16 h with IgE and then activated with
Ag (100 ng/ml) or not (0 h) for the indicated time intervals.
ORMDL3, ORMDL2, and ORMDL1 mRNAs were quantified by
RT-qPCR and normalized as described in ‘‘Materials and methods’’.
The means and SEMs were calculated from three independent
experiments performed in duplicate. b Immunoblot quantification of
ORMDL proteins at various time intervals after activation of IgE-
sensitized BMMCs with Ag (100 ng/ml). Numbers under the
immunoblots indicate the relative amounts of ORMDL3 normalized
to its amount in nonactivated cells and the amounts of HPRT, b-actin,
and GRB2 were used as loading controls (Average fold change). A
representative immunoblot from seven independent experiments with
similar results is shown. c Statistical evaluation of ORMDL proteins
expression is shown. ORMDL3 was normalized to its amount in
nonactivated cells and the amount of the average fold change of three
loading controls mentioned above. d RT-qPCR quantification of
ORMDL3 in nonactivated (control) or Ag-activated (100 ng/ml; 1 h)
BMMCs with the empty vector (pLKO.1) or O3_KD. Data are
normalized as in a. The means and SEMs were calculated from six
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Fig. 3 Early activation events
in BMMCs with enhanced or
reduced ORMDL3 expression.
a Ag-induced tyrosine
phosphorylation of SYK as
determined by immunoblotting
of whole-cell lysates from
BMMCs with O3_KD or control
cells transfected with empty
pLKO.1. IgE-sensitized cells
were activated for various time
intervals with Ag (100 ng/ml).
The positions of pSYK and
SYK, used as loading controls,
are indicated by arrows.
b Phosphorylation of SYK was
examined as in a, except that the
lysates were from cells with
O3_OE or control cells
transfected with empty pCDH.
Representative immunoblots
from at least three performed in
each group are shown in a and
b. Numbers under the
immunoblots indicate the
relative amounts of pSYK
normalized to its amounts in
nonactivated cells transduced
with empty vectors and total
amounts of SYK in individual
samples (fold change). c, d b-
Glucuronidase release in IgE-
sensitized BMMCs. The cells
were activated with various
concentrations of Ag and after
30 min b-glucuronidase
released into the supernatant
was determined. Data presented
are means and SEMs for cells
with O3_KD (c, n = 19),
pLKO.1 controls (c, n = 19),
O3_OE (d, n = 8), and pCDH
control cells (d, n = 5). e,
f Calcium response in IgE-
sensitized BMMCs activated
with Ag (100 ng/ml) for various
time intervals. Arrows show the
time points when Ag was added.
Means and SEMs were
calculated for cells with O3_KD
(e, n = 16), pLKO.1 controls (e,
n = 8), O3_OE (f, n = 3), and
pCDH controls (f, n = 5). g,
h RT-qPCR quantification of
SERCA2b mRNA in resting and
activated BMMCs with O3_KD
(g, n = 4) pLKO.1 controls (g,
n = 4), O3_OE (h, n = 4) and
pCDH controls (h, n = 4). Data
for SERCA2b mRNA were
normalized as described in
‘‘Materials and methods’’
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Fig. 4 Expression of cytokine and chemokine genes and production
of cytokines in BMMCs with O3_KD and O3_OE. a RT-qPCR
quantification of mRNAs encoding TNF-a, IL-6, and IL-13 in
nonactivated or Ag-activated (100 ng/ml; 1 h) BMMCs with O3_KD
and the corresponding control cells, pLKO.1. Means and SEMs were
calculated from 13 to 16 independent experiments. b RT-qPCR
quantification of mRNA for CCL3 and CCL4 chemokines from cells
as in a. The means and SEMs were calculated from six to eight
experiments. Data in a and b were normalized as described in
‘‘Materials and methods’’. c, d Quantification of cytokines TNF-a, IL-
6, and IL-13 secreted into the supernatants of nonactivated or Ag-
activated (100 ng/ml; 6 h) BMMCs with O3_KD or pLKO.1 control
(c) and O3_OE or pCDH control (d) as determined by nano-iPCR.
The means and SEMs were calculated from four to five independent
experiments
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kinase, used as a loading control, showed significantly
higher IjBa phosphorylation in O3_KD cells than control
pLKO.1 cells (Fig. 6b). BMMCs with O3_OE showed a
small, but nonsignificant decrease of IjBa phosphorylation
(not shown). Based on these data, we next examined the
consequences of reduced ORMDL3 levels on translocation
of the NF-jB p65 subunit into the nucleus in BMMCs. We
found that Ag-induced translocation of the p65 subunit into
the nucleus was higher in BMMCs with O3_KD than in
control cells (Fig. 6c). The difference was statistically
significant (Fig. 6d). Interestingly, resting BMMCs with













































































































Fig. 5 Negative regulatory role
of ORMDL3 in Ag-mediated
chemotaxis, but not cell
spreading on fibronectin. a,
b Migration of BMMCs toward
various concentrations of Ag
was determined in IgE-
sensitized BMMCs with
O3_KD (a) or O3_OE (b) and
the corresponding controls. The
means and SEMs were
calculated from four to eight
independent experiments
performed in duplicate. c–
f Spreading of BMMCs with
O3_KD (c, d), O3_OE (e, f),
and the corresponding controls.
The cells were attached to
fibronectin-coated slides and
activated with Ag (100 ng/ml)
for 30 min. Representative
fluorescent images are shown in
c and e; bars 10 lm.
Quantification and statistical
evaluation of data obtained as in
c and e are shown in d and f,
respectively. The means and
SEMs were calculated from five
independent experiments
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when compared with resting control pLKO.1 cells. These
data are consistent with the findings that basal levels of
mRNAs for cytokines (Fig. 4a) and chemokines (Fig. 4b)
were higher in cells with O3_KD than in control cells. We
also compared cells transduced with pLKO.1 and WT cells
and found that p65 nuclear localization after activation was
not changed by lentivirus transduction (Fig. S3g).
To determine which signaling pathways are involved in
enhanced IjBa phosphorylation we examined phosphory-
lation of ERK kinase, which is involved in IjBa
phosphorylation [50]. We found that mast cells with
decreased expression of ORMDL3 exhibited similar ERK
phosphorylation as pLKO.1 control cells (Fig. 6e, f). Next,
we therefore tested phosphorylation of AKT kinase, which
is a positive regulator of NF-jB signaling [51]. Interest-
ingly, BMMCs with O3_KD exhibited significantly
enhanced phosphorylation of AKT at Ser 473 at all
examined time points, but phosphorylation of AKT at Thr
308 was not significantly affected (Fig. 6g–i). To exclude
the possibility that the observed immunological responses
are not specifically activated by siRNA [52], we compared
the phosphorylation of IjBa and AKT (at Ser 473) in WT
cells, BMMCs transduced with empty pLKO.1, or cells
transduced with NT shRNA (Fig. S6a). We found that cells
with O3_KD showed enhanced responses when compared
with all controls. We also used the same controls in
experiments with cytokines to demonstrate that lentiviral
transduction had no impact on cytokine production and that
cytokines were specifically increased by O3_KD
(Fig. S6b–d). Collectively, these data demonstrate that
decreased expression of ORMDL3 is accompanied in Ag-
activated cells by enhanced phosphorylation of AKT,
increased translocation of the p65 subunit into the nucleus,
and enhanced production of cytokines.
ORMDL3 is a negative regulator of COX-2
expression and PGD2 synthesis
We also examined the expression of an inducible enzyme,
COX-2, which is regulated by NF-jB [53, 54]. COX-2
converts arachidonic acid to PGH2, a precursor of PGD2
and PGE2 [28]. When compared with control cells
(pLKO.1), BMMCs with O3_KD exhibited significantly
higher levels of COX-2 mRNA than both resting and Ag-
activated control cells (Fig. 7a), while cells with O3_OE
showed decreased COX-2 mRNA expression when com-
pared with the control cells (pCDH); however, the
difference was not significant (Fig. 7b). These data were
corroborated by studies of the COX-2 protein in Ag-acti-
vated BMMCs. After 5 h stimulation with Ag, we observed
a higher increase of COX-2 levels in cells with O3_KD
than in control cells (Fig. 7c); this difference was
significant (P\ 0.05; n = 3). On the other hand, Ag-ac-
tivated cells with O3_OE showed lower COX-2 levels than
the corresponding control cells (Fig. 7d); however, this
difference was not significant (P[ 0.05; n = 3). The
stronger band of exogenous ORMDL3-myc after 5 h of
activation in Fig. 7d was reproducibly observed. Ag-in-
duced activation apparently induces enhanced transcription
from the CMV promoter. We found that this enhancement
was not ORMDL3 specific, rather it depended on the CMV
promoter, as several other ORMDL family nonrelated
proteins cloned into the same pCDH vector exhibited a
similar increase (data not shown).
Supernatants collected from the experiments as depicted
in Fig. 7 c, d were assessed for PGD2 levels. We found that
Ag-activated mast cells with O3_KD released significantly
higher amounts of PGD2 than appropriate controls
(Fig. 7e). Furthermore, PGD2 expression was not signifi-
cantly changed in mast cells with O3_OE (Fig. 7f). To
show that COX-2 expression is independent of immuno-
logical responses toward dsRNAs, we compared COX-2
production in cells with O3_KD and controls (NT and
WT). We found that in O3_KD cells activated with Ag, the
levels of COX2 were more elevated than in control cells
(Fig. S6e). These data support the negative regulatory role
of ORMDL3 in the activation of the NF-jB signaling axis.
cFig. 6 Negative regulatory role of ORMDL3 in AKT and NF-jB
signaling axis in Ag-activated BMMCs. a Phosphorylation of IjBa
and its amount was determined by immunoblotting of whole-cell
lysates from BMMCs with O3_KD and control cells (pLKO.1) with
the corresponding antibodies. Representative immunoblots from four
independent experiments areshown. Numbers under the immunoblots
indicate the relative amounts of pIjBa and IjBa normalized to their
amounts in nonactivated pLKO.1 control cells and the amount of Lyn
used as a loading control (Fold change). b Quantification and
statistical evaluation of pIjBa in pLKO.1 control cells and O3_KD
cells activated with Ag for 5 min as in a. Means and SEMs were
calculated from four independent experiments. c Representative
confocal microscopy pictures of NF-jB p65 subunit (p65) localiza-
tion in the nuclei (stained with Hoechst 33258) and cytoplasm in
nonactivated or Ag-activated (100 ng/ml; 30 min) BMMCs with
O3_KD or pLKO.1 control; bars 10 lm. d Quantification of NF-jB
p65 subunit localization in the nucleus of nonactivated or Ag-
activated (100 ng/ml, 30 min) O3_KD and pLKO.1 control cells.
Values from two independent experiments as in c (50–100 cells per
experiment) were plotted; each symbol represents one cell, red
horizontal lines indicate means. e–i Phosphorylation of ERK at Tyr
204 (e, f), AKT at Ser 473 (g, h), and AKT at Thr 308 (g, i) was
assessed by immunoblotting with the corresponding antibodies of the
whole-cell lysates from BMMCs with O3_KD or pLKO.1 controls.
Representative immunoblots from at least three in each group are
shown in e and g. Numbers under the immunoblots indicate the
relative amounts of pERK (e) or pAKT (g) normalized to their
amounts in nonactivated pLKO.1 control cells and the amount of
ERK or AKT used as loading controls (fold changes). Quantification
and statistical analyses of differences in fold changes between cells
with O3_KD and pLKO.1 controls in pERKY204 (f), pAKTS473 (h),
and pAKTT308 (i) are also shown. Means and SEMs were calculated
from three experiments in each group
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Silencing of ORMDL3 enhances mast cell-dependent
PCA
To evaluate whether ORMDL3 has a function in mast cells
in vivo, we silenced ORMDL3 locally by intradermal
injection of the ORMDL3 siRNA pool. First, we examined
the efficiency of ORMDL3 siRNA in vitro. When com-
pared with BMMCs exposed to nontargeting control
siRNA pool, the ORMDL3 siRNA pool reduced ORMDL
expression by approximately 60 % as determined by
immunoblotting (Fig. 8a, b; serum specific for all members
of murine ORMDL family). For FceRI-mediated PCA
reactions, mice were intradermally injected with ORMDL3
siRNAs together with TNP-specific IgE into the right ears
and control siRNAs together with TNP-specific IgE into
the left ears. After 48 h, mice were challenged
intravenously with Ag (TNP–BSA) and Evans blue dye and
2 h later Evans blue in both ears was quantified. Data
presented in Fig. 8c show that ears injected with ORMDL3
siRNA displayed significantly higher amounts of Evans
blue than ears injected with control siRNA. These data
corroborate previous results obtained with BMMCs
in vitro. Based on these results, we conclude that silencing
of ORMDL3 in vivo leads to enhanced local inflammation
triggered by mast cells.
Discussion
In this study, we examined the role of ORMDL3 protein in
Ag-mediated mast cell signaling. Although enhanced or
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Fig. 7 Increased COX-2
expression and PGD2 synthesis
in nonactivated or Ag-activated
BMMCs with O3_KD. a, b RT-
qPCR quantification of COX-2
mRNAs in nonactivated or Ag-
activated (100 ng/ml; 1 h)
BMMCs with O3_KD (a),
O3_OE (b), and the
corresponding controls, pLKO.1
(a) and pCDH (b). The means
and SEMs were calculated from
five independent experiments. c,
d Amount of COX-2 protein in
nonactivated or Ag-activated
(100 ng/ml; 5 h) BMMCs with
O3_KD (c), O3_OE (d), and the
corresponding controls, pLKO.1
(c) and pCDH (d). Numbers
under the COX-2 immunoblots
indicate the relative amount of
COX-2 normalized to its levels
in nonactivated control cells and
to the amount of b-actin, used as
a loading control, in individual
samples (fold change). Levels of
ORMDL3 normalized as above
are also shown. Representative
immunoblots from three
independent experiments are
shown. e, f Levels of PGD2
released into supernatants of
nonactivated or Ag-activated
(100 ng/ml; 5 h) BMMCs with
O3_KD (e), O3_OE (f), and the
corresponding controls, pLKO.1
(e) and pCDH (f). The means
and SEMs were calculated from
three independent experiments
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induced degranulation and calcium responses, several lines
of evidence presented in this study indicate that ORMDL3
is a negative regulator of proinflammatory activities of
mast cells (Table 1). Increased expression of cytokines,
chemokines, and COX-2 in O3_KD cells could be
explained by our observation that BMMCs with O3_KD
exhibited enhanced phosphorylation of IjBa, which is a
regulator of transcription factor NF-jB [24]. Indeed,
localization of the NF-jB p65 subunit was increased in the
nuclei of Ag-activated ORMDL3-deficient mast cells. It is
known that enhanced nuclear localization of the NF-jB
p65 subunit leads to increased transcription of NF-jB-
regulated genes encoding various cytokines, including
TNF-a, IL-6 and IL-13, chemokines, CCL3 and CCL4, and
COX-2 enzyme [44–48, 53–55]. Moreover, improperly
regulated NF-jB causes a broad variety of inflammatory
diseases [25–27]. Our findings regarding the regulatory
roles of ORMDL3 are different from those obtained with
other cell types, demonstrating a positive regulatory role of
ORMDL3 in cell signaling. For example, eosinophils
overexpressing ORMDL3 exhibited enhanced localization
of the phosphorylated NF-jB p65 subunit in the nucleus
[20]. Furthermore, transfection of ORMDL3 into lung
epithelial cell line A549 increased the expression of several
genes, including those for metalloproteases, ADAM-8 and
MMP-9, chemokines CXCL-10, CXCL-11, IL-8, CCL-20,
and oligoadenylate synthetases [18]. It has also been shown
that the expression of several genes, including TGF-b1,
ADAM8, MMP9, and CXCL-10, is enhanced in the
bronchial epithelium of transgenic mice overexpressing
ORMDL3 [19]. Recent studies showed that in eosinophils
with O3_OE, ERK kinase played a role in regulating NF-
jB signaling [20]. However, mast cells with O3_KD or
O3_OE (not shown) exhibited similar ERKY204 phospho-
rylation when compared with control cells. Although we
did not exclude the possibility that phosphorylation of
other targets in ERK could be affected by changing
ORMDL3 levels, we focused on another potent activator of
the NF-jB pathway, AKT kinase. We found that AKT
kinase is more phosphorylated at the Ser 473 (but not at the
Thr 308) in BMMCs with O3_KD than control cells. These
data suggested a regulatory role of AKT in NF-jB sig-
naling in mast cells with O3_KD. However, the exact
molecular mechanism by which ORMDL3 activates AKT
kinase remains unclear. To exclude the possibility that
immunological responses toward dsRNAs could non-
specifically activate IjBa/AKT phosphorylation, COX-2
expression, and cytokine production, we included cells
transduced with pLKO.1 containing NT shRNA as a con-
trol. It should be mentioned that BMMCs poorly expressed
toll-like receptors recognizing dsRNA, and their activation
by specific ligands had little impact on TNF-a, IL-6, and
IL-13 expression [56].
It has been shown that silencing of all three members
of the ORMDL family potentiates de novo synthesis of
sphingolipids [11]. In our study, we used shRNA to
decrease the expression of ORMDL3 and found that
expression of the other two members, ORMDL1 and
ORMDL2, remained unchanged. Thus, we propose that in
mast cells, a decrease in ORMDL3 expression alone is
capable of promoting inflammation without the coordinate
silencing of the ORMDL family genes. It should be noted
that the NF-jB transcription factor is activated by multi-
ple stimuli and that the multiprotein NF-kB signaling
complex is subjected to extensive regulation [24]. TNF-a
is known to be involved in the phosphorylation of IjBa
[57, 58], and autocrine activation of NF-jB by TNF-a was
observed in human mast cells [59]. Collectively, our data
suggest a unique role of ORMDL3 in mast cells in the
negative regulation of proinflammatory mediator synthe-
sis. Interestingly, mast cells with O3_OE exhibited no
significant inhibition of IjBa/AKT signaling and no sup-
pression of proinflammatory mediator production. This
could be explained at least in part by a recently published
study, which showed that the expression levels of
ORMDL3 were crucial for regulation of cell signaling in
lipopolysaccharide-mediated activation of RAW264.7
macrophage cell line and A549 lung epithelial cells [60].
Thus, the relatively low overexpression of ORMDL3 in
BMMCs could be under the threshold to regulate signaling
pathways leading to the changes in cytokine expression.
Our attempt to increase the exogenous expression of
ORMDL3 in BMMCs failed because of enhanced mor-
tality of BMMCs.
As already mentioned, no significant changes in calcium
mobilization were found in Ag-activated BMMCs with
O3_KD or O3_OE. These findings are different from those
obtained with ORMDL3-deficient BM-derived eosinophils
which, when compared with wild-type cells, showed
reduced Ca2? response after activation with eotaxin-1 [20].
On the other hand, Jurkat T cells with an siRNA-mediated
O3_KD exhibited elevated mobilization of Ca2? when
activated via CD3, while a decreased Ca2? response was
observed in Jurkat cells with O3_OE [17]. Recent data
showed that transgenic mice with elevated expression of
ORMDL3 exhibited enhanced lung expression of SER-
CA2b, a known regulator of cytosolic calcium
concentrations [19]. In contrast, our data with BMMCs
showed that the expression of SERCA2b was not affected
by changes in the ORMDL3 levels. These data are in line
with our finding that BMMCs with decreased or enhanced
expression of ORMDL3 exhibited similar levels of basal
[Ca2?]i, and Ag-induced calcium mobilization when
compared with corresponding control cells.
ORMDL3 has been described as an inducible gene upon
Alternaria allergen challenge of mouse lung epithelial cells,
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lung eosinophils, and lung macrophages, but not lung
neutrophils [18]. Moreover, IL-4 and IL-13 were capable of
inducing ORMDL3 expression in lung epithelial cells [18].
These data were extended to mouse BM-derived eosino-
phils, which exhibited IL-3- and eotaxin-1-dependent
induction of ORMDL3 expression [20]. In contrast to these
data, our studies with mouse mast cells showed that
expression of the ORMDL3 gene was downregulated after
FceRI triggering. Interestingly, a similar decrease was
observed in our previous study in which gene expression
was analyzed in nonactivated and Ag-activated BMMCs
(Gene Expression Omnibus repository dataset GSE40731
[61]). The data show that 2 h after FceRI triggering,
ORMDL3 was decreased to 0.6 in WT and to 0.43 in
pLKO.1-transduced cells (n = 3 for each group, adj.
P value \0.006). There were no significant changes
between ORMDL1 and ORMDL2. The amounts of all
ORMDL family members were not significantly changed
between WT and pLKO.1 BMMCs. These data suggest a
distinct regulation of ORMDL3 gene expression in Ag-ac-
tivated mast cells when compared with activated
eosinophils, macrophages, and lung epithelial cells [18, 20].
Recently, it has been shown that lipopolysaccharide acti-
vation of macrophage cell line RAW267.4 induces
coordinated transient suppression of expression of genes
encoding the ORMDL family and in this way regulates
sphingolipids homeostasis [14]. Chemotaxis is another
example of distinct ORMDL3 regulatory roles in mast cells
and eosinophils. ORMDL3-deficient eosinophils exhibited
decreased chemotaxis toward eotaxin-1 [20], while we
showed that BMMCs with O3_KD increasingly migrate
toward Ag. Moreover, O3_KD exhibited decreased Ag-in-
duced spreading on fibronectin. These data are consistent
with previous observations of indirect relationship between
mast cell migration and cell spreading [62]. The observed
difference between mast cells and eosinophils could be
caused by distinct chemoattractants and different methods
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Fig. 8 Enhanced PCA in mice pretreated with ORMDL3 siRNA (O3
siRNA). a Specificity of the O3 siRNA. BMMCs were exposed to O3
siRNA pool or non-targeting control siRNA. 48 h later, the cells were
lysed and analyzed for ORMDL3 and b-actin by immunoblotting. The
position of ORMDL3 and b-actin, used as a loading control, is
indicated by an arrow. Numbers under immunoblots indicate the
relative amount of ORMDL3 normalized to its level in cells
nucleofected with control siRNA and the amount of b-actin.
b Quantification of ORMDL3 from data as in a. Means ± SEMs
are shown (n = 5). c Role of ORMDL3 in PCA. TNP-specific IgE
and O3 siRNA were injected intradermally into the right ears and
TNP-specific IgE and control siRNA into the left ears. After 48 h,
TNP–BSA was administered intravenously together with Evans blue
dye and mice were killed 2 h later. Extravasation of Evans blue in
both ears was determined. Means ± SEMs are shown (n = 7)
Table 1 Summary of Ag-induced responses of BMMCs with




Ca2? response – –
SERCA2b (mRNA) – –
Chemotaxis toward Ag : ;
Adhesion to fibronectin – –
Spreading on fibronectin ; –
F-actin content – –
Phosphorylation of IjBa (Ser 32/36) : –
Phosphorylation of AKT (Ser 473) : –
Phosphorylation of AKT (Thr 308) – –
Phosphorylation of ERK (Tyr 204) – –
Nuclear p65 subunit of NF-jB : –




Production of chemokines (mRNA)
CCL3 : –
CCL4 : –
Expression of COX-2 (mRNA and protein) : –
PGD2 synthesis : –
BMMCs with O3_KD or O3_OE exhibited unchanged (–), decreased
(;) or increased (:) responses when compared to control cells trans-
duced with the corresponding empty vectors (pLKO.1 or pCDH)
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used and/or different involvement of ORMDL3 in chemo-
taxis of BMMCs and bone marrow-derived eosinophils.
Dysregulation of ORMDL3 expression is linked to
various inflammatory diseases [1, 4–7]. It has been shown
that upregulation of ORMDL3 stimulates the release of
proinflammatory mediators [18, 20] and that ORMDL3
transgenic mice exhibit the proinflammatory phenotype
[19]. On the other hand, decreased expression of all
members of the ORMDL family led to activation of sph-
ingolipid synthesis [11]. In this study, we showed for the
first time that O3_KD alone is able to enhance the
inflammatory response of mast cells. In BMMCs with
O3_KD, we described a complex phenotype based on the
enhanced AKT–NF-jB signaling axis, followed by
increased secretion of TNF-a, IL-6, and IL-13 and
enhanced expression of COX-2 associated with increased
PGD2 synthesis. In addition, the chemotactic response of
IgE-sensitized BMMCs to Ag was increased in cells with
O3_KD and decreased in O3_OE. Moreover, we have
found that ORMDL3 mRNA levels are decreased after
challenge of IgE-sensitized BMMCs with Ag. These data
were corroborated by an in vivo study, which showed that
decreased ORMDL3 expression in mast cells was capable
of inducing Ag-dependent inflammation. The opposite
results obtained in mast cells versus other cell types
described in the literature could be explained by formation
of different functional complexes of ORMDL3 with other
molecules in various cell types. Clarification of this issue
and ORMDL3 properties in human mast cells requires
further studies.
Collectively, our data show that ORMDL3 is predomi-
nantly a negative regulator of proinflammatory responses
in Ag-activated murine mast cells, both in vitro and in vivo.
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Abstract
Ethanol has multiple effects on biochemical events in a variety of cell types, including the
high-affinity immunoglobulin E receptor (FcεRI) signaling in antigen-activated mast cells.
However, the underlying molecular mechanism remains unknown. To get better under-
standing of the effect of ethanol on FcεRI-mediated signaling we examined the effect of
short-term treatment with non-toxic concentrations of ethanol on FcεRI signaling events in
mouse bone marrow-derived mast cells. We found that 15 min exposure to ethanol inhibited
antigen-induced degranulation, calcium mobilization, expression of proinflammatory cyto-
kine genes (tumor necrosis factor-α, interleukin-6, and interleukin-13), and formation of
reactive oxygen species in a dose-dependent manner. Removal of cellular cholesterol with
methyl-β-cyclodextrin had a similar effect and potentiated some of the inhibitory effects of
ethanol. In contrast, exposure of the cells to cholesterol-saturated methyl-β-cyclodextrin
abolished in part the inhibitory effect of ethanol on calcium response and production of reac-
tive oxygen species, supporting lipid-centric theories of ethanol action on the earliest stages
of mast cell signaling. Further studies showed that exposure to ethanol and/or removal of
cholesterol inhibited early FcεRI activation events, including tyrosine phosphorylation of the
FcεRI β and γ subunits, SYK kinases, LAT adaptor protein, phospholipase Cγ, STAT5, and
AKT and internalization of aggregated FcεRI. Interestingly, ethanol alone, and particularly in
combination with methyl-β-cyclodextrin, enhanced phosphorylation of negative regulatory
tyrosine 507 of LYN kinase. Finally, we found that ethanol reduced passive cutaneous ana-
phylactic reaction in mice, suggesting that ethanol also inhibits FcεRI signaling under in vivo
conditions. The combined data indicate that ethanol interferes with early antigen-induced
signaling events in mast cells by suppressing the function of FcεRI-cholesterol signalo-
somes at the plasma membrane.
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Introduction
Although it is known that ethanol has multiple effects on a variety of cells types, the molecular
mechanisms of its action are far from understood. There are two basic theories of ethanol
action on the cells, lipid-centric and protein-centric [1]. The lipid theory of ethanol action pos-
tulates that ethanol, similarly to anesthetics [2,3], dissolves in cellular lipids and acts by non-
specific mechanisms. This theory was supported by experiments showing that alcohols and
anesthetics induce changes in properties of cellular membranes, including fluidity [4], lateral
mobility of lipid molecules [5], phase transition temperature [6,7], and membrane permeability
[8]. The protein theory of alcohol and anesthetics action proposes that the drugs interact spe-
cifically with certain proteins and in this way affect their properties [9]. This theory was mostly
based on experiments suggesting that binding of alcohols and anesthetics induces conforma-
tional changes that diminish or abolish the function of some proteins, such as those forming
neurotransmitter-gated ion channels [10–13]. However, concentrations of ethanol required to
cause significant changes in the receptor functions were often greater than those attainable in
vivo, and effects mediated by lower concentrations have not always been replicated [14].
Previous studies showed that alcohol modulates various components of the immune system
[15–17]. Acute exposure to ethanol resulted in reduced monocyte/macrophage phagocytosis
[18,19], T-cell receptor signaling [20], Toll-like receptor-mediated activation of macrophages
[21,22], and reduced neutrophil migration [23]. It has also been reported that in vitro exposure
of mast cells to ethanol for 1 hour or longer inhibited the high-affinity immunoglobulin E
(IgE) receptor (FcεRI)-induced degranulation and production of tumor necrosis factor (TNF)-
α and interleukin (IL)-8 [24,25]. Although these data suggested that ethanol inhibits signal
transduction from the immunoreceptors, molecular mechanisms of the inhibitory action of
ethanol on early steps of immunoreceptor signaling remained enigmatic.
In this study we used primary mouse bone marrow-derived mast cells (BMMCs) and exam-
ined sensitivity to ethanol of the earliest signaling events after FcεRI triggering. We also exam-
ined effect of ethanol on FcεRI activation in cells with reduced levels of cholesterol and on
passive cutaneous anaphylaxis (PCA) in mice. Our data indicate that ethanol inhibits tyrosine
phosphorylation of the FcεRI β and γ subunits, the first biochemically defined event after anti-




Mice were bred and maintained in specific pathogen free facility of the Institute of Molecular
Genetics and used in compliance with the Institute guidelines. All protocols, including killing
mice by decapitation, was approved by the Animal Care and Use Committee of the Institute of
Molecular Genetics (Permit number 12135/2010-17210) and was in compliance with the EU
Directive 2010/63/EU for animal experiments. All efforts were made to minimize suffering of
the mice.
Bone marrow mast cells were isolated from femurs and tibias of C57BL/6 mice (females,
6–8 weeks old). The cells were cultured in RPMI-1640 medium supplemented with 100 U/ml
penicillin, 100 μg/ml streptomycin, 71 μM 2-mercaptoethanol, minimum essential medium
non-essential amino acids, 0.7 mM sodium pyruvate, 2.5 mM L-glutamine, 12 mMD-glucose,
recombinant mouse stem cell factor (SCF; 20 ng/ml, ProSpec), mouse recombinant IL-3 (20
ng/ml, ProSpec) and 10% fetal calf serum (FCS). For PCA experiments, BALB/c male mice
aged 8–12 weeks were used.
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Antibodies and reagents
The following monoclonal antibodies (mAbs) were used: anti-FcεRI β chain [26], trinitrophe-
nol (TNP)-specific IgE mAb (IGEL b4 1) [27], anti-LAT [28], anti-LYN [29], and anti-NTAL
[30]. Polyclonal antibodies specific for LYN and LAT were prepared by immunization of rab-
bits with the corresponding recombinant proteins or their fragments [31]. Rabbit anti-IgE was
prepared by immunization with whole IGEL b4.1. Polyclonal antibodies specific for phospholi-
pase C (PLC)γ1, phospho(p)PLCγ1 (Tyr 783), STAT5, ERK, pERK (Tyr 783), AKT, pAKT (Ser
473) as well as horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG, and goat anti-
rabbit IgG, were obtained from Santa Cruz Biotechnology Inc. Antibodies specific for pSYK
(Tyr 525/Tyr 526), pSTAT5 (Tyr 694), pLYN (Tyr 507), and pLYN (Tyr 416) were obtained
from Cell Signaling. Antibody specific for pLAT (Tyr 191) cross-reacting with pNTAL was
obtained fromMerc-Millipore. PAG-specific rabbit polyclonal antibody was from Exbio.
V450-conjugated rat anti-mouse CD107a (LAMP1) and HRP-conjugated anti- phosphotyro-
sine mAb (PY-20) were obtained from BD Biosciences. Anti-mouse FcεRI labeled with fluores-
cein isothiocyanate (FITC) and anti-mouse KIT-allophycocyanin conjugates were obtained
from eBiosciences. Donkey anti-mouse Ig-Alexa Fluor 568 conjugate was obtained from Invi-
trogen. All other reagents were from Sigma-Aldrich.
Flow cytometry
For flow cytometry measurements, BMMCs (105/sample) were used. To analyze the surface
levels of FcεRI and Kit receptor, the labeling proceeded as described previously [32]. For analy-
sis of surface CD107a (LAMP1), BMMCs were activated with various concentrations of antigen
for 10 min at 37°C. Activation was stopped by pelleting the cells at 4°C. Cells were then resus-
pended in 50 μl of phosphate-buffered saline (PBS) containing 1% bovine serum albumin
(BSA) and 1:200 diluted V450-conjugated rat anti-mouse CD107a (LAMP1). After 30 min on
ice, the cells were washed with ice-cold PBS and analyzed by an LSRII flow cytometer (BD Bio-
sciences). Median fluorescence intensities were determined and further processed using FlowJo
software (Ashland).
Cell activation
BMMCs were cultured for 48 hours in medium without SCF, followed by incubation in SCF-
and IL-3-free medium supplemented with TNP-specific IgE (1 μg/ml). After 14 hours the cells
were washed in buffered salt solution (BSS; 20 mMHEPES, pH 7.4, 135 mM NaCl, 5 mM KCl,
1.8 mM CaCl2, 5.6 mM glucose, 1 mMMgCl2) supplemented with 0.1% BSA and incubated
with or without ethanol and/or other drugs. After 15 min, antigen was added and the cells were
activated in the presence or absence of the drugs. The degree of degranulation was determined
as the amount of β-glucuronidase released into the supernatant as described [32].
Measurement of free intracellular calcium
Changes in concentrations of free intracellular calcium were determined using cell permeant
Fura-2 acetoxymetyl ester (Fura-2 AM; Life Technologies) as a reporter. IgE-sensitized cells
were harvested, washed in BSS-0.1% BSA and transferred to BSS-0.1% BSA supplemented with
Fura-2 AM (1 ng/ml) and probenecid (2.5 mM) used to prevent dye leakage [33], and incu-
bated in the shaker for 30 min at 37°C, 500 rpm. Fura-2 loaded cells were washed twice with
2.5 mM probenecid in BSS-0.1% BSA and then transferred to BSS-0.1% BSA supplemented
with 2.5 mM probenecid and various drugs as specified in the Results. Cells were then incu-
bated in Thermomixer (Eppendorf; 10 min, 37°C, 500 rpm). For measurement in the presence
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of extracellular calcium, cells were pelleted by centrifugation 500 x g for 3 min, resuspended in
BSS-0.1% BSA and transferred to white polysorp 96 well plate (NUNC, Thermo Scientific). To
determine free intracellular Ca2+ levels in the absence of extracellular Ca2+, cells were pelleted
by centrifugation, washed in Ca2+-free BSS-0.1% BSA and transferred to the plate. Free intra-
cellular Ca2+ was measured on INFINITE M200 (Tecan) as Fura-2 emission at 510 nm after
excitation with 340 nm and 380 nm. Basal level of calcium was usually measured in the first 60
sec, followed by addition of antigen (TNP-BSA, final concentration 100 ng/ml) in BSS-0.1%
BSA. Measurement continued up to 350 s. In the absence of extracellular calcium the cells were
activated with antigen for 5 min followed by addition of CaCl2 to final concentration 1 mM
and measurement continued up to 600 s.
Immunoprecipitation and immunoblotting
Activated or nonactivated cells were solubilized in ice-cold lysis buffer (25 mM Tris-HCl, pH
8.0, 140 mMNaCl, 1 mMNa3VO4, 2 mM EDTA, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 mM
phenylmethylsulfonyl fluoride) supplemented with 0.2% Triton X-100 (for FcεRI immunopre-
cipitation). After incubation on ice for 30 min, the lysates were centrifuged (16,000 x g for 5
min at 4°C) and postnuclear supernatants were immunoprecipitated with rabbit anti-IgE anti-
body prebound to UltraLink-immobilized protein A (Pierce, Thermo Scientific). The immuno-
precipitated proteins were size-fractionated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), transferred to nitrocellulose membrane and immunoblotted with
PY-20-HRP conjugate or with FcεRI-β chain-specific antibody followed by HRP-conjugated
anti-mouse IgG. For immunoblotting analysis of other proteins, the cells were solubilized in
lysis buffer supplemented with 1% n-dodecyl β-D-maltoside and 1% Nonidet P-40 and post-
nuclear supernatants were directly analyzed by SDS-PAGE followed by immunoblotting with
phospho-protein-specific or the corresponding protein-specific antibodies and HRP-conju-
gated secondary antibodies. The HRP signals were detected by chemiluminescence, quantified
by luminescent image analyzer LAS-3000 (Fuji Photo Film Co), and further analyzed by Aida
image analyzer software (Raytest). The amount of phosphorylated proteins was normalized to
the loading controls, run in parallel experiments [32]. We found that this approach gave more
reliable data than normalization towards specific proteins after stripping of the membranes.
Sucrose density gradient fractionation and expression of cytokine genes
Sucrose density gradient separations were performed as previously described [32] and individ-
ual fractions were analyzed by SDS-PAGE followed by immunoblotting with PY-20-HRP and
protein-specific antibodies. Expression of cytokine genes was examined by quantitative poly-
merase chain reaction (qPCR) as described [32].
Confocal microscopy
The wells of microscopy slides (CN Biomedicals) were coated with CellTak (BD Biosciences;
8 μl in 1 ml PBS). IgE-sensitized cells were left to attach to the coated wells for 15 min in BSS-
0.1% BSA and then activated or not with Ag. After 15 min, the cells were fixed for 30 min with
3% paraformaldehyde in PBS and then permeabilized with 0.1% Triton X-100 in PBS for 30
min. After washing with PBS, the samples were blocked in PBS-1% BSA, and subsequently IgE
was detected with Alexa Fluor 568-labeled donkey anti-mouse Ig. After labeling, the cells were
washed and mounted in glycerol mounting solution supplemented with Hoechst 33258 stain
to label nuclei. Samples were examined with a confocal laser scanning microscope Leica TCS
SP5 equipped with an X63/1.4.N.A. oil-immersion objective. The image analysis was per-
formed using a pipeline generated in CellProfiler software (Broad Institute, Boston) [34].
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ROSmeasurements
Reactive oxygen species (ROS) were examined with cell-permeant 2',7'-dichlorodihydrofluores-
cein diacetate (H2DCFDA; Life Technologies) as a reporter. Cells were sensitized for 16 hours
with anti-TNP IgE (1 μg/ml) at 37°C in culture medium supplemented with 10% FCS, but
devoid of SCF and IL-3. Then, the cells were washed and loaded into the wells of a 96-well
plate (0.25 x 106 cells/well) in 100 μl of the same medium supplemented with H2DCFDA (5 μg/
ml) in the presence of probenecid (2.5 mM) and various concentrations of ethanol. After 15
min, the cells were centrifuged and resuspended in 50 μl BSS-BSA. Activation was triggered by
adding 50 μl of 500 ng/ml TNP-BSA (final concentration 250 ng/ml) in the absence or presence
of different concentrations of ethanol. Alternatively, in the experiment with methyl-β-cyclo-
dextrin (Mβ) and cholesterol-saturated Mβ (sMβ), the cells were stained with H2DCFDA as
above, washed and incubated 15 min in BSS-BSA supplemented or not with 0.5% (v/v) ethanol,
2 mMMβ, and/or 2 mM sMβ. The activation was triggered by antigen (TNP-BSA; 250 ng/ml
final concentrations) in the presence of the drugs; sMβ was prepared as previously described
[35]. After 10 min, changes in fluorescence intensity were monitored in an LSRII flow cytome-
ter (BD Biosciences; Ex/Em 488/505-535 nm).
PCA
Mice were anesthetized by intraperitoneal injection of a cocktail containing ketamine (Narke-
tan 10; 40 mg/kg, final concentration), xylazine (Xylapan; 10 mg/kg), and atropine (Atropin
Biotika; 0.1 mg/kg) and then sensitized by intradermal injection of 20 μl of anti-TNP-specific
IgE (50 μg/ml) in PBS into the left ear; the right ear was injected with 20 μl of PBS alone.
Twenty-four hours later, 5% (v/v), 10% or 20% absolute ethanol in PBS was injected intraperi-
toneally (0.5 ml per mouse weighing 20 g). Mice injected with 0.5 ml of 10% or 20% ethanol
exhibited reduced motoric activity, which lasted for 30 min or 90 min, respectively. Mice chal-
lenged with 0.5 ml of 5% ethanol were without any clinical signs. One hour after ethanol in
PBS or PBS alone injection, each mouse was challenged with an intravenous injection of anti-
gen (TNP-BSA, 100 μg) in 200 μl of PBS containing 1% Evans blue. The mice were killed 30
min later and their ears were removed for measurement of the amount of the Evans blue
extravasated. The dye was extracted by adding 1 ml of formamide to each ear, followed by
homogenization with the IKA T-25 ULTRA-TURRAX digital high-speed homogenizer sys-
tems (IKA) and incubation at 80°C. After 2 h, the formamide solution was centrifuged for 15
min at 13.000 x g and absorbance at 620 nm was determined in the supernatants.
Statistical analysis
Statistical significance of intergroup differences was determined by one-way ANOVA with
Tukey’s post-test using the Prism version 5.04 graphics and statistics software package (Graph-
Pad); , P<0.05; , P<0.01, , P<0.001.
Results
Short-term exposure to ethanol inhibits FcεRI-induced degranulation
and calcium response
To examine the inhibitory effect of ethanol on antigen-induced activation of mast cells, we iso-
lated bone marrow cells from C57BL/6 mice and cultured them for 6–12 weeks in culture
media supplemented with SCF and IL-3. More than 98% of the cells were mast cells as deduced
from expression of both FcεRI and KIT receptors (see below). Exposure of BMMCs for 15
min– 2 hours with ethanol at concentrations up to 2% had no toxic effect, as determined by
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trypan blue dye exclusion test (not shown). Pretreatment of IgE-sensitized BMMCs for 15 min
with ethanol at concentrations 0.2–1%, inhibited degranulation induced by multivalent antigen
in a dose-dependent way. Significant inhibition was observed at all concentrations of ethanol
tested when the cells were activated with antigen (50 ng/ml or 100 ng/ml) for 5 min or 15 min,
except for cells treated with 0.2% ethanol and stimulated with antigen (50 ng/ml) for 5 min
(Fig 1A and 1B).
Ethanol at all concentrations used also inhibited, in a dose-dependent way, the calcium
response after stimulation of IgE-sensitized cells with antigen in the presence of extracellular
calcium (Fig 1C). When the cells were stimulated with antigen in the absence of extracellular
calcium, the calcium response was significantly inhibited by 0.5% and 1% ethanol. Addition of
extracellular calcium resulted in increased calcium response, which was significantly lower in
cells exposed to 0.2%, 0.5% or 1% ethanol (Fig 1D). These data suggested that ethanol could act
on early signaling events leading to the release of calcium from internal stores as well as on cal-
cium channels directing influx of calcium from the extracellular space. When the cells were
pretreated with 4-methylpyrazole (4-MP; 0.1 or 1 mM), a known inhibitor of alcohol dehydro-
genase [36], the inhibitory effect of ethanol was not affected (Fig 2), suggesting that ethanol
itself, rather than its metabolite product, is responsible for the inhibitory effect.
Involvement of cholesterol in the inhibitory effect of ethanol on FcεRI-
mediated activation
Recently, Setiawan and Blanchard showed that ethanol interferes with the size and distribution
of cholesterol domains in planar lipid bilayer structures [37]. To determine whether plasma
membrane cholesterol could be involved in the inhibitory effect of ethanol, we evaluated the
effect of Mβ alone or together with ethanol on FcεRI-mediated degranulation. Mβ is a water-
soluble cyclic heptasaccharide that binds cholesterol and can extract cholesterol from the exo-
plasmic leaflet of the plasma membrane by harboring cholesterol in a hydrophobic cavity
[35,38,39]. Exposure of cells for 15 min to 2 mMMβ alone or in combination with 0.5% etha-
nol had no significant effect on spontaneous release of β-glucuronidase (Fig 3A–3C). In cells
activated with antigen at a concentration 50 ng/ml or 100 ng/ml for 5 (Fig 3A) or 15 min (Fig
3B), degranulation was significantly reduced by both Mβ and ethanol. When ethanol and Mβ
were used together, the inhibition of degranulation was higher than in cells treated with ethanol
or Mβ alone. Mβ is not specific for cholesterol, but has pleiotropic effects on the level and dis-
tribution of various membrane components [40]. Next, we therefore evaluated antigen-induced
degranulation in cells pretreated with cholesterol-saturated Mβ (sMβ), which increases plasma
membrane cholesterol [35]. We found that sMβ, in contrast to Mβ, had no significant inhibi-
tory effect on degranulation (Fig 3C). Interestingly, sMβ-treatment did not protect the cells
from the inhibitory effect of ethanol (Fig 3B and 3C). We also found that exposure of cells to 2
mMMβ or sMβ with or without ethanol for 15 min had no effect on the FcεRI expression as
determined by flow cytometry (not shown).
Degranulation is accompanied by enhanced surface expression of CD107a (LAMP1), a
secretory granule/lysosomal marker detectable by flow cytometry [41]. In agreement with anti-
gen-induced β-glucuronidase release, 2 mMMβ and 0.5% ethanol alone inhibited CD107a
(LAMP1) surface expression, even though ethanol was less potent. An additive effect of the
drugs was observed when the cells were activated with antigen at optimal (100 ng/ml) and
supra-optimal (500 ng/ml) concentrations (Fig 3D).
We also analyzed the combined effect of Mβ and/or ethanol pretreatment on antigen-induced
calcium response. The data indicate that pretreatment with Mβ did not intensify the inhibitory
effect of ethanol (Fig 4A). When the cells were activated in the absence of extracellular calcium,
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the inhibitory effect of ethanol was abrogated by Mβ. After addition of calcium, both ethanol
and ethanol+Mβ showed comparable responses (Fig 4B). Cells pretreated with sMβ showed
increased calcium response and were more resistant to the inhibitory effect of ethanol (Fig 4C).
When the difference between sMβ + ethanol and ethanol was calculated, it was lower than the
difference between sMβ and controls (Fig 4D). The data suggest that manipulation with the cel-
lular cholesterol modulates sensitivity of antigen-induced calcium response to ethanol, and thus
support the lipid-centric hypothesis of ethanol action in this system.
Ethanol exposure or cholesterol removal inhibit expression of cytokine
genes in antigen-activated BMMCs
Next we examined the effect of short-term pretreatment of BMMCs with various concentra-
tions of ethanol (0–1%) on antigen-induced expression of cytokines. Data presented in Fig 5A
indicate dose-dependent inhibition of antigen-induced mRNA production of TNF-α, IL-6 and
IL-13, as determined by qPCR. Transcriptional inhibition of cytokines was also observed in
cells with reduced levels of cholesterol after pretreatment with Mβ. When the cells were
Fig 1. Short-term exposure to ethanol inhibits antigen-induced degranulation and calcium response
in BMMCs. IgE-sensitized cells were preincubated for 15 min with various concentrations of ethanol (0–1%),
which was also present during antigen-mediated activation. (A, B) Degranulation (release of β-glucuronidase)
was measured 5 min (A) or 15 min (B) after exposure of the cells to the indicated concentrations of antigen.
(C, D) Calcium response after addition of antigen (arrow, Ag, 100 ng/ml) was measured in the presence of 1
mM extracellular calcium (C), or in its absence (D), followed by addition of 1 mM calcium (arrow, Ca2+ in D).
Calcium levels in the absence of antigen activation but in the presence of 1% ethanol is also shown in C and
D (empty circles). Data are means ± SEs (n = 6–8). Statistical significance of intergroup differences is shown
in A and B. In C and D, statistical significance of differences between control cells (0% ethanol) and cells
exposed to 0.2% ethanol (violet line), 0.5% ethanol (green line) or 1% ethanol (red line) calculated for the
corresponding time intervals (coloured lines) are also indicated.
doi:10.1371/journal.pone.0144596.g001
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pretreated simultaneously with both Mβ and ethanol, less-than-additive effects were observed
(Fig 5B). These data suggest that both drugs could inhibit a similar signaling pathway.
Protective effect of cholesterol against ethanol-mediated inhibition of
ROS in antigen-activated BMMCs
Recent studies indicated that exposure of macrophages to ethanol promoted generation of ROS
[42–44]. To determine whether ROS could also be generated by ethanol in BMMCs, we first
measured ROS production in cells exposed to various concentrations of ethanol. Our data
show that short-term exposure to ethanol had no effect on production of ROS in non-activated
cells (Fig 6A). In cells activated with antigen, in accord with previous studies [45,46], ROSs
were increased. Pretreatment with ethanol resulted in a dose-dependent decrease of ROS after
activation with antigen (Fig 6A). Next we examined whether cholesterol could be involved in
ROS production (Fig 6B). IgE-sensitized cells were pretreated or not with ethanol, Mβ, and/or
sMβ. In non-activated cells, ethanol had no significant effect on ROS, but pretreatment with
Mβ reduced baseline ROS production. sMβ had a lower inhibitory effect on ROS levels than
Mβ. In antigen-activated cells, ROS production was more inhibited by Mβ than by ethanol. In
contrast, pretreatment with sMβ followed by antigen activation resulted in higher ROS produc-
tion than in control cells. When ethanol was combined with Mβ, strong inhibition of antigen-
induced ROS production was observed, whereas ethanol had no inhibitory effect in cells
exposed to sMβ. These data suggest that cholesterol has a dramatic effect on ROS production
and its sensitivity to ethanol.
Inhibitory effect of ethanol on tyrosine phosphorylation of FcεRI-related
signal transduction proteins
The first biochemically well-defined step in FcεRI signaling is tyrosine phosphorylation of the
receptor subunits, followed by formation of the FcεRI signalosome and phosphorylation of
Fig 2. The inhibitory effect of ethanol on antigen-induced degranulation is not affected by blocking
alcohol dehydrogenase. IgE-sensitized cells were pretreated or not (Ctrl) for 15 min with ethanol (0.5%)
and/or 4-MP (0.1 or 1.0 mM). The cells were non-activated or activated with antigen (100 ng/ml) in the
presence of ethanol and/or 4-MP for 15 min and degranulation was determined. Data are means ± SEs
(n = 6). Statistical significance of differences between antigen-activated control cells and ethanol-treated cells
is also shown. 4-
doi:10.1371/journal.pone.0144596.g002
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other substrates [47]. Next, we therefore investigated global tyrosine phosphorylation of pro-
teins in non-activated or antigen-activated cells pretreated or not with various concentrations
of ethanol. To determine whether there are any changes in association of the tyrosine phos-
phorylated proteins with membrane domains, the cells were solubilized in solubilization buffer
containing 1% Brij-96 and fractionated on sucrose density gradient to separate cellular compo-
nents according to their solubility in detergents and density. Data presented in Fig 7A indicate
distribution of tyrosine phosphorylated proteins in non-activated control cells, not exposed to
ethanol. In low-density detergent-resistant membranes (DRM, fractions 1–3), the key tyrosine
phosphorylated proteins were transmembrane adaptor proteins PAG and NTAL and SRC fam-
ily kinase LYN, as determined by immunoblotting with protein-specific antibodies. A number
of other tyrosine phosphorylated proteins were observed in detergent-soluble fractions (frac-
tions 6–9). In cells pretreated with various concentrations of ethanol (Fig 7B–7D), there were
dose-dependent changes in the distribution of some tyrosine phosphorylated proteins in the
low-density and high-density fractions. Densitometry analysis of the immunoblots showed a
significant increase in the percentage of tyrosine phosphorylated PAG (Fig 7G) and LYN (Fig
7H) in DRMs from cells exposed to low concentrations of ethanol (0.2%). However, when etha-
nol was used at a higher concentration (1%), percentage of tyrosine phosphorylated LYN (Fig
7H) and NTAL (Fig 7I) in DRMs was significantly reduced (Fig 7D). In antigen-activated cells,
some proteins were more tyrosine phosphorylated in both low- and high-density fractions
Fig 3. Involvement of cholesterol in the inhibitory effect of ethanol on FcεRI-mediated degranulation.
(A, B) IgE-sensitized BMMCs were preincubated for 15 min without (Ctrl) or with Mβ (2 mM), and/or ethanol
(0.5%), followed by exposure to the indicated concentrations of antigen in the presence of the drugs.
Degranulation was measured 5 min (A) or 15 min (B) after triggering. (C) IgE-sensitized cells were
preincubated for 15 min without (Ctrl) or with Mβ (2 mM), sMβ (2 mM), and/or ethanol (0.5%) and then
activated (Ag; 100 ng/ml) or not in the presence of the drugs. Degranulation was determined 15 min after
triggering. (D) IgE-sensitized cells were preincubated with various drugs as above, then exposed to various
concentrations of antigen and cell activation, measured by CD107a (LAMP1) expression, was determined by
flow cytometry. Data are means ± SEs (n = 4–12). Statistical significance of the intergroup differences is also
shown.
doi:10.1371/journal.pone.0144596.g003
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(compare Fig 7A and 7E). After activation, the percentage of tyrosine phosphorylated LYN in
DRMs was increased by ethanol (Fig 7H). When PAG-, LYN-, or NTAL-specific antibodies
were used, no significant differences in the distribution of proteins in DRMs from control and
ethanol-pretreated cells were observed (Fig 7G–7H). These data suggest that ethanol at the
concentrations used caused fine changes in the cross-talk between signaling molecules rather
than global changes in the detergent solubility of plasma membrane proteins.
To determine changes in tyrosine phosphorylation of FcεRI, the receptor was immunopre-
cipitated and analyzed by immunoblotting with phosphotyrosine-specific antibody, PY-
20-HRP conjugate. In non-activated cells, the receptor β and γ subunits exhibited weak tyro-
sine phosphorylation, and ethanol (0.5%) with or without Mβ had no significant effect on their
phosphorylation (Fig 8A). In cells exposed to Mβ alone, a significant increase in tyrosine phos-
phorylation of FcεRI β and γ subunits was observed, which is in line with our previous studies
indicating that cholesterol removal enhances phosphorylation of various substrates in mast
cells [48]. Tyrosine phosphorylation of FcεRI β and γ subunits was increased after FcεRI trig-
gering, as expected [47], and pretreatment with Mβ, ethanol, and especially Mβ+ethanol, sig-
nificantly reduced this phosphorylation (Fig 7A).
Fig 4. Involvement of cholesterol in the inhibitory effect of ethanol on FcεRI-mediated calcium
response. (A, B) IgE-sensitized BMMCs were incubated for 15 min without (Ctrl) or with ethanol (Et, 0.5%)
and/or Mβ (2 mM). Calcium response after adding antigen (arrow, Ag; 100 ng/ml) was measured in the
presence of the drugs as indicated. The cells were activated in the presence of extracellular calcium (A) or in
its absence, followed by addition of 1 mM calcium (B, Ca2+, arrow). (C) IgE-sensitized cells were incubated
for 15 min in medium alone (Ctrl) or medium supplemented with ethanol (Et; 0.5%), Mβ saturated with
cholesterol (sMβ; 2 mM), or sMβ (2mM) and ethanol (0.5%). The cells were activated in the presence of the
drugs with antigen (arrow, Ag; 100 ng/ml) and calcium response was determined. (D) Data from Fig 4C were
used to calculate the difference between calcium response in cells exposed to sMβ or Ctrl and sMβ+Et or Et.
Data are means ± SEs (n = 6–12). Statistical significance of differences in A and B [Ctrl versus Et-treated
cells (green line) and Ctrl versus Mβ+Et-treated cells (brown line)], C [sMβ versus Ctrl (green line) and
sMβ+Et versus Et (red line)], and D [sMβ—Ctrl versus sMβ+Et—Et (black line)] calculated for the
corresponding time intervals (coloured lines) are also indicated.
doi:10.1371/journal.pone.0144596.g004
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Tyrosine phosphorylation of several other proteins involved in FcεRI signaling was exam-
ined by direct immunoblotting of size-fractionated cell lysates with phosphotyrosine protein-
specific antibodies. For these experiments we used IgE-sensitized cells pretreated or not with
Mβ and/or ethanol (Fig 8B and 8C). The cells were either non-activated or activated with
Fig 5. Ethanol or cholesterol removal inhibit expression of cytokine genes in antigen-activated
BMMCs. (A) IgE-sensitized cells were preincubated for 15 min with the indicated concentrations of ethanol,
which were also present during activation with antigen (100 ng/ml). mRNAs for TNF-α, IL-6, and IL-13 were
isolated one hour after triggering and quantified by qPCR. (B) The cells were exposed to medium alone (-),
ethanol (0.5%) and/or Mβ (2 mM) and mRNAs for TNF-α, IL-6, and IL-13 were quantified as above. Data are
means ± SEs (n = 6–8). The statistical significance of the intergroup differences is also shown.
doi:10.1371/journal.pone.0144596.g005
Fig 6. Protective effect of cholesterol against ethanol-mediated inhibition of ROS production in
antigen-activated BMMCs. (A) IgE-sensitized cells were incubated for 15 min with the indicated
concentrations of ethanol, which was also present during the activation. Then the cells were activated or not
with antigen (250 ng/ml) and ROSs were determined using H2DCFDA as a substrate. The values on y-axes
indicate fluorescence intensities observed 10 min after triggering. (B) The cells were exposed to BSS-BSA
supplemented or not with ethanol (0.5%), Mβ (2 mM) and/or sMβ (2 mM), and after 20 min activated or not
with antigen (250 ng/ml). ROSs were determined as above. Data are means ± SEs (n = 6–8). The statistical
significance of the intergroup differences is also shown.
doi:10.1371/journal.pone.0144596.g006
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Fig 7. Ethanol-induced changes in protein tyrosine phosphorylation in the plasmamembrane
domains. (A–F) IgE-sensitized BMMCs were pretreated or not with the indicated concentrations of ethanol
for 15 min and then non-activated (A–D) or activated with antigen (E and F; 100 ng/ml) for 5 min. Then the
cells were solubilized in 1% Brij-96-containing lysis buffer and fractionated on sucrose density gradient.
Individual fractions were collected from the top of the gradient (fraction 1), size fractionated by SDS-PAGE
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antigen for 5 min. For these studies we selected proteins involved in tyrosine phosphorylation
of the FcεRI subunits (LYN and SYK), regulation of calcium response (LAT and PLCγ), and
transcriptional regulation of cytokines (STAT5, ERK, AKT). We found that in non-activated
cells, Mβ alone and/or ethanol either had no effect (SYK, LAT, pLCγ1, STAT5, and AKT) or
slightly but significantly increased phosphorylation of the target (ERK). In antigen-activated
cells, pretreatment with Mβ alone and/or ethanol reduced tyrosine phosphorylation of several
target proteins (SYK, LAT, STAT5, and AKT). When pPLCγ1 was analyzed, only ethanol and
Mβ+ethanol showed inhibitory effects, whereas in the case of pERK, only ethanol alone was
inhibitory.
Activity of mouse LYN kinase is regulated by tyrosine phosphorylation of Tyr 507 (a nega-
tive regulator; Fig 8D) and Tyr 416 (a positive regulator; Fig 8E). To determine whether Mβ
and/or ethanol interfere with phosphorylation of these tyrosines, we performed immunoblot-
ting with LYN-tyrosine-specific antibodies. We found that pretreatment of cells with 0.5% eth-
anol enhanced phosphorylation at LYN-Tyr 507 15 min after FcεRI triggering. Mβ together
with ethanol increased phosphorylation of LYN-Tyr 507 at all intervals. In contrast, LYN-Tyr
416 did not exhibit any significant changes in phosphorylation after Mβ and/or ethanol expo-
sure and antigen activation. These data suggest that ethanol could inhibit FcεRI activation by
enhancing tyrosine phosphorylation of LYN-Tyr 507.
Pretreatment with ethanol and/or cholesterol removal does not interfere
with FcεRI expression but affects its internalization
Previous studies with other cell types showed that ethanol interferes with internalization of
plasma membrane receptors, their trafficking, endocytosis, and recycling [49–51]. FcεRI is rap-
idly internalized upon antigen triggering [52,53]. Next, we therefore compared internalization
of antigen-aggregated FcεRI in BMMCs pretreated or not with ethanol and/or Mβ. Data pre-
sented in Fig 9A indicate that 15 min pretreatment with 0.5% ethanol and/or 2 mMMβ had no
effect on the surface expression of the FcεRI and KIT. When the cells were pretreated with eth-
anol and/or Mβ and then permeabilized and stained for total IgE, no significant differences in
the amount of internalized IgE were determined in non-activated cells. In cells activated with
antigen for 15 min, IgE was internalized, and pretreatment with ethanol together with Mβ sig-
nificantly reduced the internalization. Pretreatment with ethanol or Mβ alone had no signifi-
cant effect on internalization of the antigen-IgE-receptor complexes (Fig 9B and 9C).
Ethanol suppresses IgE-mediated PCA in mice
Finally, we examined whether ethanol could have an inhibitory effect on mast cells under in
vivo conditions. We used PCA in which local activation of mast cells results in increased vascu-
lar permeability, as visibly manifested by leakage of the Evans blue dye into the reaction site of
the ear. This leakage was not affected by intraperitoneal administration of 0.5 ml PBS contain-
ing 5% ethanol (Fig 10A and 10B; compare 0% and 5%) 30 min before the antigen. In contrast,
in mice that were injected with 10% or 20% ethanol in PBS, the vascular permeability of the
and examined for tyrosine phosphoproteins by immunoblotting (IB) with PY-20-HRP conjugate (PY-20) or
with antibodies specific for PAG, LYN, and NTAL). Positions of PAG, LYN, and NTAL are indicated by arrows
on the left. Fractions (1–3) containing detergent-resistant membranes are marked (DRM). Numbers on the
right indicate positions of molecular weight markers in kDa. Representative immunoblots from three to four
independent experiments are shown. (G–I) All immunoblots were analyzed by densitometry, and the relative
amounts of PAG (G), LYN (H), and NTAL (I) and their tyrosine phosphorylated forms (PY-20) in DRMs were
determined. Means ± S.E. were calculated and the statistical significance of intergroup differences was
determined.
doi:10.1371/journal.pone.0144596.g007
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Fig 8. Pretreatment with ethanol inhibits tyrosine phosphorylation of FcεRI β and γ subunits and
some other proteins involved in FcεRI signaling. (A) IgE-sensitized cells were preincubated for 15 min
with BSS-BSA alone (Ctrl) or supplemented with ethanol (0.5%) and/or Mβ and then activated or not with
antigen (100 ng/ml) in the presence or absence of the compounds. After 5 min the cells were solubilized in
0.2% Triton X-100 and FcεRI was immunoprecipitated (IP) from postnuclear supernatants. The
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ears was attenuated, as evaluated by the extent of Eva blue staining (Fig 10A, 10% and 20%)
and amounts of Evans blue extracted from the ears (Fig 10B). The difference in PCA between
mice injected with 0.5 ml PBS alone or 0.5 ml PBS containing 10% or 20% ethanol was signifi-
cant (Fig 10B). No significant intergroup differences were noticed when control ears (not sensi-
tized with IgE) were evaluated. The data suggest that ethanol inhibits FcεRI-induced mast cell
activation in vivo.
Discussion
Data presented in this study show that short-term exposure of BMMCs to nontoxic concentra-
tions of ethanol inhibits FcεRI-mediated degranulation, calcium response, and production of
several cytokines (TNF-α, IL-6, and IL-13) in a dose-dependent manner. To understand the
molecular mechanism of the inhibitory effect of ethanol on these activation events we exam-
ined various candidate targets. Several lines of evidence suggest that ethanol interferes with the
function of FcεRI-cholesterol signalosomes and support the lipid-centric theory of ethanol
action in this system, at least at the early stages of cell activation
First, pretreatment of the cells with 4-MP, an inhibitor of alcohol dehydrogenase, together
with ethanol had no effect on the inhibitory action of ethanol on degranulation. Thus, inhibi-
tion of mast cell activation seems to be caused by ethanol itself and not its metabolites. This
conclusion is supported by the finding that up to 2 hours exposure to 2% ethanol in BSS-BSA
at 37°C was not toxic to BMMCs. It should also be noted that the cells in this study were pre-
treated with ethanol only for 15 min before activation, which makes less likely that metabolites
are formed and affect signaling pathways.
Second, antigen-mediated degranulation, calcium response, and production of cytokines
were also inhibited by Mβ. In cells treated with Mβ, the inhibitory effect of ethanol on degranu-
lation, and IgE receptor internalization was potentiated. Interestingly, when the cells were pre-
treated with Mβ saturated with cholesterol, the inhibitory effect of ethanol on calcium response
was reduced. These data suggest that cholesterol is involved in the inhibitory effect of ethanol.
Third, production of ROS after FcεRI triggering was also inhibited by ethanol in a dose-
dependent manner and treatment together with Mβ potentiated the inhibitory effect of ethanol.
These findings are in accord with previous data showing that lowering cellular cholesterol by
Mβ in hepatocytes inhibits ROS production [54]. Interestingly, exposure of the cells to sMβ
enhanced ROS production, and the inhibitory effect of ethanol was abolished, confirming that
cholesterol interferes with the inhibitory activity of ethanol.
immunoprecipitates were resolved by SDS-PAGE and analyzed by immunoblotting with PY-20-HRP
conjugate. For loading controls, the samemembrane was stripped and re-blotted with FcεRI-β-chain-specific
antibody. Representative immunoblots from three to five independent experiments are shown on the left. The
immunoblots were analyzed by densitometry and the fold increase in tyrosine FcεRI-β and -γ chain
phosphorylation, normalized to non-activated cells and the amount of FcεRI-β chain, is also shown on the
right. (B) IgE-sensitized cells were incubated and activated as above. Five min after triggering the cells were
solubilized, size fractionated, and tyrosine phosphorylated proteins were detected by immunoblotting with the
phosphoprotein-specific antibodies. Antibodies for the corresponding proteins were used for detection of
loading controls. Representative immunoblots from three to four independent experiments are shown. (C)
The immunoblots were analyzed by densitometry. Fold increases of protein tyrosine phosphorylation,
normalized to control (Ctrl) non-activated cells and the corresponding protein loads are shown. (D and E) IgE-
sensitized cells were incubated with the drugs as in A and then activated with antigen (100 ng/ml) in the
presence of the drugs for the indicated time intervals. The cells were solubilized, size fractionated, and LYN
phosphorylated on Tyr 507 (D) or Tyr 416 (E) was detected by immunoblotting with the corresponding
antibodies. After stripping, the membranes were developed for LYN used as a loading control. Fold increase
in protein tyrosine phosphorylation, normalized to non-activated cells (Ctrl) and protein load, is also shown.
Means ± SEs and the statistical significance of differences in A, C, E, and D were calculated from three to five
independent experiments.
doi:10.1371/journal.pone.0144596.g008
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Fig 9. Pretreatment with ethanol and cholesterol removal do not interfere with the FcεRI expression
but affect its internalization. (A) The cells were incubated or not for 15 min with BSS-BSA alone (Ctrl) or
supplemented with ethanol (0.5%) and/or Mβ (2 mM) and then stained for surface KIT and FcεRI by direct
immunofluorescence followed by flow cytometry analysis. (B) IgE-sensitized cells were incubated with the
drugs as above and activated or not with antigen (500 ng/ml). After 15 min the cells were fixed,
permeabilized, labeled for IgE and analyzed by confocal microscopy. Bars = 5 μm. (C) Distribution of IgE in
individual cells was evaluated and the fraction of IgE detected in the cytoplasm was determined. Each spot
represents one cell, bars indicate means. Statistical significance of intergroup differences is also indicated.
doi:10.1371/journal.pone.0144596.g009
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Fourth, immunoprecipitation and immunoblotting analyses showed that ethanol inhibits
tyrosine phosphorylation of FcεRI β and γ subunits in antigen-activated cells. Phosphorylation
of these targets is the first biochemically well-defined step after FcεRI triggering and depends
on the topography and activity of protein tyrosine kinase LYN and protein tyrosine phospha-
tases in the vicinity of the FcεRI [55,56]. The impaired tyrosine phosphorylation of the FcεRI β
and γ subunits could explain reduced tyrosine phosphorylation of the downstream substrates,
Fig 10. Inhibitory effect of ethanol onmast cell-mediated PCA. PCA was performed as described in
Materials and methods. Sensitizing IgE in PBS and PBS alone were injected into left and right ears,
respectively. (A) Representative photographs of ears of the mice injected intraperitoneally with 0.5 ml (per
mouse weighing 20 g) PBS alone (0%) or with 0.5 ml of PBS containing 5%, 10%, or 20% ethanol, followed
by intravenous administration of Evans blue and antigen in PBS. (B) Quantitative data for ear-tissue extracted
Evans blue from left (IgE) and right (PBS) ears in mice treated as above. Means ± SEs were calculated from
3–4 animals in each group. Statistically significant differences between control mice injected with PBS alone
and mice injected with 10% or 20% ethanol in PBS are shown.
doi:10.1371/journal.pone.0144596.g010
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including SYK, LAT, PLCγ, AKT, and STAT5 in ethanol-treated cells. Tyrosine phosphoryla-
tion of these substrates was also inhibited by Mβ, but no clear additive effect of ethanol and Mβ
was observed. This could be related to a similar mechanism of inhibition of both drugs. The
reduced phosphorylation of FcεRI by ethanol was neither caused by reduced phosphorylation
of the positive regulatory Tyr 416 of LYN nor by enhanced phosphorylation of the negative
regulatory Tyr 507 of LYN, which showed enhanced phosphorylation only 15 min after activa-
tion. Surprisingly, when Mβ and ethanol were used together, enhanced Tyr 507 phosphoryla-
tion was observed at all time intervals after activation and even in non-activated cells. Tyr 507
is phosphorylated by CSK, which is presumably anchored to the plasma membrane via phos-
phorylated PAG [32]. However, our study did not show enhanced tyrosine phosphorylation of
PAG in the cells pretreated with ethanol. The enhanced phosphorylation of Tyr 507 of LYN
could be related to our recent findings that PAG is both a positive and negative regulator of
FcεRI signaling and that in mast cells there are some other not yet discovered anchors of CSK
[32]. Enhanced phosphorylation of LYN Tyr 507 in cells pretreated with ethanol alone, but not
in cells treated with Mβ alone, was not accompanied by the corresponding inhibition of SYK
phosphorylation, which was observed in cells pretreated with both ethanol alone and Mβ
alone. Thus, rather than changes in activity of the LYN kinase, ethanol and Mβ could interfere
with formation of the FcεRI signalosome in which cholesterol could play a key role and in
which kinases and phosphatases are at equilibrium in nonactivated cells [55]. Nanoscale
changes in lateral organization of proteins and lipids in the plasma membrane and enhanced
actin polymerization have recently been described in ethanol-pretreated cells [57]. In fact,
there could be a direct cross-talk between ethanol and cholesterol, as was noticed in other sys-
tems. For example, Furlow and Diamond showed that the interplay between membrane choles-
terol and ethanol contributes to alterations of the membrane fluidity, viscosity, and
redistribution of surface molecules, which affects neutrophil adhesion, rolling, and tethering
behavior [58].
Fifth, internalization of antigen-aggregated FcεRI was significantly inhibited by 15 min pre-
treatment with Mβ and ethanol. In our previous study we found that cholesterol removal by
Mβ enhanced antigen-mediated clustering of the FcεRI [48]. These findings, together with a
previous report that aggregated FcεRI can be endocytosed by a clathrin-independent mecha-
nism that appears to be mediated by membrane structures enriched in cholesterol [52], suggest
that Mβ and ethanol prevent internalization of the receptor aggregates, which remain for pro-
longed time intervals on the cell surface.
The capacity of externally added cholesterol to reduce the inhibitory effect of ethanol on cal-
cium and ROS responses are more compatible with the lipid-centric theory than the protein-
centric theory of the inhibitory effect of ethanol. How exactly ethanol interacts with lipids and/
or how it affects lipid-protein interactions is not known but could involve direct interaction of
ethanol with cholesterol [59] and the ability of ethanol to mediate and modify organization of
the lipid bilayer structures [7,37]. However, our data do not rule out the possibility that etha-
nol-protein interactions are also involved in the inhibitory effect of ethanol as was observed in
other systems [12,60–62]. This could explain different effects of enhanced cholesterol levels on
the inhibitory action of ethanol in various signaling pathways. For example, the observed
decrease in the inhibitory effect of ethanol on calcium or ROS responses in cells with enhanced
cholesterol levels could reflect the reduced penetration of ethanol through lipid bilayers with
increased rigidity caused by cholesterol [63]. On the other hand, ethanol could act directly as
an inhibitor of some enzymes involved at later stages of degranulation; this could be an expla-
nation of our finding that degranulation was not protected from the inhibitory effect of ethanol
in cells pretreated with sMβ. In this context, Lisboa et al showed that phosphatidic acid pro-
duced by phospholipase D (PLD) plays an important role in promoting IgE-dependent
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signaling events within lipid microdomains in mast cells [64]. As a tool they used 1-butanol,
which subverts production of phosphatidic acid to the biologically inert phosphatidyl butanol.
Similarly, the presence of ethanol could lead to production of phosphatidyl ethanol instead of
phosphatidic acid [65] and in this way inhibit FcεRI signaling. However, our and others’ data
Fig 11. Model of FcεRI-mediated activation in ethanol-pretreated mast cells. In nonactivated cells (A), the topography of FcεRI and other signaling
molecules, such as SRC family kinase LYN, protein tyrosine phosphatase (PTP), and adaptor proteins (LAT, PAG, and NTAL), prevents signaling. An
important role in this process is played by the plasmamembrane cholesterol. Aggregation of the FcεRI-IgE complexes by multivalent antigen (B) induces
topographical changes that lead to formation of the FcεRI signalosome and enhanced tyrosine phosphorylation of the FcεRI β and γ subunits by LYN and
SYK kinases. This results in enhanced degranulation, calcium response, cytokine production and numerous other events. In the cells exposed to ethanol
and/or with reduced amount of cholesterol (C), the topography of plasmamembrane molecules is slightly modified, resulting in increased tyrosine
phosphorylation of some signaling molecules even in nonactivated cells. Aggregation of the receptor in ethanol-treated cells leads to suboptimal
topographical changes resulting in reduced tyrosine phosphorylation of the FcεRI β and γ subunits by LYN and SYK kinases and/or enhanced activity of the
corresponding phosphatases (D). This leads to reduced degranulation, calcium response, cytokine production and other events. Ethanol could also bind
directly to some cytoplasmic or plasmamembrane proteins, such as ion channel proteins, and in this way inhibit the cell signaling.
doi:10.1371/journal.pone.0144596.g011
Ethanol Inhibits FcεRI-cholesterol Signalosome
PLOSONE | DOI:10.1371/journal.pone.0144596 December 14, 2015 19 / 24
158
suggest that ethanol inhibits FcεRI signaling by another mechanism. We found that the inhibi-
tory effect of ethanol on calcium response and ROS production was blocked by exposure of the
cells to sMβ, which is unlikely to change production of PA and/or activity of PLD. Further-
more, it has been recently found that mice deficient in PLD1 and PLD2, which do not produce
any PA, show no changes in early signaling events after FcεRI triggering [66].
Model of ethanol action on mast cells and their activation by antigen is shown in Fig 11.
Exposure of the cells to ethanol leads to changes in properties of plasma membrane and topog-
raphy of plasma membrane components, resulting in the observed increase in basal tyrosine
phosphorylation of some membrane proteins, including FcεRI. When IgE-sensitized and etha-
nol-treated cells are activated by antigen, tyrosine phosphorylation of the FcεRI β and γ sub-
units is reduced reflecting suboptimal topography and/or reduced activity of LYN and SYK
kinases and/or enhanced activity of protein tyrosine phosphatases in the vicinity of the recep-
tor. Ethanol could also bind to ion channels or some other plasma membrane or cytoplasmic
proteins and in this way inhibit various signaling events, including degranulation, calcium
response and production of cytokines.
The inhibitory effect of ethanol on mast cell activation was confirmed by experiments in
vivo in which mast cells were sensitized locally by IgE, and ethanol and antigen was adminis-
tered intraperitoneally and intravenously, respectively. The results of PCA assays, which reflect
the activity of mast cells [67] support previous findings indicating that excessive ethanol con-
sumption is associated with increased risk of infection [68]. Experimental studies with animal
and human subjects given ethanol in a controlled setting showed suppression of the innate
immunity and inflammation [69–71]. Attention was focused mainly on the inhibitory effect of
ethanol on activation of macrophages [72,73], monocytes [74] and T cells [20,75–77].
Although previous studies also indicated that mast cells could be the target of ethanol [24,25],
this is the first study showing that ethanol inhibits the earliest events in FcεRI signaling and
demonstrate the inhibitory effect of ethanol on mast cells in vivo.
Conclusions
In this study we found that 15 min treatment with non-toxic concentrations of ethanol in vitro
inhibited antigen-induced tyrosine phosphorylation of the FcεRI β and γ subunits, SYK kinase,
NTAL adaptor protein, PLCγ, calcium response, production of ROS, degranulation, and
expression of cytokine genes in a dose-dependent manner. Early activation events were also
inhibited by Mβ, suggesting that cholesterol could be involved. The role of cholesterol in the
inhibitory effect of ethanol was supported by the finding that sMβ reduced the inhibitory effect
of ethanol on calcium and ROS responses. The data support the lipid-centric theory of ethanol
action on the initial stages of FcεRI signaling. The inhibitory effect of ethanol on mast cell acti-
vation was also observed in a mouse PCA model in vivo, explaining previous findings of the
reduced inflammatory response associated with enhanced consumption of ethanol.
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Background: Chemotaxis is regulated by chemoattractants and poorly understood intrinsic regulators.
Results: Aggregation of tetraspanin CD9 leads to activation of mast cells and inhibition of their antigen-driven chemotaxis.
Conclusion:Chemotaxis toward antigen involves cross-talk between immunoreceptor, CD9, transmembrane adaptor proteins,
and cytoskeleton-regulatory proteins.
Significance: Tetraspanin CD9 is defined as a novel regulator of mast cell chemotaxis.
Chemotaxis, a process leading to movement of cells toward
increasing concentrations of chemoattractants, is essential,
among others, for recruitment ofmast cells within target tissues
where they play an important role in innate and adaptive immu-
nity. Chemotaxis is driven by chemoattractants, produced by
various cell types, as well as by intrinsic cellular regulators,
which are poorly understood. In this study we prepared a new
mAbspecific for the tetraspaninCD9.Bindingof the antibody to
bonemarrow-derivedmast cells triggered activation events that
included cell degranulation, Ca2 response, dephosphorylation
of ezrin/radixin/moesin (ERM) family proteins, andpotent tyro-
sine phosphorylation of the non-T cell activation linker (NTAL)
but only weak phosphorylation of the linker for activation of T
cells (LAT). Phosphorylation of the NTAL was observed with
whole antibody but not with its F(ab)2 or Fab fragments. This
indicated involvement of the Fc receptors. As documented by
electron microscopy of isolated plasma membrane sheets, CD9
colocalized with the high-affinity IgE receptor (FcRI) and
NTAL but not with LAT. Further tests showed that both anti-
CD9 antibody and its F(ab)2 fragment inhibited mast cell che-
motaxis toward antigen. Experiments with bone marrow-de-
rived mast cells deficient in NTAL and/or LAT revealed
different roles of these two adaptors in antigen-driven che-
motaxis. The combined data indicate that chemotaxis toward
antigen is controlled in mast cells by a cross-talk among FcRI,
tetraspanin CD9, transmembrane adaptor proteins NTAL and
LAT, and cytoskeleton-regulatory proteins of the ERM family.
Mast cells are derived from progenitors that are released
from bone marrow into circulation, and subsequently migrate
to peripheral tissues where they undergo differentiation and
maturation (1). The process plays a vital role in innate and/or
adaptive immune response and is controlled by a plethora of
different chemoattractants, which require sophisticated mech-
anisms for their recognition and proper cellular responses
(2–4). It is obvious that suchmechanismsmust involve efficient
cross-talk between surface receptors, plasma membrane com-
ponent organizers, such as tetraspanin, signal transducers,
cytoskeletal effectors, and others. Signal transductionmediated
by two important mast cell receptors, the high-affinity IgE
receptor (FcRI)5 and the stem cell factor (SCF) receptor (KIT),
is dependent on the presence of two transmembrane adaptor
proteins (TRAPs), the linker for activated T cells (LAT) and the
non-T cell activation linker (NTAL, also called LAB or LAT2)
(5–8). Both adaptors are structurally similar and serve as
plasma membrane docking sites for cytoplasmic signal trans-
duction molecules. TRAPs are characterized by a short extra-
cellular domain, a single transmembrane domain, and a cyto-
plasmic tail, which has no intrinsic enzymatic activity but
possesses various tyrosine-containing motifs and domains.
The properties of transmembrane domains and the presence of
palmitoylation sites determine the solubility of LAT andNTAL
in non-ionic detergents, distribution in the plasma membrane,
and some other functional properties (9–11). Despite their
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structural similarity, NTAL and LAT were found in different
microdomains in plasma membrane (5, 11). Studies with mast
cells generated fromNTALor LATKOmice (5, 6), humanmast
cells with NTAL knockdown (KD) (7), or rat basophilic leuke-
mia cells with enhanced or reduced NTAL levels (12) showed
that NTAL could act either as positive or negative regulator of
FcRI signaling, whereas LAT acts as positive regulator (4, 13).
Although the role of these two adaptors in immunoreceptor
signaling has been extensively studied, their function in mast
cell migration is not fully understood. We have previously
shown that NTAL serves as a negative regulator of bone mar-
row-derived mast cells (BMMCs) migration toward antigen
(Ag) but has no apparent role in migration toward SCF (14).
However, the role of LAT ablation either alone or together with
NTAL on Ag-mediated chemotactic response is unknown.
Tetraspanins, similarly as TRAPs, have no enzymatic activity
and regulate signaling events by cross-talk with other plasma
membrane-associated protein molecules, including integrins
(15–21), G-protein-coupled receptors (21–23), several immu-
noglobulin superfamily members (24, 25), and PKC (26).
Although tetraspanins are involved in a variety of biological and
pathological processes (27, 28), it is not clear whether tetraspa-
nins interact with TRAPs and what are consequences of such
interactions.
In this studywe aggregated tetraspaninCD9on the surface of
mast cells and investigated signaling events elicited by such
treatment. We also analyzed the effect of CD9 aggregation on
cell activation events induced by Ag-mediated aggregation of
the FcRI, including degranulation, calcium response, phos-
phorylation of cytoskeleton-regulatory proteins of the ezrin/
radixin/moesin (ERM) family, and chemotaxis. Usingmast cells
derived from NTAL- and/or LAT-deficient mice we studied a
cross-talk of these adaptors with CD9 and its impact on mast
cell chemotaxis. Finally, we investigated the role of CD9 in acti-
vation through the FcRI and membrane topography of CD9
with respect to NTAL, LAT, and FcRI. Our data indicate that
chemotaxis toward Ag in mast cells is regulated by a cross-talk
among CD9, FcRI, TRAPs, and cytoskeleton-regulatory ERM
family proteins.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents—Anti-CD9 mAb (clone 2H9, IgG1
type) was generated by immunizing a rat (Wistar strain) with
BMMCs permeabilized with 0.1% saponin and washed.
Hybridoma production and mAb selection was done as
described previously (29) with the exception that rat spleen
cells instead of mouse spleen cells were used. Specificity of the
2H9 antibody was verified by immunoprecipitation followed by
mass spectrometry analysis as described (30) and by cross-im-
munoprecipitation using commercially available anti-CD9
antibody (KMC8.8, Santa Cruz Biotechnology, Inc.). Isotyping
was performed with the IsoStrip Isotyping kit (Roche Diagnos-
tics) following the manufacturer’s protocol. F(ab)2 and Fab
fragments of the 2H9 antibody were generated using, respec-
tively, F(ab)2 and Fab Preparation Kits (Pierce) according to the
manufacturer’s protocol. Functionality of both types of the
fragments was verified by FACS analysis and SDS-PAGE
electrophoresis.
The following mAbs were used: 2,4,6-trinitrophenol (TNP)-
specific IgE, clone IGEL b4 1 (31), anti-FcRI -subunit (JRK)
(32), anti-NTAL (NAP-07) (33), anti-LAT (34), anti-Lyn (35),
and anti-CD16/CD32 (2.4G2; directed against extracellular
domains ofmouse receptors FcRIIB and FcRIII; a gift fromV.
Horejsi). Polyclonal antibodies specific for LAT,NTAL, and IgE
have been prepared in this laboratory after immunizing rabbits
with the corresponding recombinant proteins or their frag-
ments (36). Polyclonal antibodies specific for phospho-ERK
(phospho-Y204), phospho-Akt (phospho-S473), phospho-c-Kit
(phospho-Y568/570), anti-integrin 1 (CD29), as well as HRP-
conjugated goat anti-mouse IgG, and goat anti-rabbit IgG were
obtained from Santa Cruz Biotechnology, Inc.; antibodies
against phospho-p38 (Y182/T180; pp38Y/T), phospho-Ezrin
(T567)/Radixin (T564)/Moesin (T558) (pERMT), phospho-Syk
(Y525/Y526; pSykY), phospho-Akt (T308; pAktT), and HRP-con-
jugated goat anti-rat IgG were obtained from Cell Signaling.
Phospho-Tyr-specific mAb (PY-20) conjugated to HRP, anti-
CD9 (KMC8), and anti-integrin1 (HM1–1) were purchased
from BD Biosciences. Anti-mouse FcRI-FITC conjugate and
anti-mouse CD117 (KIT)-APC conjugate were obtained from
eBioscience; anti-mouse integrin 1-FITC was fromMillipore.
Recombinant mouse IL-16 was obtained from Prospec. All
other chemicals were obtained from Sigma.
Cells and Lentiviral Infection—BMMCs were derived from
C57BL.6 mice of WT (Ntal/ or Lat/) or from Ntal/,
Lat/ orNtal//Lat/ double KO (2KO)mice (5). In some
experiments, Balb/c mice were also used as indicated in the text.
All work with animals was conducted in accordance with institu-
tional (33/2008) and national (2048/2004–1020) guidelines. Bone
marrow cells were isolated and cultured as previously described
(5). BMMCs deficient in Lyn (Lyn/) and their WT controls
(Lyn/) were kindly provided byM. Hibbs (Ludwig Institute for
CancerResearch,Melbourne,Australia) (37).HEK293T/17pack-
aging cells were purchased from American Type Culture Collec-
tion. The cells were grown as adherent monolayer culture in
DMEM containing 10% FCS, 100 units/ml of penicillin, and 100
g/ml of streptomycin. Cultures were passaged regularly every
4–5 days and kept at 37 °C in an atmosphere of 5% CO2. The
cells used for lentivirus production were at passage 4–15. Len-
tiviral infection was done as described previously (38). A set of
murine CD9 shRNAs cloned into the pLKO.1 vector
(TRCN0000066393, TRCN0000066394, TRCN0000066395,
TRCN0000066396, and TRCN0000066397) were purchased
fromOpenBiosystems. Stable selectionwas achieved by cultur-
ing the transfected cells for 2 weeks in the presence of puromy-
cin (5 g/ml). Cells were analyzed for CD9 expression by
immunoblotting and FACS. Cells with the highest reduction
of CD9 protein, obtained with TRCN0000066393 and
TRCN0000066395,were selected for further experiments. Cells
transfected with empty pLKO.1 vector were used as negative
controls.
-Glucuronidase Release, Ca2 Response, Protein Phosphor-
ylation, and Immunoprecipitation—BMMCswere sensitized in
SCF- and IL-3-free culture medium supplemented with IGEL
b4 1 mAb (1 g/ml) for 16 h, unless stated otherwise. Then the
cells were washed in buffered saline solution (BSS) supple-
mented with 0.1% BSA (BSSA), and activated with Ag (TNP-
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BSA conjugate, 15–25 mol of TNP/mol of BSA; 100–500
ng/ml, depending on batch), SCF (20–100 ng/ml, depending on
batch), or anti-CD9 (0.04–20 g/ml) at concentrations and
times giving maximum degranulation or protein phosphoryla-
tion, respectively. For inhibition experiments cells were pre-
treated with different concentrations of anti-CD9 mAb for 15
min. The extent of secretion was determined by determining
the concentration of -glucuronidase as described previously
(39) except that the Infinite 200M (TECAN) plate reader
instrument at excitation and emission wavelengths of 355 and
460 nm, respectively, was used. Cells used in calcium response
assays were loaded with Fura-2AM as described previously (40)
and changes in concentrations of intracellular Ca2 ([Ca2]i)
were determined by spectrofluorometry as the changes in ratios
of emissions at 510 nm when the cells were excited at 340 and
380 nm; selected cell activators were added automatically using
the injector system (TECAN).
Protein phosphorylationwas analyzed by immunoblotting of
size-fractionated cell lysates. Cells were centrifuged and resus-
pended in sample buffer containing 10% SDS with or without
2-mercaptoethanol (2-ME) and then sonicated (3  10 s),
resolved by SDS-PAGE, and immunoblotted with PY-20-HRP
conjugate or with protein-specific antibodies followed by the
corresponding secondary antibodies: HRP-conjugated anti-
mouse, anti-rat, or anti-rabbit IgG. HRP signal was detected by
the ECL reagent (Amersham Biosciences) and quantified by
Luminescent Image Analyzer LAS 3000 (Fuji Photo Film Co.).
Aida software (Raytest GmbH) was used for analysis.
For immunoprecipitation, postnuclear supernatants were
prepared from 10–50  106 cells lysed in ice-cold lysis buffer
(40) supplemented with 1%Nonidet P-40 and 1% n-dodecyl--
D-maltoside (for LAT and NTAL immunoprecipitation), 1%
CHAPS (for CD9 immunoprecipitation), or 0.2% Triton X-100
(for FcRI immunoprecipitation). Target proteins were immu-
noprecipitated with appropriate antibodies attached to protein
A/G PLUS-agarose (Santa Cruz) or Protein A UltraLink Resin
(ThermoScientific).
Flow Cytometry Analysis—To quantify surface expression of
CD9, BMMCs (3  105/ml) were exposed for 30 min on ice to
1–10 g/ml of anti-CD9 followed by a 30-min incubation with
FITC-conjugated anti-rat antibody. For detection of other
membrane proteins, the cells were directly labeled with anti-
mouse FcRI-FITC, anti-mouse CD117-APC, or anti-mouse
integrin 1-FITC conjugate. After a 30-min incubation on ice
the cells were washed in ice-cold PBS and evaluated with LSRII
flow cytometer (BD Biosciences). Median fluorescence intensi-
ties were determined in the FITC or APC channel and further
processed using FlowJo software (Ashland, OR). For inhibition
experiments, cells were pretreated with anti-CD9 mAb (10
g/ml) for 15 min.
Chemotactic Response—Chemotactic responses were assayed
using 24-well Transwell chambers (Corning) with 8-m poly-
carbonate filters in the upper wells. Chemoattractants were
added to the lower wells in 0.6 ml of chemotactic medium
(RPMI 1640 supplementedwith 1%BSA and 20mMHEPES, pH
7.4). BMMCs (0.3  106 cells in 120 l of chemotactic media)
were added into each upper well. In experiments with Ag-me-
diated chemotaxis the cells were sensitized with IgE before the
assay. Cells migrating into lower wells within the 8-h incuba-
tion period (37 °C, 5%CO2 in air) were counted usingAccuri C6
Flow Cytometer (BD Biosciences).
Electron Microscopy of Immunogold-labeled Membrane
Sheets—Ultraclean glass coverslips (15 mm in diameter) were
prepared as previously described (11). The coverslips in 24-well
plates were coated by overnight incubation at 4 °C with
fibronectin (50 g/ml in PBS), followed by washing with dis-
tilled water, and used immediately. BMMCs (1.5  106) were
washed twice with BSSA and then incubated on fibronectin-
coated glass coverslips. After 1 h the cells were washed with
BSSA and incubated with anti-CD9 antibody (15 g/ml) in
BSSA at room temperature. After 10min the cells were washed
3 times in PBS and subsequently incubated with the secondary
antibody conjugated with 12-nm gold particles. Alternatively,
the cells were prefixed in 2% paraformaldehyde for 7 min,
washed 3 times in PBS, and immersed in ice-cold HEPES buffer
(25 mM HEPES, pH 7.0, 25 mM KCl, 2.5 mM magnesium ace-
tate). Plasma membrane sheets were isolated and fixed in 2%
paraformaldehyde in HEPES buffer for 10 min. After fixation,
electron microscopy grids were transferred to PBS and target
epitopes located on the cytoplasmic side of the plasma mem-
brane were labeled with specific primary antibodies in 0.1%
BSA in PBS (rabbit anti-NTAL, 1:200; rabbit anti-LAT, 1:200;
mouse anti-FcRI- subunit mAb, clone JKR, 4 g/ml) washed
4 times and subsequently labeled with goat anti-rabbit or anti-
mouse secondary antibodies conjugated to gold nanoparticles.
After extensive washing the membrane sheets were fixed in
2.5% glutaraldehyde in PBS for 10min and the grids were trans-
ferred to PBS. After 10 min the membranes were stained with
1% OsO4 in PBS, washed three times for 5 min in water, incu-
bated for 10 min with 1% aqueous tannic acid, washed again in
water, and stained for 10 min with 1% aqueous uranyl acetate.
Finally, samples were washed twice with water for 5 min, air-
dried, and observed with FEI Morgagni 268 electron micro-
scope (FEI Czech Republic) operating at 80 kV. Typically, 10
micrographs covering 22.2 m2 of the cell surface were
obtained from each grid; at least three independent experi-
ments weremade for each condition tested. The coordinates of
gold particles were determined by ImageJ (National Institutes
of Health). Statistical evaluation of colocalization of two types
of particles was based on the program Gold using pair cross-
correlation function (PCCF) (41).
Cell Adhesion and Spreading—IgE-sensitized BMMCs were
loaded with Calcein-AM and incubated or not with anti-CD9
mAb (10 g/ml) and/or anti-1 integrin antibody (20 g/ml)
for 15 min before their transfer into fibronectin-coated wells.
Cell adhesion was determined after a 30-min activation of the
cells with Ag (50 ng/ml of TNP-BSA) using a TECAN fluorom-
eter with excitation at 485 nm and emission at 538 nm. For cell
spreading, wells of 96-well glass-bottom plates (InVitroSci)
were coated with 50 l of fibronectin in PBS (50 g/ml). After
1 h at 22 °C the wells were washed with PBS, and 30  103 cells
in BSSAwere added into eachwell. Cells were allowed to attach
for 30 min at 37 °C, gently washed, and then activated or not
with Ag. After 20 min the cells were fixed for 30 min at room
temperature with 3% paraformaldehyde in PBS. For filamen-
tous (F)-actin staining, the cells were washed with 50 mM gly-
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cine in PBS and then exposed to Alexa Fluor 488-phalloidin
conjugate diluted 1:100 in PBS supplemented with L--lyso-
phosphatidylcholine (120 g/ml). After 1 h, the cells were
washed in PBS, fixed, and kept in PBS supplemented with
Hoechst 33258 stain. They were then examined with theOlym-
pus Scan system. Image processing and analysis were com-
pleted by means of CellProfiler software (Broad Institute, Bos-
ton, MA) (42).
Statistical Analysis—Unless specified otherwise, the signifi-
cance of intergroup differences was evaluated by Student’s t
test.
RESULTS
Aggregation of CD9 Causes Activation of Mast Cells and
Tyrosine Phosphorylation ofNTALbutNot LAT—In an attempt
to contribute to elucidating the role ofmembrane glycoproteins
inmast cell signaling and chemotaxis we studied the properties
of a newmAbprepared after immunization of a rat with cellular
ghosts obtained after permeabilization of BMMCs with sapo-
nin. Previously we (30, 35, 40) and others (43, 44) showed that
such ghosts are deprived of soluble cytoplasmic proteins, but
possess plasma membrane proteins, cytoskeletal proteins, and
nucleus. One of the mAbs prepared against such ghosts, the
2H9, was found to bind to the plasma membrane target (see
below) and activate mast cells in a manner different from that
known for other mast cell activators, the SCF and IgE-Ag com-
plexes. When BMMCs were exposed to the 2H9 mAb, an
increased degranulation (Fig. 1A) and calcium response (Fig.
1B) were noticed. The responses were comparable with those
induced by SCF and lower than those observed in cells activated
by Ag. The 2H9mAb-induced tyrosine phosphorylation of sev-
eral protein substrates in whole cell lysates was determined by
immunoblotting with PY-20-HRP conjugate (Fig. 1C). The
phosphorylation profile was, however, different from that
induced by SCF orAg (Fig. 1C). To identify the proteins that are
phosphorylated in cells activated by 2H9 we analyzed several
signaling targets using phosphospecific antibodies. For com-
parisonwe also quantified the extent of phosphorylation in cells
activated by SCF and Ag. Data presented in Fig. 1D show that
binding of 2H9 mAb had no effect on phosphorylation of Akt
on Thr308 or Ser473, and induced a weak phosphorylation of
ERK and p38. Tyrosine phosphorylation profile of the whole
cell lysate (Fig. 1C) suggested that NTAL (25–30 kDa) and LAT
(36–38 kDa) could be among the proteins phosphorylated in
2H9-activated cells. To verify this, NTAL and LATwere immu-
noprecipitated from nonactivated or activated cells and tyro-
sine phosphorylation was determined using PY-20-HRP conju-
gate. Data in Fig. 1E show that tyrosine phosphorylation of
NTAL in 2H9-activated cells was more pronounced than in
SCF-activated cells but weaker than in Ag-activated cells. Sim-
ilar analysis of LAT immunoprecipitates showed that 2H9 trig-
gering caused only a weak LAT phosphorylation, comparable
with that observed in SCF-activated cells. This was in sharp
contrast to Ag-induced activation, which induced a strong
phosphorylation of LAT.
Next, we attempted to identify which kinases are involved in
NTALphosphorylation in 2H9-activated cells. Previous studies
showed that NTAL in Ag-activated mast cells is phosphory-
FIGURE 1. Activation events in mast cells caused by 2H9 mAb. BMMCs
derived from WT C57BL.6 mice were sensitized overnight with TNP-specific
IgE. A, the cells were exposed to BSSA (nonactivated control, C) or activated
with 2H9 mAb (10 g/ml), SCF (100 ng/ml), or Ag (500 ng/ml TNP-BSA) for 30
min. -Glucuronidase released into supernatant was determined as
described under “Experimental Procedures.” Mean  S.D. were calculated
from 3 independent experiments performed in triplicates. B, IgE-sensitized
BMMCs were loaded with Fura-2AM and exposed (arrow) to BSSA (Co.), 2H9
mAb (10 g/ml), SCF (100 ng/ml), or Ag (500 ng/ml of TNP-BSA). Changes in
[Ca2]i were determined by spectrofluorometry as the ratio of emissions at
510 nm when the cells were excited at 340 and 380 nm. C, D, and F, IgE-
sensitized BMMCs were exposed to BSSA (Co.) or activated for 3 min with 2H9
mAb (1 g/ml), SCF (100 ng/ml), or Ag (100 ng/ml TNP-BSA). Whole cell
lysates were fractionated by SDS-PAGE and analyzed by immunoblotting
with phosphotyrosine-specific mAb PY-20-HRP conjugate (C), antibodies
specific for the indicated phosphotyrosines, pAkt-T308 (pAktT), pAkt-S473
(pAktS), pErk-Y204 (pErkY), and pp38-Y182/T180 (pp38Y/T) (D), or antibodies spe-
cific for pSyk-Y525/526 (pSykY), or pc-Kit-Y568/570 (pc-KitY) (F). In D and F, anti-Lyn
mAb (Lyn) was used as a loading control. E and G, IgE-sensitized BMMCs
derived from C57BL.6 mice (E) or Lyn/ or Lyn/ (G) were nonactivated (Co.)
or activated with 2H9 mAb, SCF (E only), or Ag as above. The cells were solu-
bilized in lysis buffer containing 1% Nonidet P-40 and 1% n-dodecyl--D-
maltoside and postnuclear supernatants were immunoprecipitated (IP) with
NTAL- or LAT-specific rabbit antibodies immobilized on protein A. The immu-
noprecipitates were analyzed by immunoblotting (IB) with phosphotyrosine-
specific PY-20-HRP conjugate (PY20). Protein loading was determined by
LAT- or NTAL-specific mAbs. In D-G, fold-increase in protein phosphorylation
normalized to phosphorylation in nonactivated cells and protein loading is
also shown. Typical results from at least 4 experiments performed are shown.
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lated by the Src family kinase Lyn, Syk kinase, and/or by KIT
(45). Proper kinase activity of Syk and KIT is associated with
their increased tyrosine phosphorylation (46, 47); we therefore
first analyzed changes in phosphorylation of Syk and KIT. We
found that these two kinases do not exhibit enhanced phosphor-
ylation after 2H9 treatment (Fig. 1F). Control experiments
showed, as expected, that Syk and KIT were phosphorylated in
cells activated by Ag or SCF, respectively. To determine
whether Lyn kinase is involved in 2H9-induced NTAL phos-
phorylation, NTAL was immunoprecipitated from BMMCs
derived from Lyn/ mice or WT (Lyn/) mice. Data in Fig.
1G show that the absence of Lyn caused no increase in NTAL
phosphorylation in 2H9-treated cells. The data suggest that Lyn
is the kinase required for phosphorylation of NTAL after expo-
sure of the cells to 2H9 mAb.
To identify the target recognized by the 2H9mAb, we immu-
noprecipitated the target Ag from the lysate of resting BMMCs.
The isolatedmaterial was digestedwith trypsin and analyzed by
peptide mass mapping and peptide sequencing. Both analyses
showed that 2H9 mAb binds to mouse CD9 (Fig. 2, A-C). The
identity of the target was confirmed by decreased binding of the
antibody to the cells with decreased expression of CD9 (see
below). Furthermore, as determined by immunoblotting exper-
iments, 2H9 mAb recognized a protein with a molecular mass
of 22 kDa, corresponding toCD9; only unreduced sampleswere
reactive (Fig. 2D). Finally, CD9 immunoprecipitated with com-
mercially available CD9-specific antibody (KMC8.8) reacted by
immunoblotting with 2H9 and vice versa (Fig. 2E). The com-
bined data indicate that binding of anti-CD9 2H9mAb induces
mast cell signaling events that are different from those induced
by Ag or SCF.
CD9 Colocalizes with NTAL—Previous studies showed that
despite their similarity in structure and resistance to solubiliza-
tion in nonionic detergents, NTAL and LAT occupy different
membranemicrodomains (5, 11). Tetraspanins are known to be
present in both raft and nonraft regions of the plasma mem-
brane and therefore it was of interest to determine whether
CD9 colocalizes with NTAL and/or LAT. For co-localization
experiments we used plasma membrane sheets isolated from
BMMCs and probed them with immunogold labeling on the
cytoplasmic (NTAL and LAT) or extracellular (CD9) side.
Plasma membrane sheets isolated from BMMCs were fixed (i)
before anti-CD9 (2H9) mAb exposure, (ii) 5 min after incuba-
tion with 2H9 mAb at 37 °C to induced CD9 dimerization, or
(iii) after extensive aggregation of CD9–2H9 complexes with
secondary anti-rat antibody (Fig. 3). As inferred from repre-
sentative figures and PCCF analysis, NTAL exhibited some
colocalization with CD9 in membranes obtained from cells
FIGURE 2. Identification of CD9 as the target protein of 2H9 mAb. 2H9 mAb covalently bound to protein G resin by dimethylpimelimidate was used to
pulldown the target Ag from postnuclear supernatant of BMMCs lysed in a lysis buffer containing 1% Triton X-100. Bound material was eluted from the resin
by SDS-PAGE sample buffer, size-fractionated on 12% SDS-PAGE, and stained with Coomassie Brilliant Blue. The major band was excised and analyzed with
HPLC in combination with electrospray ionization tandem mass spectrometry (microHPLC-ESI-MS/MS) and MALDI-Fourier transform mass spectrometry
(MALDI/FTMS). A, the chart represents the spectrum of detected peptides from trypsin-digested immunoprecipitated protein. Masses of identified peptides
(MH) and their corresponding peaks are indicated. B, table shows sequences identified by MS analysis with mass of their appropriate MH ions. C, positions
of the identified sequences (underlined) in the whole CD9 protein (NCBI Reference Sequence NP_031683.1). D, lysates from BMMCs were diluted with SDS-PAGE
sample buffer supplemented with () or without () 2-mercaptoethanol (ME), size fractionated by SDS-PAGE, and analyzed by immunoblotting with 2H9 mAb
followed by anti-rat IgG HRP conjugate. The arrow indicates the migration of the 2H9 target protein and numbers on the left represent the position of the
molecular mass markers in kDa. E, BMMCs were lysed as in A and postnuclear supernatants were immunoprecipitated (IP) with 2H9 or KMC8.8 antibodies
immobilized to protein G resin. Material released from the resin was fractionated on a 12% SDS-PAGE gel and analyzed by immunoblotting (IB) with 2H9 or
KMC8.8 Abs. The data presented in D and E are typical results from at least 3 experiments performed.
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fixed before labeling (Fig. 3, A and D). Antibody-mediated
dimerization of CD9 before fixation promoted this colocaliza-
tion (Fig. 3, B and E) and extensive CD9 aggregation with sec-
ondary antibody led to localization of both CD9 and NTAL in
large separated clusters (Fig. 3, C and F). In contrast, LAT
showed no significant colocalizationwith CD9 at any condition
tested (Fig. 3,G-L). These data suggest thatNTAL (unlike LAT)
is located together with CD9 in membrane microdomains; this
could form amechanistical basis for their functional cross-talk.
Inhibitory Effect of Anti-CD9 on Ag-mediated Chemotaxis—
Previous studies showed that tetraspanins are involved in reg-
ulation of chemotaxis in several cell types, including mast cells
(48, 49). In further experiments we therefore tested the effect of
the 2H9 anti-CD9mAb on chemotaxis driven by Ag.We found
that pretreatment of IgE-sensitized BMMCs with anti-CD9
mAb inhibitedmigration towardAg even at low concentrations
of the mAb (Fig. 4A). Visual microscopic inspection showed
that exposure of the cells to all concentrations of the 2H9 mAb
tested in the chemotaxis assays did not induce aggregation of
BMMCs (not shown), which could be responsible to the
observed inhibitory effect. When commercially available CD9-
specific mAb, KMC8, was used, the binding to BMMCs was
comparable with 2H9, but no inhibition of Ag-driven che-
motaxis was observed (not shown). This suggests unique bind-
ing properties of 2H9 mAb. Previous studies showed that mast
cells use tetraspanin CD9 as an alternate IL-16 receptor (48).
Next we therefore examined whether anti-CD9 antibodies will
interfere with IL-16-driven chemotaxis. Data presented in Fig.
FIGURE 3. Different colocalization of CD9 with NTAL or LAT. BMMCs were prefixed in 2% paraformaldehyde and then stained with 2H9 mAb followed by
secondary antibody conjugated to 12 nm of gold (A, D, G, and J). Alternatively, the cells were first treated with 2H9 mAb and then fixed and stained (B, E, H, and
K) or the cells were first treated with 2H9 mAb followed by its aggregation with secondary antibody followed by fixation (C, F, I, and L). Plasma membrane sheets
were then isolated and NTAL (A-F) or LAT (G-L) on the cytoplasmic side of the plasma membrane were labeled with primary antibodies followed by secondary
antibodies conjugated to 6-nm gold particles. Topography of gold particles was evaluated by electron microscopy. Representatives from 3 independent
experiments performed are shown (A-C and G-I). Evaluation of colocalization of 6- and 12-nm gold particles is represented as PCCF analysis for CD9/NTAL
labeling (D-F) and CD9/LAT labeling (J-L). For calculation of PCCF, 20 m2 of the plasma membrane sheets was used in each experiment. PCCF indicates
colocalization when experimental values (solid line) are higher than random distribution of particles presented by a dotted line. Bars, 200 nm.
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4B indicate that both 2H9 and KMC8 inhibited chemotaxis
toward IL-16; 2H9 was more potent than KMC8 at all concen-
trations tested.
To find out whether binding of 2H9 mAb to CD9 is indeed
involved in chemotaxis inhibition, we prepared BMMCs with
CD9 KD after infection of the cells with lentiviral vectors con-
taining CD9 shRNA. From the 5 vectors used, two of them
(TRCN0000066393 (93) and TRCN0000066395 (95)) strongly
inhibited CD9 expression as detected by immunoblotting (Fig.
4C) and flow cytometry analysis (Fig. 4D) and were used in
further experiments. Both vectors gave comparable results and
therefore experimental data were pooled for presentation. Data
shown in Fig. 4E indicate that chemotaxis toward Ag was not
reduced by anti-CD9 in cells with CD9KD, but was inhibited in
control cells with empty pLKO vector. Interestingly, cells with
reduced expression of CD9 showed normal migration toward
Ag. These data indicate that reduced expression of CD9 is com-
patible with chemotaxis but not with the inhibitory effect of
anti-CD9.
Inmacrophages (50) and platelets (51–53) anti-CD9 induced
changes in signaling pathways that were caused by co-cross-
linking of CD9 with FcRs. Next we therefore studied the role
of FcRs in anti-CD9 mAb-mediated inhibition of chemotaxis.
We prepared Fab and F(ab)2 fragments of 2H9 mAb and com-
pared their effects on Ag-driven chemotaxis. Pretreatment of
BMMCs with anti-CD9 F(ab)2 fragments had a similar inhibi-
tory effect on chemotaxis towardAg as caused by thewhole IgG
(compare Fig. 4, A and F). However, when Fab fragments were
used only minimal effects were observed (Fig. 4F). These find-
ings suggest that inhibition of chemotaxis is caused by aggrega-
tion of CD9 and does not require co-cross-linking of CD9 with
FcR. It should be noted that the binding capacity of the whole
2H9 IgG or its F(ab)2 and Fab fragments to BMMCs was com-
parable as determined by flow cytometry (not shown).
CD9, Fc Receptors, and NTAL Phosphorylation—As shown
in Fig. 1,E andG, NTALbecomes tyrosine phosphorylated after
exposure of the cells to anti-CD9 mAb 2H9. The logical next
stepwas therefore to find outwhether FcRs are involved in the
process. Whereas intact 2H9 mAb induced strong tyrosine
phosphorylation of NTAL (Fig. 4G, line 4), F(ab)2 as well as Fab
fragments of the mAb were without any effect (Fig. 4G, lines 2
and 3). In this context it should be mentioned that phosphory-
lation of NTAL was observed when F(ab)2 or Fab fragments of
the 2H9 mAb were aggregated by anti-rat IgG antibodies (not
shown). These data together with the finding that 2H9 F(ab)2
FIGURE 4. Anti-CD9 mAb inhibits chemotaxis toward Ag and induces
tyrosine phosphorylation of NTAL by different mechanism. A, IgE-sensi-
tized BMMCs were pretreated with the indicated concentrations of anti-CD9
mAb 2H9 for 15 min and their chemotactic response toward Ag (250 ng/ml of
TNP-BSA in the lower chamber) was determined in the Transwell system. B,
BMMCs were pretreated or not with the indicated concentrations of anti-CD9
antibodies (2H9 or KMC8) for 15 min and their chemotactic response toward
IL-16 (50 ng/ml) was determined as above. Data were normalized toward the
maximum response attained in the absence of antibody pretreatment. Migra-
tion in the absence of IL-16 is also shown. C and D, a set of murine CD9 shRNAs
cloned into the pLKO.1 vector (TRCN0000066393 (93), TRCN0000066394 (94),
TRCN0000066395 (95), TRCN0000066396 (96), TRCN0000066397 (97)) was
used for lentiviral infection of BMMCs. After selection in puromycin, the cel-
lular proteins were size fractionated by SDS-PAGE and analyzed by immuno-
blotting (IB) with anti-CD9 mAb 2H9. Actin was used as a loading control.
Immunoblots were evaluated by densitometry and data were normalized to
noninfected controls (NI) and actin amount. Similar results were obtained in
at least three independent experiments. D, flow cytometry analysis of surface
expression of CD9 in clones selected for further studies, 93 (dotted line) and 95
(dashed line). Gray filled region represents control cells exposed to secondary
anti-rat Alexa 488 antibody alone. Thick line indicates cells infected with
empty vector (pLKO). E, BMMCs were deprived of CD9 after infection with CD9
shRNA-containing vector (CD9 KD), uninfected cells (Co.), or cells infected
with empty vector (pLKO) served as controls. Ag-mediated chemotaxis in the
cells was measured as in A. F, BMMCs were not exposed (Co.) or exposed for 15
min to 2H9 mAb Fab or F(ab)2 fragments, each at a concentration 2 or 20
g/ml. Their chemotaxis was determined as in A. G, BMMCs were exposed to
BSSA (negative control, Co., line 1), 2H9 mAb Fab fragment (line 2), 2H9 mAb
F(ab)2 fragment (line 3), or 2H9 whole molecule (CD9; line 4); each at a con-
centration of 10 g/ml. After 5 min the cells were solubilized in lysis buffer
containing 1% Nonidet P-40 and 1% n-dodecyl--D-maltoside and post-
nuclear supernatants were immunoprecipitated (IP) with rabbit anti-NTAL
antibody. The immunoprecipitates were analyzed by immunoblotting (IB)
with phosphotyrosine-specific antibody PY-20-HRP conjugate (PY20) or
NTAL-specific antibody as a loading control. Fold-increase in protein tyrosine
phosphorylation, normalized to phosphorylation in nonactivated cells and
NTAL amount is also indicated. A typical experiment from 4 performed is
shown. H, BMMCs were pretreated or not with anti-CD16/CD32 (2.4G2; 1:50
diluted supernatant) and/or anti-CD9 mAb 2H9 (1 g/ml, CD9) for 15 min
and then exposed to control BSSA (Co., line 1), anti-CD9 (1 g/ml, lines 2 and
3), 2.4G2 antibody (1:50 diluted supernatant, line 4), or anti-rat IgG (1 g/ml,
lines 5 and 6). After 3 min the cells were lysed and NTAL was immunoprecipi-
tated and analyzed as in G. Typical results from at least 3 experiments per-
formed are shown. Mean  S.D. in A, B, E, and F were calculated from 3 to 5
independent experiments.
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fragments inhibit Ag-directed chemotaxis indicate that there is
no simple connection between 2H9-induced chemotaxis inhi-
bition and NTAL tyrosine phosphorylation. It should be also
mentioned that 2H9 mAb was able to induce a weak tyrosine
phosphorylation of NTAL in CD9 KD cells (not shown). This
indicates that aggregation of residual CD9 on cells with CD9
KD (Fig. 4D) is still capable to induce NTAL phosphorylation,
but is no longer capable of inhibiting chemotaxis (Fig. 4E).
To confirm the role of Fc receptors in NTAL phosphoryla-
tion induced by 2H9mAbwe used rat 2.4G2 antibody, which is
specific for mouse FcRIIB/FcRIII. BMMCs pretreated or not
with a saturating concentration of 2.4G2mAb and/or anti-CD9
mAb (1st step) was followed by exposure to anti-CD9 mAb,
2.4G2 mAb, or anti-rat IgG antibody (2nd step). The results
show that the 2.4G2 antibody alone caused weak phosphoryla-
tion of NTAL (Fig. 4H, compare line 1with line 4). Phosphory-
lation ofNTALwas enhancedwhen 2.4G2mAbwas aggregated
in the 2nd step by anti-rat IgG (Fig. 4H, line 5). Pretreatment of
the cells with 2.4G2 mAb followed by exposure to anti-CD9
mAb resulted in lower phosphorylation of NTAL (Fig. 4H, line
3) than after exposure of the cells to anti-CD9 alone (Fig. 4H,
line 2). Maximum NTAL phosphorylation was observed when
both FcR and CD9 were extensively aggregated with the first
and second layer of antibodies (Fig. 4H, line 6).
CD9 Aggregation Does Not Interfere with Early FcRI-medi-
ated Signaling Events—Because 2H9 binding inhibited che-
motaxis toward Ag, we were curious to know whether other
Ag-induced signaling pathways are affected and whether CD9
colocalizes with FcRI. Our data show that FcRI exhibited
colocalization with CD9 after CD9 dimerization or a more
extensive aggregation (Fig. 5, A-F). Furthermore, we could
demonstrate that Ag-induced degranulation (Fig. 5G), Ca2
release (Fig. 5H), and tyrosine phosphorylation of Akt, ERK,
and pp38 (Fig. 5I) were not affected by anti-CD9 mAb binding.
We also found that phosphorylation of the FcRI- subunit was
not changed (Fig. 5J). These data thus indicate that signaling
pathways leading to degranulation after FcRI triggering were
not affected by anti-CD9. The experiments presented in Fig. 5
were performed with BMMCs from Balb/c mice, but similar
results were obtained with BMMCs derived from C57BL/6
mice (not shown).
Different Roles of LAT and NTAL in Mast Cell Chemotaxis
and Cross-talk with CD9—Data presented above show that
anti-CD9 inhibits chemotaxis toward Ag and induces disparate
phosphorylation of NTAL and LAT. Next we investigated the
role of NTAL and LAT in mast cell chemotaxis and their sen-
sitivity to the inhibitory effect of anti-CD9. For such experi-
ments, BMMCs were obtained by growing progenitors from
bone marrow of Ntal/, Lat/, 2KO mice, and correspond-
ing controls. The cells were sensitized with TNP-specific IgE
overnight and their migration toward Agwas investigated. Sur-
prisingly, LAT-deficient cells (Lat/) showed similar Ag-me-
diated chemotaxis as WT (Lat/) cells (Fig. 6A). In accor-
dance with our previous findings (14), BMMCs derived from
Ntal/ mice exhibited significantly higher migration toward
Ag than the correspondingWT (Ntal/) cells (Fig. 6A). These
data confirm that NTAL is a negative regulator of Ag-driven
chemotaxis. Interestingly, 2KO cells exhibited higher migra-
tion toward Ag than WT (Ntal/ or Lat/) cells or Lat/
cells, but lowermigration thanNtal/ cells. This suggests that
in the absence of NTAL even LAT negatively regulates che-
motaxis. To verify that LAT and NTAL had the anticipated
regulatory roles in Ag-induced degranulation, we also tested
the release of -glucuronidase after activation of the cells with
Ag. Data shown in Fig. 6B indicate, as expected, decreased
degranulation in Lat/ and even more in 2KO cells and an
enhanced response in Ntal/ cells, when compared with the
corresponding WT (Ntal/ or Lat/) controls.
To examine a functional regulatory cross-talk between
NTAL and CD9 in chemotaxis, we compared the effect of anti-
CD9 on Ag-driven chemotaxis of Ntal/ and WT Ntal/
cells. Data presented in Fig. 6C show that treatment with
anti-CD9 mAb inhibited chemotaxis toward Ag in both Ntal/
cells andNtal/ cells. However,Ntal/ cells were more per-
ceptive to the inhibitory effect of anti-CD9 than Ntal/ cells.
CD9 Forms Complex with 1-Integrin but Anti-CD9 Does
Not Interfere with 1-Integrin Function—The most prominent
partners of tetraspanins are integrins (15–17, 20, 21). Next, we
therefore investigated the effect of anti-CD9 mAb on integrin-
mediated signaling pathways. Pretreatment of BMMCs with
anti-CD9mAb inhibited the binding of1-integrin antibody to
the cells (Fig. 7,A andD). The inhibitory effect was not affected
by pretreatment with F-actin disrupting drugs, latrunculin B
(0.4 M, 30 min) or cytochalasin D (1 M, 30 min; data not
shown). This suggests that F-actin-dependent events, such as
internalization, are not responsible for the observed inhibitory
effect. On the other hand, pretreatment of the cells with anti-
CD9 mAb had no effect on the binding of antibodies against
FcRI andKIT (Fig. 7,B-D); these data support the concept that
integrin is in close proximity to CD9. Immunoprecipitation
data indicated that CD9 and 1-integrin are physically associ-
ated in complexes after solubilization of the cells in lysis buffer
containing 1% CHAPS (Fig. 7E). To investigate the functional
cross-talk between CD9 and 1-integrin, we tested the effect of
anti-CD9 on Ag-induced adhesion of mast cells to fibronectin.
It is remarkable that although anti-CD9mAb blocked the bind-
ing of anti-1 integrin antibody to the cells, no significant inhi-
bition of anti-CD9 on adhesion to fibronectin was observed. As
a control we used antibody against1-integrin and found that it
significantly inhibited adhesion of BMMCs to the fibronectin
(Fig. 7F). We also tested the effect of anti-CD9 on Ag-induced
spreading ofmast cell on surfaces coated with fibronectin. Data
presented in Fig. 7, G and H, indicate that binding of anti-CD9
at saturation concentrations to BMMCs had no significant
effect on Ag-induced spreading of the cells to fibronectin. The
combined data indicate that although CD9 forms complexes
with 1-integrin, binding of anti-CD9 mAb does not interfere
with the studied 1-integrin functions.
Cross-talk between CD9 and Cytoskeleton-regulatory Pro-
teins of the ERM Family—An important feature of cell activa-
tion and chemotaxis is a rapid and extensive communication
between plasma membrane components and cellular cytoskel-
eton. This process is regulated by conformational changes in
ERM family proteins caused by transient dephosphorylation of
their regulatory threonines. Although such changes have been
documented in immunoreceptor-activated B cells, T cells, and
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mast cells (54–58), whether aggregation of CD9 could also
induce such dephosphorylations is unknown. We have exam-
ined the phosphorylation status of the regulatory threonine
after exposure of BMMCs to anti-CD9 mAb 2H9, SCF, or Ag
and found that all 3 activators significantly reduced phosphor-
ylation of the regulatory threonine (Fig. 7, I and J).
DISCUSSION
Migration of mast cell progenitors from bone marrow to
connective tissues and subsequent movement of mature mast
cells to the sites of inflammation is crucial for proper function-
ing of innate and adaptive immunity. Mast cell migration is
directed by chemoattractants, which are produced by a variety
of cells localized in different target tissues, as well as by intrinsic
mast cell regulators that are still poorly understood (2). This
study was initiated by functional screening of mAbs prepared
after immunization of rats with cellular ghosts obtained by
treatment of BMMCswith saponin.One of the antibodies, 2H9,
recognizing tetraspanin CD9, was found capable to induce cell
activation and inhibit Ag-driven mast cell chemotaxis. Several
lines of evidence presented in this study indicate that 2H9-me-
diated CD9 aggregation triggers signaling pathways, which are
different from those activated through FcRI or KIT, and have
impact on mast cell chemotaxis.
First, exposure of BMMCs to CD9-specific mAb 2H9
resulted in phosphorylation of several signal transduction pro-
teins. Importantly, the phosphorylation profile of the target
proteins differed from that produced by SCF- or Ag-mediated
FIGURE 5. CD9 colocalizes with FcRI on the plasma membrane but CD9 aggregation does not interfere with early Ag-induced activation events. A and
D, BMMCs derived from Balb/c mice were prefixed with paraformaldehyde and then labeled with anti-CD9 mAb 2H9 followed by secondary anti-rat anti-
body-12 nm gold conjugate. Plasma membrane sheets were then isolated and the FcRI- subunit was labeled on the cytoplasmic side of the membrane with
JRK mAb followed by secondary anti-mouse antibody-6 nm gold conjugate. Colocalization of CD9 (12 nm gold particles) and FcRI- (6-nm gold particles) was
analyzed by electron microscopy (A) and evaluated by PCCF (D) as described in the legend to Fig. 3. B and E, BMMCs were exposed to 2H9 mAb (CD9 dimerized)
before fixation and labeling for CD9; other procedures and evaluations were as in A and D. C and F, the cells were exposed to 2H9 mAb followed by the
secondary anti-mouse antibody (CD9 aggregation) and then fixed and further processed as in A and D. In A-C representatives from 3 independent experiments
are shown. Bars, 200 nm. G-J, IgE-sensitized BMMCs derived from Balb/c mice were pretreated (CD9) or not (Co.; ) with anti-CD9 mAb 2H9 (10 g/ml) for 15
min before activation. G, the cells were exposed to various concentrations of Ag (0 –500 ng/ml TNP-BSA) or 500 nM thapsigargin (Th.) and 30 min later amounts
of -glucuronidase released into the cell supernatants were determined. Mean  S.D. were calculated from at least 3 independent experiments performed in
triplicates. H, the cells were loaded with Fura-2AM at the time of exposure to anti-CD9 and stimulated (arrow) with Ag (500 ng/ml of TNP-BSA). [Ca2]i was
measured as described in the legend to Fig. 1B. Mean  S.D. were calculated from 3 independent experiments performed in triplicates. I, IgE-sensitized BMMCs
were exposed () or not () to anti-CD9 mAb 2H9 and then activated () or not () with Ag (100 ng/ml of TNP-BSA) for 3 min. Whole cell lysates were prepared
and analyzed by immunoblotting with antibodies specific for pAkt-S473 (pAktS), pErk-Y204 (pErkY) or pp38-Y182/T180 (pp38Y/T); anti-Lyn mAb (Lyn) was used as
a loading control. Fold-increase in protein phosphorylation, normalized to phosphorylation in nonactivated cells and protein loading is also shown. Typical
results from at least 4 experiments performed are shown. J, IgE-sensitized BMMCs were exposed () or not () to anti-CD9 mAb and then activated by Ag (;
250 ng/ml of TNP-BSA) or not (). After 5 min the cells (15  106 per sample) were solubilized in lysis buffer containing 0.2% Triton X-100 and FcRI was
immunoprecipitated from postnuclear supernatants by anti-IgE antibody immobilized to Protein A beads. Tyrosine phosphorylation of the receptor subunits
was evaluated with PY-20-HRP conjugate (PY-20). The amount of immunoprecipitated receptor was estimated by immunoblotting (after stripping of the
membrane) with JRK mAb recognizing FcRI  subunit. A typical experiment from 3 performed is shown.
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activation (Table 1). Specifically, 2H9 mAb induced stronger
phosphorylation of NTAL than activation through KIT but
weaker than activation via FcRI. On the other hand, several
proteins, which were phosphorylated in KIT- and FcRI-acti-
vated cells, were either not at all or only weakly phosphorylated
after CD9 triggering (Akt, Erk, and p38). Other proteins, which
were strongly phosphorylated after Ag-induced activation (Syk
and LAT), showed no or only weak tyrosine phosphorylation
after CD9 triggering. Enhanced phosphorylation of NTAL in
anti-CD9-treated cells was only observed when whole IgG was
used; Fab and F(ab)2 fragments had no effect. This suggested
that co-cross-linking of CD9 and Fc receptor(s) is required for
tyrosine phosphorylation of NTAL and other targets. This con-
clusion was corroborated by experiments where antibody spe-
cific for FcRIIB/FcRIII induced tyrosine phosphorylation of
NTAL, on the one hand, and, on the other, partially inhibited
NTAL phosphorylation after exposure to anti-CD9. Involve-
ment of Fc receptors in CD9 signaling was also described in
CD9-dependent activation of platelets (53, 59) and macro-
phages (50).
Second, binding of anti-CD9 to target structures on the sur-
face of mast cells resulted in weak calcium and degranulation
responses, comparable with those observed in SCF-activated
cells (Table 1). However, because tyrosine phosphorylation of
LAT was lower in cells activated through CD9 than through
KIT and because phosphorylatedNTAL is unable to bind phos-
pholipase  and thus substitute for phosphorylated LAT in cal-
cium metabolism (5, 6), it is evident that activation through
CD9 or KIT is initiated by different activation pathways. In this
connection it should be noted that pretreatment with anti-CD9
had no significant effect on subsequent binding of IgE to FcRI
and on Ag-induced degranulation, Ca2 responses, and tyro-
sine phosphorylation of numerous substrates. In this respect,
CD9 seems to differ from CD81, another tetraspanin, whose
Ab-mediated aggregation inhibited Ag-induced degranulation
in rat basophilic leukemia cells without affecting the Ca2
response or protein tyrosine phosphorylation (60).
Third, electronmicroscopy studies on isolated plasmamem-
brane sheets disclosed colocalization of CD9 with NTAL, but
not with LAT, in quiescent cells. After CD9 dimerization the
colocalization of CD9 with NTAL became even more promi-
nent. This finding and the potent phosphorylation of NTAL
after CD9 triggering suggest that these twomolecules are phys-
ically and functionally coupled. This could explain our previous
findings that although NTAL and LAT are very similar TRAPs,
they, nevertheless, occupy different membrane domains (5).
CD9 also colocalized with FcRI. However, this colocalization
was clearly seen only after Ab-mediated dimerization or exten-
sive aggregation of CD9.
Fourth, pretreatment of BMMCs with anti-CD9 mAb abol-
ished chemotaxis toward Ag. The inhibitory effect was
observed not only with intact mAb but also with the corre-
sponding F(ab)2 fragment. These data suggest that the inhibi-
tory effect is caused by CD9 aggregation and is not dependent
on signals derived from cross-linking of CD9 with FcR. This
conclusion is further supported by findings that chemotaxis
was not affected by Fab fragments of the anti-CD9mAb.When
another CD9-specific mAb, KMC8, was tested, no inhibition of
chemotaxis was observed. This finding could be related to dif-
ferent epitopes recognized by 2H9 and KMC8 antibodies
and/or other differences between the antibodies, such as con-
figurational constraints (61). On the other hand, both antibod-
ies inhibited IL-16-mediated chemotaxis by a mechanism,
which seems to involve blocking binding of IL-16 to its alternate
receptor, CD9 (48). We have also noticed that chemotaxis
toward Ag was not affected in BMMCs with CD9 KD. This
suggests that CD9 is dispensable for Ag-driven chemotaxis or
that the remaining CD9 is sufficient for signal processing.
Alternatively, it is possible that antibody-mediated aggregation
of CD9 and CD9-bound proteins leads to uncoupling of key
elements important for chemotaxis (see below).
The molecular mechanism of the inhibitory effect of anti-
CD9 on Ag-induced chemotaxis seems to be complex and
involves TRAPs. We found that anti-CD9 mAb was more
potent in inhibitingAg-induced chemotaxis inNTAL-deficient
cells than in WT cells. This could be related to the multiple
regulatory roles of NTAL and its cross-talk with CD9 and LAT
(Fig. 8).
Fifth, extensive communication between plasma membrane
components and the cellular cytoskeleton is crucial for immu-
noreceptor activation and chemotaxis. This process is regu-
lated by conformational changes in ERM family proteins
reflecting the phosphorylation status of their regulatory threo-
nine. Our finding of increased dephosphorylation of ERM pro-
FIGURE 6. Different roles of LAT and NTAL in mast cell chemotaxis and cross-talk with CD9. A, BMMCs derived from Lat/, Ntal/, 2KO, and correspond-
ing littermate (Lat/, Ntal/) control mice were sensitized overnight with TNP-specific IgE and their migration toward Ag (250 ng/ml of TNP-BSA) was tested
in the Transwell system. B, the same IgE-sensitized BMMCs as in A were activated with Ag (250 ng/ml TNP-BSA) for 30 min and -glucuronidase released into
the supernatant was determined as described under “Experimental Procedures.” C, BMMCs from Ntal/ and Ntal/ mice were sensitized with IgE and treated
with the indicated concentrations of anti-CD9 mAb 2H9. Chemotaxis toward Ag was determined as in A. Numbers of cells migrating toward Ag were
normalized to controls, 2H9 nontreated cells. Mean  S.D. were calculated from 3 to 5 independent experiments performed in duplicates. **, p  0.01; ***, p 
0.001.
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teins in cells exposed to anti-CD9 suggested that anti-CD9
interferes with the process of phosphorylation/dephosphory-
lation of ERM family members, and in this way could interfere
with chemotaxis. The molecular mechanism of the cross-talk
between CD9 and ERM family members is unknown. Recent
studies imply an important role of the phosphorylation state of
threonine in actin-binding domains of ERM proteins in cell
chemotaxis (54–57). The proteins exist in an open (active) con-
formation with regulatory threonine phosphorylated, or closed
(inactive) conformation with the regulatory threonine dephos-
FIGURE 7. CD9 aggregation does not interfere with 1-integrin function, but induces dephosphorylation of ERM proteins. A-D, BMMCs were pretreated
or not with anti-CD9 mAb 2H9 (1 g/ml) for 15 min and the binding anti-integrin-1-FITC conjugate (A), anti-FcRI-FITC conjugate (B), and anti-c-Kit-APC
conjugate (C) were estimated by flow cytometry. Gray filled regions represent control cells not exposed to antibodies; dashed and thick lines indicate antibody
binding to anti-CD9 treated (dashed; CD9) or nontreated cells (thick; Co.). D, data obtained as in A-C were normalized to maximal values obtained in the
absence of anti-CD9; mean  S.D. were determined from at least 3 independent experiments. E, BMMCs (107 per sample) were solubilized in lysis buffer
supplemented with 1% CHAPS. CD9 was immunoprecipitated from postnuclear supernatants by 2H9 mAb immobilized on protein A/G beads (line 1). Material
bound to protein A/G beads without 2H9 mAb (line 2) or 2H9 mAb armed protein A/G beads without cell lysate (line 3) served as negative controls. Whole lysates
from 2.5  105 cells were used as positive controls (Co.; line 4). Immunoprecipitated material and controls were recovered in SDS-PAGE sample buffer with or
without 2-mrecaptoethanol. Reduced and unreduced samples were immunoblotted with anti-1 integrin (1) or anti-CD9 (CD9), respectively. F, cell adhesion
to fibronectin. IgE-sensitized and Calcein-loaded BMMCs were incubated with () or without () anti-CD9 mAb 2H9 and/or anti-1 integrin antibody for 15
min before their transfer into fibronectin-coated wells. Adherence to fibronectin was determined by fluorometry after a 30-min exposure of the cells to Ag ()
or BSSA alone (). Fluorescence was evaluated before (100%) and after washing out the non-adherent cells and percentages of adherent cells were calculated.
G, cell spreading on fibronectin. IgE-sensitized BMMCs were pretreated () or not () with anti-CD9 mAb 2H9 and allowed to attach to fibronectin immobilized
on glass surface. Then the cells were exposed () or not () to Ag for 20 min, fixed, permeabilized, and stained for actin with Alexa Fluor 488-phalloidin
conjugate. Examples of the cells are shown. Bars, 20 m. H, average areas of the cells processed as in G were calculated using automated CellProfiller software.
Mean  S.D. from three independent experiments, each involving 500 cells, are shown. I, IgE-sensitized BMMCs were nonactivated (Co.) or activated with 2H9
mAb (CD9), SCF, or Ag for 3 min. Whole cell lysates were prepared and analyzed by immunoblotting with p-ERMT-specific Ab; anti-Lyn was used as a loading
control. Numbers correspond to the fold-increase in phosphorylation after normalization to the total amount of protein and phosphorylation in nonactivated
cells. Typical results are shown. J, mean  S.D. were calculated from 10 to 18 independent experiments performed as in I. **, p  0.01; ***, p  0.001.
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phorylated (62, 63). In the case of ezrin, the open conformation
enables its binding through the actin-binding domain to F-actin
and through the FERM domain to phosphatidylinositol 4,5-
biphosphate on the plasma membrane, to adapter proteins or
directly to cytoplasmic portions of the transmembrane mole-
cules (59, 64). Transient dephosphorylation of the regulatory
threonine disrupts this binding and has been shown to be cru-
cial for migration of lymphocytes (54–57). A recent study with
mast cells showed that dephosphorylation of the regulatory
tyrosine is mediated by activity of the protein phosphatase 2A
after interaction with the p21-activated kinase 1 (58). Based on
our own findings and published data we propose that aggrega-
tion of CD9 leads to dephosphorylation of ERM proteins lead-
ing to their dissociation from themembrane and restrictions in
communication ofmembrane proteins with actin cytoskeleton.
This in combination with some other events involving NTAL
and/or LAT contributes to inhibition of Ag-driven chemotaxis
(Fig. 8). As shown in experiments with F(ab)2 fragments, tyro-
sine phosphorylation ofNTAL is not required for the inhibitory
effect of anti-CD9 mAb. Nevertheless, it is possible that NTAL
functions in chemotaxis even in the absence of its phosphory-
lation, similarly to its role in phospholipase C-independent
calcium uptake (12).
The combined data support the view that chemotaxis and
early activation events leading to degranulation and cytokine
production are processes that use different signaling pathways.
The differences could be important for switching between the
migratory and secretory phases depending on the concentra-
tions of Ag and/or other chemoattractant mast cell encounters
(65). At low concentrations of theAg,mast cellsmigrate toward
its higher concentrations. When regions of higher concentra-
tions of the Ag are attained, the cells stop moving and activate
the signaling pathways leading to secretion of the preformed
allergy mediators and production and release of cytokines, leu-
kotrienes, and other inflammatory mediators that then act as
chemoattractants for other cells and/or orchestrate local
immune responses. Tetraspanin CD9 andNTAL are important
regulators of these events. CD9 could regulate chemotaxis
throughdirect or indirect interactionswith FcRI, other plasma
membrane receptors, and cytoskeletal components. On the
other hand NTAL, which acts as a negative regulator of che-
motaxis, could contribute to fine tuning of chemotaxis by com-
peting with LAT, as suggested for its negative role in mast cell
degranulation (5).
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34. Tolar, P., Tůmová, M., and Dráber, P. (2001) Folia Biol. 47, 215–217
35. Dráberová, L., Amoui, M., and Dráber, P. (1996) Thy-1-mediated activa-
tion of rat mast cells. The role of Thy-1membranemicrodomains. Immu-
nology 87, 141–148
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other brain diseases. Enzyme-linked immunosorbent assays (ELISAs) have been mostly used for
quantification of tau and other biomarkers in CSF. However, these assays do not have sufficient
sensitivity and dynamic range. In this study we tested the suitability of gold nanoparticles
functionalized with tau-specific monoclonal antibody and oligonucleotide template for immuno-
polymerase chain reaction (Nano-iPCR) quantification of tau protein in human CSF samples and
compared it with ELISA, either commercial or newly developed with tyramide signal amplification.
Our data indicate thatNano-iPCR is superior in sensitivity anddetection range to ELISA in tau protein
detection.





Cerebrospinal fluid (CSF) is an important source of protein
biomarkers that reflect pathological changes in the brain and
provide information necessary for diagnosis and treatment of
various brain-associated diseases. One of the meaningful CSF
biomarkers of neuronal and axonal degeneration is the tau
protein. Very high levels of tau are characteristic for patients
with extensive neuronal degeneration, such as Creutzfeldt–
Jacob disease (Otto et al., 1997). Enhanced levels of total and
phosphorylated tau associated with decreased levels of the 42
amino acid form of β-amyloid in CSF have been used fornsduction, Institute of
h Republic, Vídeňská
+420 241062468;
180diagnosis of Alzheimer's disease (AD), the most frequent form
of dementia (Dubois et al., 2007). Quantification of total tau
and other CSF markers of AD is mostly done with commercial
enzyme-linked immunosorbent assays (ELISAs). However,
these assays are expensive and do not have the desirable
dynamic range. New low-cost methods for simultaneous
detection of samples with both low and high levels of tau
proteins are therefore needed.
We and others have recently introduced the polymerase
chain reaction (PCR) combined with sandwich ELISA-like
strategy where the target antigen is immobilized by antibodies
to PCR plate wells and subsequently detected by immuno-PCR
using gold nanoparticles (Au-NPs) functionalized with both
antigen-specific antibody and PCR oligonucleotide template.
This assay, called Nano-iPCR, proved superior in detection of
cytokines and viral proteins to standard ELISAs (Potůčková et
al., 2011; Chen et al., 2009; Perez et al., 2011). Here we present
data confirming the utility of Nano-iPCR for quantification of
tau protein in CSF samples. Compared to commercial or newly
138 L. Stegurová et al. / Journal of Immunological Methods 406 (2014) 137–142developed ELISAs, quantification of tau proteinwith Nano-iPCR
is superior in sensitivity and detection range.
2. Materials and methods
2.1. Materials and reagents
Purified mouse monoclonal antibody specific for tau protein,
HT7 (IgG1), and its biotinylated form were purchased from
Autogen Bioclear (Calne, UK; Cat. No. 90222 and 90214). The
antibody recognizes an epitope located in amino acid region
159–163, according to the human full-length four-repeat tau, tau
40 (Goedert et al., 1989). Purified mouse monoclonal antibody,
TAU-5 (IgG1),which recognizes an epitope located in amino acid
region 210–230 in tau 40 (Carmel et al., 1996), was obtained
from Abcam (Cambridge, UK; Cat. No. ab80579). The kit for
determination of total tau (INNOTEST hTAU Ag) was from
Innogenetics (Gent, Belgium). Recombinant human Tau-441
protein (2N4R variant) was purchased from Enzo Life Sciences
(Farmingdale, NY, USA). Colloidal Au-NPs (30 nm in diameter)
at a concentration of approximately 2 × 1011 particles/ml were
obtained from BBInternational (Cardiff, UK). 5′-thiol-modified
oligonucleotide primer 1 [5′-(5ThioMC6-D//iSp18)CCTTGAACC
TGTGCCATTTGAATATATTAAGACTATACGCGGGAACA-3′], where
iSp18 is an 18-atom hexa-ethyleneglycol spacer connecting
the thiol reactive group and the DNA sequence, primer 2
(5′-CCTTGAACCTGTGCCATTTG-3′) and primer 3 (5′-GTCCCTCC
ATCTTCCTACTGTTCCACATGTTCCCGCGTATAGTCTT-3′) were ob-
tained from IDT (Coralville, IA, USA). Other chemical were
from Sigma-Aldrich (St. Louis, MO, USA). Lumbar CSFs from
32 individuals were collected, centrifuged, aliquoted in 1 ml
polypropylene tubes and stored at −80 °C in accordance with
established guidelines (Teunissen et al., 2009) until analysis. All
participants signed an informed consent form. The study was
approved by the Ethics Committees of the University Hospital,
Královské Vinohrady and Prague Psychiatric Center.
2.2. Preparation of functionalized gold nanoparticles
Au-NPs functionalizedwith antibodies and oligonucleotides
were prepared as described previously (Hill and Mirkin, 2006;
Potůčková et al., 2011) with some modifications. Briefly, 1 ml
of colloidal Au-NPs (30 nm in diameter) was incubated for
30 min at room temperature with HT7 antibody at optimal
concentration (10 μg/ml), determined by Au-NP-antibody
loading test (Hill and Mirkin, 2006); suboptimal concentration
of the antibody resulted in rapid aggregation of the particles,
whereas excess antibody prevented binding of the thiolated
oligonucleotides in a later step. Then, 10% Tween20 (10 μl) and
2 M NaCl in PBS (10 mM phosphate, 150 mM NaCl, pH 7.4;
100 μl) were added, followed by 5′-thiol-modified oligonucle-
otide primer 1 at final concentration 4 nmol/ml. After over-
night incubation at 4 °C with gentle stirring, the samples were
salted by adding 50 μl aliquots of 2 M NaCl in PBS in four 1-h
steps. The armed Au-NPs were further stabilized by adding
20 μl of 10% bovine serum albumin (BSA) and incubating
for 30 min at room temperature. Free oligonucleotides were
removed by three centrifugation steps through discontinuous
glycerol gradient (Potůčková et al., 2011); the pellet was finally
resuspended in 1 ml of PBS containing 20% glycerol, 1% BSA,
0.05% Tween 20, and 0.02% NaN3.1812.3. Nano-iPCR
Fifty microliter aliquots of capture antibody (2.5 μg/ml
TAU-5) in 50 mM borate buffer (pH 9.5) were dispensed into
wells of a real-time 96-well plate (Eppendorf, Hamburg,
Germany). After overnight incubation at 4 °C the wells were
washed (200 μl/well; four times per washing step, if not
specified otherwise) with TBS (10 mM Tris–HCl, pH 7.4,
150 mM NaCl) containing 0.05% Tween 20 (TBST) and the
remaining binding sites were blocked by 6-h incubation
at 4 °C with TBST supplemented with 1% BSA and 1% casein.
The wells were then washed with TBST followed by addition
of 50 μl serially diluted recombinant human tau protein
(Tau-441; 1–100,000 pg/ml in PBS-0.1% casein), PBS-0.1%
casein alone (negative control) or undiluted human CSF
samples. After overnight incubation at 4 °C, the wells were
washed with TBST, followed by addition of 50 μl aliquots of
Au-NPs armed with thiolated DNA oligonucleotide and HT7
monoclonal antibody, diluted 1:10,000 in PBS-0.1% casein.
The wells were incubated for 1 h at 37 °C, washed with
200 μl TBST and finally with 200 μl MilliQ water. Next, 50 μl
aliquots of PCR master mix solution containing Taq DNA
polymerase, nucleotides, SYBR green I, 1,2-propanediol, and
trehalose (Horáková et al., 2011) and supplemented with
60 nM oligonucleotide primers 2 and 3 were dispensed
into each well. The plates were then sealed with Light cycler
480 sealing foil (Roche, Mannheim, Germany) and the amount
of template DNA bound to antigen-anchored functionalized
Au-NPs was evaluated by real-time PCR using Realplex4
Mastercycler (Eppendorf, Hamburg, Germany) with the fol-
lowing cycling parameters: denaturation at 94 °C for 1 min,
followed by 40 cycles at 94 °C for 20 s, 53 °C for 20 s, and 72 °C
for 20 s. The samples without template DNAwere used in each
run as negative controls.2.4. Sandwich ELISAs
Newly developed sandwich ELISA with tyramide signal
amplification (TSA) was routinely performed in high-binding
96-well half-area plates (Costar Corning Inc., Corning, NY,
USA) or TopYield Strips (Nunc, Roskilde Site, Denmark).
Capture anti-tau antibody, TAU-5, was coated at a concen-
tration of 2.5 μg/ml in borate buffer pH 9.5 (30 μl/well)
by overnight incubation at 4 °C. The plates were washed
with TBST and free binding sites were blocked by adding TBS
with 2% BSA (TBS-2% BSA; 185 μl/well). After 6 h at room
temperature the plates were washed again with TBST and
incubated overnight at 4 °C with recombinant human tau
standard (Tau-441) diluted in PBS-1% BSA or tested samples
(30 μl/well). Similar results were obtained when the samples
were diluted in PBS-0.1% casein.Wells washed with TBST were
then incubated for 1 h at room temperature with biotinylated
anti-tau antibody HT7 at concentration 0.5 μg/ml in TBST-1%
BSA (30 μl/well). After washing, the plates were incubated
for 45 min at room temperature with extravidin-peroxidase
diluted 1:5000 in TBST-1% BSA (30 μl/well). Sensitivity of the
assay was increased by biotinyl-tyramide signal amplification
(TSA) using the ELAST ELISA Amplification System (tyramide;
PerkinElmer Life Sciences, Boston) as previously described
(Dráberová et al., 2013). Absorption was measured at 450 nm
139L. Stegurová et al. / Journal of Immunological Methods 406 (2014) 137–142with a Sunrise plate Reader (TECAN). Background of the
negative control was subtracted from the determined values.
The Innotest hTAU Ag (Innogenetics, Gent, Belgium, Cat.
No. 80323) commercial kit for tau protein quantification was
used according to the manufacturer's directions.
2.5. Statistics
Calibration curves were constructed after plotting the
quantification cycle (Cq) values or absorbance against tau
concentrations using a four-parameter logistic regression
model function (variable slope) and linear regression showing
the regression correlation coefficient (R2). The limit of detection
(LOD) was calculated as the mean of the negative control (NC;
sample diluent) plus 3× standard deviations of NC. Correlation
analyses were performed using Pearson's coefficient for normal-
ly distributed and Spearman's coefficient for non-Gaussian data.
Bland–Altman curveswere constructed for comparison between
differentmethods for detection of the tau protein level. Precision
profiles, reproducibility, and accuracy were expressed by the
intra- and inter-assay coefficients of variation (CV). Mean of
individual CVs was calculated for each standard and sample as
standard deviation divided by the mean. The results were then
multiplied by 100 for expression as a percentage. For recovery
experiments, high (4000 pg/ml), medium (800 pg/ml) and low
(100 pg/ml) concentrations of recombinant tauwere spiked into
validated samples and analyzed in Nano-iPCR. The results are
expressed as a percentage of analyte recovered. Linearity of
dilution was determined in CSF samples diluted 2–16-fold and
expressed as percent linearity for all samples in the dilution
series.
All statistical analyses were performed using program
Prism 5 (GraphPad Software, La Jolla, CA, USA).
3. Results and discussion
3.1. Quantification of recombinant tau protein by Nano-iPCR
and comparison with ELISA
The Nano-iPCR method for quantification of tau protein is
based on immobilization of the protein on TAU-5 antibody
directly in PCR wells and its detection by real-time PCR with
the Au-NPs functionalized with tau-specific monoclonal anti-
body HT7 and a single-stranded thiolated oligonucleotide. In
pilot experiments, the Au-NP-antibody loading test was used
to determine the optimum concentration of the HT7 antibody
for Au-NP loading. From a range of HT7 antibody concentra-
tions (1–16 μg/ml), 10 μg/ml was found optimal for antibody
and oligonucleotide arming as determined by sensitivity of tau
detection and real-time PCR analysis (Potůčková et al., 2011),
respectively. Moreover, Au-NPs functionalized with HT7 at the
optimal concentration showed the best performance during
storage for up to eight months. PCR amplification is extremely
sensitive to the presence of very low amounts of antibody/
oligonucleotide-functionalized Au-NPs bound nonspecifically
to the walls of PCR wells, which can enhance the background
signal. This problemwas solved by optimizing thewashing and
blocking conditions, and using a routine protocol for tau
analysis as described in Section 2.3.
Sensitivity of the Nano-iPCR for quantification of tau
protein was tested by immobilizing recombinant tau at a182concentration range from 1 to 100,000 pg/ml in TAU-5
antibody-coated wells of the PCR plate and then exposing
the wells to Au-NPs functionalized with HT7 antibody and
oligonucleotide primer 1. Detection by real-time PCR followed
after washing off unbound particles. Fig. 1A shows a standard
curve in the range of Cq values from 17.9 (at the tau
concentration of 100,000 pg/ml) to 32.6 (at 1 pg/ml). Negative
control (without tau protein) showed Cq values of about 33.
The curve was linear from 10 to 10,000 pg/ml of recombinant
tau proteinwith regression correlation coefficient (R2) equal to
0.9918 (Fig. 1B). The LOD was found to be 5 pg/ml.
For comparison, recombinant tau protein was also
quantified by ELISA-TSA using the same tau-specific antibody
set (TAU-5 and HT7). Different concentrations of recombi-
nant tau protein were added into wells with immobilized
TAU-5. After incubation and washing off unbound tau, the
wells were exposed sequentially to biotinylated anti-tau
specific antibody HT7 and extravidin-peroxidase conjugates.
The signal was enhanced by biotinyl-TSA. Absorbance values
corresponding to different concentrations of tau protein
(0–1200 pg/ml) are shown in Fig. 1C. The curve was linear
in the range from 75 to 600 pg/ml of tau protein with
regression correlation coefficient 0.9653 and LOD 140 pg/ml
(Fig. 1D). The data clearly show that Nano-iPCR has a broader
detection range and more than 30-fold higher sensitivity
than ELISA-TSA. The broad detection range of Nano-iPCR was
also demonstrated by precision profiles (Fig. 2E).
3.2. Quantification of tau protein in CSF by Nano-iPCR and
comparison with ELISA
Next the amount of tau protein in 32 human CSF samples
was examined by Nano-iPCR, ELISA-TSA and/or commercial
ELISA. First we compared two ELISAs, ELISA-TSA and a
commercial ELISA kit. Data presented in Fig. 2A show good
correlation between tau concentrations as determined by
ELISA-TSA (based on TAU-5 and HT7 antibodies) and the
commercial kit with correlation coefficient r = 0.636 and
p b 0.0001. This conclusion was corroborated by Bland–
Altman plot (Fig. 2B). Precision, reproducibility and accuracy
of ELISA-TSA was characterized by intra- and inter-assay CVs.
The average of the intra-assay CV was 8.9% (range, 1.5-12%)
for tau standards and 5.4% (range, 0–15%) for CSF samples.
The average of inter-assay CV for ELISA-TSA based on CSF
samples was 18% (range, 4–31%). Coefficient of variation
between ELISA-TSA and ELISA kit based on CSF samples was
30.6% (range, 1–65%). The higher CV values could be caused
by different standards used in the commercial ELISA kit and
ELISA-TSA and different conditions for performing the assays.
Next, we compared the performance of Nano-iPCR and
ELISA kit. Data presented in Fig. 2C show good correlation
between tau concentrations as determined by Nano-iPCR and
ELISA kit; correlation coefficient r = 0.730 and p b 0.0001.
This findingwas supported by the Bland–Altman plot (Fig. 2D).
Precision, reproducibility and accuracy of Nano-iPCR were
again characterized by intra- and inter-coefficients of variabil-
ity. The average of intra-assay CV was 2.1% (range, 1–4%)
for tau standards and 12.6% (range, 1–36%) for CSF samples.
The inter-assay CV of Nano-iPCR based on CSF was 12.2%
(range, 1.5–42%). Coefficient of variation between Nano-iPCR












































































Fig. 1. Calibration curves of recombinant tau protein as determined by Nano-iPCR and ELISA-TSA. (A, B) Tau protein was detected by Nano-iPCR at concentrations
ranging from 1 to 100,000 pg/ml (A); the curve was linear between 10 and 10,000 pg/ml (B). (C, D) Tau protein was detected by ELISA-TSA at a concentration
range 15–1200 pg/ml (C); the curve was linear between 75 and 600 pg/ml (D). (E) Precision profile for Nano-iPCR. Estimated errors (expressed as % CVs) at
various doses of recombinant tau protein were determined in each experiment from triplicates. Means ± SD were calculated from two independent experiments
performed in triplicate (A, B) or duplicate (C, D), or six independent experiments (E).
140 L. Stegurová et al. / Journal of Immunological Methods 406 (2014) 137–142between these two assays is probably caused by different
standards and different assay conditions. For recovery exper-
iments, high (4000 pg/ml), medium (800 pg/ml), and low
(100 pg/ml) concentrations of recombinant tau protein were
spiked into CSF samples. Tau levels were determined with
Nano-iPCR with recovery (89%–113%). Finally, we attempted
to determine the contribution of interfering factors present in
CSF on linearity of the assay.We diluted CSF samples 2–16-fold
and analyzed the amount of tau protein in the samples by
Nano-iPCR. The observed mean value 107% (range, 91%–136%)
indicated good linearity of the assay. These data indicate that
Nano-iPCR gives results that could be used for determination of
tau protein in clinical studies.183In conclusion, Nano-iPCR where Au-NPs functionalized
with anti-tau monoclonal antibody and template oligonucle-
otide are used for real-time PCR detection of tau protein
immobilized in wells of a PCR plate is fully suitable for
tau protein detection. The assay is superior in sensitivity
and detection range to ELISA-TSA based on the same set of
anti-tau monoclonal antibodies or to a commercial ELISA kit.
Nano-iPCR could be of importance for simplified determination
of excessively high concentrations of tau protein in patients
with Creutzfeldt–Jakob disease. The commercial availability
of monoclonal antibodies suitable for tau protein detection
by Nano-iPCR and the easy preparation of functionalized
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Fig. 2. Quantification of tau protein in CSF by various assays. (A, B) Comparison of ELISA-TSA and ELISA kit for tau protein level determination; (A) correlation plot
and (B) Bland–Altman plot. (C, D) Comparison of Nano-iPCR and ELISA kit for tau protein level determination; correlation plot (C) and Bland–Altman plot (D). In
correlation plots, the dashed line represents 95% line of identity; r means correlation coefficient; n means the number of samples analyzed. In Bland–Altman plots,
the averages of the two methods of rating are shown along the horizontal axis and their difference along the vertical axis. The solid line represents the mean
difference, and the upper and lower dotted lines represent 95% limits of agreement (±1.96 times the standard deviation of the differences).
141L. Stegurová et al. / Journal of Immunological Methods 406 (2014) 137–142least 10 times when compared to assays based on commer-
cial kits.
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Available online 10 July 2013Microtubules formed by αβ-tubulin dimers represent cellular structures that are indispensable
for the maintenance of cell morphology and for cell motility generation. Microtubules in intact
cells are in highly regulated equilibrium with cellular pools of soluble tubulin dimers. Sensitive,
reproducible and rapid assays are necessary to monitor tubulin changes in cytosolic pools after
treatment with anti-mitotic drugs, during the cell cycle or activation and differentiation events.
Here we describe new assays for α-tubulin quantification. The assays are based on sandwich
ELISA, and the signal is amplified with biotinyl-tyramide or immuno-PCR. Matching monoclonal
antibody pair recognizes phylogenetically highly conserved epitopes localized outside the
C-terminal isotype-defining region. This makes it possible to detect α-tubulin isotypes in
different cell types of various species. Biotinyl-tyramide amplification and immuno-PCR amplifica-
tion enable detection of tubulin at concentrations 2.5 ng/ml and 0.086 ng/ml, respectively.
Immuno-PCR detection shows enhanced sensitivity andwider dynamic rangewhen compared to
ELISA with biotinyl-tyramide detection. Our results on taxol-treated and activated bonemarrow-
derived mast cells demonstrate, that the assays allow sensitive quantification of tubulin in
complex biological fluids.






Microtubules are highly dynamic structures vital for
numerous cellular processes, including cellular organiza-
tion, intracellular trafficking, migration, and cell division.
Microtubules can rapidly reorganize their arrangementsast cell; BSA, bovine
tification cycle; ELISA,




1 062 632; fax: +420
ll rights reserved.
187depending on external signals. They usually consist of 13
laterally associated protofilaments made up of αβ-tubulin
dimers. In vertebrates tubulins are encoded by multiple
genes and their products, tubulin isotypes, differ mainly in
their C-terminal regions. Certain isotypes are tissue specific,
and the isotype composition affects microtubule properties
(Ludueña and Banerjee, 2008). Multiple α- and β-tubulin
isotypes can be present in the same cell, and tubulin heteroge-
neity is further enhanced by various posttranslational modifi-
cations (Linhartová et al., 1992). In intact cells a highly regulated
equilibrium exists between microtubules and the pools of
soluble tubulin dimers. Tubulin binds to tubulin-binding
agents, small molecule inhibitors, such as anti-mitotic drugs
(e.g. taxol, vinblastin, nocodazole, colchicine) that can change
the ratio between polymeric and soluble tubulin pools (Katsetos
and Dráber, 2012).
64 E. Dráberová et al. / Journal of Immunological Methods 395 (2013) 63–70Sensitive, reproducible and rapid assays are needed for
monitoring tubulin changes in cytosolic pools after treatment
with anti-mitotic drugs, during the cell cycle, and activation or
differentiation events. Several methods have been described
for quantification of total tubulin in cells or tissue extracts,
including colchicine binding (Pipeleers et al., 1977;Wilson,
1970) or radioimmunoassay (Bulinski et al., 1980; Das et
al., 1989). However, both the colchicine binding assay and
radioimmunoassay use radioactive compounds. Competitive
enzyme-linked immunosorbent assay (ELISA) was alternatively
elaborated for quantification of tubulin pools (Thrower et al.,
1991) or β-tubulin isotypes (Dozier et al., 2003); the detection
limit is around 1 μg/ml.
Mast cells play an essential role in innate immunity, allergy
and inflammation.When activated they release mediators that
are pivotal for initiation of inflammatory reactions associated
with allergic disorders (Rivera et al., 2008). In the course of
mouse bone marrow-derived mast cell (BMMC) activation,
substantial changes in reorganization of microtubules take
place (Hájková et al., 2011). However, it is not known whether
or not activation-induced changes, degranulation and/or
exosome release also lead to the release of tubulin into
extracellular space. Such process has been documented for
some other cellular components (Valadi et al., 2007).
Herewe report on the development of new sensitive assays
for tubulin quantification. The assays are based on sandwich
ELISA, and the signal is amplified with biotinyl-tyramide or
immuno-polymerase chain reaction (PCR). The key compo-
nent of the system is a matching antibody pair recognizing
phylogenetically highly conserved epitopes localized out-
side the C-terminal isotype-defining region. This makes it
possible to detect α-tubulin isotypes in different cell types
of various species. The results on taxol-treated and activated
BMMCs confirm, that the techniques offer sensitive alternative
of quantification of tubulin in complex biological fluids.
2. Material and methods
2.1. Tubulin preparation
Microtubule proteinwas purified fromporcine brain by two
temperature-dependent cycles of assembly and disassembly
(Shelanski et al., 1973), followed by subsequent purification by
phosphocellulose chromatography (Weingarten et al., 1975).
The eluted tubulin in column buffer (100 mM PIPES pH 6.9,
1 mM EGTA, 1 mM MgCl2, 1 mM DTT, 0.5 mM GTP) was
supplemented with GTP to 1 mM and polymerized by sodium
glutamate added to final concentration 1.0 M. Pelleted micro-
tubules were resuspended in BRB80 buffer (80 mM PIPES
pH 6.8, 1 mMEGTA, 1 mMMgCl2) supplementedwith 0.1 mM
GTP (BRB80-GTP) and depolymerized by cold. Tubulin con-
centration in supernatant was checked by measuring the
absorbance at 280 nm using an extinction coefficient at
280 nm of 115,000 M−1 cm−1. Recycled tubulin was more
than 98% pure as determined by SDS-PAGE, and it was stored
in liquid nitrogen in aliquots at ~200 μM concentration.
Alternatively, tubulin at concentration ~200 μM was freeze-
dried in small aliquots in the presence of trehalose and stored at
ambient temperature (Dráberová et al., 2010). Freeze-dried
tubulin was rehydrated with cold Millipore water at 4 °C to
the original aliquot volume and incubated on ice for 20 min.188Concentrated tubulin samples were diluted in precooled
BRB80-GTP to the concentration ~50 μM and centrifuged at
300,000 ×g for 5 min at 4 °C; to remove any aggregates.
Tubulin concentration in supernatants was determined by
absorbance at 280 nm.
2.2. Cells
Mouse cell line of BMMCs, which grow in the absence of
stem cell factor, was provided by M. Hibbs (Ludwig Institute
for Cancer Research, Melbourne, Australia) (Hibbs et al.,
1995). The cells were incubated in suspension cultures in
freshly prepared culture medium (RPMI 1640 supplemented
with 20 mM HEPES, pH 7.5, 100 U/ml penicillin, 100 μg/ml
streptomycin, 100 μM MEM nonessential amino acids, 1 mM
sodiumpyruvate) supplementedwith 10% fetal calf serum (FCS)
and 10% WEHI-3 cell supernatant as a source of interleukin 3.
Mouse embryonal fibroblasts NIH 3T3 were obtained from the
American Type Culture Collection. Cells were cultured in
Dulbecco's modified Eagle's medium (DMEM) containing 10%
FCS, penicillin (100 U/ml), and streptomycin (0.1 mg/ml). Cells
were grown at 37 °C in 5% CO2 in air and passaged every 2 days.
To compare tubulin concentration in extracts prepared
from control and taxol-treated cells, BMMCs in culture media
were incubated for 2.5 h in the absence or presence of taxol
at final concentration 10 μM. Cells were pelleted by centri-
fugation (240 ×g, 5 min, 25 °C), washed in ice-cold HEPES
buffer (50 mM HEPES adjusted to pH 7.6 with KOH, 75 mM
KCl, 1 mM EGTA, 1 mM MgCl2), pelleted and counted after
resuspension. Samples of 10 × 106 cells were resuspended in
1 ml of ice-cold HEPES buffer supplemented with protease
(Protease inhibitor cocktail tablets; Roche) and phosphatase
(1 mM Na3VO4 and 1 mM NaF) inhibitors and 1% NP-40.
After 10 min incubation at 4 °C, cell extracts were centri-
fuged (20,000 ×g, 15 min, 4 °C) and collected supernatants
were used for determination of tubulin concentration.
To quantify the release of tubulin from thapsigargin-
activated cells into the culture medium, BMMCs (44 × 106
cells) were resuspended in 1 ml of buffered saline solution
(BSS; 20 mMHEPES, pH 7.4, 135 mMNaCl, 5 mMKCl, 1.8 mM
CaCl2, 5.6 mM glucose, 2 mMMgCl2) supplemented with 0.1%
BSA (Sigma-Aldrich, Cat. No. A7030) (BSS-BSA) and incubated
for 20 min at 37 °C in the absence or presence of thapsigargin
(Sigma-Aldrich; Cat. No. 79033) at final concentration 2 μM.
Cells were pelleted by centrifugation (240 ×g, 5 min, 25 °C)
and the collected supernatant was further centrifuged
(200,000 ×g, 4 min, 4 °C) to remove any cellular debris.
Collected supernatants were used for determination of tubulin
concentration.
2.3. Antibodies
Purified mouse monoclonal antibody DM1A (IgG1) to
α-tubulin (Blose et al., 1984) at 1 mg/ml concentration was
bought fromAbcam(Cat. No. ab7291). The antibody recognizes
epitope located in the C-terminal region ofα-tubulin (a.a. 426–
451) of various species; amino acids within the positions 426
and 430 are particularly important for antibody reactivity
(Breitling and Little, 1986). The mouse monoclonal antibody
TU-07 (IgM) against α-tubulin of various species (Dráber
et al., 1986), recognizes the epitope exposed on the surface
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et al., 1997).
TU-07 was purified from ascitic fluid by ammonium sulfate
precipitation followed by gel chromatography on the column of
Sepharose 6B. Purity verified by SDS-PAGE exceeded 85% as
TU-07 antibody was biotinylated using EZ-Link Sulfo-NHS-LC-
biotin from Pierce according to manufacturer's recommen-
dation. Conjugated antibody was dialyzed against phos-
phate buffer solution (PBS; 10 mM phosphate, 150 mM NaCl,
pH 7.4) and stored in 50% glycerol at −20 °C (final antibody
concentration = 0.6 mg/ml). The capability of biotinylated
antibody to bind tubulin was verified by immunoblotting on
total 3T3 lysate, by staining of microtubules in fixed 3T3 cells
(Dráber et al., 1989) and by indirect ELISA on immobilized
tubulin. The antibody reacted on immunoblotswithprotein band
corresponding to tubulin, stained interphase and mitotic micro-
tubules, and bound to purified tubulin in ELISA (not shown).
Mouse monoclonal antibody TUB 2.1 (IgG1) to β-tubulin
labeled with indocarbocyanate (Cy3) was from Sigma-Aldrich.
Anti-mouse antibody conjugated with horseradish peroxidase
was purchased from Promega Biotec.
2.4. Epitope mapping
Synthetic overlapping peptides (15-meric peptides with 5
amino acid overlaps) were prepared by SPOT synthesis (Jerini
Peptide Technologies, Berlin, Germany). Each spot carried
approximately 5-nmol peptide covalently bound to cellulose-β-
alanine membrane. Peptide scans (45 peptides) covered the
sequences 1–451 of porcine (Sus scrofa) α-tubulin 1A (TUBA1A,
accession number P02550 in the UniProtKB/Swiss-Prot data-
base). Epitope mapping was performed using horseradish-
conjugated anti-mouse antibody and chemiluminescent detec-
tion of bound antibodies as described (Blume et al., 2010).
2.5. Gel electrophoresis and immunoblotting
SDS-PAGE on 12% polyacrylamide gel and immunoblotting
were performed using standard protocols (Sulimenko et al.,
2002). Protein quantifications in cell lysates were performed
with bicinchoninic acid assay (Thermo Scientific, Cat. No.
23227). DM1A and purified TU-07 were diluted 1:5000
and 1:1000, respectively. Peroxidase-conjugated second-
ary anti-mouse antibody (Promega, Cat. No. W4028) was
diluted 1:10,000. Bound antibodies were detected by Super-
Signal WestPico Chemiluminescent reagents (Pierce).
2.6. Sandwich ELISA
The assay was routinely performed in high binding
96-well half-area polystyrene plates (Corning Inc.; Cat. No.
3690). Alternatively, polycarbonate TopYield Strips (Nunc;
Cat. No. 248917) were used. Washings throughout the assay
(200 μl/well, four times per washing step, if not specified
otherwise) were carried out by means of automatic washing
device HydroFlex Platform (TECAN) with Tris buffer solution
(TBS; 10 mM Tris–Cl, pH 7.4, 150 mM NaCl) containing
0.05% Tween 20 (TBST). Anti-tubulin antibody DM1A was
coated at a concentration of 5 μg/ml in PBS (30 μl/well)
overnight (~16 h) at 4 °C. After washing, the plates were
blocked by adding 2% BSA in TBS (BSA/TBS) (185 μl/well) for1896 h at room temperature. The plates were then washed and
incubated overnight (~16 h) at 4 °C with tubulin standards
or tested samples diluted in 1% BSA in PBS (30 μl/well). The
sample diluent served as negative control. Washed plates were
then incubated for 1 h at room temperature with biotinylated
anti-tubulin antibody TU-07 at concentration 1 μg/ml in 1%
bovine serum albumin (BSA) in TBST (BSA/TBST) (30 μl/well).
Washed plates were incubated for 45 min at room tempera-
ture with extravidin-horseradish peroxidase (Sigma-Aldrich,
Cat. No. E2886) diluted 1:5000 in BSA/TBST (30 μl/well).
After repeated washing, the sensitivity of the assay was
augmented by biotinyl-tyramide signal amplification using
the ELAST ELISA Amplification System (PerkinElmer, Cat. No.
NEP116001EA) according to the manufacturer's directions.
Shortly, plates were incubated with biotinyl-tyramide, diluted
1:500 in amplification diluent (30 μl/well) for 15 min at room
temperature in dark, washed (5 times) and incubated with
streptavidin-peroxidase diluted 1:1000 in BSA/TBST (30 μl/well)
for 30 min at room temperature in dark. The plateswerewashed
(5 times) and incubated with 3,3′,5,5′-tetramethylbenzidine
(TMB) Liquid Substrate (Sigma-Aldrich, Cat. No. T8665)
(30 μl/well). Reaction was stopped after 13 min by adding
Stop Reagent for TMB Substrate (Sigma-Aldrich) (30 μl/well).
Absorptionwas determined at 450 nmon Sunrise plate Reader
(TECAN). Background values of negative controls were
subtracted from the readings.
For long-term storage, TopYield Strips were coated with
DM1A antibody and blocked with BSA; excess blocking solution
was removed before air-drying. Precoated strips were stored at
4 °C in the presence of desiccant. Wells were rehydrated by
adding BSA/TBS for 30 min at room temperature. The stripswere
then washed and incubated with samples.
2.7. Immuno-PCR
The immuno-PCR was performed as described (Niemeyer
et al., 2005; Potůčková et al., 2011) with some modifications.
Twenty-five microliter aliquots of capture anti-tubulin anti-
body DM1A (5 μg/ml) in 100 mM borate buffer (pH 9.5)
were dispensed into each well of TopYield strips. The wells
were incubated for 2 h at 37 °C and washed four times with
200 μl of TBST. Free binding sites were blocked with BSA/TBS.
After 2 h at 37 °C, the strips were washed again four times,
followed by adding 25 μl of tubulin standards or tested
samples diluted in 1% BSA in PBS. The strips were further
incubated for 1 h at 37 °C and then overnight at 4 °C, followed
by four washings. Subsequently, 25 μl aliquots of biotinylated
anti-tubulin antibody TU-07 (1 μg/ml in TBS–1% BSA) were
added and the samples were incubated for 1 h at 37 °C. After
washing four times, the wells were filled with 25 μl aliquots of
extravidin (0.1 μg/ml, Sigma-Aldrich, Cat. No. E2511) in TBS–
1% BSA, incubated for 1 h at 37 °C and then washed as before.
The next step consists in the addition of 25 μl of biotinylated
DNA template (0.27 pg/ml). The template was prepared by
amplification of a DNA fragment corresponding to nucleo-
tides 989–1209 of human tyrosine-protein kinase ABL1
(GenBank accession no. M14752) with biotinylated primer
5B-HRM1-F, 5′-biotin-AAACTCATCACCACGCTCCATTA-3′, and
HRM1-R, 5′-TCTTCCACCTCCATGGTGTC-3′ (Generi Biotech,
Czech Republic). The strips were then incubated for 1 h at
37 °C followed by washing four times with TBST and twice
Fig. 1. Epitope mapping. Immunostaining of peptide scans covering porcine
α-tubulin 1A sequence with monoclonal antibodies TU-07 and DM1A.
Peptide scans were prepared by immobilization of 45 linear 15-meric peptides
with 5 amino acid overlaps. Numbers at the left and right denote positions of
peptide spots in the upper,middle and lower rows of the scan; 1, a.a. 1–15 from
the N-terminal end.
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thewells was quantified by real-time PCR. An aliquot of 25 μl
of master mix solution was added into each well containing
75 mM Tris–HCl (pH 8.8), 20 mM (NH4)2SO4, 2.5 mM MgCl2,
200 μM dATP, 200 μM dGTP, 200 μM dCTP, 200 μM dTTP, Taq
DNA polymerase (25 U/ml; TopBio, Czech Republic), 2 μM
SYTO-9 (Invitrogen) and primers (200 nM each); forward
HRM1-F (5′-CTCATCACCACGCTCCATTA-3′) and reverse HRM1-R
(see above). Finally, each well was overlaid with 5 μl of light
mineral oil (TopBio) and sealed with Light cycler sealing foil
(Roche). The cycling conditions were as follows: 2 min at 95 °C
as an initial denaturation step and 40 cycles consisting of 15 s at
95 °C, 60 s at 60 °C, and elongation step for 60 s at 72 °C using
Realplex4 Mastercycler (Eppendorf, Hamburg, Germany). The
Cq (quantification cycle) values were determined using the
software of the cycler.
2.8. Degranulation assay
The degree of degranulation was quantified as the release
ofβ-glucuronidase from control or thapsigargin-activated cells,
using 4-methylumbelliferyl β-D-glucuronide as a substrate
(Surviladze et al., 2001). The total content of the enzymewas
evaluated in supernatants from cells lysed by 0.1% Triton
X-100.
2.9. Microscopy and FACS
Immunofluorescence microscopy was performed on fixed
cells as described (Dráberová and Dráber, 1993). Shortly, cells
were rinsed with microtubule-stabilizing buffer (0.1 M MES,
pH 6.9, 2 mMEGTA, 2 mMMgCl2, 4% polyethylene glycol 6000),
fixed for 20 min in 3% formaldehyde in microtubule-stabilizing
buffer and extracted for 4 min with 0.5% Triton X-100 in
microtubule-stabilizing buffer. TUB 2.1 mAb conjugated with
Cy3 was diluted 1:600. The preparations were examined with
Olympus A70 Provis microscope.
Data obtained with Accuri cytometer (BD Accuri Cytometers
Inc.) were employed to compare the total numbers and the
viability of cells before and after activation with thapsigargin.
2.10. Data analysis
Calibration curves were constructed after plotting the
absorbance or Cq values against tubulin concentrations and
using a four-parameter logistic regression model function
(variable slope) within GrafPad Prism 5 (GraphPad Software).
The limit of detection (LOD) was calculated as the mean of the
sample diluent plus 3 standard deviations of the sample diluent.




Sandwich ELISA requires a matched pair of antibodies
recognizing non-overlapping native epitopes on the same
target. Previously we have shown that some monoclonal
antibodies to C-terminal domain of α-tubulin, including the
TU-07 antibody, recognize epitopes exposed on the surface of190tubulin molecule (Dráber et al., 1989). Peptide scan of
immobilized overlapping peptides covering porcine α-tubulin
(a.a. 1–451; 45 linear 15-meric peptides with 5 amino acid
overlaps) was used for a more accurate epitope location of
TU-07. Results of immunostaining with antibody TU-07 and
with another anti-α-tubulin antibody, DM1A, are shown in
Fig. 1. Epitope mapping revealed the localization of TU-07
epitope to the a.a. region 406–410 (sequence HWYVG). The
epitope recognized by DM1A antibody was located to the a.a.
region 426–430 (sequence AALEK); this is in accordance with
previous data inferred from reactivity of the antibody with
tryptic and cyanogen bromide peptides of pig brain α-tubulin
(Breitling and Little, 1986). Antibodies TU-07 and DM1A thus
recognize non-overlapping epitopes on α-tubulin molecule.
Immunoblotting analysis revealed that the two antibodies are
capable of reacting with full length tubulin isolated from
porcine brain as well as with full length tubulins in cells as
demonstrated on1%NP-40 lysates frommouse BMMCs (Fig. 2).
Moreover, the antibodies react with α-tubulins of various
species (human, rat, chicken, plant Nicotiana tabacum) and do
not bind to β- or γ-tubulins (not shown).
3.2. ELISA with biotinyl-tyramide signal amplification
To set up sandwich ELISA for quantification of α-tubulin,
we used 96-well half-area plates (Corning) or TopYield Strips
(Nunc). Antibodies, tested samples and reagents amounted to a
volume of 30 μl/well. DM1A antibody was used as the capture
antibody and biotinylated TU-07 antibody was applied for
detection of bound tubulin. Immobilized biotinylated anti-
body was detected by extravidin-horseradish peroxidase
and the enzyme signal was augmented by biotinyl-tyramide
amplification. TMB was used as chromogen. Reaction was
stopped, and absorption determined at 450 nm. Highly purified
polymerization-competent porcine brain tubulin stored either in
liquid nitrogen or at room temperature after freeze-drying in the
presence of trehalose (Dráberová et al., 2010) was used to
generate calibration curves. Concentrated tubulin samples were
prediluted to ~50 μM, and any aggregates originating from the
thawing and/or rehydrating process were removed by centri-
fugation. Actual concentration of tubulin in supernatant was
checked spectrophotometrically and tubulin was then diluted
to the required concentration. A typical calibration curve
obtained by sandwich ELISA with biotinyl-tyramide amplifica-
tion is shown in Fig. 3. Absorbance at 450 nmwasmeasured at
different tubulin concentrations ranging from 0.5 to 250 ng/ml
(Fig. 3A), the curve was linear in the range of 5 to 100 ng/ml
(Fig. 3B). The LODwas found to be 2.5 ng/ml. Nodifferencewas
Fig. 2. Immunoblot analysis of BMMC cell extracts with monoclonal
antibodies DM1A and TU-07. Porcine brain tubulin (lane 1) or 1% NP40 cell
lysate from BMMCs (lane 2) was separated on 12% SDS-PAGE. Aliquots of
tubulin (20 ng) were loaded in lane 1 and 4 μg of protein in lane 2. Bars on
the left margin denote position of molecular weight markers in kilodaltons.
Tb denotes position of tubulin.
Fig. 3. Detection of tubulin at various concentrations by ELISA with biotinyl-
tyramide amplification. (A) Tubulin concentration range from 0.5 to 250 ng/ml.
(B) Tubulin concentration range from 5 to 100 ng/ml; R denotes correlation
coefficient. Data represent mean ± SD (n = 2).
67E. Dráberová et al. / Journal of Immunological Methods 395 (2013) 63–70observed when tubulin was stored in liquid nitrogen or in
freeze-dried form. Very similar results were obtained when
rehydrated strips, precoatedwith capture antibody and blocking
BSA, were used after 6 months of storage at 4 °C. Usage of
precoated strips can significantly save time of the assay.
3.3. Quantification of tubulin by immuno-PCR
The assay was carried out on polycarbonate TopYield strips
fitting into the wells of the 96-well real-time PCR cyclers.
Biotinylated TU-07 antibody was detected after incubation with
extravidin followed by incubation with biotinylated DNA
template. Template DNA immobilized on tubulin was quantified
by real-time PCR. Compared to the widely used polypropylene
PCR wells, wells of TopYield strips have a large diameter and
possess a higher protein binding capacity. To prevent evapora-
tion of PCR mixes from the wells during PCR cycling, it is
essential to cover the surface of each well with light mineral oil
before they are sealed (Potůčková et al., 2011). Detection of
tubulin by sandwich ELISA with PCR amplification is shown in
Fig. 4. Standard curves were produced with different concentra-
tions of tubulin in the range of 0.01 to 1000 ng/ml (Fig. 4A), and
the curve was linear from 0.1 to 1000 ng/ml of isolated tubulin
(Fig. 4B). The LOD was found to be 0.086 ng/ml. Compared to
biotinyl-tyramide signal amplification assay, the immuno-PCR
amplification is characterized by broader range of detectable
tubulin concentrations and higher sensitivity.
3.4. Tubulin detection in cell lysates and culture media
To prove the capability of the sandwich ELISA for monitor-
ing the amount of tubulin, its concentrations were determined
in BMMC extracts prepared from untreated and taxol-treated
cells. Taxol treatmentmakesmore tubulin in cell to polymerize191intomicrotubules that remain stable at 4 °C (Schiff and Horwitz,
1980). In taxol-treated BMMCs typical microtubule bundles are
formed and can be detected by immunofluorescencemicroscopy
(Fig. 5). BMMCs were solubilized in 1% NP-40 at 4 °C, and
supernatants were analyzed after spinning-down the cell debris.
Tubulin concentration in control cells, determined by sandwich
ELISA with biotinyl-tyramide signal amplification, was 2331 ±
74.6 ng/ml (mean ± SEM, n = 3). However, preincubation of
the cells for 2.5 h with 10 μM taxol reduced free tubulin
concentrations to 478 ± 14.1 ng/ml (mean ± SEM, n = 3).
These data document that exposure of cells to taxol leads to a
substantial depletion of soluble tubulin (Fig. 6A).
Substantial changes in cell morphology and reorgani-
zation of microtubules occur during activation of BMMCs
with thapsigargin (Hájková et al., 2011). Furthermore, the cells
release granules containing various mediators (Dráberová
et al., 2007). To find outwhether thapsigargin-induced changes
are accompanied by the release of tubulin into culturemedium,
tubulin concentrations were determined by immuno-PCR in
media from resting and activated cells. While the tubulin
concentration in resting cells medium was 5.3 ± 1.2 ng/ml
(mean ± SEM, n = 3), it increased to 18.7 ± 5.5 ng/ml
(mean ± SEM, n = 3) after thapsigargin-activation (Fig. 6B).
To rule out that the increase is due to changes in cell
viability, FACS measurements were performed in control
and thapsigargin-activated BMMCs. The results revealed
Fig. 4. Detection of various tubulin concentrations by immuno-PCR. (A) Tubulin
concentration range from 0.01 to 1000 ng/ml. (B) Tubulin concentration range
from 0.1 to 1000 ng/ml; R denotes correlation coefficient. Data represent
mean ± SD (n = 2).
Fig. 5. Bundling of microtubules in BMMCs pretreated with anti-mitotic drug
taxol. Immunofluorescence staining of control (A,−Taxol) and taxol-treated
cells (B, +Taxol) with anti-tubulin antibody. Bar, 10 μm.
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samples (not shown). Activation of cells was confirmed by
degranulation assay checking the level of β-glucuronidase.
In control cells β-glucuronidase reached 1 ± 0.4% (mean ±
SEM, n = 3) of total content of the enzyme, whereas in
thapsigargin-activated cells it reached 58.4 ± 3.8% (mean ±
SD, n = 3) of total enzyme content. The data thus confirm that
activation of BMMCs is accompanied by release of cytosolic
tubulin into medium.
4. Discussion
We have developed a new sensitive sandwich ELISA with
biotinyl-tyramide or PCR signal amplification for quantification
of α-tubulin isotypes in various cell types of different species.
While biotinyl-tyramide amplification enhances the signal from
an analyte-dependent reporter enzyme (horseradish peroxi-
dase) (Bobrow et al., 1989), the PCR signal amplification uses
analyte-dependent biotinylated DNA template for quantification
by real-time PCR (Adler et al., 2003; Potůčková et al., 2011).
The components of critical importance in immunoassays
are antibodies, since they can differ in their specificity, affinity
to target antigen as well as non-specific binding to solid phase
(Niemeyer et al., 2007). In search for biotinylated antibodies
suitable for sandwich ELISA to quantify α-tubulin, we tested192several commercially available conjugated antibodies as
well as our own monoclonal antibodies of the TU-series
(Dráber et al., 1989). Biotinylated mouse monoclonal antibody
TU-07 showed the lowest nonspecific binding to “blocked”
solid phase, and was therefore combined with mouse
monoclonal antibody DM1A to form a matching antibody
pair.
Compared to commercial PathScan Total α-Tubulin
Sandwich ELISA kit (Cell Signaling), reported assays are
more sensitive. Using the commercial kit, we were able to
detect purified tubulin at the lowest concentration limit of
100 ng/ml (Dráberová, unpublished result), while the range
of detectability was 5 to 100 ng/ml and 0.1 to 1000 ng/ml,
respectively, for ELISA with biotinyl-tyramide signal ampli-
fication (Fig. 3B) and immuno-PCR (Fig. 4B). Immuno-PCR
shows a N4 log dynamic range and femtomolar detection
limit for tubulin dimer. The immuno-PCR thus enables to
assess tubulin concentration in lysates prepared from cells,
which are available only in limited amounts, e.g. cells in
primary culture. Specifically in case of BMMCs, 200 cells are
sufficient for determination of tubulin concentration (30 μl
sample in triplicate). Performing the assays in half-area
polystyrene plates or polycarbonate strips saves precious
samples and reagents that are applied at volumes of only
25–30 μl. When precoated strips are used the whole assay
can be performed during a single day.
Antibodies specific for α-tubulin, DM1A and TU-07, recog-
nize amino acid sequences AALEK and HWYVG, respectively,
that are evolutionarily highly conserved and are preserved
from human to plants. The epitopes are located outside the
C-terminal isotype-defining regions, beyond a.a. residue 430
(Khodiyar et al., 2007), and are identical in a great majority of
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TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBA8;
nomenclature according to HGNC [HUGO Gene Nomenclature
Committee]), mouse (Mus musculus genes Tuba1a, Tuba1b,
Tuba1c, Tuba3a, Tuba3b, Tuba4a, Tuba8; nomenclature
according to MGNC [Mouse Genomic Nomenclature Com-
mittee]) or mouse-ear cress (Arabidopsis thaliana genes
TUA1, TUA2, TUA3, TUA4, TUA5, TUA6; nomenclature according
to The Arabidopsis Information Resource [TAIR]). The matching
antibody pair thus enables quantification of α-tubulin isotypes
in phylogenetically distant species. Moreover, porcine brain
tubulin, on which epitope mapping for antibodies DM1A and
TU-07 was performed, can be utilized for the preparation of
calibration curves, and controls using tubulins isolated from the
same species are therefore unnecessary. Although the epitopes
are located in the C-terminal region of tubulin molecule, that
might potentially be cleaved off. Immunoblotting analysis
revealed that antibodies recognize full-length tubulins and
proteolytic fragments of tubulin were not generated during
sample preparation (Fig. 2).
Epitopes recognized by DM1A and TU-07 antibodies are
located outside the very C-terminal regions of α-tubulin
molecules where multiple posttranslational modifications
including polyglycylation and polyglutamylation were iden-
tified (Janke and Bulinski, 2011). Thus, binding of antibodies
to target epitopes should not be affected by posttranslationalFig. 6. Determination of tubulin concentration changes. (A) Concentration of
cytosolic tubulin in untreated (−Taxol) or taxol-treated (+Taxol) BMMCs
determined by ELISA with biotinyl-tyramide amplification. Bundling of
microtubules by taxol leads to depletion of cytosolic tubulin. (B) Concentration of
tubulin in BMMC culture media from untreated (−TG) or thapsigargin-treated
(+TG) cells determined by immuno-PCR. Activation of BMMCswith thapsigargin
leads to release of tubulin into media. Data are presented as the means ± SEM
obtained from three independent experiments with duplicate samples.
**p b 0.01; ***p b 0.001.
193modifications. On the other hand one cannot rule out that
epitopes might in cells be masked by microtubule-associated
proteins or by formation of tubulin oligomers (Mozziconacci
et al., 2008). For these reasons, the assays described in this
study are primarily intended for relative profiling of tubulin
concentrations in lysates from different cell types and for
monitoring tubulin changes after pretreatment of the cells
with agents affecting equilibrium between polymeric and
soluble tubulin pools. This is evident e.g. in the case of taxol
that generates microtubule bundles (Fig. 5B) and depletes
cytosolic tubulin from BMMCs (Fig. 6A). On the other hand,
pretreatment of BMMCs with nocodazole at a concentration
that depolymerizes microtubules (10 μM for 1 h) resulted in an
increase of tubulin concentration in cytosolic pool (Dráberová,
unpublished results).
Activation of mouse BMMCs, leading to the release of
various mediators into extracellular space, is accompanied by
dramatic changes in cell morphology and reorganization of
microtubules (Dráber et al., 2012). Our data indicate, for the
first time, that a small amount of tubulin during this process is
also released into the culture medium (Fig. 6B). An association
of tubulin with plasma membrane and detergent-resistant
membranes was reported in various systems (Wolff, 2009;
Macurek et al., 2008), and membrane-bound tubulin might be
released into extracellular space during degranulation. Alterna-
tively, tubulin could originate fromdamaged exosomes, secreted
microvesicles, where tubulin subunits were also identified
(Valadi et al., 2007).
It has been reported that patients with progressive multiple
sclerosis, unlike healthy people, have increased tubulin concen-
tration in cerebrospinal fluid (Semra et al., 2002; Madeddu et al.,
2013). It has also been shown that evaluation of βIII-tubulin
isotype levels in sera frompatientswith advanced gastric cancer,
receiving paclitaxel treatment, is relevant prognostically for
evaluation of clinical outcome (Yu et al., 2012). Due to high
sensitivity of new sandwich ELISA-based assays we described
here, changes in tubulin levels might be easier to detect in
human body fluids.
In conclusion, sandwich ELISA assays for detection of
α-tubulin isotypes make it possible to profile tubulin concen-
tration in lysates of various cell types of different species, as
well as monitor changes in tubulin concentration after treat-
ment of cells with microtubule stabilizing or destabilizing
agents. Immuno-PCR detection shows enhanced sensitivity
and wider dynamic range than ELISA with biotinyl-tyramide
detection. Detection of tubulin concentration at subnanogram
levels might advance application of the new immunoassay for
monitoring changes in tubulin concentration in body fluids
during neurological or oncological diseases.
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Available online 24 June 2011Reliable and simple methods are required for detection of low concentrations of cytokines and
some other proteins in complex biological fluids. This is especially important when monitoring
the immune responses under various physiological and pathophysiological conditions in vivo
or following production of these compounds in in vitro systems. Cytokines and other
immunologically active molecules are being predominantly detected by enzyme-linked
immunosorbent assays (ELISA) and newly also by immuno-polymerase chain reactions
(iPCR). New simplified variants of iPCR have recently been described where antibodies are
connected with multiple DNA templates through gold nanoparticles (Au-NPs) to form a new
class of detection reagents. In this study we compared functionalized Au-NP-based iPCR (Nano-
iPCR) with standard ELISA and iPCR for the detection of interleukin (IL)-3 and stem cell factor
(SCF). The same immunoreagents (IL-3- and SCF-specific polyclonal antibodies and their
biotinylated forms) were used throughout the assays. The obtained data indicate that both
Nano-iPCR and iPCR are superior in sensitivity and detection range than ELISA. Furthermore,
Nano-iPCR is easier to perform than the other two methods. Nano-iPCR was used for
monitoring changes in concentration of free SCF during growth of mast cells in SCF-conditioned
media. The results show that growing cultures gradually reduce the amount of SCF in
supernatant to 25% after 5 days. The combined data indicate that Nano-iPCR assays may be
preferable for rapid detection of low concentrations of cytokines in complex biological fluids.
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196important mediators of the immune system. Abnormal
activities of several cytokines, including interleukin (IL)-3,
have been reported in schizophrenia (Chen and Kendler,
2008), and elevated levels of stem cell factor (SCF) have been
detected in asthmatic patients (Lei et al., 2008). Sensitive,
simple and robust methods are required for diagnostic
purposes to determine low concentrations of cytokines in
complex biological fluids. They are needed for monitoring
immune responses in vivo as well as for rapid analysis of the
quality of conditioned media used in culturing cytokine-
dependent cells. Growth of mouse bone marrow-derived
mast cells (BMMCs) in vitro, is promoted by two cytokines,
IL-3 and SCF (Tsuji et al., 1991). Concentrations of these and
other cytokines are being determined by several methods,
such as bioassays employing cytokine-dependent freshly
isolated cells or cell lines (Chen et al., 1993). Although very
useful, these assays are time consuming and inaccurate.
39L. Potůčková et al. / Journal of Immunological Methods 371 (2011) 38–47Widespread methods used for detection of cytokines are
enzyme-linked immunosorbent assays (ELISA) utilizing anti-
bodies specific for the target proteins (Silman and Katchalski,
1966; Engvall and Perlmann, 1971). However, the sensitivity
of these assays is not always sufficient. It has been shown that
the amount of cytokine produced by cells correlates with the
expression of cytokine-specific mRNA; reverse-transcription
(RT) polymerase chain reactions (PCR) have therefore also been
widely used. Although RT-PCRs are fast, sensitive and simple
methods to detect the expression levels of cytokine genes, the
results do not always agree with those of bioassays and ELISA,
and do not allow exact determination of cytokine concentra-
tions. Other assays have therefore been explored. In 1992 a new
technique was described, combining molecular specificity of
antibodies with the amplification power and sensitivity of PCR
(Sanoet al., 1992). In this technique, called immuno-PCR (iPCR),
theantibodyused for detection of target compound is combined
with the DNA which serves as a template in PCR. Different
strategies have been applied for linking antibodies with DNA
templates, like streptavidin bridge combined with biotinylated
antibody and biotinylated DNA template, or chemically conju-
gated antibody-DNA complexes (Lind and Kubista, 2005;
Niemeyer et al., 2007). The amount of DNA amplified during
PCR corresponds to the amount of target structure recognized
by the antibody, and can be detected by electrophoresis (Zhou
et al., 1993) or by ELISA, utilizing digoxigenin- or biotin-labeled
PCR products (Niemeyer et al., 1997; Smrž and Dráber, 2003).
Later, immunodetection was combined with real-time PCR and
used for quantification of vascular endothelial grow factor
(Sims et al., 2000). The method was further modified in
such a way that both protein detection and real-time PCR
were performed in the same well of the TopYield strip
(Niemeyer et al., 2007). Furthermore, a gold nanoparticle
(Au-NP)-based bio-bar code assay for ultrasensitive detec-
tion of proteins has been developed. The assay utilizes Au-
NPs functionalized with both thiolated single-strand DNA
oligonucleotide and an antibody to the target antigen
(Nam et al., 2003, 2004; Georganopoulou et al., 2005).
Finally, PCR assays based on antibody- and oligonucleotide-
functionalized Au-NPs were used for detection of Hantaan
virus nucleocapsid protein (Chen et al., 2009) and respira-
tory syncytial viruses (Perez et al., 2011). Although the
assays showed high sensitivity for virus detection, they
required two sets of wells (for immunodetection and PCR)
and therefore were not suitable for high throughput
screening andwere fraught with high risk of contamination.
Here we tested the suitability of functionalized Au-NPs-
based iPCR (Nano-iPCR) for detection of low concentrations
of cytokines in cell culture supernatants, and changes in
cytokine concentration in aging cultures of BMMCs. We
defined the conditions for simplified detection of cytokines
by Nano-iPCR, and compared the performance of assays
based on antibodies anchored either directly on the plastic
surface or through extravidin. The assays were carried out
in PCR polypropylene wells or wells of TopYield polycar-
bonate strips which allow more efficient binding of
antibodies. We further compared Nano-iPCR with iPCR
and ELISA; outline of the assays is shown in Fig. 1. For these
comparisons we utilized identical immunoreagents in all
assays. The data indicate that Nano-iPCR offers a sensitive,
rapid and robust assay for detection of low concentrations197of cytokines in complex biological fluids. Advantages and
drawbacks of different assays are discussed.2. Materials and methods
2.1. Materials
Rabbit anti-murine IL-3 and rabbit anti-murine SCF poly-
clonal antibodies and their biotinylated forms, recombinant (r)
murine IL-3 and rSCF were all obtained from PeproTech
(London, UK). Colloidal Au-NPs (30 nm), containing approxi-
mately 2×1011 Au-NPs/ml, were obtained from BBInterna-
tional (Cardiff, UK). Au-NPs (5 nm) conjugated with goat anti-
rabbit IgG were bought from Jackson ImmunoResearch Lab.,
Inc. (West Grove, PA, USA). 5′thiol-modified oligonucleotide
primer (Pri)1 [5′-(5ThioMC6-D//iSp18)CCTTGAACCTGTGCCAT
TTGAATATATTAAGACTATACGCGGGAACA-3′] where iSp18 is
an 18-atom hexa-ethyleneglycol spacer connecting the thiol
reactive group and the DNA sequence, Pri2 (5′-CCTTGAACCTGT
GCCATTTG-3′) and Pri3 (5′-GTCCCTCCATCTTCCTACTGTTCCA-
CATGTTCCCGCGTATAGTCTT-3′) were obtained from IDT, (Cor-
alville, IA,USA). Biotinylated forwardprimer5B-HRM1-F (5′-CT
CATCACCACGCTCCATTA-3′) and its non-biotinylated form
(HRM1-F) and reverse primer HRM1-R (5′-TCTTCCACCTCCAT
GGTGTC-3′) were obtained from Generi Biotech (Hradec
Králove, Czech Republic). SYTO-9 and geneticin (G418) were
obtained from Invitrogen (Eugene, OR, USA). Glutaraldehyde
was bought from Fluka, Chemie GmbH (Buchs, Switzerland).
All other chemicals were from Sigma-Aldrich (St. Louis, MO,
USA).2.2. Cells
BMMCs were isolated from C57BL/6 mice according to the
previously reported protocol (Volná et al., 2004). All mice
were maintained and used in accordance with the Institute of
Molecular Genetics guidelines. The cells were seeded in
complete culture medium RPMI-1640 containing 10% heat
inactivated (56 °C, 30 min) fetal bovine serum (FBS), 50 μM
2-mercaptoethanol, antibiotics (100 U/ml penicillin and
100 μg/ml streptomycin) and further supplemented with
fresh rSCF (15 ng/ml) and 10% culture supernatant of confluent
D11 cells as a source of IL-3 (Cao et al., 2007). BMMCs were
culturedat37 °C inanatmosphereof 5%CO2 inair.D11cellswere
grown adherent in tissue culture flasks in Dulbecco's modified
Eaglemedium(DMEM) supplementedwith 10%heat inactivated
FBS, antibiotics and 0.3 mg/ml of geneticin. The cells were
detached from the flasks by incubation for 5–10 min at room
temperature with 0.05% trypsin in phosphate buffered saline
(PBS; 10 mM phosphate, pH 7.4, 150 mM NaCl) supplemented
with 0.02% EDTA. After centrifugation at 280 ×g for 5 min, cells
were resuspended inDMEM-10%FCSwithgeneticin. After 3 days
of culturing, the medium was aspirated and fresh DMEM
medium without geneticin was added. Cells were cultured for
additional week. Supernatant containing IL-3was then collected,
centrifuged at 5500 ×g for 15 min, filtered through a 0.22 μm
membrane and stored in aliquotes at−20 °C. For determination
of SCF, supernatant from cultured BMMCswas collected daily for
5 days.
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Functionalized Au-NPs were prepared as previously de-
scribed (Hill and Mirkin, 2006) with some modifications. One
milliliter of 30 nmAu-NPs solution was incubated for 30 min at
room temperaturewith 4 μg of polyclonal antibody (anti-IL-3 or
anti-SCF) under gentle shaking. Tenmicroliters of 10%Tween20
was then added, followed after 5 min by 50 μl of 2 M NaCl in
10 mM PBS (Hurst et al., 2008). The particles were then
modified with 5′-thiolated oligonucleotide (final concentration
4 nmol/ml) under gentle shaking at 4 °C. After overnight
incubation the samples were further salted by adding 50 μl
aliquotes of 2 MNaCl in 10 mMPBS in 4 subsequent steps, each
for 1 h. FunctionalizedAu-NPswere stabilized by adding20 μl of
10% bovine serum albumin (BSA), followed by gentle shaking
for 30 min at room temperature. Unbound oligonucleotides
were removed by three times centrifugation (9.300 ×g for
10 min) through a discontinuous glycerol gradient in 2 ml
Eppendorf tubes. The gradient consisted of 800 μl PBS contain-
ing 30% glycerol (w/v) and 1% BSA (w/v), overlaid with 1 ml of
functionalized Au-NPs. The pellet was finally resuspended in
1 ml of PBS containing1%BSA, 0.05%Tween20, 20%glycerol and
0.02% NaN3. In some experiments Au-NPs were functionalized
with BSA instead of antibody. Absorption spectrawere recorded
with a UV-1601 spectrophotometer (Shimadzu Corporation,
Kyoto, Japan) equipped with software package UVProbe
(Shimadzu) and quartz cells (200 μl) with 10 mm path length.
2.4. Electron microscopy
Nickel electron microscopy grids coated with pioloform
were glow discharged and coated with poly-L-lysine. Au-NPs
functionalized with antibodies or with BSA were allowed to
settle on the coated grids. After 10 min, the grids were washed
in PBS and free protein-binding sites were blocked for 15 min
with 0.1% BSA in PBS. Grids with bound Au-NPs were then
incubated with the secondary antibody (goat anti-rabbit IgG,
conjugated with 5 nm Au-NPs), diluted 1:10 in PBS-0.1% BSA.
After 30 min the grids were washed three times for 5 min each
with PBS. The gridswerefixed in 2.5% glutaraldehyde in PBS for
10 min. Finally, samples were washed twice with MilliQ water
(Millipore, Billerica, MA, USA) for 1 min, air-dried and
examined with a JEOL JEM-1200EX transmission electron
microscope (JEOL, Tokyo, Japan) operating at 60 kV.
2.5. Nano-iPCR
For detection of cytokines by Nano-iPCR, two methods
were used differing in the mode of anchoring the antibodies
to plastic surface. In Nano-iPCR I biotinylated antibody wasFig. 1. Schematic illustration of the immunoassays used in this study. In Nano-iPCR I
with extravidin (ExAv) to which biotinylated antigen-specific antibody (Ab-Bt) wa
added and bound to the immobilized antibody. The antibody anchored antigen was
oligonucleotide which served as a template in subsequent real-time PCR with a set
using DNA binding dye SYTO-9. In Nano-iPCR II method, the antibody (Ab) was b
binding sites with BSA; all other steps were the same as in Nano-iPCR I. In iPCR and
well, followed by BSA block. Antigen was then added and detected by biotinylate
biotinylated antibody and biotinylated DNA template (DNA-Bt) added during the n
template-specific primers), and the amplicons were detected by means of SYTO-9
streptavidin-HRP conjugate (S-HRP). The enzymatic activity was detected using a co
quantified by spectrophotometery.
198attached to immobilized extravidin, whereas in Nano-iPCR II
the antibody was directly bound to the plate.
2.5.1. Nano-iPCR I
One hundred microliter aliquotes of extravidin (1–2 μg/ml
in 100 mM borate buffer, pH 9.5) were added into each well of
real-time 96-well plate or real-time tube strip (Eppendorf,
Hamburg, Germany) and incubated for 1 h at 37 °C. After
adsorption of the protein, the wells were washed with PBS
containing 0.05% Tween 20 (TPBS) and the remaining binding
sites were blocked by 2 h incubation at 37 °C with TPBS
supplementedwith 2% BSA. The wells were then washed three
times with 200 μl of TPBS, followed by addition of 100 μl
biotinylated anti-SCF or anti-IL-3 antibody (1 μg/ml in TPBS-1%
BSA). After incubation for 1 h at 37 °C, unbound antibody was
rinsed out and 100 μl sample aliquotes were probed for the
presence of SCF or IL-3. The samples were incubated overnight
at 4 °C, and after washing four times with TPBS, 100 μl of
Au-NPs armedwith thiolatedDNAoligonucleotide andanti-SCF
or anti-IL-3 (diluted 1/10,000 in TPBS-1% BSA) were applied
into each well. The wells were incubated for 1 h at 37 °C,
washed 4 times with 200 μl TPBS followed by double washing
with MilliQ water. Next, aliquotes of 25 μl of master mix
solution containing 75 mM Tris–HCl (pH 8.8), 20 mM
(NH4)2SO4, 2.5 mM MgCl2, 200 μM dATP, 200 μM dGTP,
200 μM dCTP, 200 μM dTTP, Taq DNA polymerase (25 U/ml),
2 μM SYTO-9 and 60 nM oligonucleotide primers Pri2 and Pri3
were dispensed into each well. Plates were sealed with Light
cycler 480 sealing foil (Roche, Mannheim, Germany) and PCR
strips with Masterclear cap strips (Eppendorf). The amount of
template DNA bound to antigen-anchored functionalized
Au-NPs was evaluated by real-time PCR using Realplex4
Mastercycler (Eppendorf, Hamburg, Germany) with the
following cycling conditions: 1 min at 94 °C, followed by 40
cycles of 20 s at 94 °C, 20 s at 53 °C and20 s at 72 °C. The control
without template DNA was used for PCR mix in every run to
check for contamination.
2.5.2. Nano-iPCR II
Twenty-fivemicroliter aliquotes of capture antibody (5 μg/ml
anti-IL-3 or anti-SCF; Peprotech) in 100 mM borate buffer (pH
9.5) were distributed into each well of TopYield strips (NUNC,
Roskilde, Denmark). After 1 h incubation at 37 °C and overnight
incubationat 4 °Ceachwellwaswashed four timeswith200 μl of
TPBS, and free binding sites were blocked with TPBS-2% BSA for
2 h at 37 °C. Each well was washed four times with TPBS,
followed by addition of 25 μl of the tested sample containing IL-3
or SCF and incubation for 1 h at 37 °C. Other stepswere the same
as in Nano-iPCR I. Cycling conditions were as follows: 2 min at
95 °C, 40 cycles of 15 s at 95 °C, 60 s at 60 °C and 60 s at 72 °C.method, wells of real-time 96-well plate or real-time tube strips were coated
s anchored. BSA was used to block free binding sites. Antigen (Ag) was then
detected by Au-NPs functionalized by antigen-specific antibody and thiolated
of template-specific primers. DNA amplicons were detected by fluorometry
ound directly to the TopYield strip wells followed by blocking free protein-
ELISA, the Ag-specific antibody was adsorbed directly onto the surface of the
d antibody. In iPCR, extravidin was supplied to form a bridge between the
ext step. Template DNA was then amplified by real-time PCR (using a set of
DNA dye. In ELISA, biotinylated antibody immobilized on Ag reacted with
lorimetric reaction with OPD as a substrate. The colored end-product (P) was
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The method was performed as previously described
(Niemeyer et al., 2007) with some modifications. Biotinylated
DNA template (221 bps) was obtained by PCR using biotiny-
lated forward primer 5B-HRM1-F (200 nM), reverse primer
HRM1-R (800 nM) and amplified template DNA (0.1 ng;
GenBank accession no. M14752). The following cycling condi-
tionswere used: 2 min at 95 °C, followed by 30 cycles of 15 s at
95 °C, 30 s at 58 °C and 20 s at 72 °C. Each well of the TopYield
strip contained 25 μl polyclonal antibody specific for IL-3 or SCF
(5 μg/ml, in 100 mM borate buffer pH 9.5). The wells were
incubated for 1 h at 37 °C and overnight at 4 °C, followed by
washing four timeswith 200 μl of TPBS. Free binding sites were
blocked by incubation with TPBS-2% BSA. After 2 h at 37 °C, the
wells were again washed four times and overlaid with 25 μl of
tested samples containing various concentrations of IL-3 or SCF.
Thewellswere further incubated for 1 h 37 °C and thenwashed
4 timeswith TPBS. Subsequently, 25 μl aliquotes of biotinylated
antibody specific for IL-3 or SCF (1 μg/ml in TPBS-1% BSA)were
dispensed and the samples were incubated for 1 h at 37 °C.
After washing four times, the wells were covered with 25 μl of
extravidin (0.1 μg/ml) in TPBS-1% BSA, incubated for 1 h at
37 °C and washed as before. After this step, biotinylated DNA
template (25 μl; 0.27 pg/ml) was added and the strips were
incubated for 1 h at 37 °C. Next, the wells were washed four
times with TPBS and twice with MilliQ water. The amount of
biotinylatedDNA template immobilized in individualwellswas
quantified by real-time PCR using master mix supplemented
with HRM1-F and HRM1-R primer set (200 nM each). The
following cycling conditions were used: 2 min at 95 °C as an
initial denaturation step and 40 cycles consisting of 15 s at
95 °C, 60 s at 60 °C and elongation for 60 s at 72 °C.
2.7. ELISA
ELISA was performed as previously described (Engvall and
Perlmann, 1971) with some modifications. Wells of the
TopYield strips were coated with Ag-specific polyclonal
antibody, blocked with TPBS-2% BSA and then mixed with
antigen as described above for iPCR. The wells were then
washed three times with TPBS, followed by addition of 100 μl
biotinylated antibody (1 μg/ml, in TPBS-1% BSA), incubation for
1 h at 37 °C and washing three times with TPBS. One hundred
microliters of streptavidin-horseradish peroxidase (HRP) con-
jugate (0.1 μg/ml) was then added. After incubation for 1 h at
37 °C the wells were washed three times with TPBS. Finally,
100 μl PBS containing o-phenylenediamine (OPD; 0.5 mg/ml)
and H2O2 (0.015%) was dispensed into each well. After 10 min
at 37 °C, the reaction was stopped by adding 100 μl of H2SO4
(4 M). The absorbancewasdetermined at492 nmusing Infinite
M200 plate reader (TECAN, Männedorf, Switzerland).
2.8. Data analysis
For calibration curves, absorbance or quantification cycle
(Cq) valueswereplottedagainst SCFor IL-3 concentrationsusing
a four-parameter logistic regression model function (variable
slope) within GrafPad Prism 5 (GraphPad Software, La Jolla, CA,
USA). For calculation of IL-3 or SCF concentrations in the tested
samples, the same mathematical model was used, using200MasterPlex ReaderFit software (Hitachi Solutions America, Ltd,
MiraiBio Group, South San Francisco, CA, USA).
3. Results
3.1. Characterization of functionalized Au-NPs
Au-NPs functionalized with thiolated oligonucleotides and
antibodies were initially characterized by two methods. The
presence of antibodies bound to 30 nm Au-NPs was verified by
means of secondary anti-immunoglobulin-specific antibodies
conjugated to 5 nm Au-NPs. Formation of rosettes of 30 nm
Au-NPs surrounded by 5 nm-Au-NPs detectable by electron
microscopy was taken as an evidence of the presence of
antibodies on 30 nm Au-NPs. As shown in Fig. 2A, all 30 nm
Au-NPs formed rosettes with 5 nm particles. The binding was
specific as indicated by the absence of rosettes in samples
containing30 nmAu-NPs coveredwithBSA insteadof antibodies
(Fig. 2B) orwith thiolated oligonucleotides alone (not shown). A
typical distributionpattern of 30 nmAu-NPs associatedwith 1–7
gold5 nmparticles is shown inFig. 2C. It shouldbenoted that the
number of 5 nm particles bound to 30 nm Au-NPs is under-
estimated because a fraction of 5 nm particles is overshadowed
by the dense bodies of 30 nm particles.
Concentrations and physical properties of functionalized
Au-NPs were characterized by means of UV–vis spectropho-
tometry (Fig. 2D). Unconjugated 30 nm Au-NPs showed an
absorption peak at 525 nm. This changed to higher wavelength
values by 5–10 nm if the particles were functionalized by
antibodies and oligonucleotides. Absorption maxima at values
N535 nm were indicative of suboptimal performance of the
particles in Nano-iPCR. The actual values of the 525–535 nm
peak and calculated extinction coefficient [ε528 nm=3.7 x
109 cm−1 M−1 (Jin et al., 2003)]made it possible to determine
the number of particles present in the sample.
The number of single-stranded oligonucleotides bound
to 30 nm Au-NPs was evaluated by a modified real-time PCR-
basedmethod (Kim et al., 2006)where DNA binding dye SYTO-
9was used instead of a fluorescence probe. Au-NPswith bound
thiolated Pri1 oligonucleotide were directly diluted into SYTO-
9-containing PCRmastermix supplementedwith primers (Pri2
and Pri3), and analyzed by real-time PCR (Fig. 3A). Linearity of
the data and regression coefficients close to 1 indicated that the
presence of 30 nm Au-NPs did not interfere with the assay and
therefore was not necessary to dissociate oligonucleotide
template from Au-NPs before the PCR. Similar good linearity
and reasonable regression coefficients were observed in assays
containing a defined amount of free Pri1 oligonucleotide
(Fig. 3B). Based on the results of such assays and estimated
numberof goldparticles in stock solutionsof functionalizedAu-
NPs it was possible to calculate the number of oligonucleotides
per one oligonucleotide- and antibody-functionalized particle
as 83±26 (mean±S.D.; n=5). The 1/104 dilution of functio-
nalized Au-NPs in Nano-PCR assays corresponds to approxi-
mately 1.4 pmol/l of Pri1 oligonucleotide.
3.2. Optimization of the Nano-iPCR
The sensitivity of immunoassays is limited by background
signal caused by nonspecific binding of assay components (pri-








































Fig. 2. Characterization of antibody-functionalized Au-NPs. (A, B) Electron microscopy visualization of polyclonal antibody bound to Au-NPs. (A) 30 nm Au-NPs
were conjugated with polyclonal antibody followed by an exposure to secondary 5 nm Au-NP labeled with anti-IgG. After washing the particles were observed by
electron microscopy. (B) Control 30 nm Au-NPs were conjugated with BSA, followed by an exposure to 5 nm Au-NP-labeled anti-IgG antibody. (C) Distribution of
5 nm Au-NPs (armed with anti-rabbit IgG) bound to 30 nm Au-NPs functionalized with polyclonal rabbit antibody. In total, 84 particles of 30 nm size were
evaluated. (D) UV–vis spectrophotometry of control (Au-NP) and oligonucleotide- and antibody-functionalized particles (F-Au-NP).
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other and plastic surfaces of the wells. In pilot experiments we
therefore tried to define the optimal conditions for iPCR. We
compared the performance of two buffers (PBS or HEPES)
supplemented with several blocking agents at different concen-
trations (2–5% BSA, 2% ovalbumin or 2% casein) and twoBA










Fig. 3. Characterization of oligonucleotide-functionalized Au-NPs. (A) Real-time
oligonucleotide. (B) Real-time PCR detection of various concentrations of oligonucle
from 3 independent experiments performed in triplicates.
201differentdetergents at various concentrations (0.01–0.2%Tween
20 or 0.1–2% Pluronic F68). A series of optimization experiments
showed that themost effective agents for blocking andwashing
were TPBS-2% BSA and TPBS, respectively.
In initial experiments with TopYield strips we noticed, in
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PCR performance of various dilutions of Au-NPs functionalized with Pri1
otide Pri1 alone. Correlation coefficients (R), means and S.D. were calculated
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results and poor sensitivity. One possible cause was inferior
heat transfer in wells of the TopYield strips during PCR. This
was solved by extending the synthesis phase of the PCR
cycles. Another problem was that larger surface area caused
higher evaporation of PCR mixes, even though the wells were
sealed with light cycler 480 sealing foil. We therefore added
5 μl of mineral oil into each well before they were sealed.
Mineral oil prevented evaporation and improved the perfor-
mance of detection of various concentrations of rIL-3 (Fig. 4)
and rSCF (not shown).
3.3. Comparison of various immunoassays
To compare various immunoassays for detecting cytokines,
we tested theperformance ofNano-iPCR I and II, iPCRandELISA
for detection of rIL-3 and rSCF at various concentrations. For
IL-3, polypropylenewells of the 96-well PCR plate (Eppendorf)
were coated with extravidin, followed by anti-IL-3 polyclonal
antibody (Nano-iPCR I). Alternatively, wells of TopYield
strips (NUNC) were coated directly with anti-IL-3 antibody
(Nano-iPCR II, iPCR and ELISA). Next, free binding sites were
blocked with TPBS-2% BSA and rIL-3 at various concentrations
was added. After incubation, unbound IL-3 was removed by
washing with TPBS. Further course of the procedures differed
depending on the method used (see Section 2 and Fig. 1).
Analysis of data obtained showed that Nano-iPCR I (Fig. 5A)
exhibited clear concentration-dependent differences in the
range of 0.01–100 ng/ml of IL-3 with Cq values from ~35 (at
100 ng/ml) to ~46 (at 0.01 ng/ml). These relatively high values
probably reflect low protein binding capacity of PCR polypro-
pylenewells.Nano-iPCR II (Fig. 5C)performed inpolycarbonate
TopYiled strips showed lower Cq values in the range from ~19
(at 100 ng/ml) to ~32 (at 0.01 ng/ml). With iPCR (Fig. 5E), the
dose–response curve was similar to that of Nano-iPCR II assay,
except for even lowerCq values, from~15(at 100 ng/ml) to ~24
(at 0.01 ng/ml). This was in part caused by lower Cq values
in negative controls (without IL-3) in iPCR compared to Nano-
iPCR, and could be related to higher nonspecific binding of the
biotinylated template used for iPCR. In contrast to Nano-iPCR
and iPCR, ELISA assay (Fig. 5G)was less sensitive and the range










Fig. 4. The effect of mineral oil overlay on iPCR detection of IL-3 in wells o
TopYield strips. Various concentrations of IL-3 were detected by iPCR in wells
of TopYield strips overlaid (+) or not (−) with 5 μl of light mineral oil and
sealed with real-time PCR transparent foil. Means and S.D. were calculated
from 3 independent experiments performed in triplicates.f
202(between 0.1 and 10 ng/ml).
Similar data were obtained when various assays were
used for detection of rSCF. Thus, Nano-iPCR I (Fig. 5B),
compared to Nano-iPCR II (Fig. 5D) and iPCR (Fig. 5F), was
characterized by relatively high Cq values (including negative
controls without rSCF) and higher sensitivity at low concen-
tration of rSCF. ELISA assay (Fig. 5H) was again less sensitive,
and also the range of rSCF concentrations detectable by the
assay was reduced (0.1–10 ng/ml). The data indicate that
Nano-iPCRs and iPCRs are superior in sensitivity and exhibit
broader range of detectable concentrations than ELISA.
3.4. Cytokine detection in cell culture supernatants
To prove the convenience of Nano-iPCR we attempted to
determine changes in the amount of rSCF during growth of
BMMCs in RPMI-1640medium supplemented with 10% FCS and
SCF. Cell-free samples from cell cultures were collected at 24 h
intervals for 5 days. In parallel, samples were also collected from
cultures containing medium alone to determine the rate of
degradationofSCFduring incubatedat37 °C.Data in Fig. 6Ashow
that growing cells gradually deplete the amount of rSCF. At the
beginning of the experiment, samples contained SCF at concen-
tration 15 ng/ml, but after 5 days, only about 3.7 ng SCF/ml
remained (75% reduction). Similar data were obtained with
ELISA. Degradation of rSCF in cell-free culture media had little
effect, since the slight decrease there (9.5%) was only observed
after 24 h of incubation and then remained constant. Binding of
rSCF to the plasma membrane receptor (c-kit) and its internal-
ization and subsequent degradation seems to be main cause of
the observed depletion of rSCF from culture medium.
Next, we compared the efficiencies of various immunoas-
says for detection of IL-3 released into culture supernatant by
growing D11 fibroblasts. Concentration of IL-3 was determined
by Nano-iPCR II, iPCR and ELISA. Data presented in Fig. 6B
indicate that D11 supernatant diluted 1:16 with TPBS-1% BSA
contained 21.6±2.0 ng/ml IL-3 (mean±S.D.; n=3), corre-
sponding to 346±32 ng/ml of undiluted supernatant. Higher
dilutions of the supernatant had no effect on calculated
concentration of IL-3. Similar data were obtained with iPCR
(359±90 ng/ml) or ELISA (384±58 ng/ml).
4. Discussion
We compared three different immunoassays (Nano-iPCR,
iPCR and ELISA) for detection of low concentrations of cytokines.
Nano-iPCR was used in two formats differing in the mode how
the antigen-specific antibodies were anchored to the reaction
wells. In Nano-iPCR I, biotinylated antibody was anchored to
immobilized extravidin, whereas in Nano-iPCR II the antibody
wasbounddirectly to theplastic surface. Bothmodificationsused
Au-NPs functionalizedwith single-strandedoligonucleotides and
polyclonal antibodies specific for the cytokine in question. The
assays gave reasonable concentration-dependent Cq values,
although Nano-iPCR II showed higher nonspecific binding
reflected by lower Cq values even in the absence of antigen. The
components of the critical importance and limiting factors in all
immunoassays are the antibodies, since they can differ in
specificity and affinity for the target antigen, as well as
nonspecific binding to the solid phase (McKie et al., 2002; Lind














































































































Fig. 5. Detection of various concentrations of rIL-3 and rSCF in particular immunoassays. Nano-iPCR I (A and B), Nano-iPCR II (C and D), iPCR (E and F) and ELISA (G
and H) were used for detection of various concentrations of rIL-3 (A, C, E, G) or rSCF (B, D, F, H) in TPBS-1% BSA. Results are means±S.D. from 3 to 6 independent
experiment performed in triplicates or duplicates.
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specific for IL-3 or SCF. The observed differences are thus
attributable to the characteristics of the assays rather than
antibodies.
The particular assays differed in a number of features which
are summarized in Table 1. First, Nano-iPCR assays utilize
functionalized Au-NPs. Production of such particles possessing
both antibody and single-stranded oligonucleotides is more
time consuming than preparation of biotinylated antibodies for
ELISA and iPCR, or biotinylated double stranded oligonucleo-
tides for iPCR. On the other hand, preparation of Au-NP
conjugates is substantially easier than direct conjugation of
antibodies with oligonucleotide templates (Lind and Kubista,
2005). As shown in this study, bindingof theantibody toAu-NPs
can be quantified by electron microscopy. The analysis proved
that almost all Au-NPs bound several antibody molecules. The
number of oligonucleotides bound to a particlewas determined
by real-time PCR using functionalized Au-NPs diluted directly
into PCR mixes. Interestingly, even though each functionalized
Au-NP possessed in average 80 oligonucleotides, performance
of Nano-iPCR was comparable to the detection range of iPCR.
This can be related to a higher background reflected in lower Cq
values in iPCR calibration curves, including negative controls.
Second, an important parameter of immunoassays is the
type of wells or tubes in which the assays are performed. An
extensive array of various tubes, strips and plates fitting to
different real-time PCR cyclers is available for PCR. However,
these tubes and wells are often made of polypropylene and
therefore exhibit a relatively low protein-binding capacity. At
present, only the TopYield polycarbonate strips have antibody
binding capacity comparable to polystyrene strips or plates
widely used for ELISA, and have a shape compatible with
heating blocks of various PCR cyclers. Our initial experiments
showed that real-time PCR performance of TopYield strips was
poor even in cyclers with heated lid. This was however
improved by changing the cycling conditions and covering
PCR master mixes with mineral oil. This obviously reduced
evaporation fromrelatively large surface area of TopYieldwells.
Third, both Nano-iPCR and iPCR detected the antigen with
















Fig. 6. Determination of SCF and IL-3 in culture media used for growth of BMMCs. (A
The cells (1.0×106/ml) were cultured in complete RPMI-1640 medium supplement
intervals for 120 h. The amount of rSCF was determined with Nano-iPCR I (circles)
control, supernatants from cell-free cultures were also analyzed in parallel by ELISA
Supernatant was diluted 16-fold, 32-fold or 64-fold in TPBS-1% BSA and the amount
curves. Means and S.D. were calculated from 3 independent experiments.
204amplify even a very small number of template DNA molecules.
Initial studies indeed demonstrated a dramatic enhancement
(approximately five orders of magnitude) in detection sensi-
tivity when iPCR was used instead of ELISA (Sano et al., 1992).
However, these assays were performed under optimal condi-
tions where antigen (BSA) was directly immobilized to wells
and a potent monoclonal antibody specific for BSA was
available. When the antigen is present in a complex protein
mix, such as in serum-containing culture medium or in crude
body fluids, and analyzed in a sandwich assay, Nano-iPCR and
iPCR usually detect the antigen with 1–3 orders higher
sensitivity than ELISA (Adler et al., 2003; Lind and Kubista,
2005; Chen et al., 2009; Perez et al., 2011). In a study aimed at
detecting mumps-specific IgG in serum samples, sensitivity of
the iPCR did not exceed that of conventional ELISA. It should be
kept in mind that Nano-iPCR and iPCR assays are substantially
less sensitive for quantification of antigenic molecules when
compared to real-timePCR for quantification of DNA templates.
This is attributable to high specificity of PCR and zero
amplification in the absence of DNA template.
Fourth, another important factor is thevariabilityof theassays
and the rangeof detectable concentrations of antigen. It is known
that real-time PCR gives exponential signal amplification and
real-timedetection.Under optimal conditions (100%efficiency) a
10-fold increase in the amount of DNA template is associated
with a decrease in Cq value by a factor of 3.4. IPCR-based assays
are therefore especially useful for detection of target antigens at
large quantitative differences. In contrast, standard ELISA gives
linear signal amplificationandendpointdetectionand, therefore,
suits better for detection of smaller differences at lower range of
concentrations; meaningful calibration curves for ELISA span
usually two orders of magnitude or less.
Fifth, the labor requirement of the assaysmust also be taken
into consideration. As shown in Fig. 1, Nano-iPCR based assays
are less laborious because they have fever steps than iPCR or
ELISA. Once the probes (functionalized Au-NPs) are prepared
they can be stored for severalmonths and used immediately for
easy quantification of the antigen.
Our primary intention was to develop an assay for detection















) Changes in concentration of rSCF in culture mediumwith the length of time
ed with 15 ng/ml rSCF (0 h). Cell culture supernatants were collected at 24-h
or ELISA (squares) using the corresponding calibration curves. As a positive
(triangles). (B) Quantification of IL-3 in supernatant from cultured D11 cells
of IL-3 was determined with Nano-iPCR II using the corresponding calibration.
.
Table 1
Comparison of the immunoassays used.
Parameter Nano-iPCR iPCR ELISA
Reagents preparation + ++ ++
Tolerance for matrix + ++ ++
Sensitivity +++ +++ ++
Quantification range +++ +++ +
Linearity +++ +++ ++
Variability ++ ++ +++
Robustness ++ ++ +++
Assay time +++ + ++
+++, the best attribute; ++, the medium attribute; +, the worst attribute.
47L. Potůčková et al. / Journal of Immunological Methods 371 (2011) 38–47iPCR performed in TopYield strips with master mixes covered
with oilfilmand transparent foil offers a simple and robust assay
for rapid detection of IL-3 and SCF using commercially available
antibodies and their biotinylated forms. The binding of antibody
and thiolated oligonucleotide template to Au-NPs is an easy
method of how to combine antibodies and oligonucleotides into
a complex suitable for the assays. The assay can be used for
quantification of other ligands, provided good monoclonal or
polyclonal antibodies and their biotinylated forms are available.
In conclusion, Nano-iPCR assay shows enhanced sensitivity
and wider dynamic range than ELISA and is easier to perform
than iPCR. It can be expected that further improvement of the
Nano-iPCR assays, namely introduction of better detection
probes with higher ligand specificity and lower nonspecific
binding will advance the application of these tests for routine
detection of cytokines as well as other ligands. Synthetically
prepared tailoredDNAor RNAaptamers (Jayasena, 1999; Khati,
2010) and tailored recombinant binding proteins (Binz et al.,
2005) could provide such probes.
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8 GENERAL DISCUSSION 
Understanding molecular mechanisms leading to allergy and other inflammatory 
responses is a fundamental question in mast cell signaling research. Activation of mast 
cells through the FcɛRI, results in release of biologically active proinflammatory 
mediators which are responsible for variety of mast cells-mediated diseases [15]. 
Current research focuses on searching for master signaling molecules, which drive mast 
cell degranulation and cytokines production and potentially serve as therapeutic targets 
to dampen mast cell responses at initial stages of FcɛRI activation. It has been shown 
that inhibitor of SYK can be successfully used for treatment of patients with rheumatoid 
arthritis [120]. Also, inhibitors targeting PI3K pathway have a clinical potential in 
allergic rhinitis [121] and asthma [122]. However, number of targets used clinically is 
rather limited. Thus, searching for a new signaling molecules and pathways which 
regulate mast cell degranulation is required.  
 
PAG in mast cell signaling 
A key role of TRAPs in immune cells is diversification of downstream signaling 
after immunoreceptor triggering [50]. In this thesis we focused on understanding 
function of one of them, the adaptor protein PAG. Our results showed that activation of 
mast cell derived from PAG-KO mice led to decreased antigen-mediated calcium 
mobilization and degranulation, although activity of SFKs was increased. This finding 
was unexpected because phosphorylated PAG has been proposed to mediate membrane 
recruitment of CSK, playing a major role in inactivation of SFKs [55, 56]. Several 
previous studies using primary T cells and T cell lines showed that PAG acts as a 
negative regulator of TCR signaling [57]. It has been shown that phosphorylated PAG 
together with associated CSK set an activation threshold of TCR signaling [57]. In line 
with these findings it has been shown that T cells with mutant PAG, which are unable 
to bind CSK, have impaired response to TCR stimulation [123]. Furthermore, T cells 
isolated from transgenic mouse, in which PAG is overexpressed, showed impaired TCR 
signaling as well [124]. However, in a more recent study it was shown, that effector T 
cells from PAG-KO mice showed enhanced TRC-mediated activation demonstrated by 
increase in cell proliferation and cytokine production; surprisingly, in naive T cells PAG 
has no appreciable role [59]. It has been shown that overexpression of PAG resulted in 
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reduced degranulation in RBL-2H3 cell line [125]. It should be noted, that the different 
role of PAG in mast cells is unlikely to be a consequence of the compensatory 
developmental alterations in PAG-KO mice used in our study, because we observed 
similar phenotype in PAG-KD cells where PAG expression was down regulated by 
RNA interference.  
It is widely excepted that passive systemic anaphylaxis (PSA) is initiated by 
inflammatory mediators released from activated mast cells during degranulation [126]. 
A key role in this process has histamine which is known to reduce body temperature 
[127] and thus control anaphylactic reaction in mice [35]. Thus, our finding of impaired 
PSA in PAG-KO mice could be directly related to decreased degranulation in PAG-KO 
cells.  Furhermore, in this study we demonstrated for the first time that PAG-KO mice 
exhibit distinct phenotype when compared to WT mice. 
Our data showed that reduced calcium response and degranulation in PAG-KO 
mast cells are caused at least in part by inhibition of the earlies stages of FcɛRI signaling, 
including phosphorylation of the FcεRI β and γ subunits, phosphorylation of SYK 
kinase, adaptor protein LAT, and PLCγ. Reduced calcium response in PAG-KO cells 
could be attributed to the reduced tyrosine phosphorylation and activity of PLCγ, which 
cleaves the plasma membrane-bound phosphatidylinositol 4,5-bisphosphate into 
diacylglycerol and inositol 1,4,5-trisphosphate; that the latter binds to its receptors and 
regulates the release of calcium from cytoplasmic stores. An increase in cytoplasmic 
calcium leads to the influx of extracellular calcium into the cytoplasm through SOC 
channels [128]. Our hypothesis that PAG is a positive regulator of antigen-induced 
calcium mobilization and degranulation, is supported by enhanced phosphorylation of 
phosphatase SHIP1 and LYN kinase, the negative regulators of FcɛRI-mediated 
signaling [52].  
It should be noted, that important differencies has been described between early 
regulatory events induced by stimulation of TCR and FcεRI in term of PAG. It has been 
shown that in resting T cells, PAG is constitutively phosphorylated via association with 
FYN [129]. Upon TCR engagement, PAG is rapidly dephosphorylated following release 
of CSK and this leads to increase in activity of LCK [81, 130]. In contrast, in mast cells, 
PAG is phosphorylated by LYN and FcεRI triggering results in increased 
phosphorylation of PAG and binding of CSK [123]. However, we observed no 
daramatic changes in tyrosine phosphorylation of PAG in the course of FcεRI-induce 
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activation (data not shown). This could reflect different methods used for mast cell 
activation. 
An important result of this study is a finding of a positive regulatory role of PAG 
in production of proinflammatory cytokines and chemokines upon FcɛRI-induced mast 
cell activation. Present data indicate that changes in transcription of genes for cytokines 
and chemokines as well as changes at the protein levels could be a direct consequece of 
impaired phosphorylation of STAT5, as publication in Mol. Cell. Biol., 2014 showed. 
The results are in line with the previous findings that phosphorylated STAT5 serves as 
a transcription factor for a number of proinflammatory genes [131] and that STAT5 
defficiency leads to impaired responses in FcεRI activated mast cells [132]. Molecular 
mechanism, which controls STAT5-dependent cytokines production upon FcεRI 
triggering is not completely understood.  It has been shown that IgE-mediated STAT5 
phosphorylation is dependent on FYN kinase which is enhanced in context of LYN 
deficiency, but is independent of SYK and PI3K-AKT pathway [117]. Other study, 
however, showed that FYN has no effect on activation of MAPK ERK and production 
of TNF-α, while SYK and GAB2 seems to be a potent regulator of FcεRI-induced 
degranulation and activation of NFAT and NF-κB pathways [133]. Related to these 
results, we observed impaired phosphorylation of SYK kinase and ERK in PAG-KO 
cells, which could support the hypothesis that reduced activity of transcription factor 
STAT5 could be rather a consequence of impaired SYK and STAT5 pathway. 
 
CSK in regulation of mast cell signaling 
One of the key finding of this study was contribution to elucidation of the role 
of CSK in mast cell degranulation and cytokine production. Our primary goal was to 
examine whether widely accepted view of CSK as a negative regulator of various cell 
responses, and as a major interaction partner of PAG, anchoring CSK to plasma 
membrane, applies also to mast cells. In accord with previous studies our data showed 
that mast cells with CSK-KD exhibited elevated degranulation, not only upon FcɛRI-
induced activation, but also in nonactivated state, spontaneous degranulation. The 
finding that CSK acts in setting of mast cell activation threshold is supported by the 
observations in T cells [134] and granulocytes [85], which pointed out that CSK is a 
major regulator of  early signaling events after triggering of MIRRs and other surface 
receptors. Despite of intensive studies of CSK, there has been only one study carried 
out in mast cell-related line (RBL) in FcεRI-mediated signaling [86]. Our data are in 
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agreement with this study, which showed that RBL cells with overexpressed CSK, 
exhibited delayed early stages of FcɛRI degranulation [86]. Similarly, it has been shown 
that CSK-deficient granulocytes exhibit elevated ligand-induced degranulation [85]. We 
confirmed a negative regulatory role of CSK in mast cell degranulation by analysis of 
surface expression of CD107a, a lysosomal marker of degranulation. However, we were 
not able to detect reduced degranulation in mast cells overexpressing myc-hCSK or 
mCherry-hCSK. Our attempt to increase exogenous expression of CSK in BMMCs 
failed because of enhanced mortality of such mast cells. Collectively, these data, 
together with those from the previously published studies on CSK, support the concept 
that CSK is a negative regulator of mast cell degranulation.  
Enhanced concentration of free cytoplasmic calcium is essential for 
degranulation and optimal production of cytokines in mast cells [128]. Our data showed 
enhanced calcium response in mast cells with CSK-KD upon FcɛRI-induced activation. 
It has been shown, that calcium response in antigen-activated mast cells is dependent on 
LYN-SYK-LAT-PLCγ-dependent signaling pathway [135]. CSK-KD had stimulatory 
effect on this pathway as reflected by significantly increased tyrosine phosphorylation 
of SYK, LAT and PLC-γ. Our data are thus in line with previously published data 
showing that in  T cells with reduced catalytic activity of CSK, whose catalytic activity 
was inhibited by a small inhibitor, exhibited significantly enhanced phosphorylation of 
SYK (ZAP-70 in T cell), LAT and PLCγ when compared to control cells [134]. 
Interestingly, in BMMCs with CSK-OE, no significant changes in antigen-induced 
calcium response were observed.  This observation is in accord with previous studies 
using WEHI-231 cells in which CSK-OE was unable to alter BCR-induced signaling 
[136] and RBL cells in which CSK-OE displayed only delayed calcium response [86]. 
Data obtained with BMMCs contrast with those showing that overexpression of CSK in 
T cell line resulted in significant inhibition of TCR-induced activation events [137]. Our 
data also suggest that the downstream signal following FcɛRI crosslinking in mast cells 
with CSK-KD is distinctly diversified signal and thereby represents unique modulation 
of mast cell responses, such as chemotaxis. This hypothesis is supported by another 
study in which we found unique mechanism of chemotaxis controlled by complexes of 
tetraspanin CD9 and NTAL where NTAL adaptor served as negative regulator of this 
process, but LAT had no effect. Similarly, we found unchanged tyrosine 
phosphorylation of LAT, but significantly decreased tyrosine phosphorylation of NTAL 
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in cells with CSK-KD, which could explain enhanced chemotaxis towards antigen and 
SCF.  
CSK is generally considered as a major negative regulator of SFKs through 
phosphorylation of its regulatory C-terminal tyrosine [66]. The importance of this 
tyrosine for control of both proximal and distal signaling pathways in FcεRI-activated 
cells was shown [86].  Our data showed that although mast cells with CSK-KD revealed 
dramatic defect in tyrosine phosphorylation of LYN at Y508, tyrosine phosphorylation 
of LYN at Y397 was unchanged and even kinase activity of LYN was reduced in such 
cells. Interestingly, FYN kinase activity was unaffected by CSK-KD. It has been shown 
that LYN negatively regulates mast cell activation in vitro and in vivo [138, 139]. In 
addition, considerably different molecular mechanism of various immunoreceptor 
signaling uderlines the fact that in mast cells upon FcɛRI triggering, LYN kinase is 
transiently hyperphosphorylated on its inhibitory C-terminal tyrosine (Y487) resulting in 
decrease of LYN kinase activity [108]. In contrast, studies on LCK in T cells showed 
decreased phosphorylation of C-terminal regulatory trosine and thus enhanced kinase 
activity of LCK [81].  
 
Unexpected was our finding of positive regulatory role of CSK on production of 
proinflammatory cytokines (TNF-α, IL-13, IL-6) and chemokines (CCL-3, CCL-4) in 
FcɛRI-activated cells. This finding is different from those observed in LPS-activated 
macrophage cell line in which CSK-OE resulted in reduced production of TNF-α, IL-1a 
and IL-6  [140]. Furthermore it has been reported that conditionally reduced CSK in 
keratinocytes resulted in elevated levels of TNF-α [84].  In addition, recent study using 
mice with conditionally abolished CSK in granulocytes and macrophages, showed 
increased TNF-α in serum; however, in vitro analyses showed no changes [85]. It should 
be mentioned that positive regulatory role of CSK in production of TNF-α and IL-6 has 
been also described in macrophage cell line RAW 264.7 [141]. Based on the data 
obtained in this study we propose that silencing of CSK in BMMCs leads to alteration 
of the balance between PTPs and PTKs in early stages of FcɛRI-induced signaling. In 
cells with CSK-KD, SHP-1 phosphatase becomes more active and probably recognizes 
its substrate LYN via recently described unique inhibitory motif, KTIM, only found in 
LYN [103], and thus repress its activity. Activated SHP-1 is in turn able to 
dephosphorylate Y694 at STAT5 and thereby negatively regulate production of cytokines 
in cells with CSK-KD.  Our results are in accord with previous reports that SHP-1-
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defficient cells exhibit increased cytokine production, but reduced calcium response and 
degranulation, implying that SHP-1 has both positive and negative regulatory role in 
mast cells [94].  
 
Our finding that CSK-mediated regulation of FcεRI signaling does not require 
adaptor protein PAG supports our hypothesis about existence of CSK binding proteins, 
other than PAG, which are more relevant for the inhibitory action of CSK in mast cells.  
Firstly, we observed significantly elevated degranulation, calcium response and 
chemotaxis in PAG-KO cells in which CSK-KD was introduced in comparison with 
PAG-KO alone, resembling to phenotype cells with CSK-KD. These aspects are 
discussed in more detail in manuscript presented at pages 67-116 in this thesis.  
Second, our data published in Mol. Cell. Biol., 2014, revealed that only a very 
small fraction of CSK (~4%) colocalized with PAG in lipid raft fraction in WT cells and 
that this fraction was not changed upon FcɛRI-induced activation.  
Third, there are discrepancies between the data considering role of PAG as a 
major CSK adaptor protein. It has been shown that PAG is major anchor of CSK in lipid 
raft from mouse thymocytes [142]. Another study showed, however, that amount of lipid 
raft associates-CSK in thymus is not affected by the absence of PAG [143]. Based on 
our data we suggest that the hypothetical CSK anchor could resides in detergent soluble 
fraction of the cell extracts. 
Fourth, we determined several aspect of mast cells signaling carried out in CSK-
KD, PAG-KD, PAG-KO and double-deficient CSK-KD/PAG-KO cells and observed 
distinct or even opposite roles of PAG and CSK in regulation of individual signaling 
events including, degranulation, calcium response, adhesion to fibronectin, chemotaxis 
towards antigen and SCF, and tyrosine phosphorylation of several signaling molecules. 
As was mentioned above, reduced expression of CSK is accompanied by decreased 
phosphorylation of NTAL, however LAT is unchanged, while PAG has opposite effect 
on phosphorylation of these TRAPs. 
Fifth, the observed additive effect of double-deficient cells (CSK-KD/PAG-KO) 
on cytokine production suggests that CSK and PAG could regulate this event by 
independent pathways which converge at the level of STAT5 tyrosine phosphorylation.  
Finally, the results obtained in our studies allowed us to propose a new model 
(at page 105 and 116 in this thesis) suggesting that in mast cells CSK binds not only to 
PAG, but also to some other anchors, which could serve better than PAG for positioning 
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CSK in the vicinity of SFKs and thus more efficiently contribute to inactivation of SFKs 
involved in FcεRI signaling. These alternative CSK anchor proteins remains to be 
identified. 
 
Other FcεRI signaling regulators 
    In the course of the studies on this project we noticed that FcεRI-mediated 
activation is strongly affected by short-term treatment of mast cells with low 
concentrations of ethanol, which suppressed phosphorylation of FcεRI β and γ subunits 
and all other downstream signal transduction events, including phosphorylation of SYK, 
LAT, PLCγ, STAT5, and AKT, calcium response, degranulation and production of 
proinflammatory cytokines. Based on various experiments and literature data we 
proposed hypothesis that cholesterol, rather than proteins, could be the target of ethanol. 
This hypothesis was supported by findings that MβCD, a cholesterol sequestering drug, 
had similar effect as ethanol on properties of mast cells and that MβCD saturated with 
cholesterol, which is known to increase amount of cholesterol in the plasma membrane, 
reversed at least in part the inhibitory effect of ethanol. This finding is in line with the 
observation on neutrophiles, in which ethanol inhibits production of TNF-α and 
modulates redistribution of surface molecules on the plasma membrane [144], 
membrane fluidity [145], and membrane viscosity, resulting in changes in cell adhesion, 
rolling, lateral mobility of lipid molecules and tethering behaviour [144]. The inhibitory 
effect of ethanol on mast cell degranulation and cytokines release was corroborated by 
in vivo PCA experiments, in which mice were localy senzitized by IgE, peritoneally 
treated by ethanol and finally intravenously challanged by antigen, as shown in our 
publication in Plos One. How exactly ethanol interacts with lipids and/or how it affects 
lipid-protein interactions is not known but could involve direct interaction of ethanol 
with cholesterol [146] and the ability of ethanol to mediate and modify organization of 
the lipid bilayer structures [147]. The amphiphilic character of ethanol gives it the 
capability to be attracted simultaneously to both hydrophobic and hydrophilic targets in 
the plasma membrane.  
 Another molecule we touched in the course of these studies is  ORMDL3, which 
in mast cells serve as a negative regulator of cytokine and chemokine production. 
Interestingly, our data concurrently indicated that reduced or enhanced expression of 
ORMDL3 had no effect on antigen-induced degranulation and calcium mobilization. 
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Based on previously published studies, involvement of ORMDL3 in regulation of 
calcium response seems to vary depending on the cell type examined. For instance, it 
has been shown that reduced expression of ORMDL3 in T cells led to increased calcium 
response [148]. In contrast, eosinophils with reduced expression of ORMDL3, displayed 
reduced calcium mobilization even at basal level [149]. Moreover, enhanced 
localization of phosphorylated NF-κB p65 subunit in the nucleus has been shown in 
such cells [149].  
It is known that enhanced nuclear localization of NF-κB p65 subunit is a step 
followed by increased transcription of NF-κB regulated genes encoding various 
cytokines and chemokines [150]. Therefore, we focused in detail on analyses of these 
events and observed enhanced localization of NF-κB in the nucleus, which was driven 
by increased phosphorylation of AKT at Ser473. This molecular mechanism could 
explain elevated level of cytokines (TNF-α, IL-13 and IL-6) and chemokines (CCL3, 
CCL4) in mast cells with ORMDL3-KD. Interestingly, no significant inhibition of 
IκBα/AKT signaling and unchanged release of cytokines were observed in mast cells 
with ORMDL3-OE. However, the direct connection between AKT- and ORMDL3-
mediated regulations are not yet solved. These data support an important role of 
ORMDL3 in mast cell mediated inflammation.  
 
Detection of proinflammatory cytokines 
Therapeutics against mast cells related diseases target variety of substances 
released during mast cells degranulation, such as histamine, leukotrienes or numerous 
cytokines [118]. Impact of cytokines de novo synthetized and released by mast cells, 
including TNF-α, IL-13, IL-10, IL-6, and IL-4 has been demonstrated in allergy and 
numerous inflammatory disorders, such as pollen and food allergy, asthma, allergic 
rhinitis, and various autoimmune disorders [151]. For this purpose, sensitive and simple 
detection methods for quantification of mast cell mediators are required [152]. 
Widespread methods for detection of cytokines are ELISAs, which are based on 
a highly specific antibody-antigen interaction. However, some protein biomarkes are 
under the detection limit of ELISAs and therefore here a new methods have been 
developed. Previous studies showed that iPCR method by combining versatility of 
ELISAs with the amplification power and sensitivity of PCR, allows sensitive detection 
of target proteins [153-155]. One of the initial methodological aims of this project was 
214 
 
to use gold nanoparticles conjugated with both antibodies and short oligonucleotides 
and in this way to increase simplicity of iPCR methods [156, 157].  
The results presented in this disertation show that when the same antibodies were 
used throughout the individual assays, newly developed iPCR method based on armed 
gold nanoparticles, called nano-iPCR, offers enhaced sensitivity, wider dynamic range, 
is easier to perform and is more cost-efficient than ELISA and classical iPCR. In our 
approach, several modifications of this metod were introduced allowing detection of 
variety of cytokines and other molecules released or utilized by mast cells. Using nano-
iPCR we showed that both IL-3 and SCF are critical growth factors for BMMCs in vitro, 
which have regulatory roles on certain mast cell signaling pathways and thereby 
modulates mast cells responsivenes to stimuli [158]. For these reasons, we used nano-
iPCR method and monitor routinely IL-3 and SCF levels in supernatants from WEHI 
and CHO cells. Routine measurement of IL-3 and SCF levels in the supernatants 
allowed us to avoid buying expensive recombinant proteins. 
Besides measuring levels of IL-3 and SCF in cell supernatants used for growth 
of BMMCs, we used our newly nano-iPCR method extensively for quantification of 
proinflammatory cytokines (TNF-α, IL-13 and IL-6) released from mast cells in the 
course of activation [34]. In our study published in J. of Immunol. Methods 2014, we 
showed that Nano-iPCR method is suitable not only for basic research aplications, but 
also for sensitive detection of clinically relevant markers present in complex biological 
fluids, such as cerebrospinal fluid. Nano-iPCR assays have been rutinely used in several 
projects in our laboratory and the results have been presented in six publications 








1. Our results showed that adaptor protein PAG plays a role as a positive or 
negative regulator of BMMCs signaling, depending on the signaling pathway 
involved. For the first time, we showed the physiological impact of PAG in 
immune cells under in vivo condition. 
 
a. Interestingly, PAG-KO cells exhibited decrease in several aspects of 
mast cell signaling, such as degranulation and pro-inflammatory 
cytokines (TNF-α, IL-13 and IL-6) production upon antigen activation.  
b. In vivo experiments showed, that PAG is a positive regulator of IgE-
mediated PSA, however PAG-KO mice exhibited normal level of IgE.  
 
2. Our results support the notion that CSK in mast cells is a negative regulator 
of calcium response, degranulation and migration, whereas in production of 
cytokines and adhesion to fibronectin CSK plays a positive regulatory role. 
Obtained data also indicated that, some of these events could be regulated by 
CSK independently of the PAG.  
a. BMMCs with CSK-KD exhibited elevated degranulation, calcium 
mobilization and migration toward antigen and SCF, accompanied by 
altered phosphorylation of FcεRI β and γ subunits, LYN, SYK, NTAL, 
and PLCγ. 
b. In contrast to CSK-KD, BMMCs with CSK-OE showed CD107a surface 
expression and calcium mobilization at normal levels. 
c. Surprisingly, production of cytokines and chemokines was reduced in 
antigen-activated BMMCs with CSK-KD by a mechanism dependent on 
transcription factor STAT5. 
d. We observed altered balance between PTKs and PTPs in cells with CSK-
KD, where increased phosphatase activity of SHP-1 in turn negatively 
regulated LYN and STAT5 activity. 
e. Based on the results obtained, we proposed a model of FcεRI-mediated 




3. We found out that ORMDL3 is involved in development of local 
inflammation initialized by FcεRI triggering under in vitro and in vivo 
conditions.  
a. Downregulation of ORMDL3 was associated with an increased 
expression of proinflammatory cytokines, chemokines, and 
cyclooxygenase-2 dependent synthesis of prostaglandin D2 regulated via 
AKT and NF-κB signaling pathways. In contrast, degranulation was 
unchanged. 
b. On the other hand, enhanced expression of ORMDL3 in BMMCs leads 
to unchanged production of proinflammatory cytokines. 
c. Mice with locally silenced ORMDL3 by siRNA exhibited enhanced IgE-
antigen-dependent PCA. 
 
4. Results obtained in studies investigating effect of ethanol helped us to better 
understand early signaling events mediated by triggering of FcεRI. Our data 
showed that ethanol interferes with early antigen-induced signaling events in 
mast cells by suppressing the function of FcεRI-cholesterol signalosomes at 
the plasma membrane. These data were corroborated by reduced PCA 
reaction in mice, suggesting inhibitory role of ethanol under in vivo 
conditions. 
 
5. Data based on studying CD9 revealed that chemotaxis toward antigen is 
controlled by a cross-talk between FcεRI, CD9, NTAL, and proteins of the 
ERM family. Newly prepared mAb specific for the tetraspanin CD9 induced 
activation of several signaling pathways, including mast cell chemotaxis. 




6. We developed a nano-iPCR method for detection of proteins in complex 
biological fluid. Our data indicate that this assay is suitable for detection of 
immune responses under physiological and pathophysiological conditions. 
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a. Nano-iPCR was optimized and implemented for detection of SCF, IL-3, 
TNF- α, IL-6, IL-13, tau protein, and α-tubulin. 
b. This assay served as a helpful approach for monitoring changes in 
concentration of grow factors in culture media during mast cell 
cultivation. 
c. The method was widely used for rapid detection of pro-inflammatory 
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